{"metadata":"one-liner|ards_prone|ARDS - Prone Positioning|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"ARDS - Prone Positioning\".\nSet the \"topic\" field in the JSON to \"ards_prone\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.32028291549091675,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Prone positioning in ARDS primarily improves oxygenation by which mechanism?\",\n    \"options\": {\n      \"A\": \"Increasing cardiac output\",\n      \"B\": \"Improving V/Q matching\",\n      \"C\": \"Decreasing pulmonary vascular resistance\",\n      \"D\": \"Reducing intrapulmonary shunt\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"Prone positioning redistributes ventilation and perfusion, recruiting previously collapsed dorsal lung regions, reducing shunt, and making ventilation more uniform, thus improving V/Q matching. While it reduces shunt, improving V/Q matching is a broader and more encompassing primary mechanism.\",\n    \"highYieldPearl\": \"The main benefit of prone positioning is improved V/Q matching and recruitment of dorsal lung, leading to better oxygenation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and C are hemodynamic, not primary respiratory mechanisms. Option D (reducing intrapulmonary shunt) is a component of improved V/Q matching, but B is a more complete description of the overall physiological improvement.\"\n  },\n  {\n    \"question\": \"What PaO2/FiO2 ratio typically indicates consideration for prone positioning in ARDS?\",\n    \"options\": {\n      \"A\": \"<300 mmHg\",\n      \"B\": \"<200 mmHg\",\n      \"C\": \"<150 mmHg\",\n      \"D\": \"<100 mmHg\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"The PROSEVA trial, which demonstrated a mortality benefit with prone positioning, included patients with severe ARDS defined by a PaO2/FiO2 ratio of <150 mmHg on FiO2 >0.6 and PEEP >5 cmH2O.\",\n    \"highYieldPearl\": \"PROSEVA criteria for prone positioning in ARDS: PaO2/FiO2 <150 mmHg.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other ratios (A, B) define ARDS severity, but <150 mmHg is the specific threshold associated with a mortality benefit in the key clinical trial for prone positioning.\"\n  },\n  {\n    \"question\": \"Prone positioning in severe ARDS has been shown to improve which outcome?\",\n    \"options\": {\n      \"A\": \"Duration of mechanical ventilation\",\n      \"B\": \"ICU length of stay\",\n      \"C\": \"28-day mortality\",\n      \"D\": \"Incidence of ventilator-associated pneumonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"The PROSEVA trial demonstrated a significant reduction in 28-day and 90-day mortality in severe ARDS patients treated with prolonged prone positioning. While it might indirectly affect other outcomes, mortality reduction is the primary, statistically significant, and clinically impactful outcome.\",\n    \"highYieldPearl\": \"Prone positioning reduces mortality in severe ARDS, as evidenced by the PROSEVA trial.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While there might be trends or indirect effects on other options, the robust evidence points to a direct reduction in mortality as the key benefit.\"\n  },\n  {\n    \"question\": \"Prone positioning primarily recruits which lung regions in ARDS?\",\n    \"options\": {\n      \"A\": \"Ventral\",\n      \"B\": \"Apical\",\n      \"C\": \"Dorsal\",\n      \"D\": \"Basal\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"In supine ARDS, the dorsal (posterior) lung regions are often compressed by the heart, mediastinum, and abdominal contents, leading to collapse and atelectasis. Prone positioning redistributes these forces, allowing for recruitment and improved ventilation of these previously collapsed dorsal areas.\",\n    \"highYieldPearl\": \"Key benefit of proning is recruitment of previously collapsed dorsal lung units.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Ventral lung regions are typically better ventilated in the supine position. Apical and basal are less specific to the gravitational effects addressed by proning compared to the dorsal-ventral axis.\"\n  },\n  {\n    \"question\": \"Which condition is an absolute contraindication for prone positioning in ARDS?\",\n    \"options\": {\n      \"A\": \"Mild ARDS\",\n      \"B\": \"Recent spinal surgery\",\n      \"C\": \"Chronic obstructive pulmonary disease\",\n      \"D\": \"Morbid obesity\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"Spinal instability, such as recent spinal surgery, unstable pelvic fractures, or cervical spine injuries, is an absolute contraindication due to the high risk of neurological damage during patient turning and positioning.\",\n    \"highYieldPearl\": \"Unstable spine or pelvis is a critical absolute contraindication for prone positioning.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Mild ARDS is an indication issue (prone reserved for severe ARDS). COPD and morbid obesity can make proning technically challenging but are not absolute contraindications if benefits outweigh risks and resources are available.\"\n  },\n  {\n    \"question\": \"What is the recommended minimum daily duration for prone positioning in severe ARDS?\",\n    \"options\": {\n      \"A\": \"4-6 hours\",\n      \"B\": \"8-10 hours\",\n      \"C\": \"12-16 hours\",\n      \"D\": \"20-22 hours\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"The PROSEVA trial, which showed a mortality benefit, used prone positioning for at least 16 hours per day. Current guidelines generally recommend a minimum of 12-16 hours per day to achieve sustained physiological benefits and improve outcomes.\",\n    \"highYieldPearl\": \"Prolonged prone positioning (12-16 hours/day) is crucial for mortality benefit.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Shorter durations (A, B) have not consistently shown the same mortality benefits. While longer durations might be tolerated, 12-16 hours is the evidence-based minimum for significant impact.\"\n  },\n  {\n    \"question\": \"Prone positioning typically affects chest wall compliance in ARDS patients how?\",\n    \"options\": {\n      \"A\": \"Decreases\",\n      \"B\": \"Increases\",\n      \"C\": \"No change\",\n      \"D\": \"Highly variable\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"In the prone position, the chest wall becomes more compliant. This is partly due to the redistribution of the heart and abdominal contents, which reduces the compressive forces on the dorsal lung and allows for more uniform expansion of the chest wall and lung parenchyma.\",\n    \"highYieldPearl\": \"Prone position increases chest wall compliance, facilitating lung expansion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While overall respiratory system compliance can be complex, the effect on chest wall compliance specifically is an increase due to mechanical advantages in the prone position. Lung compliance often improves due to recruitment, but chest wall is distinct.\"\n  },\n  {\n    \"question\": \"A significant ocular complication associated with prolonged prone positioning is?\",\n    \"options\": {\n      \"A\": \"Conjunctivitis\",\n      \"B\": \"Corneal abrasion\",\n      \"C\": \"Retinal detachment\",\n      \"D\": \"Glaucoma\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"Pressure on the eyes or inadequate padding during prone positioning can lead to corneal abrasions, ulcers, or even ischemic optic neuropathy. Meticulous eye care and protection are essential to prevent these complications.\",\n    \"highYieldPearl\": \"Corneal abrasions are a common and preventable complication of prone positioning; meticulous eye care is vital.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Conjunctivitis is less specific to proning. Retinal detachment and glaucoma are less directly or acutely caused by positioning compared to direct pressure-related injuries like corneal abrasions.\"\n  },\n  {\n    \"question\": \"How does prone positioning potentially mitigate ventilator-induced lung injury (VILI) in ARDS?\",\n    \"options\": {\n      \"A\": \"By reducing tidal volume\",\n      \"B\": \"By increasing plateau pressure\",\n      \"C\": \"By promoting more homogeneous ventilation\",\n      \"D\": \"By decreasing PEEP\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"By recruiting collapsed dorsal lung regions and redistributing stress and strain more evenly across the lung parenchyma, prone positioning reduces regional overdistension and cyclic collapse, thereby promoting more homogeneous ventilation and reducing VILI.\",\n    \"highYieldPearl\": \"More homogeneous ventilation in the prone position helps reduce VILI.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Reducing tidal volume and decreasing PEEP are ventilator settings, not direct effects of proning. Increasing plateau pressure is generally undesirable and associated with increased VILI risk, not mitigation.\"\n  },\n  {\n    \"question\": \"Prone positioning in hemodynamically stable ARDS patients typically has what effect on cardiac output?\",\n    \"options\": {\n      \"A\": \"Significantly increases\",\n      \"B\": \"Significantly decreases\",\n      \"C\": \"No significant change\",\n      \"D\": \"Initially decreases then increases\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_prone\",\n    \"deepDiveExplanation\": \"While transient changes can occur during turning, overall, in hemodynamically stable patients, prone positioning does not significantly alter cardiac output. Some studies even suggest a slight increase due to improved right ventricular function and reduced pulmonary vascular resistance, but 'no significant change' is the most accurate general statement.\",\n    \"highYieldPearl\": \"Cardiac output generally remains stable in hemodynamically stable ARDS patients during prone positioning.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Significant increases or decreases are not typical in a stable patient population. Transient decreases might occur during the turn, but the sustained effect is usually stability.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-785.6539916992188}],"createTime":"2025-12-31T07:45:12.102038Z","modelVersion":"gemini-2.5-flash","responseId":"iNRUaZadBpO1hMIP5fTY-Ak","usageMetadata":{"billablePromptUsage":{"textCount":1023},"candidatesTokenCount":2453,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2453}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":2091,"totalTokenCount":4908,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:00.453252+00:00"}
{"metadata":"one-liner|ards_definition|ARDS - Definition and Berlin Criteria|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"ARDS - Definition and Berlin Criteria\".\nSet the \"topic\" field in the JSON to \"ards_definition\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3232877543506645,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"According to Berlin criteria, ARDS onset must occur within how many days of a known clinical insult?\",\n    \"options\": {\n      \"A\": \"3\",\n      \"B\": \"5\",\n      \"C\": \"7\",\n      \"D\": \"10\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin Definition (2012) mandates that respiratory symptoms must have occurred within one week (7 days) of a known clinical insult or new/worsening respiratory symptoms. This timeline helps distinguish ARDS from chronic lung conditions or long-standing issues.\",\n    \"highYieldPearl\": \"Acute onset within 7 days of an insult is a core temporal criterion for ARDS diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options are close numbers, testing precise recall of the definition's temporal component. Incorrect recall of the exact number is a common error.\"\n  },\n  {\n    \"question\": \"What characteristic radiographic finding is required for ARDS diagnosis by Berlin criteria?\",\n    \"options\": {\n      \"A\": \"Unilateral consolidation\",\n      \"B\": \"Bilateral opacities\",\n      \"C\": \"Pleural effusion\",\n      \"D\": \"Cavitation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin definition specifies bilateral opacities on chest radiograph, CT scan, or ultrasound. These opacities must not be fully explained by effusions, lobar/lung collapse, or nodules, indicating widespread alveolar injury and pulmonary edema.\",\n    \"highYieldPearl\": \"Bilateral opacities on imaging, not explained by other causes, are a hallmark criterion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Unilateral consolidation is common in pneumonia but not typical for ARDS's diffuse nature. Pleural effusion and cavitation are not primary ARDS features.\"\n  },\n  {\n    \"question\": \"The pulmonary edema in ARDS, as per Berlin criteria, is primarily classified as what type?\",\n    \"options\": {\n      \"A\": \"Hydrostatic\",\n      \"B\": \"Cardiogenic\",\n      \"C\": \"Non-cardiogenic\",\n      \"D\": \"Obstructive\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"A critical component of ARDS is that the respiratory failure, and thus the pulmonary edema, is not fully explained by cardiac failure or fluid overload. This explicitly distinguishes ARDS from hydrostatic (cardiogenic) pulmonary edema.\",\n    \"highYieldPearl\": \"ARDS involves non-cardiogenic pulmonary edema, a key differentiator from heart failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Hydrostatic and cardiogenic are the main differentials that must be ruled out or deemed not the sole cause for ARDS diagnosis.\"\n  },\n  {\n    \"question\": \"What is the minimum PEEP level required when evaluating the PaO2/FiO2 ratio for ARDS diagnosis?\",\n    \"options\": {\n      \"A\": \"0 cmH2O\",\n      \"B\": \"2 cmH2O\",\n      \"C\": \"5 cmH2O\",\n      \"D\": \"8 cmH2O\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin definition standardizes the assessment of oxygenation impairment by requiring a minimum PEEP of 5 cmH2O (or CPAP) when measuring the PaO2/FiO2 ratio. This ensures a consistent baseline for evaluating lung recruitment and oxygenation efficiency, making the ratio more comparable.\",\n    \"highYieldPearl\": \"A PEEP of ≥ 5 cmH2O is essential for accurate and standardized PaO2/FiO2 assessment in ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Other values might seem plausible, but 5 cmH2O is the specific threshold mandated by the Berlin criteria for ratio assessment.\"\n  },\n  {\n    \"question\": \"A PaO2/FiO2 ratio between 200 and 300 mmHg with PEEP ≥ 5 cmH2O defines which ARDS severity?\",\n    \"options\": {\n      \"A\": \"Mild\",\n      \"B\": \"Moderate\",\n      \"C\": \"Severe\",\n      \"D\": \"Critical\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin criteria classify ARDS into three severity categories based on the PaO2/FiO2 ratio, always with a minimum PEEP of 5 cmH2O: Mild (200-300 mmHg), Moderate (100-200 mmHg), and Severe (<100 mmHg).\",\n    \"highYieldPearl\": \"Recall the specific PaO2/FiO2 ranges for each ARDS severity classification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This question directly tests recall of the severity classifications, which are fundamental to the Berlin criteria.\"\n  },\n  {\n    \"question\": \"A PaO2/FiO2 ratio between 100 and 200 mmHg with PEEP ≥ 5 cmH2O defines which ARDS severity?\",\n    \"options\": {\n      \"A\": \"Mild\",\n      \"B\": \"Moderate\",\n      \"C\": \"Severe\",\n      \"D\": \"Very Severe\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"As per the Berlin Definition, Moderate ARDS is characterized by a PaO2/FiO2 ratio between 100 mmHg and 200 mmHg, while on a minimum PEEP of 5 cmH2O. This indicates a significant impairment in oxygenation requiring closer monitoring and management.\",\n    \"highYieldPearl\": \"Knowing the exact cutoff for Moderate ARDS (100-200 mmHg) is crucial for classification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Similar to the Mild ARDS question, this tests precise recall of the PaO2/FiO2 ranges for severity classification.\"\n  },\n  {\n    \"question\": \"What PaO2/FiO2 ratio defines Severe ARDS when assessed with PEEP ≥ 5 cmH2O?\",\n    \"options\": {\n      \"A\": \"< 300 mmHg\",\n      \"B\": \"< 200 mmHg\",\n      \"C\": \"< 100 mmHg\",\n      \"D\": \"< 50 mmHg\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"Severe ARDS, according to the Berlin criteria, is diagnosed when the PaO2/FiO2 ratio is less than 100 mmHg, measured with a PEEP of at least 5 cmH2O. This signifies profound hypoxemia and is associated with higher mortality.\",\n    \"highYieldPearl\": \"The threshold for severe ARDS (<100 mmHg) is a critical prognostic indicator and guides management decisions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options are decreasing values, testing the exact severe ARDS cutoff. Misremembering the precise threshold can lead to misclassification.\"\n  },\n  {\n    \"question\": \"In ARDS diagnosis, what condition must be ruled out as the sole explanation for hypoxemia and bilateral opacities?\",\n    \"options\": {\n      \"A\": \"Asthma exacerbation\",\n      \"B\": \"COPD flare\",\n      \"C\": \"Cardiac failure\",\n      \"D\": \"Pneumothorax\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin criteria emphasize that the respiratory failure must not be fully explained by cardiac failure or fluid overload. If there is objective evidence of cardiac failure (e.g., echocardiogram showing left atrial hypertension, elevated BNP), additional assessment is needed to differentiate from ARDS or determine if ARDS is co-occurring.\",\n    \"highYieldPearl\": \"Exclusion of cardiogenic pulmonary edema as the *sole* cause is a cornerstone of ARDS diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Other options are respiratory conditions but are not the primary differential for the *origin of edema* that ARDS criteria specifically address.\"\n  },\n  {\n    \"question\": \"The primary purpose of the Berlin criteria's PEEP requirement for PaO2/FiO2 calculation is to ensure what?\",\n    \"options\": {\n      \"A\": \"Lung protection\",\n      \"B\": \"Standardized oxygenation assessment\",\n      \"C\": \"Recruitment maneuver\",\n      \"D\": \"Reduced cardiac output\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"Requiring a minimum PEEP of 5 cmH2O ensures that the PaO2/FiO2 ratio is assessed under conditions that minimize atelectasis and optimize gas exchange, making the ratio a more reliable and comparable measure across patients and studies. It standardizes the measurement of oxygenation impairment.\",\n    \"highYieldPearl\": \"The PEEP minimum in the criteria is for standardization of oxygenation assessment, not just therapeutic effects.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Lung protection and recruitment are important benefits of PEEP, but the *primary reason* for its inclusion in the *diagnostic criteria* is to standardize the PaO2/FiO2 ratio for consistent severity classification.\"\n  },\n  {\n    \"question\": \"Which of the following is NOT an imaging modality acceptable for diagnosing bilateral opacities in ARDS per Berlin criteria?\",\n    \"options\": {\n      \"A\": \"Chest X-Ray\",\n      \"B\": \"CT scan\",\n      \"C\": \"Lung Ultrasound\",\n      \"D\": \"MRI Chest\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ards_definition\",\n    \"deepDiveExplanation\": \"The Berlin criteria state that bilateral opacities can be identified on chest X-ray, CT scan, or lung ultrasound. While MRI can visualize lung pathology, it is not explicitly listed or commonly used for routine ARDS diagnosis due to practical limitations, cost, and less utility for diffuse alveolar damage compared to CT or X-ray.\",\n    \"highYieldPearl\": \"Know the three accepted imaging modalities for ARDS diagnostic criteria: X-ray, CT, and Ultrasound.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"MRI is a valid imaging technique but is not specifically mentioned or commonly utilized within the Berlin criteria for ARDS diagnosis, making it the 'not acceptable' option in this context.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-824.0604858398438}],"createTime":"2025-12-31T07:46:21.553719Z","modelVersion":"gemini-2.5-flash","responseId":"zdRUafflIfK53NoPy4ivuQM","usageMetadata":{"billablePromptUsage":{"textCount":1039},"candidatesTokenCount":2549,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2549}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2773,"totalTokenCount":5687,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:25.415611+00:00"}
{"metadata":"one-liner|lights_criteria|Transudative vs Exudative (Light's Criteria)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Transudative vs Exudative (Light's Criteria)\".\nSet the \"topic\" field in the JSON to \"lights_criteria\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.33709176136002894,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which parameter is NOT part of the standard Light's Criteria for classifying pleural effusions?\",\n    \"options\": {\n      \"A\": \"Pleural fluid protein/serum protein ratio\",\n      \"B\": \"Pleural fluid LDH/serum LDH ratio\",\n      \"C\": \"Pleural fluid glucose level\",\n      \"D\": \"Pleural fluid LDH concentration\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"Light's criteria include Pleural fluid protein/serum protein ratio > 0.5, Pleural fluid LDH/serum LDH ratio > 0.6, and Pleural fluid LDH > 2/3 upper limit of normal serum LDH. Pleural fluid glucose is important for complicated parapneumonic effusions but not for the initial transudate/exudate classification by Light's.\",\n    \"highYieldPearl\": \"Remember the three specific ratios/values that define an exudate. Glucose is for infection, not initial classification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse general pleural fluid analysis parameters with the specific components of Light's Criteria. Glucose is a common pleural fluid test but not a Light's criterion.\"\n  },\n  {\n    \"question\": \"A pleural effusion is classified as an exudate if it meets how many of Light's Criteria?\",\n    \"options\": {\n      \"A\": \"Exactly one\",\n      \"B\": \"At least one\",\n      \"C\": \"At least two\",\n      \"D\": \"All three\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"According to Light's Criteria, an effusion is considered an exudate if it meets even a single one of the three criteria. If none are met, it is a transudate.\",\n    \"highYieldPearl\": \"An effusion is an exudate if it satisfies 'at least one' of Light's criteria.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misunderstanding the 'or' condition within Light's criteria can lead to selecting 'All three' or 'At least two'.\"\n  },\n  {\n    \"question\": \"A pleural effusion is classified as a transudate if it meets how many of Light's Criteria?\",\n    \"options\": {\n      \"A\": \"None of\",\n      \"B\": \"Exactly one\",\n      \"C\": \"At least two\",\n      \"D\": \"All three\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"A pleural effusion is defined as a transudate if it fails to meet any of the three Light's Criteria. This implies low protein and LDH content, reflecting systemic rather than local pathology.\",\n    \"highYieldPearl\": \"Transudates meet 'none' of Light's criteria.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Could be confused with the exudate definition if not careful, leading to selection of options other than 'none'.\"\n  },\n  {\n    \"question\": \"According to Light's Criteria, an exudate is suggested if the pleural fluid protein to serum protein ratio exceeds what value?\",\n    \"options\": {\n      \"A\": \"0.3\",\n      \"B\": \"0.4\",\n      \"C\": \"0.5\",\n      \"D\": \"0.6\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"One of Light's Criteria for an exudate is a pleural fluid protein to serum protein ratio > 0.5. This ratio reflects increased protein leakage into the pleural space due to inflammation or altered capillary permeability.\",\n    \"highYieldPearl\": \"The protein ratio cutoff for an exudate is 0.5.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Remembering specific cutoff values can be challenging. Other ratios (like LDH) have different cutoffs, which might lead to confusion.\"\n  },\n  {\n    \"question\": \"An exudate is indicated by a pleural fluid LDH level greater than what fraction of the upper limit of normal for serum LDH?\",\n    \"options\": {\n      \"A\": \"1/3\",\n      \"B\": \"1/2\",\n      \"C\": \"2/3\",\n      \"D\": \"3/4\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"One of Light's Criteria is a pleural fluid LDH level greater than 2/3 (or approximately 0.67) the upper limit of normal for serum LDH. This indicates increased cellular damage or inflammation in the pleural space.\",\n    \"highYieldPearl\": \"The LDH fraction cutoff is 2/3 or 0.67.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Recalling the exact fraction (2/3) versus other common fractions or decimal values can be tricky under exam pressure.\"\n  },\n  {\n    \"question\": \"Impaired lymphatic drainage of the pleural space primarily contributes to which type of pleural effusion?\",\n    \"options\": {\n      \"A\": \"Transudative\",\n      \"B\": \"Exudative\",\n      \"C\": \"Chylous\",\n      \"D\": \"Hemorrhagic\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"Impaired lymphatic drainage, often due to malignancy or inflammation, leads to accumulation of protein-rich fluid in the pleural space, classifying the effusion as an exudate.\",\n    \"highYieldPearl\": \"Exudates are due to local factors like increased capillary permeability or decreased lymphatic drainage. Transudates are due to systemic factors.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While chylous effusions involve lymphatic issues, the primary classification based on protein/LDH is exudative. The question asks about the general 'type' of effusion, not specific causes of lymphatic impairment.\"\n  },\n  {\n    \"question\": \"Decreased plasma oncotic pressure is the main pathophysiological mechanism for which type of pleural effusion?\",\n    \"options\": {\n      \"A\": \"Exudative\",\n      \"B\": \"Transudative\",\n      \"C\": \"Parapneumonic\",\n      \"D\": \"Malignant\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"Decreased plasma oncotic pressure (e.g., in cirrhosis, nephrotic syndrome) or increased hydrostatic pressure (e.g., in heart failure) are the hallmarks of transudative effusions, where fluid leaks due to systemic imbalances rather than local pleural pathology.\",\n    \"highYieldPearl\": \"Transudates arise from systemic factors like altered hydrostatic or oncotic pressure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing systemic (transudate) vs. local (exudate) causes of pleural effusions.\"\n  },\n  {\n    \"question\": \"Light's Criteria may inaccurately classify a transudate as an exudate in patients with what clinical scenario?\",\n    \"options\": {\n      \"A\": \"Nephrotic syndrome\",\n      \"B\": \"Cirrhosis with ascites\",\n      \"C\": \"Congestive heart failure on diuretics\",\n      \"D\": \"Hypothyroidism\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"Diuretic therapy in CHF patients can concentrate pleural fluid protein and LDH, causing a true transudate to meet one or more of Light's criteria, leading to misclassification as an exudate (a 'pseudoexudate').\",\n    \"highYieldPearl\": \"CHF on diuretics is the classic exception where Light's criteria can fail, leading to false exudate classification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Students might think other transudative causes are more likely to be misclassified, but diuretic use is the specific confounder for Light's in CHF.\"\n  },\n  {\n    \"question\": \"Light's Criteria are highly sensitive for detecting exudates but have limited specificity, meaning they can misclassify what?\",\n    \"options\": {\n      \"A\": \"Exudates as transudates\",\n      \"B\": \"Transudates as exudates\",\n      \"C\": \"Chylous effusions as complicated\",\n      \"D\": \"Hemorrhagic effusions as transudates\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"The high sensitivity of Light's Criteria means few exudates are missed. However, the limited specificity implies that some true transudates (especially those concentrated by diuretic therapy) might be incorrectly identified as exudates.\",\n    \"highYieldPearl\": \"High sensitivity, low specificity means Light's criteria are good at finding exudates, but sometimes 'over-call' transudates as exudates.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Confusing sensitivity and specificity definitions or their implications in the context of Light's Criteria.\"\n  },\n  {\n    \"question\": \"For pleural effusions misclassified by Light's Criteria due to diuretic use, which gradient helps reclassify them as transudates?\",\n    \"options\": {\n      \"A\": \"Pleural fluid glucose\",\n      \"B\": \"Serum-effusion albumin gradient\",\n      \"C\": \"Pleural fluid amylase\",\n      \"D\": \"Serum-effusion cholesterol gradient\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lights_criteria\",\n    \"deepDiveExplanation\": \"A serum-effusion albumin gradient (> 1.2 g/dL) is often used to reclassify effusions as transudates, particularly in cases of CHF on diuretics where Light's Criteria may falsely identify them as exudates due to concentration.\",\n    \"highYieldPearl\": \"The serum-effusion albumin gradient is crucial for reclassifying diuretic-induced 'pseudoexudates' back to transudates.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Difficult\",\n    \"trapAnalysis\": \"Knowing the specific alternative criteria used for this particular limitation of Light's. Other options are for different types of effusions or not relevant for this specific reclassification.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-829.5828247070313}],"createTime":"2025-12-31T07:45:40.763642Z","modelVersion":"gemini-2.5-flash","responseId":"pNRUafrNLt_2nvgPyOfVsAE","usageMetadata":{"billablePromptUsage":{"textCount":1047},"candidatesTokenCount":2461,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2461}],"promptTokenCount":371,"promptTokensDetails":[{"modality":"TEXT","tokenCount":371}],"thoughtsTokenCount":3525,"totalTokenCount":6357,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:10.897072+00:00"}
{"metadata":"one-liner|sarcoidosis|Sarcoidosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Sarcoidosis\".\nSet the \"topic\" field in the JSON to \"sarcoidosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.238956913803563,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The histological hallmark of sarcoidosis is the presence of?\",\n    \"options\": {\n      \"A\": \"Caseating granulomas\",\n      \"B\": \"Non-caseating granulomas\",\n      \"C\": \"Necrotizing vasculitis\",\n      \"D\": \"Lymphocytic interstitial pneumonia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Sarcoidosis is characterized by the presence of non-caseating (non-necrotizing) granulomas in affected tissues. These granulomas are composed of epithelioid cells, multinucleated giant cells, and lymphocytes. The absence of central necrosis is a key feature distinguishing sarcoid granulomas from those seen in tuberculosis or fungal infections.\",\n    \"highYieldPearl\": \"Non-caseating granulomas are central to sarcoidosis diagnosis, but also seen in Crohn's disease, primary biliary cholangitis, and berylliosis, requiring careful clinical correlation and exclusion of other causes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Option A (Caseating granulomas) is the classic hallmark of tuberculosis, a major differential diagnosis for sarcoidosis. Distinguishing between caseating and non-caseating granulomas is crucial for diagnosis.\"\n  },\n  {\n    \"question\": \"Elevated serum angiotensin-converting enzyme (ACE) levels in sarcoidosis correlate best with?\",\n    \"options\": {\n      \"A\": \"Disease activity\",\n      \"B\": \"Lung fibrosis\",\n      \"C\": \"Extrapulmonary involvement\",\n      \"D\": \"Response to therapy\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Serum ACE levels are elevated in approximately 60-80% of patients with active sarcoidosis, particularly in those with a high granuloma burden. ACE is produced by epithelioid cells within the granulomas. While not diagnostic on its own, elevated ACE often reflects active disease and can be used to monitor disease activity and treatment response, though its utility is limited by low sensitivity and specificity.\",\n    \"highYieldPearl\": \"Serum ACE is a supportive marker of sarcoidosis activity but is neither sensitive nor specific enough for diagnosis. It can be normal in active disease and elevated in other conditions like Gaucher's disease or hyperthyroidism.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While ACE levels can decrease with effective therapy (suggesting response), its primary correlation is with the underlying inflammatory activity. It does not directly correlate with the degree of lung fibrosis, and while extrapulmonary involvement contributes to activity, 'disease activity' is the overarching concept.\"\n  },\n  {\n    \"question\": \"Bilateral hilar lymphadenopathy without parenchymal involvement on chest X-ray corresponds to which Scadding stage of sarcoidosis?\",\n    \"options\": {\n      \"A\": \"Stage 0\",\n      \"B\": \"Stage I\",\n      \"C\": \"Stage II\",\n      \"D\": \"Stage III\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"The Scadding stages categorize pulmonary sarcoidosis based on chest X-ray findings: Stage 0 (normal CXR), Stage I (bilateral hilar lymphadenopathy only), Stage II (bilateral hilar lymphadenopathy with parenchymal infiltrates), Stage III (parenchymal infiltrates without hilar lymphadenopathy), and Stage IV (pulmonary fibrosis). Stage I has the highest rate of spontaneous remission.\",\n    \"highYieldPearl\": \"Scadding staging is a prognostic indicator, not a measure of disease severity. Stage I sarcoidosis has the best prognosis, with up to 90% spontaneous resolution.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing the stages is a common error. Stage 0 is a normal CXR, Stage II includes parenchymal involvement, and Stage III involves parenchymal disease without hilar lymphadenopathy, making Stage I the correct answer for isolated hilar lymphadenopathy.\"\n  },\n  {\n    \"question\": \"The most common cutaneous manifestation of sarcoidosis is?\",\n    \"options\": {\n      \"A\": \"Erythema nodosum\",\n      \"B\": \"Lupus pernio\",\n      \"C\": \"Maculopapular rash\",\n      \"D\": \"Subcutaneous nodules\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Erythema nodosum (EN) is the most common acute cutaneous manifestation of sarcoidosis, often presenting as painful, tender, red nodules on the shins. It is a non-specific inflammatory reaction associated with acute sarcoidosis, particularly Lofgren's syndrome, and generally indicates a good prognosis. Lupus pernio, while highly specific for sarcoidosis, is a chronic manifestation and less common overall.\",\n    \"highYieldPearl\": \"Erythema nodosum is a marker of acute sarcoidosis and often correlates with a favorable prognosis, particularly when part of Lofgren's syndrome. Lupus pernio, however, indicates chronic, often severe disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Lupus pernio (Option B) is highly specific for sarcoidosis and often associated with chronic, severe disease, but it is not the most *common* cutaneous manifestation. Maculopapular rash and subcutaneous nodules are also seen but less frequently than erythema nodosum.\"\n  },\n  {\n    \"question\": \"First-line treatment for symptomatic pulmonary sarcoidosis is typically?\",\n    \"options\": {\n      \"A\": \"Methotrexate\",\n      \"B\": \"Infliximab\",\n      \"C\": \"Oral corticosteroids\",\n      \"D\": \"Hydroxychloroquine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Oral corticosteroids, such as prednisone, are the cornerstone of treatment for symptomatic pulmonary sarcoidosis and other severe manifestations. Treatment is typically initiated for progressive lung disease, significant extrapulmonary involvement (e.g., cardiac, neurological, ocular), or debilitating symptoms. Other agents like methotrexate, azathioprine, or biologics are considered for steroid-sparing effects or refractory disease.\",\n    \"highYieldPearl\": \"Initiate corticosteroids for symptomatic sarcoidosis, particularly if affecting vital organs or causing significant functional impairment. The goal is to control inflammation and prevent irreversible organ damage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A, B, and D are all steroid-sparing agents or biologics used in sarcoidosis, but they are typically reserved for patients who are refractory to corticosteroids, cannot tolerate them, or require a steroid-sparing approach. Oral corticosteroids remain the first-line therapy.\"\n  },\n  {\n    \"question\": \"The triad of bilateral hilar lymphadenopathy, erythema nodosum, and polyarthralgia defines which sarcoidosis syndrome?\",\n    \"options\": {\n      \"A\": \"Heerfordt's syndrome\",\n      \"B\": \"Lofgren's syndrome\",\n      \"C\": \"Mikulicz's syndrome\",\n      \"D\": \"Sjögren's syndrome\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Lofgren's syndrome is an acute presentation of sarcoidosis characterized by the classic triad of bilateral hilar lymphadenopathy, erythema nodosum, and polyarthralgia (often ankle periarthritis). It generally has a benign course with a high rate of spontaneous remission and a good prognosis. Heerfordt's syndrome (uveoparotid fever) involves fever, parotid enlargement, anterior uveitis, and facial nerve palsy.\",\n    \"highYieldPearl\": \"Lofgren's syndrome is a classic acute presentation of sarcoidosis with a favorable prognosis and high likelihood of spontaneous resolution, often requiring only symptomatic treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Heerfordt's syndrome (Option A) is another specific sarcoidosis syndrome, but its features (uveitis, parotid enlargement, facial palsy, fever) are distinct from Lofgren's. Mikulicz's and Sjögren's are unrelated or differential diagnoses.\"\n  },\n  {\n    \"question\": \"Hypercalcemia in sarcoidosis results from which mechanism?\",\n    \"options\": {\n      \"A\": \"Increased parathyroid hormone\",\n      \"B\": \"Increased calcitonin\",\n      \"C\": \"Increased 1-alpha hydroxylase activity\",\n      \"D\": \"Decreased vitamin D receptor sensitivity\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"The granulomas in sarcoidosis contain macrophages that express 1-alpha hydroxylase, an enzyme that converts inactive 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D (calcitriol). This unregulated production of calcitriol leads to increased intestinal calcium absorption and bone resorption, resulting in hypercalcemia and hypercalciuria, independent of parathyroid hormone levels.\",\n    \"highYieldPearl\": \"Hypercalcemia in sarcoidosis is due to extrarenal production of calcitriol by activated macrophages within granulomas, leading to PTH-independent vitamin D overproduction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Primary hyperparathyroidism (Option A) also causes hypercalcemia but is characterized by elevated PTH. In sarcoidosis, PTH levels are typically suppressed or normal. Calcitonin (Option B) lowers calcium. Decreased vitamin D receptor sensitivity (Option D) would lead to hypocalcemia, not hypercalcemia.\"\n  },\n  {\n    \"question\": \"Confirmation of sarcoidosis diagnosis typically requires which combination?\",\n    \"options\": {\n      \"A\": \"Clinical features + imaging + elevated ACE\",\n      \"B\": \"Clinical features + imaging + biopsy\",\n      \"C\": \"Clinical features + imaging + positive Kveim test\",\n      \"D\": \"Clinical features + imaging + serum calcium\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"The definitive diagnosis of sarcoidosis generally requires a compatible clinical picture, characteristic radiological findings (e.g., bilateral hilar lymphadenopathy), and histopathological evidence of non-caseating granulomas from an involved organ, after excluding other granulomatous diseases. While elevated ACE and hypercalcemia are supportive, they are not diagnostic. The Kveim test is historical and no longer used.\",\n    \"highYieldPearl\": \"Diagnosis of sarcoidosis is one of exclusion; histological confirmation of non-caseating granulomas is essential, but only in the context of typical clinical and radiological features and after ruling out other causes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Elevated ACE (A) and serum calcium (D) are supportive but not diagnostic. The Kveim test (C) is an old skin test, no longer used due to lack of standardization and availability. Biopsy (B) provides the definitive histological evidence.\"\n  },\n  {\n    \"question\": \"Which Scadding stage of sarcoidosis is most likely to resolve spontaneously?\",\n    \"options\": {\n      \"A\": \"Stage 0\",\n      \"B\": \"Stage I\",\n      \"C\": \"Stage II\",\n      \"D\": \"Stage III\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Stage I sarcoidosis, characterized by bilateral hilar lymphadenopathy without parenchymal involvement, has the highest rate of spontaneous remission, occurring in up to 90% of cases. Spontaneous remission rates decrease with increasing stages, with Stage II resolving in 50-70% and Stage III in 10-30% of cases. Stage 0 implies no radiological disease, so there's nothing to resolve.\",\n    \"highYieldPearl\": \"Spontaneous resolution is common in Stage I sarcoidosis, often negating the need for systemic corticosteroid therapy unless severe symptoms or extrapulmonary involvement are present.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While Stage 0 technically has no disease to resolve, Stage I is the first stage with active disease that shows the highest rate of spontaneous resolution. Stages II and III have progressively lower rates of spontaneous remission, making Stage I the best answer.\"\n  },\n  {\n    \"question\": \"The most common neurological manifestation of neurosarcoidosis is?\",\n    \"options\": {\n      \"A\": \"Cranial nerve palsy\",\n      \"B\": \"Seizures\",\n      \"C\": \"Peripheral neuropathy\",\n      \"D\": \"Aseptic meningitis\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"sarcoidosis\",\n    \"deepDiveExplanation\": \"Cranial neuropathies are the most frequent neurological manifestation of neurosarcoidosis, occurring in 50-75% of neurosarcoidosis patients. The facial nerve (CN VII) is most commonly affected, often bilaterally, leading to Bell's palsy-like symptoms. Aseptic meningitis is also common, but cranial nerve palsies are the single most frequent presentation.\",\n    \"highYieldPearl\": \"Facial nerve palsy (often bilateral) is the hallmark neurological presentation of sarcoidosis. Neurosarcoidosis can mimic many other neurological conditions, requiring a high index of suspicion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While aseptic meningitis (D) and peripheral neuropathy (C) are common in neurosarcoidosis, cranial nerve palsies, particularly facial nerve palsy, are cited as the single most frequent manifestation. Seizures (B) are less common than other manifestations.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-757.0155029296875}],"createTime":"2025-12-31T07:46:32.675829Z","modelVersion":"gemini-2.5-flash","responseId":"2NRUafWfKdrThMIP1dG5yAs","usageMetadata":{"billablePromptUsage":{"textCount":1014},"candidatesTokenCount":3168,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3168}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":1369,"totalTokenCount":4899,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:48:23.76545+00:00"}
{"metadata":"one-liner|pneumothorax|Pneumothorax|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Pneumothorax\".\nSet the \"topic\" field in the JSON to \"pneumothorax\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4002189370145054,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most sensitive imaging modality for detecting a small pneumothorax, especially in supine patients, is?\",\n    \"options\": {\n      \"A\": \"Chest X-Ray\",\n      \"B\": \"CT Thorax\",\n      \"C\": \"Ultrasound\",\n      \"D\": \"MRI Chest\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumothorax\",\n    \"deepDiveExplanation\": \"Point-of-care ultrasound (POCUS) has emerged as a highly sensitive and specific tool for diagnosing pneumothorax, particularly in emergency settings and for small or occult pneumothoraces. It can detect the absence of 'lung sliding' and the 'barcode sign' in M-mode, which are pathognomonic for pneumothorax. While CT Thorax is the gold standard for definitive anatomical detail, ultrasound is more sensitive than plain chest X-ray for small pneumothoraces and can be performed at the bedside.\",\n    \"highYieldPearl\": \"Lung ultrasound is more sensitive than supine chest X-ray for detecting pneumothorax and is crucial in trauma settings (E-FAST protocol) or critically ill patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Many might choose Chest X-Ray as the initial diagnostic, or CT Thorax as the 'gold standard' for imaging. However, for 'most sensitive' and 'bedside' detection, ultrasound surpasses CXR, especially for small or occult pneumothoraces in non-erect patients.\"\n  },\n  {\n    \"question\": \"In primary spontaneous pneumothorax, the recommended initial intervention for a large pneumothorax (>2 cm at hilum) with minimal or no symptoms is?\",\n    \"options\": {\n      \"A\": \"Observation\",\n      \"B\": \"Simple aspiration\",\n      \"C\": \"Small bore chest tube insertion\",\n      \"D\": \"Large bore chest tube insertion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumothorax\",\n    \"deepDiveExplanation\": \"According to British Thoracic Society (BTS) guidelines and American College of Chest Physicians (ACCP) consensus, for a primary spontaneous pneumothorax (PSP) larger than 2 cm (measured from the lung apex to the cupola or at the hilum), simple aspiration is the recommended initial management if the patient is minimally symptomatic or asymptomatic. If aspiration fails, then a small-bore chest tube is indicated. Observation is for small, asymptomatic PSPs (<2cm).\",\n    \"highYieldPearl\": \"Simple aspiration is the first-line intervention for large PSPs in stable, minimally symptomatic patients, before considering chest tube insertion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Students might immediately think of chest tube for a 'large' pneumothorax. However, guidelines specifically recommend simple aspiration as the initial step for stable, large PSPs, reserving chest tubes for aspiration failure or symptomatic patients.\"\n  },\n  {\n    \"question\": \"Tension pneumothorax results from a one-way valve effect causing air accumulation in the pleural space, leading to mediastinal shift and impaired...\",\n    \"options\": {\n      \"A\": \"Systemic vascular resistance\",\n      \"B\": \"Cardiac output\",\n      \"C\": \"Pulmonary vascular resistance\",\n      \"D\": \"Renal blood flow\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumothorax\",\n    \"deepDiveExplanation\": \"In tension pneumothorax, air enters the pleural space during inspiration but cannot exit during expiration, leading to progressive air accumulation. This positive pressure compresses the ipsilateral lung and shifts the mediastinum, kinking the great veins (superior and inferior vena cava). This kinking significantly reduces venous return to the heart, directly impairing cardiac preload and consequently leading to a drastic fall in cardiac output and hemodynamic collapse.\",\n    \"highYieldPearl\": \"The life-threatening consequence of tension pneumothorax is obstructive shock due to decreased venous return and subsequent reduction in cardiac output.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other options might be indirectly affected, the primary and immediate life-threatening physiological impairment in tension pneumothorax is the reduction in cardiac output due to decreased venous return.\"\n  },\n  {\n    \"question\": \"The most definitive surgical intervention for preventing recurrence of primary spontaneous pneumothorax is?\",\n    \"options\": {\n      \"A\": \"Chemical pleurodesis\",\n      \"B\": \"Talc pleurodesis\",\n      \"C\": \"VATS pleurectomy\",\n      \"D\": \"Simple aspiration\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumothorax\",\n    \"deepDiveExplanation\": \"For patients with recurrent primary spontaneous pneumothorax or those at high risk (e.g., specific professions), definitive preventive measures are indicated. Surgical pleurodesis, particularly VATS (Video-Assisted Thoracoscopic Surgery) pleurectomy, involves removing the parietal pleura, which is generally considered the most effective method for preventing recurrence with a very low recurrence rate (1-5%). Chemical pleurodesis (e.g., with talc, doxycycline) is also definitive but typically has a higher recurrence rate than surgical pleurectomy.\",\n    \"highYieldPearl\": \"VATS pleurectomy offers the lowest recurrence rate for PSP, making it the most definitive surgical option.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Chemical pleurodesis (including talc) is also a definitive treatment, but VATS pleurectomy (mechanical pleurodesis) typically has a superior efficacy in preventing recurrence, making it the 'most definitive surgical intervention'.\"\n  },\n  {\n    \"question\": \"Birt-Hogg-Dube syndrome is associated with an increased risk of which type of pneumothorax?\",\n    \"options\": {\n      \"A\": \"Traumatic\",\n      \"B\": \"Iatrogenic\",\n      \"C\": \"Secondary spontaneous\",\n      \"D\": \"Primary spontaneous\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pneumothorax\",\n    \"deepDiveExplanation\": \"Birt-Hogg-Dube (BHD) syndrome is an autosomal dominant disorder characterized by skin fibrofolliculomas, renal cell carcinoma, and pulmonary cysts. These pulmonary cysts (often multiple and bilateral, located predominantly in the lower lobes) predispose patients to recurrent primary spontaneous pneumothorax. It is a key genetic syndrome to consider in patients with recurrent PSP.\",\n    \"highYieldPearl\": \"Think Birt-Hogg-Dube syndrome in patients with recurrent primary spontaneous pneumothorax, especially if associated with skin lesions or renal tumors.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This question tests knowledge of specific genetic syndromes linked to lung disease. While other types of pneumothorax exist, BHD syndrome specifically increases the risk of primary spontaneous pneumothorax due to structural lung abnormalities (cysts).\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-631.145263671875}],"createTime":"2025-12-31T07:45:40.749410Z","modelVersion":"gemini-2.5-flash","responseId":"pNRUaeLeLaq2698P386OQA","usageMetadata":{"billablePromptUsage":{"textCount":1015},"candidatesTokenCount":1577,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1577}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":1230,"totalTokenCount":3169,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:08.484399+00:00"}
{"metadata":"one-liner|lung_pregnancy|Lung in Pregnancy|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung in Pregnancy\".\nSet the \"topic\" field in the JSON to \"lung_pregnancy\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.49612058263246706,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which pulmonary physiological parameter significantly decreases during normal pregnancy?\",\n    \"options\": {\n      \"A\": \"Tidal Volume\",\n      \"B\": \"Minute Ventilation\",\n      \"C\": \"Inspiratory Capacity\",\n      \"D\": \"Functional Residual Capacity\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_pregnancy\",\n    \"deepDiveExplanation\": \"During pregnancy, the enlarging uterus elevates the diaphragm, leading to a reduction in residual volume (RV) and expiratory reserve volume (ERV). The sum of RV and ERV is the Functional Residual Capacity (FRC), which consequently decreases by approximately 20-25%. This reduction is compensated by an increase in tidal volume and minute ventilation to meet increased oxygen demands.\",\n    \"highYieldPearl\": \"The decrease in FRC during pregnancy predisposes pregnant women to earlier desaturation during apnea and rapid atelectasis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Tidal volume and minute ventilation *increase* during pregnancy. Inspiratory capacity may remain unchanged or slightly increase. The key change is the decrease in FRC, RV, and ERV due to diaphragmatic elevation.\"\n  },\n  {\n    \"question\": \"Which anti-tuberculous drug is absolutely contraindicated in pregnancy due to its teratogenic potential?\",\n    \"options\": {\n      \"A\": \"Isoniazid\",\n      \"B\": \"Rifampicin\",\n      \"C\": \"Ethambutol\",\n      \"D\": \"Streptomycin\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_pregnancy\",\n    \"deepDiveExplanation\": \"Streptomycin is an aminoglycoside antibiotic that crosses the placenta and is known to cause irreversible ototoxicity (vestibular and auditory damage) in the fetus. Therefore, it is absolutely contraindicated during pregnancy. First-line drugs like Isoniazid, Rifampicin, and Ethambutol are generally considered safe and recommended for treating TB in pregnant women.\",\n    \"highYieldPearl\": \"While Pyrazinamide's safety in pregnancy was historically debated, current guidelines (e.g., WHO, CDC) generally consider it safe and recommend its use in pregnant women with TB, especially for drug-sensitive TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Isoniazid, Rifampicin, and Ethambutol are cornerstone drugs for TB treatment and are considered safe during pregnancy. Pyrazinamide is also generally considered safe. Streptomycin is the clear contraindication due to fetal ototoxicity.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-291.7189025878906}],"createTime":"2025-12-31T07:45:10.707190Z","modelVersion":"gemini-2.5-flash","responseId":"htRUafaUK8HEnvgPpK-byA8","usageMetadata":{"billablePromptUsage":{"textCount":1020},"candidatesTokenCount":588,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":588}],"promptTokenCount":361,"promptTokensDetails":[{"modality":"TEXT","tokenCount":361}],"thoughtsTokenCount":1284,"totalTokenCount":2233,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:48.996332+00:00"}
{"metadata":"one-liner|bronchoprovocation|Bronchoprovocation Testing|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Bronchoprovocation Testing\".\nSet the \"topic\" field in the JSON to \"bronchoprovocation\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3998509945069286,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"A positive methacholine challenge test is defined by what percentage fall in FEV1 from baseline?\",\n    \"options\": {\n      \"A\": \"10%\",\n      \"B\": \"15%\",\n      \"C\": \"20%\",\n      \"D\": \"25%\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchoprovocation\",\n    \"deepDiveExplanation\": \"The methacholine challenge test assesses airway hyperresponsiveness. A positive test is defined as a 20% fall in FEV1 (PC20 or PD20) from baseline after inhaling a specific cumulative dose of methacholine. This threshold is widely accepted for diagnosing asthma when baseline spirometry is normal.\",\n    \"highYieldPearl\": \"PC20 (Provocative Concentration causing a 20% fall in FEV1) is the critical value for a positive methacholine challenge test.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors represent other arbitrary percentages. Knowing the exact 20% threshold is fundamental for diagnosis and interpretation.\"\n  },\n  {\n    \"question\": \"Which of the following is an absolute contraindication for methacholine challenge testing?\",\n    \"options\": {\n      \"A\": \"Current smoking\",\n      \"B\": \"Pregnancy\",\n      \"C\": \"Recent myocardial infarction (within 3 months)\",\n      \"D\": \"FEV1 65% of predicted\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchoprovocation\",\n    \"deepDiveExplanation\": \"Absolute contraindications for methacholine challenge testing include recent myocardial infarction or stroke (within 3 months), uncontrolled hypertension, aortic aneurysm, FEV1 < 50% predicted or < 1.0 L, and inability to perform spirometry. Pregnancy is a relative contraindication, and FEV1 65% is not an absolute contraindication.\",\n    \"highYieldPearl\": \"Patient safety is paramount; severe cardiovascular or respiratory instability precludes bronchoprovocation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Many conditions are relative contraindications. Distinguishing absolute from relative is crucial. FEV1 < 50% predicted is an absolute contraindication, while FEV1 65% is not.\"\n  },\n  {\n    \"question\": \"Methacholine induces bronchoconstriction primarily by stimulating which receptor type in the airways?\",\n    \"options\": {\n      \"A\": \"Beta-2 adrenergic receptors\",\n      \"B\": \"Muscarinic M3 receptors\",\n      \"C\": \"Histamine H1 receptors\",\n      \"D\": \"Alpha-1 adrenergic receptors\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchoprovocation\",\n    \"deepDiveExplanation\": \"Methacholine is a cholinergic agonist that mimics acetylcholine. It directly stimulates muscarinic M3 receptors located on airway smooth muscle cells, leading to increased intracellular calcium and subsequent bronchoconstriction. This mechanism is central to its use in bronchoprovocation testing.\",\n    \"highYieldPearl\": \"Methacholine's action is via the parasympathetic pathway, directly on muscarinic receptors.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Distractors represent other common receptor types involved in airway physiology. Understanding the specific mechanism of methacholine is key.\"\n  },\n  {\n    \"question\": \"The primary indication for performing a methacholine challenge test is to diagnose asthma in patients with which spirometry finding?\",\n    \"options\": {\n      \"A\": \"Fixed airway obstruction\",\n      \"B\": \"Normal FEV1/FVC ratio and FEV1\",\n      \"C\": \"Restrictive ventilatory defect\",\n      \"D\": \"Significant bronchodilator reversibility\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchoprovocation\",\n    \"deepDiveExplanation\": \"Bronchoprovocation testing is most useful for confirming or excluding a diagnosis of asthma in individuals who have symptoms suggestive of asthma but whose baseline spirometry (FEV1/FVC ratio and FEV1) is within normal limits. If spirometry already shows obstruction or significant reversibility, asthma is often already diagnosed.\",\n    \"highYieldPearl\": \"Bronchoprovocation helps identify airway hyperresponsiveness when routine lung function tests are normal.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The test is less useful if asthma is already evident from spirometry. Its value lies in detecting occult airway hyperresponsiveness.\"\n  },\n  {\n    \"question\": \"What is the immediate management for significant bronchospasm occurring during a methacholine challenge test?\",\n    \"options\": {\n      \"A\": \"Intravenous corticosteroids\",\n      \"B\": \"Nebulized salbutamol\",\n      \"C\": \"Oral antihistamines\",\n      \"D\": \"Supplemental oxygen only\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchoprovocation\",\n    \"deepDiveExplanation\": \"If significant bronchospasm occurs during a methacholine challenge, the immediate and most effective treatment is to administer a short-acting beta-2 agonist (SABA) such as nebulized salbutamol (albuterol). This rapidly reverses the induced bronchoconstriction, ensuring patient safety. All other options are either too slow or ineffective for acute reversal.\",\n    \"highYieldPearl\": \"Always have a bronchodilator readily available for immediate reversal during bronchoprovocation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options are treatments for asthma but not for acute, immediate reversal of induced bronchospasm. The key is rapid action.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-526.603759765625}],"createTime":"2025-12-31T07:45:11.224074Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUacrWDc6RhMIPz6CV4Q8","usageMetadata":{"billablePromptUsage":{"textCount":1034},"candidatesTokenCount":1317,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1317}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1313,"totalTokenCount":2994,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:40.825905+00:00"}
{"metadata":"one-liner|pneumonia_immunocomp|Pneumonia in Immunocompromised Host|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pneumonia in Immunocompromised Host\".\nSet the \"topic\" field in the JSON to \"pneumonia_immunocomp\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.29442825120240834,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Most common cause of pneumonia in HIV patients with CD4 count < 200 cells/mm³?\",\n    \"options\": {\n      \"A\": \"Streptococcus pneumoniae\",\n      \"B\": \"Pneumocystis jirovecii\",\n      \"C\": \"Mycobacterium tuberculosis\",\n      \"D\": \"Haemophilus influenzae\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Pneumocystis jirovecii pneumonia (PCP) is the most common opportunistic infection and cause of pneumonia in HIV-infected individuals, particularly when the CD4 count falls below 200 cells/mm³. While bacterial pneumonias (e.g., S. pneumoniae, H. influenzae) are also common in HIV, their incidence is higher at relatively higher CD4 counts or in other immunocompromised states. M. tuberculosis is also prevalent in HIV but is distinct from PCP.\",\n    \"highYieldPearl\": \"Always consider PCP in HIV patients with respiratory symptoms and CD4 < 200. Imaging often shows bilateral perihilar ground-glass opacities.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distinguishing between the most common opportunistic vs. general bacterial causes in HIV is key. S. pneumoniae is the most common bacterial cause of pneumonia in HIV, but PCP dominates below CD4 200.\"\n  },\n  {\n    \"question\": \"Drug of choice for primary prophylaxis against Pneumocystis jirovecii pneumonia?\",\n    \"options\": {\n      \"A\": \"Dapsone\",\n      \"B\": \"Atovaquone\",\n      \"C\": \"Trimethoprim-sulfamethoxazole\",\n      \"D\": \"Pentamidine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for primary and secondary prophylaxis against PCP due to its efficacy, broad spectrum, and affordability. It is typically initiated when CD4 count drops below 200 cells/mm³ or in other immunocompromised states (e.g., transplant recipients on high-dose steroids). Dapsone, atovaquone, and aerosolized pentamidine are alternative agents for patients intolerant to TMP-SMX.\",\n    \"highYieldPearl\": \"TMP-SMX is the 'go-to' drug for PCP prophylaxis and treatment. Remember the dose: 1 DS tablet daily for prophylaxis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other options are used for PCP prophylaxis, TMP-SMX is consistently the first-line and most effective choice. Knowing the alternatives is important but not for the 'drug of choice' question.\"\n  },\n  {\n    \"question\": \"Characteristic chest imaging finding in Pneumocystis jirovecii pneumonia?\",\n    \"options\": {\n      \"A\": \"Lobar consolidation\",\n      \"B\": \"Cavitary lesion\",\n      \"C\": \"Bilateral perihilar ground-glass opacities\",\n      \"D\": \"Pleural effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"The classic radiographic finding in PCP is bilateral, diffuse, interstitial infiltrates, often described as perihilar or ground-glass opacities on HRCT. These infiltrates result from alveolar inflammation and exudate. Lobar consolidation is more typical of bacterial pneumonia, cavitary lesions suggest tuberculosis, fungal infections, or necrotizing bacterial pneumonia, and pleural effusions are less common in PCP unless there are co-infections.\",\n    \"highYieldPearl\": \"Ground-glass opacities, especially bilateral and perihilar, in an immunocompromised patient with respiratory symptoms strongly suggest PCP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other options represent imaging findings of different types of pneumonia. The key is to associate ground-glass opacities with the interstitial nature of PCP.\"\n  },\n  {\n    \"question\": \"Gold standard for diagnosing Cytomegalovirus (CMV) pneumonia in immunocompromised patients?\",\n    \"options\": {\n      \"A\": \"CMV PCR from blood\",\n      \"B\": \"Bronchoalveolar lavage (BAL) PCR\",\n      \"C\": \"Bronchoalveolar lavage culture\",\n      \"D\": \"Lung biopsy with immunohistochemistry\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"While CMV PCR from blood or BAL can indicate CMV infection, a definitive diagnosis of CMV pneumonia requires histological evidence of viral cytopathic effect (e.g., 'owl's eye' inclusions) and/or positive immunohistochemistry for CMV antigens in lung tissue obtained via biopsy. Isolation of CMV from BAL culture is not sufficient as it can represent colonization without active disease, especially in transplant recipients.\",\n    \"highYieldPearl\": \"CMV viremia/DNAemia indicates infection, but tissue invasion (biopsy) is needed for definitive 'disease' diagnosis, especially for pneumonia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Many clinicians might choose BAL PCR, which indicates CMV presence in the lung. However, in immunocompromised patients, this can be colonization or reactivation without actual pneumonia. The 'gold standard' specifically for pneumonia requires evidence of tissue invasion and inflammation.\"\n  },\n  {\n    \"question\": \"Initial empiric antibiotic for febrile neutropenia with suspected pneumonia?\",\n    \"options\": {\n      \"A\": \"Ceftriaxone\",\n      \"B\": \"Azithromycin\",\n      \"C\": \"Piperacillin-tazobactam\",\n      \"D\": \"Vancomycin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"In febrile neutropenia, rapid empiric broad-spectrum antibiotic therapy is crucial. The initial regimen must cover common Gram-negative bacteria, especially Pseudomonas aeruginosa, which can cause rapidly fatal infections. Piperacillin-tazobactam is a common choice, as are other antipseudomonal beta-lactams (e.g., cefepime, meropenem, imipenem). Vancomycin is typically added only if there is suspicion for MRSA or catheter-related infection, not as initial monotherapy.\",\n    \"highYieldPearl\": \"Empiric therapy for febrile neutropenia must cover Pseudomonas. Monotherapy with an antipseudomonal beta-lactam is often sufficient initially.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Ceftriaxone lacks Pseudomonas coverage. Azithromycin is not broad-spectrum enough for empiric neutropenic fever. Vancomycin is for Gram-positive coverage and is usually an add-on.\"\n  },\n  {\n    \"question\": \"Most frequent invasive fungal pneumonia in solid organ transplant recipients?\",\n    \"options\": {\n      \"A\": \"Cryptococcus neoformans\",\n      \"B\": \"Candida albicans\",\n      \"C\": \"Aspergillus fumigatus\",\n      \"D\": \"Mucor circinelloides\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Invasive aspergillosis, primarily caused by Aspergillus fumigatus, is the most common and deadliest invasive fungal pneumonia in solid organ transplant recipients, particularly lung transplant patients. Candida species are more common causes of bloodstream infections but less frequently cause primary pneumonia. Cryptococcus is seen, but less frequently than Aspergillus, and Mucorales are associated with specific risk factors like diabetes or severe neutropenia.\",\n    \"highYieldPearl\": \"Aspergillus is the leading cause of invasive fungal pneumonia in SOT recipients. Consider it in new pulmonary infiltrates with fever.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While all listed are potential fungal pathogens in immunocompromised hosts, the question specifically asks for the 'most frequent invasive fungal pneumonia' in 'solid organ transplant recipients', pointing clearly to Aspergillus.\"\n  },\n  {\n    \"question\": \"Non-invasive diagnostic marker for invasive aspergillosis in immunocompromised hosts?\",\n    \"options\": {\n      \"A\": \"Serum CRP\",\n      \"B\": \"Procalcitonin\",\n      \"C\": \"Serum Galactomannan\",\n      \"D\": \"Sputum culture\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Serum galactomannan is a cell wall component of Aspergillus species released during invasive infection, making it a valuable non-invasive diagnostic marker for invasive aspergillosis. Beta-D-glucan is another non-specific fungal cell wall component. CRP and procalcitonin are general inflammatory markers. Sputum culture for Aspergillus can be positive due to colonization and lacks specificity for invasive disease.\",\n    \"highYieldPearl\": \"Galactomannan and Beta-D-glucan are crucial non-invasive tests for invasive fungal infections, with galactomannan being more specific for Aspergillus.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Sputum culture for Aspergillus is often a distractor because it can be positive due to colonization, making it not specific for invasive disease. CRP and procalcitonin are non-specific inflammatory markers.\"\n  },\n  {\n    \"question\": \"Adjunctive therapy for severe Pneumocystis jirovecii pneumonia with hypoxia?\",\n    \"options\": {\n      \"A\": \"IVIG\",\n      \"B\": \"Corticosteroids\",\n      \"C\": \"G-CSF\",\n      \"D\": \"Bronchodilators\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Corticosteroids are recommended as adjunctive therapy for moderate to severe PCP (PaO2 < 70 mmHg or A-a gradient > 35 mmHg) to reduce the inflammatory response that contributes to lung injury. They are typically started concurrently with TMP-SMX. IVIG and G-CSF are not indicated for PCP. Bronchodilators are for bronchospasm, not the primary treatment for PCP.\",\n    \"highYieldPearl\": \"Corticosteroids are critical in severe PCP to mitigate the inflammatory damage from dying organisms. Start them promptly with anti-PCP agents.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The key here is 'adjunctive therapy' for 'severe' PCP. While the primary treatment is TMP-SMX, corticosteroids are a well-established and life-saving adjunct in hypoxic patients.\"\n  },\n  {\n    \"question\": \"Common bacterial cause of cavitary pneumonia in chronic granulomatous disease?\",\n    \"options\": {\n      \"A\": \"Staphylococcus aureus\",\n      \"B\": \"Pseudomonas aeruginosa\",\n      \"C\": \"Nocardia asteroides\",\n      \"D\": \"Klebsiella pneumoniae\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Chronic granulomatous disease (CGD) is an inherited immunodeficiency characterized by impaired phagocyte oxidative burst, leading to increased susceptibility to catalase-positive organisms. Nocardia asteroides is a classic cause of cavitary pneumonia and disseminated infection in CGD patients. Staphylococcus aureus and Aspergillus species are also very common. Pseudomonas and Klebsiella are less specific to CGD's unique immune defect.\",\n    \"highYieldPearl\": \"In CGD, think catalase-positive organisms: Nocardia, Staphylococcus aureus, Aspergillus. These often cause granulomatous and cavitary lesions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Staphylococcus aureus is also common in CGD and can cause cavitary lesions, making it a plausible distractor. However, Nocardia is highly characteristic due to its filamentous structure and catalase positivity, and its propensity for cavitary lesions in this specific host.\"\n  },\n  {\n    \"question\": \"Prophylactic antiviral drug for high-risk CMV-seropositive solid organ transplant recipients?\",\n    \"options\": {\n      \"A\": \"Acyclovir\",\n      \"B\": \"Ribavirin\",\n      \"C\": \"Valganciclovir\",\n      \"D\": \"Oseltamivir\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumonia_immunocomp\",\n    \"deepDiveExplanation\": \"Valganciclovir is the drug of choice for CMV prophylaxis in high-risk solid organ transplant recipients (e.g., CMV-seropositive recipient with CMV-seropositive donor, or CMV-seronegative recipient with CMV-seropositive donor). It is a prodrug of ganciclovir, offering good oral bioavailability. Acyclovir is for HSV/VZV, Ribavirin for RSV/HCV, and Oseltamivir for influenza.\",\n    \"highYieldPearl\": \"Valganciclovir is the cornerstone for CMV prevention post-transplant, especially in D+/R- or D+/R+ combinations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are antiviral drugs. The key is knowing which one specifically targets CMV and is used for prophylaxis in transplant settings. Acyclovir is a common distractor but targets herpes simplex and varicella zoster viruses.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-911.5498657226563}],"createTime":"2025-12-31T07:46:19.252343Z","modelVersion":"gemini-2.5-flash","responseId":"y9RUabezD5-0gLUP9frpWA","usageMetadata":{"billablePromptUsage":{"textCount":1044},"candidatesTokenCount":3096,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3096}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":1807,"totalTokenCount":5273,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:06.349861+00:00"}
{"metadata":"one-liner|parapneumonic|Parapneumonic Effusion and Empyema|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Parapneumonic Effusion and Empyema\".\nSet the \"topic\" field in the JSON to \"parapneumonic\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.37993485236615976,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"A pleural fluid pH below which value indicates a complicated parapneumonic effusion requiring drainage?\",\n    \"options\": {\n      \"A\": \"7.0\",\n      \"B\": \"7.1\",\n      \"C\": \"7.2\",\n      \"D\": \"7.3\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"A pleural fluid pH less than 7.2 (or 7.1 in some classifications) is generally considered an indication for drainage in parapneumonic effusions due to increased risk of poor outcome with antibiotics alone. However, a pH less than 7.0 is a more definitive and widely accepted threshold for immediate and aggressive drainage, as it strongly correlates with empyema and poor prognosis without intervention. The low pH is due to bacterial metabolism producing lactic acid and carbon dioxide.\",\n    \"highYieldPearl\": \"pH < 7.0 is a strong indicator for drainage in parapneumonic effusion, signifying a high likelihood of complicated effusion or empyema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options C (7.2) is often cited as a general cut-off for 'complicated' but pH < 7.0 is the more critical and definitive threshold for mandatory drainage due to high risk of empyema and failure of conservative management.\"\n  },\n  {\n    \"question\": \"Which pleural fluid glucose level strongly suggests a complicated parapneumonic effusion or empyema?\",\n    \"options\": {\n      \"A\": \"<60 mg/dL\",\n      \"B\": \"<50 mg/dL\",\n      \"C\": \"<40 mg/dL\",\n      \"D\": \"<20 mg/dL\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"Pleural fluid glucose levels are typically low in complicated parapneumonic effusions and empyema because bacteria and activated inflammatory cells (neutrophils) metabolize glucose. A glucose level less than 40 mg/dL (<2.2 mmol/L) is a classic and highly specific indicator of a complicated effusion requiring drainage. Levels below 60 mg/dL are abnormal but <40 mg/dL is a more definitive marker for intervention.\",\n    \"highYieldPearl\": \"Pleural fluid glucose < 40 mg/dL is a critical marker for complicated parapneumonic effusion/empyema, signaling significant bacterial activity and inflammation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While <60 mg/dL is abnormal, the <40 mg/dL threshold is the most commonly cited and definitive value for complicated parapneumonic effusion/empyema in most guidelines.\"\n  },\n  {\n    \"question\": \"The fibrinopurulent stage of parapneumonic effusion is characterized by which primary process?\",\n    \"options\": {\n      \"A\": \"Unrestricted fluid flow\",\n      \"B\": \"Bacterial invasion of pleura\",\n      \"C\": \"Fibrin deposition and loculation\",\n      \"D\": \"Fibroblast proliferation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"Parapneumonic effusions progress through stages: 1. Exudative (uncomplicated, free-flowing, bacterial invasion), 2. Fibrinopurulent (complicated, bacterial invasion, significant fibrin deposition, formation of septations and loculations), and 3. Organizing (fibroblast proliferation, pleural peel formation). The fibrinopurulent stage is defined by the host's inflammatory response leading to fibrin deposition, which traps bacteria and leukocytes, forming loculations.\",\n    \"highYieldPearl\": \"Fibrinopurulent stage is key for understanding loculation formation and the need for drainage/fibrinolytics.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A refers to the early exudative stage. Option B is common across exudative and fibrinopurulent stages. Option D describes the later organizing stage.\"\n  },\n  {\n    \"question\": \"The most common bacterial genus causing community-acquired empyema in adults is?\",\n    \"options\": {\n      \"A\": \"Staphylococcus\",\n      \"B\": \"Streptococcus\",\n      \"C\": \"Klebsiella\",\n      \"D\": \"Pseudomonas\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"In community-acquired parapneumonic effusions and empyema, Streptococcus species (especially Streptococcus pneumoniae) are the most frequent causative organisms. Staphylococcus aureus is also common, particularly in hospital-acquired infections or IV drug users. Gram-negative bacilli like Klebsiella and Pseudomonas are less common in community-acquired cases but are significant in healthcare-associated or immunocompromised patients.\",\n    \"highYieldPearl\": \"Streptococcus pneumoniae is the leading cause of community-acquired parapneumonic effusions and empyema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Staphylococcus is a close second and very common in hospital-acquired settings, but for community-acquired, Streptococcus generally predominates.\"\n  },\n  {\n    \"question\": \"Which imaging modality is most effective for identifying loculations and guiding drainage in parapneumonic effusion?\",\n    \"options\": {\n      \"A\": \"Chest X-ray\",\n      \"B\": \"Ultrasound\",\n      \"C\": \"CT Thorax with contrast\",\n      \"D\": \"MRI Chest\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"While CT Thorax with contrast provides excellent anatomical detail of the pleura and lung parenchyma, ultrasound is superior for real-time, bedside identification of loculations (septations) within pleural fluid and for guiding thoracentesis or chest tube insertion into accessible pockets. It can differentiate fluid from consolidated lung or solid lesions and assess fluid characteristics dynamically. CT is often used for overall assessment, but ultrasound for specific loculation detection and procedural guidance.\",\n    \"highYieldPearl\": \"Ultrasound is the preferred bedside imaging for detecting loculations and guiding safe drainage in parapneumonic effusions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CT offers more comprehensive anatomical detail, but for *identifying loculations* and *guiding drainage* specifically, ultrasound's real-time capability and portability make it highly effective and often preferred.\"\n  },\n  {\n    \"question\": \"A complicated parapneumonic effusion with pH < 7.2 and positive Gram stain primarily requires which intervention?\",\n    \"options\": {\n      \"A\": \"Oral antibiotics only\",\n      \"B\": \"Therapeutic thoracentesis\",\n      \"C\": \"Chest tube drainage\",\n      \"D\": \"Fibrinolytic instillation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"Complicated parapneumonic effusions, characterized by low pH (<7.2), low glucose (<60 mg/dL), positive Gram stain or culture, or gross pus, require drainage in addition to antibiotics. Chest tube drainage is the primary method for continuous evacuation of infected fluid. Therapeutic thoracentesis may provide temporary relief but is insufficient for sustained drainage of complicated effusions. Fibrinolytics are considered if the chest tube drainage is inadequate due to loculations, after initial tube placement.\",\n    \"highYieldPearl\": \"Chest tube drainage is the cornerstone of management for complicated parapneumonic effusions and empyema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Therapeutic thoracentesis is for symptom relief or diagnostic purposes in uncomplicated effusions. Fibrinolytics are a secondary intervention for loculated effusions *after* chest tube insertion.\"\n  },\n  {\n    \"question\": \"Which pleural fluid characteristic is an absolute indication for immediate chest tube drainage in parapneumonic effusion?\",\n    \"options\": {\n      \"A\": \"LDH > 1000 IU/L\",\n      \"B\": \"Glucose < 60 mg/dL\",\n      \"C\": \"Gross pus\",\n      \"D\": \"Protein > 4.0 g/dL\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"The presence of gross pus in the pleural space, by definition, constitutes an empyema, which is an absolute indication for immediate and aggressive drainage via chest tube. While low glucose and high LDH are indicators of complicated effusion, gross pus is the most definitive and unequivocal finding mandating drainage.\",\n    \"highYieldPearl\": \"Gross pus in the pleural fluid equals empyema, demanding immediate chest tube drainage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options A, B, and D are supportive of an exudate or complicated effusion, but only gross pus (C) is a direct, absolute indication for drainage. Low glucose (<40 mg/dL) and pH (<7.0) are also considered absolute indications, but 'gross pus' is the most visually obvious and definitive.\"\n  },\n  {\n    \"question\": \"Intrapleural fibrinolytics primarily act by which mechanism in loculated parapneumonic effusions?\",\n    \"options\": {\n      \"A\": \"Directly killing bacteria\",\n      \"B\": \"Reducing pleural inflammation\",\n      \"C\": \"Breaking down fibrin septations\",\n      \"D\": \"Enhancing antibiotic penetration\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"Intrapleural fibrinolytics (e.g., alteplase, urokinase) are instilled into the pleural space to dissolve the fibrin septations and loculations that form in complicated parapneumonic effusions and empyema. By breaking down these fibrin barriers, they convert multiloculated effusions into drainable fluid, improving the efficacy of chest tube drainage. They do not directly kill bacteria, reduce inflammation, or enhance antibiotic penetration, although improved drainage can indirectly lead to these outcomes.\",\n    \"highYieldPearl\": \"Fibrinolytics dissolve fibrin septations, converting loculated empyema into drainable fluid.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The primary role is mechanical dissolution of fibrin. While they improve drainage and thus indirectly help with infection and inflammation, their direct mechanism is not antimicrobial or anti-inflammatory.\"\n  },\n  {\n    \"question\": \"Failure of chest tube drainage and intrapleural fibrinolytics in empyema typically indicates a need for what?\",\n    \"options\": {\n      \"A\": \"Repeat thoracentesis\",\n      \"B\": \"Higher dose systemic antibiotics\",\n      \"C\": \"Surgical decortication\",\n      \"D\": \"Bronchoscopy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"When less invasive methods like chest tube drainage and intrapleural fibrinolytics fail to achieve adequate fluid removal and clinical improvement in empyema, it indicates the presence of an organized, thick pleural peel or persistent loculations. In such cases, surgical intervention, most commonly Video-Assisted Thoracoscopic Surgery (VATS) followed by decortication, is necessary to remove the fibrinous peel and allow lung re-expansion. Repeat thoracentesis is unlikely to be effective, and higher dose antibiotics alone cannot address mechanical obstruction. Bronchoscopy is primarily for airway evaluation.\",\n    \"highYieldPearl\": \"Failed medical management (chest tube + fibrinolytics) in empyema necessitates surgical decortication to remove the pleural peel.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and B are generally ineffective at this stage. Option D is diagnostic for airway issues, not therapeutic for pleural space pathology. Surgical decortication directly addresses the organized peel.\"\n  },\n  {\n    \"question\": \"Empyema is characterized by the presence of which substance in the pleural space?\",\n    \"options\": {\n      \"A\": \"Exudative fluid\",\n      \"B\": \"Transudative fluid\",\n      \"C\": \"Gross pus\",\n      \"D\": \"Serosanguinous fluid\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"parapneumonic\",\n    \"deepDiveExplanation\": \"Empyema is defined as the presence of frank, purulent fluid (pus) in the pleural space. While empyema is always an exudative effusion, not all exudative effusions are empyema. The specific characteristic of 'gross pus' differentiates empyema from other complicated parapneumonic effusions or exudates. Serosanguinous fluid refers to blood-tinged fluid, which is distinct from pus.\",\n    \"highYieldPearl\": \"Empyema is synonymous with gross pus in the pleural cavity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While empyema is an exudative fluid, 'exudative fluid' (A) is too broad. The defining characteristic is 'gross pus' (C). Transudative and serosanguinous fluids are different types of effusions.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1152.3424072265625}],"createTime":"2025-12-31T07:45:51.886310Z","modelVersion":"gemini-2.5-flash","responseId":"r9RUaaaMNoHN1AGCsIjgBQ","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":3033,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3033}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":2114,"totalTokenCount":5517,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:16.881802+00:00"}
{"metadata":"one-liner|respiratory_failure|Respiratory Failure (Type 1 and Type 2)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Respiratory Failure (Type 1 and Type 2)\".\nSet the \"topic\" field in the JSON to \"respiratory_failure\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.30828158915433257,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary physiological derangement in Type 1 respiratory failure is?\",\n    \"options\": {\n      \"A\": \"Alveolar hypoventilation\",\n      \"B\": \"Hypercapnia\",\n      \"C\": \"Impaired oxygenation\",\n      \"D\": \"Metabolic acidosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"Type 1 respiratory failure (hypoxemic respiratory failure) is defined by a PaO2 < 60 mmHg with a normal or low PaCO2. The underlying issue is a failure of oxygen exchange at the alveolar-capillary membrane, leading to impaired oxygenation of arterial blood. Causes include V/Q mismatch, shunt, and diffusion limitation.\",\n    \"highYieldPearl\": \"Type 1 RF = Hypoxemia (PaO2 < 60 mmHg) with normal/low PaCO2. Always associated with an increased A-a gradient.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Option A and B describe Type 2 respiratory failure. Option D is a consequence, not the primary derangement.\"\n  },\n  {\n    \"question\": \"Type 2 respiratory failure is primarily characterized by which gas exchange abnormality?\",\n    \"options\": {\n      \"A\": \"Refractory hypoxemia\",\n      \"B\": \"Alveolar hypoventilation\",\n      \"C\": \"Increased A-a gradient\",\n      \"D\": \"Normal PaCO2\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"Type 2 respiratory failure (hypercapnic respiratory failure) is defined by a PaCO2 > 45 mmHg (and often an associated decrease in pH) with or without hypoxemia. It results from inadequate alveolar ventilation, meaning the lungs cannot adequately remove CO2 produced by the body.\",\n    \"highYieldPearl\": \"Type 2 RF = Hypercapnia (PaCO2 > 45 mmHg) due to alveolar hypoventilation. A-a gradient is typically normal unless there's concomitant lung disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Refractory hypoxemia (A) is characteristic of severe Type 1 RF (e.g., shunt). Increased A-a gradient (C) is for Type 1. Normal PaCO2 (D) contradicts the definition of Type 2 RF.\"\n  },\n  {\n    \"question\": \"Which respiratory failure type is characteristically associated with an increased alveolar-arterial (A-a) oxygen gradient?\",\n    \"options\": {\n      \"A\": \"Type 1\",\n      \"B\": \"Type 2\",\n      \"C\": \"Both Type 1 and Type 2\",\n      \"D\": \"Neither\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"An increased A-a gradient indicates an inefficiency in oxygen transfer from the alveoli to the arterial blood. This is the hallmark of Type 1 respiratory failure, caused by V/Q mismatch, shunt, or diffusion limitation. Pure alveolar hypoventilation (Type 2 RF) with normal lung parenchyma typically has a normal A-a gradient.\",\n    \"highYieldPearl\": \"An elevated A-a gradient points to a problem within the lung parenchyma or pulmonary circulation (Type 1 RF), not just ventilatory drive or muscle weakness (pure Type 2 RF).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While Type 2 RF can coexist with lung disease leading to an increased A-a gradient, the *characteristic* association of an *increased* A-a gradient is with Type 1 RF mechanisms.\"\n  },\n  {\n    \"question\": \"A patient with normal lung parenchyma developing Type 2 respiratory failure most likely has which primary issue?\",\n    \"options\": {\n      \"A\": \"Shunt\",\n      \"B\": \"V/Q mismatch\",\n      \"C\": \"Ventilatory pump failure\",\n      \"D\": \"Diffusion limitation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"If the lung parenchyma is normal, the issue is not primarily with gas exchange across the alveolar-capillary membrane (which would cause Type 1 RF). Instead, the problem lies with the 'pump' responsible for moving air in and out of the lungs. This includes neuromuscular disorders, chest wall deformities, or central drive depression, all leading to Type 2 RF.\",\n    \"highYieldPearl\": \"Type 2 RF with normal lungs implies a 'pump' problem: brain (central hypoventilation), nerves (GBS, ALS), muscles (myasthenia gravis), or chest wall (kyphoscoliosis).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, and D are mechanisms of Type 1 respiratory failure, implying intrinsic lung pathology.\"\n  },\n  {\n    \"question\": \"Administering high flow oxygen to a patient with severe COPD and chronic hypercapnia can acutely worsen which parameter?\",\n    \"options\": {\n      \"A\": \"PaO2\",\n      \"B\": \"pH\",\n      \"C\": \"PaCO2\",\n      \"D\": \"Bicarbonate\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"In severe COPD, oxygen administration can acutely worsen hypercapnia by several mechanisms: (1) reduction of hypoxic ventilatory drive, (2) worsening V/Q mismatch by reversing hypoxic pulmonary vasoconstriction in poorly ventilated areas, and (3) increasing the Haldane effect (deoxygenated hemoglobin carries more CO2 than oxygenated hemoglobin).\",\n    \"highYieldPearl\": \"In COPD, titrate oxygen carefully to achieve target SpO2 (e.g., 88-92%) to avoid worsening hypercapnia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While pH might decrease due to rising PaCO2, PaCO2 itself is the directly worsened parameter. PaO2 would improve, and bicarbonate changes are slower, reflecting compensation.\"\n  },\n  {\n    \"question\": \"The gold standard for diagnosing central alveolar hypoventilation syndrome is?\",\n    \"options\": {\n      \"A\": \"Spirometry\",\n      \"B\": \"Overnight polysomnography with capnography\",\n      \"C\": \"Arterial Blood Gas\",\n      \"D\": \"Chest X-ray\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"Central alveolar hypoventilation syndrome involves impaired ventilatory drive, often worse during sleep. Overnight polysomnography with continuous capnography (transcutaneous or end-tidal) provides direct measurement of ventilation and gas exchange during sleep, capturing the periods when hypoventilation is most pronounced.\",\n    \"highYieldPearl\": \"For central hypoventilation, look for nocturnal hypercapnia and hypoxemia, best detected by sleep studies with CO2 monitoring.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Spirometry assesses lung mechanics, ABG provides a snapshot but misses nocturnal events, and Chest X-ray assesses lung structure, none directly diagnose central ventilatory drive issues.\"\n  },\n  {\n    \"question\": \"The predominant mechanism of hypoxemia in Acute Respiratory Distress Syndrome (ARDS) is?\",\n    \"options\": {\n      \"A\": \"Diffusion limitation\",\n      \"B\": \"V/Q mismatch\",\n      \"C\": \"Absolute shunt\",\n      \"D\": \"Alveolar hypoventilation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"ARDS is characterized by widespread inflammation, leading to alveolar damage, collapse, and fluid filling. This results in areas of lung that are perfused but not ventilated, creating an absolute intrapulmonary shunt. Shunt is refractory to supplemental oxygen, explaining why ARDS patients often require high FiO2 and PEEP.\",\n    \"highYieldPearl\": \"Hypoxemia in ARDS is primarily due to shunt, which is minimally responsive to increasing FiO2 alone. PEEP is crucial to open collapsed alveoli and reduce shunt.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While V/Q mismatch can occur, absolute shunt is the predominant and most severe cause of hypoxemia in ARDS. Diffusion limitation is less significant, and alveolar hypoventilation is not the primary cause.\"\n  },\n  {\n    \"question\": \"Which acute condition is a primary indication for Non-Invasive Positive Pressure Ventilation (NPPV) for acute hypercapnic respiratory failure?\",\n    \"options\": {\n      \"A\": \"Severe ARDS\",\n      \"B\": \"Cardiogenic pulmonary edema\",\n      \"C\": \"COPD exacerbation\",\n      \"D\": \"Status asthmaticus\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"NPPV is a cornerstone treatment for acute exacerbations of COPD leading to hypercapnic respiratory failure. It improves gas exchange, reduces work of breathing, and decreases the need for invasive mechanical ventilation and associated complications. While NPPV is used in cardiogenic pulmonary edema, it's primarily for hypoxemia, not hypercapnia in that context. Severe ARDS is often too severe for NPPV.\",\n    \"highYieldPearl\": \"NPPV is highly effective in acute hypercapnic RF due to COPD exacerbation, reducing intubation and mortality.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Severe ARDS (A) often requires invasive ventilation. Cardiogenic pulmonary edema (B) primarily benefits from NPPV for oxygenation, though it can reduce hypercapnia. Status asthmaticus (D) might use NPPV, but COPD is the classic indication for hypercapnic RF.\"\n  },\n  {\n    \"question\": \"Positive End-Expiratory Pressure (PEEP) primarily improves oxygenation in ARDS by which mechanism?\",\n    \"options\": {\n      \"A\": \"Reducing dead space\",\n      \"B\": \"Decreasing V/Q mismatch\",\n      \"C\": \"Preventing alveolar collapse\",\n      \"D\": \"Enhancing CO2 removal\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"PEEP maintains positive pressure in the alveoli at the end of expiration, preventing their collapse (de-recruitment). This increases the functional residual capacity, recruits collapsed alveoli, and redistributes extravascular lung water, ultimately reducing intrapulmonary shunt and improving oxygenation.\",\n    \"highYieldPearl\": \"PEEP's main role in ARDS is to keep alveoli open, thereby reducing shunt and improving oxygenation. It's a key component of 'open lung' ventilation strategies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While PEEP can decrease V/Q mismatch (B) by improving ventilation in previously collapsed areas, the direct mechanism is preventing alveolar collapse (C). Reducing dead space (A) and enhancing CO2 removal (D) are not its primary effects on oxygenation.\"\n  },\n  {\n    \"question\": \"Which parameter is an early indicator of impending respiratory muscle fatigue in a patient with respiratory failure?\",\n    \"options\": {\n      \"A\": \"Rising PaCO2\",\n      \"B\": \"Decreasing PaO2\",\n      \"C\": \"Increasing respiratory rate\",\n      \"D\": \"Decreasing tidal volume\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"respiratory_failure\",\n    \"deepDiveExplanation\": \"An increasing respiratory rate (tachypnea) is often the body's initial compensatory mechanism to maintain minute ventilation in the face of increased work of breathing or impending muscle fatigue. As fatigue progresses, tidal volume may fall, and PaCO2 will eventually rise, indicating ventilatory failure.\",\n    \"highYieldPearl\": \"Tachypnea is a critical early warning sign of respiratory distress or impending failure. Don't wait for PaCO2 to rise.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Rising PaCO2 (A) and decreasing tidal volume (D) are later signs of respiratory muscle fatigue leading to ventilatory failure. Decreasing PaO2 (B) is a sign of hypoxemia, not necessarily directly muscle fatigue.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-894.3248901367188}],"createTime":"2025-12-31T07:46:27.456432Z","modelVersion":"gemini-2.5-flash","responseId":"09RUafDtG8OyvPEP9q_RgA0","usageMetadata":{"billablePromptUsage":{"textCount":1044},"candidatesTokenCount":2901,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2901}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":2225,"totalTokenCount":5496,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:54.070462+00:00"}
{"metadata":"one-liner|steroids|Corticosteroids in Pulmonary Disease|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Corticosteroids in Pulmonary Disease\".\nSet the \"topic\" field in the JSON to \"steroids\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3761615439599714,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Corticosteroids primarily exert anti-inflammatory effects through which genomic mechanism?\",\n    \"options\": {\n      \"A\": \"Inhibition of cyclooxygenase enzymes\",\n      \"B\": \"Direct bronchodilation via beta-receptor agonism\",\n      \"C\": \"Transrepression of inflammatory gene transcription\",\n      \"D\": \"Increased synthesis of pro-inflammatory cytokines\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"steroids\",\n    \"deepDiveExplanation\": \"Corticosteroids primarily act by binding to intracellular glucocorticoid receptors, which then translocate to the nucleus. Here, they can either directly bind to glucocorticoid response elements (transactivation) or, more importantly for anti-inflammatory effects, interact with and inhibit other transcription factors like NF-κB and AP-1 (transrepression), thereby downregulating the expression of inflammatory genes.\",\n    \"highYieldPearl\": \"Transrepression is the key genomic mechanism for corticosteroid anti-inflammatory action, distinct from NSAID action or direct bronchodilation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A describes NSAID action. Option B describes bronchodilators like beta-agonists. Option D is the opposite of corticosteroid action. Transrepression is the core mechanism at the genomic level for their anti-inflammatory effects.\"\n  },\n  {\n    \"question\": \"What is the primary role of systemic corticosteroids in severe acute asthma exacerbation?\",\n    \"options\": {\n      \"A\": \"Immediate bronchodilation\",\n      \"B\": \"Reduction of airway inflammation and hyperresponsiveness\",\n      \"C\": \"Mucus plug dissolution\",\n      \"D\": \"Prevention of bacterial superinfection\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"steroids\",\n    \"deepDiveExplanation\": \"Systemic corticosteroids are crucial in severe acute asthma exacerbations because they reduce the underlying airway inflammation, decrease airway hyperresponsiveness, and prevent relapse. Their effects are not immediate but become evident within hours, complementing the rapid bronchodilation provided by short-acting beta-agonists.\",\n    \"highYieldPearl\": \"Corticosteroids treat the inflammation in asthma, while bronchodilators treat bronchospasm. Both are critical in severe exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Option A is the role of bronchodilators (e.g., salbutamol). Option C is not a primary effect. Option D is not their role and antibiotics are not routinely indicated unless infection is suspected.\"\n  },\n  {\n    \"question\": \"Which is the most common local adverse effect of inhaled corticosteroids?\",\n    \"options\": {\n      \"A\": \"Adrenal suppression\",\n      \"B\": \"Oral candidiasis\",\n      \"C\": \"Osteoporosis\",\n      \"D\": \"Cataracts\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"steroids\",\n    \"deepDiveExplanation\": \"Oral candidiasis (thrush) is the most common local adverse effect of inhaled corticosteroids due to local immunosuppression in the oropharynx. This risk can be minimized by using a spacer device and rinsing the mouth with water after inhalation.\",\n    \"highYieldPearl\": \"Always advise patients to rinse their mouth after using inhaled corticosteroids to reduce the risk of oral candidiasis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Adrenal suppression, osteoporosis, and cataracts are systemic adverse effects, which are less common with inhaled corticosteroids at standard doses compared to oral systemic corticosteroids, and are not considered 'local' effects.\"\n  },\n  {\n    \"question\": \"In which pulmonary condition are systemic corticosteroids generally *not* recommended for routine chronic management?\",\n    \"options\": {\n      \"A\": \"Chronic Eosinophilic Pneumonia\",\n      \"B\": \"Sarcoidosis\",\n      \"C\": \"Idiopathic Pulmonary Fibrosis\",\n      \"D\": \"Hypersensitivity Pneumonitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"steroids\",\n    \"deepDiveExplanation\": \"Systemic corticosteroids are generally not recommended for the routine chronic management of Idiopathic Pulmonary Fibrosis (IPF). While they might be used in acute exacerbations, chronic use has not shown benefit and may even be harmful, increasing the risk of adverse events without improving survival or disease progression. In contrast, chronic eosinophilic pneumonia, sarcoidosis, and hypersensitivity pneumonitis often respond well to and are managed with corticosteroids.\",\n    \"highYieldPearl\": \"IPF is a fibrotic lung disease where corticosteroids are generally ineffective and potentially harmful for chronic management, unlike inflammatory lung diseases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All other options (A, B, D) are conditions where corticosteroids are a mainstay of chronic treatment due to their underlying inflammatory nature. IPF is primarily a fibrotic disease with a different pathogenesis.\"\n  },\n  {\n    \"question\": \"What is the current recommended duration for oral corticosteroid therapy in acute COPD exacerbation?\",\n    \"options\": {\n      \"A\": \"2-3 days\",\n      \"B\": \"5-7 days\",\n      \"C\": \"10-14 days\",\n      \"D\": \"3-4 weeks\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"steroids\",\n    \"deepDiveExplanation\": \"Current guidelines (e.g., GOLD) recommend a short course of oral corticosteroids, typically 5-7 days (often 40mg prednisone equivalent daily for 5 days), for acute exacerbations of COPD. This duration has been shown to be as effective as longer courses while reducing the risk of side effects.\",\n    \"highYieldPearl\": \"Shorter courses (5-7 days) of oral corticosteroids are now preferred for COPD exacerbations to minimize systemic side effects without compromising efficacy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Older recommendations or practices might suggest longer durations (C, D), but evidence now supports shorter courses (B) for comparable efficacy and reduced side effects. Option A is generally too short to achieve full therapeutic effect.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-526.25}],"createTime":"2025-12-31T07:46:32.226289Z","modelVersion":"gemini-2.5-flash","responseId":"2NRUafHnDZHplu8P_-zfqQw","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":1399,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1399}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1522,"totalTokenCount":3285,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:56.681253+00:00"}
{"metadata":"one-liner|ipa|Invasive Pulmonary Aspergillosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Invasive Pulmonary Aspergillosis\".\nSet the \"topic\" field in the JSON to \"ipa\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.28460559192004503,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most significant risk factor for Invasive Pulmonary Aspergillosis in hematological malignancies is?\",\n    \"options\": {\n      \"A\": \"Neutropenia\",\n      \"B\": \"Lymphopenia\",\n      \"C\": \"Thrombocytopenia\",\n      \"D\": \"Anemia\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Prolonged and profound neutropenia (<500 neutrophils/µL for >10 days) is the most critical risk factor for Invasive Pulmonary Aspergillosis (IPA), particularly in patients with hematological malignancies undergoing chemotherapy or hematopoietic stem cell transplantation. Neutrophils are crucial for clearing inhaled conidia and hyphae.\",\n    \"highYieldPearl\": \"Neutropenia is the bedrock risk factor for IPA; without it, the risk plummets significantly.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other cytopenias might be present, neutropenia directly impairs the primary host defense against Aspergillus, making it the most significant risk factor.\"\n  },\n  {\n    \"question\": \"Which imaging sign is characteristic of early Invasive Pulmonary Aspergillosis in neutropenic patients?\",\n    \"options\": {\n      \"A\": \"Tree-in-bud sign\",\n      \"B\": \"Halo sign\",\n      \"C\": \"Air bronchogram\",\n      \"D\": \"Ground-glass opacities\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"The halo sign, characterized by a nodule or mass surrounded by ground-glass attenuation, represents hemorrhage around the necrotic fungal lesion. It is highly suggestive of angioinvasive fungal infection, including IPA, in neutropenic patients and typically appears early in the disease course.\",\n    \"highYieldPearl\": \"Halo sign = hemorrhage around fungal nodule = early IPA in neutropenia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Tree-in-bud sign suggests bronchiolar inflammation/infection. Air bronchogram is common in consolidation. Ground-glass opacities are non-specific but can be part of the halo sign.\"\n  },\n  {\n    \"question\": \"The 'air-crescent sign' on CT chest is typically seen during which phase of Invasive Pulmonary Aspergillosis recovery?\",\n    \"options\": {\n      \"A\": \"Early infection\",\n      \"B\": \"Neutropenia phase\",\n      \"C\": \"Neutrophil recovery\",\n      \"D\": \"Chronic phase\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"The air-crescent sign, where a crescentic lucency separates a necrotic fungal lesion from the adjacent lung parenchyma, typically appears during the recovery phase, particularly as neutrophil counts rebound. It indicates separation of the necrotic core from the viable lung due to host inflammatory response.\",\n    \"highYieldPearl\": \"Air-crescent sign signifies neutrophil recovery and tissue demarcation in IPA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The halo sign is early (neutropenic phase), while the air-crescent sign is a later, more favorable prognostic sign associated with immune reconstitution.\"\n  },\n  {\n    \"question\": \"Which fungal polysaccharide is detected in serum or BAL fluid for diagnosing Invasive Pulmonary Aspergillosis?\",\n    \"options\": {\n      \"A\": \"(1,3)-β-D-glucan\",\n      \"B\": \"Galactomannan\",\n      \"C\": \"Chitin\",\n      \"D\": \"Mannan\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Galactomannan is a cell wall polysaccharide of Aspergillus species that is released during active fungal growth and can be detected in serum, bronchoalveolar lavage (BAL) fluid, and cerebrospinal fluid. It is a key biomarker for diagnosing IPA, especially in high-risk patients.\",\n    \"highYieldPearl\": \"Galactomannan is specific for *Aspergillus* and *Penicillium* (less commonly), differentiating it from general fungal markers.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"(1,3)-β-D-glucan is a general fungal biomarker, less specific than galactomannan for Aspergillus. Chitin is a general fungal cell wall component but not typically used as a diagnostic biomarker. Mannan is a component of *Candida* cell walls.\"\n  },\n  {\n    \"question\": \"The (1,3)-β-D-glucan assay for fungal infection diagnosis has limitations due to cross-reactivity with?\",\n    \"options\": {\n      \"A\": \"*Candida* species\",\n      \"B\": \"*Pneumocystis jirovecii*\",\n      \"C\": \"Dialysis membranes\",\n      \"D\": \"*Aspergillus* species\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"The (1,3)-β-D-glucan assay detects a common component of many fungal cell walls, making it useful for broad fungal detection. However, false positives can occur with certain medical products, including cellulose membranes used in hemodialysis, surgical gauze, and some intravenous immunoglobulins.\",\n    \"highYieldPearl\": \"Beta-D-glucan is a general fungal marker, but consider non-fungal causes for elevation, especially in critically ill patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, and D are all fungi that would typically *cause* a positive (1,3)-β-D-glucan, not cross-react in a way that limits its utility for general fungal detection. The question asks for limitations due to cross-reactivity with non-fungal sources.\"\n  },\n  {\n    \"question\": \"What is the recommended first-line antifungal agent for the treatment of Invasive Pulmonary Aspergillosis?\",\n    \"options\": {\n      \"A\": \"Fluconazole\",\n      \"B\": \"Amphotericin B deoxycholate\",\n      \"C\": \"Voriconazole\",\n      \"D\": \"Caspofungin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Voriconazole is the current first-line therapy for Invasive Pulmonary Aspergillosis, based on superior efficacy and improved survival compared to amphotericin B deoxycholate in randomized controlled trials. Isavuconazole is an alternative primary therapy.\",\n    \"highYieldPearl\": \"Voriconazole is the gold standard for IPA treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Fluconazole has no activity against *Aspergillus*. Amphotericin B was historically used but has more toxicity and less efficacy than voriconazole. Caspofungin (an echinocandin) is used as salvage therapy or in combination, not typically first-line monotherapy.\"\n  },\n  {\n    \"question\": \"Azole antifungals primarily exert their action by inhibiting which fungal enzyme?\",\n    \"options\": {\n      \"A\": \"(1,3)-β-D-glucan synthase\",\n      \"B\": \"DNA topoisomerase\",\n      \"C\": \"Cytochrome P450 14α-demethylase\",\n      \"D\": \"Chitin synthase\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Azole antifungals inhibit the fungal cytochrome P450 14α-demethylase enzyme, which is crucial for the synthesis of ergosterol, a vital component of the fungal cell membrane. This inhibition leads to cell membrane dysfunction and ultimately fungal cell death.\",\n    \"highYieldPearl\": \"Azoles target ergosterol synthesis via CYP450 14α-demethylase.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"(1,3)-β-D-glucan synthase is targeted by echinocandins. DNA topoisomerase is a target for some antibacterial/anticancer drugs. Chitin synthase is involved in cell wall synthesis, but not a primary azole target.\"\n  },\n  {\n    \"question\": \"The definitive diagnosis of Invasive Pulmonary Aspergillosis relies on demonstration of hyphae with which characteristic?\",\n    \"options\": {\n      \"A\": \"Broadly septate, parallel walls\",\n      \"B\": \"Non-septate, irregular branching\",\n      \"C\": \"Narrowly septate, acute angle branching\",\n      \"D\": \"Yeast forms with pseudohyphae\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Histopathological examination showing septate hyphae with characteristic acute angle (typically 45°) dichotomous branching within tissue is the gold standard for definitive diagnosis of IPA. This distinguishes *Aspergillus* from other fungi like *Mucorales* (non-septate, irregular branching) or *Candida* (yeast and pseudohyphae).\",\n    \"highYieldPearl\": \"Acute angle branching, septate hyphae in tissue = definitive Aspergillus.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option B describes *Mucorales*. Option D describes *Candida*. Option A is vague and less specific than the classic description for Aspergillus.\"\n  },\n  {\n    \"question\": \"Therapeutic drug monitoring is routinely recommended for which antifungal used in Invasive Pulmonary Aspergillosis?\",\n    \"options\": {\n      \"A\": \"Amphotericin B\",\n      \"B\": \"Caspofungin\",\n      \"C\": \"Voriconazole\",\n      \"D\": \"Micafungin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"Voriconazole exhibits non-linear pharmacokinetics, significant inter-patient variability, and potential for drug-drug interactions, leading to highly variable plasma concentrations. Therapeutic drug monitoring (TDM) is recommended to ensure adequate therapeutic levels while minimizing toxicity, particularly neurotoxicity and hepatotoxicity.\",\n    \"highYieldPearl\": \"Voriconazole TDM is crucial due to variable pharmacokinetics and narrow therapeutic window.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Amphotericin B and echinocandins (caspofungin, micafungin) have more predictable pharmacokinetics and broader therapeutic windows, so TDM is not routinely recommended for them.\"\n  },\n  {\n    \"question\": \"The most common mechanism of azole resistance in *Aspergillus fumigatus* is mutations in which gene?\",\n    \"options\": {\n      \"A\": \"*ERG11*\",\n      \"B\": \"*CYP51A*\",\n      \"C\": \"*FKS1*\",\n      \"D\": \"*MDR1*\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipa\",\n    \"deepDiveExplanation\": \"The most prevalent mechanism of azole resistance in *Aspergillus fumigatus* is target site modification, specifically mutations in the *CYP51A* gene. This gene encodes the 14α-demethylase enzyme, which is the direct target of azole antifungals. Common mutations include TR34/L98H and TR46/Y121F/T289A.\",\n    \"highYieldPearl\": \"Azole resistance in *Aspergillus* often linked to *CYP51A* mutations, especially TR34/L98H.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"*ERG11* is the gene encoding 14α-demethylase in *Candida* species. *FKS1* mutations are associated with echinocandin resistance. *MDR1* relates to efflux pumps, which can contribute to resistance but *CYP51A* mutations are the primary mechanism for azole resistance in *Aspergillus*.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-789.780517578125}],"createTime":"2025-12-31T07:45:52.283743Z","modelVersion":"gemini-2.5-flash","responseId":"sNRUad-oEYS7gLUPlM_J6AI","usageMetadata":{"billablePromptUsage":{"textCount":1025},"candidatesTokenCount":2775,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2775}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":2044,"totalTokenCount":5183,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:14.429661+00:00"}
{"metadata":"one-liner|dah|Diffuse Alveolar Hemorrhage|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Diffuse Alveolar Hemorrhage\".\nSet the \"topic\" field in the JSON to \"dah\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.414352014670418,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which bronchoalveolar lavage finding is diagnostic for diffuse alveolar hemorrhage?\",\n    \"options\": {\n      \"A\": \"Lymphocytosis\",\n      \"B\": \"Neutrophilia\",\n      \"C\": \"Hemosiderin-laden macrophages\",\n      \"D\": \"Eosinophilia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dah\",\n    \"deepDiveExplanation\": \"Hemosiderin-laden macrophages (siderophages) on BAL are the hallmark of DAH, indicating recurrent or ongoing bleeding into the alveolar space. They typically become positive after approximately 48-72 hours of bleeding. A progressively hemorrhagic BAL fluid across sequential aliquots (increasing bloodiness from aliquot 1 to 3-5) is also highly suggestive of active DAH.\",\n    \"highYieldPearl\": \"Hemosiderin-laden macrophages in BAL confirm alveolar bleeding, a key indicator of DAH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Lymphocytosis and neutrophilia are non-specific inflammatory findings. Eosinophilia is characteristic of eosinophilic lung diseases. While these can coexist, only hemosiderin-laden macrophages directly indicate prior or ongoing alveolar hemorrhage.\"\n  },\n  {\n    \"question\": \"The predominant pathological feature of DAH in ANCA-associated vasculitis is?\",\n    \"options\": {\n      \"A\": \"Bland hemorrhage\",\n      \"B\": \"Pulmonary capillaritis\",\n      \"C\": \"Necrotizing granulomas\",\n      \"D\": \"Endothelialitis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"dah\",\n    \"deepDiveExplanation\": \"In ANCA-associated vasculitides (e.g., Granulomatosis with Polyangiitis, Microscopic Polyangiitis), diffuse alveolar hemorrhage typically results from pulmonary capillaritis. This involves inflammation and necrosis of alveolar capillaries, leading to extravasation of red blood cells into the alveolar spaces. Bland hemorrhage lacks inflammation, while necrotizing granulomas are characteristic of GPA but are not the direct cause of acute DAH, which is capillaritis.\",\n    \"highYieldPearl\": \"ANCA-associated DAH is primarily due to pulmonary capillaritis, an inflammatory destruction of alveolar capillaries.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Necrotizing granulomas are a feature of GPA, but the *mechanism* of DAH in GPA is capillaritis. Bland hemorrhage is a distinct category of DAH without inflammation. Endothelialitis is a broader term, whereas capillaritis specifically describes alveolar capillary inflammation.\"\n  },\n  {\n    \"question\": \"First-line treatment for severe DAH associated with systemic autoimmune disease is?\",\n    \"options\": {\n      \"A\": \"Cyclophosphamide\",\n      \"B\": \"Rituximab\",\n      \"C\": \"High-dose corticosteroids\",\n      \"D\": \"Plasmapheresis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dah\",\n    \"deepDiveExplanation\": \"High-dose intravenous corticosteroids (e.g., methylprednisolone) are the cornerstone of initial therapy for severe DAH secondary to systemic autoimmune diseases or vasculitis. They aim to rapidly suppress the acute inflammatory response. While cyclophosphamide, rituximab, and plasmapheresis are often used as adjunctive or subsequent therapies depending on the underlying cause (e.g., ANCA-vasculitis, Goodpasture's syndrome), corticosteroids provide immediate anti-inflammatory action critical in acute, severe DAH.\",\n    \"highYieldPearl\": \"Acute severe DAH of autoimmune origin requires high-dose corticosteroids as initial therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Cyclophosphamide, rituximab, and plasmapheresis are vital components of therapy for specific causes of DAH (e.g., ANCA vasculitis, anti-GBM disease), but corticosteroids are almost universally the *first-line* agent for acute inflammatory DAH due to their rapid immunosuppressive effect.\"\n  },\n  {\n    \"question\": \"The gold standard for definitively diagnosing and subtyping diffuse alveolar hemorrhage is?\",\n    \"options\": {\n      \"A\": \"Chest HRCT\",\n      \"B\": \"Bronchoalveolar lavage\",\n      \"C\": \"Lung biopsy\",\n      \"D\": \"Serum anti-GBM antibodies\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dah\",\n    \"deepDiveExplanation\": \"While bronchoalveolar lavage (BAL) showing progressively bloody fluid and hemosiderin-laden macrophages is highly suggestive and often sufficient for a clinical diagnosis, a lung biopsy demonstrating alveolar hemorrhage with or without capillaritis, bland hemorrhage, or vasculitis is considered the definitive 'gold standard' for histopathological confirmation and differentiation of DAH subtypes.\",\n    \"highYieldPearl\": \"Lung biopsy provides definitive histopathological diagnosis and subtyping of DAH, making it the gold standard.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"BAL is highly sensitive and frequently used for clinical diagnosis, but it does not provide tissue architecture or definitive subtyping. HRCT shows imaging features (e.g., ground-glass opacities) but is not diagnostic. Serum anti-GBM antibodies are specific for Goodpasture's syndrome, a cause of DAH, but not for DAH in general.\"\n  },\n  {\n    \"question\": \"Which condition is typically associated with bland diffuse alveolar hemorrhage?\",\n    \"options\": {\n      \"A\": \"Microscopic polyangiitis\",\n      \"B\": \"Systemic lupus erythematosus\",\n      \"C\": \"Severe mitral stenosis\",\n      \"D\": \"Granulomatosis with polyangiitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dah\",\n    \"deepDiveExplanation\": \"Bland DAH refers to hemorrhage without associated inflammation or capillaritis on histological examination. It is commonly observed in conditions causing elevated pulmonary venous pressure, such as severe mitral stenosis or left ventricular failure, as well as in coagulopathies or thrombocytopenia. Microscopic polyangiitis and Granulomatosis with polyangiitis are ANCA-associated vasculitides that cause DAH via capillaritis. SLE can cause DAH, often with capillaritis or vasculitis, making mitral stenosis the most distinct example of bland DAH among the choices.\",\n    \"highYieldPearl\": \"Bland DAH lacks inflammation; it's often caused by increased pulmonary venous pressure (e.g., mitral stenosis) or coagulopathies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The other options (Microscopic polyangiitis, Systemic lupus erythematosus, Granulomatosis with polyangiitis) are all associated with inflammatory or vasculitic forms of DAH, not bland hemorrhage. This question tests the understanding of DAH subtypes based on underlying pathology.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-644.3173828125}],"createTime":"2025-12-31T07:48:03.215698Z","modelVersion":"gemini-2.5-flash","responseId":"M9VUaZKVDd3DgLUPqfGtgAE","usageMetadata":{"billablePromptUsage":{"textCount":1019},"candidatesTokenCount":1555,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1555}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":1791,"totalTokenCount":3709,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:49:52.323345+00:00"}
{"metadata":"one-liner|osa_diagnosis|Obstructive Sleep Apnea - Diagnosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Obstructive Sleep Apnea - Diagnosis\".\nSet the \"topic\" field in the JSON to \"osa_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3708607754966085,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the gold standard diagnostic test for Obstructive Sleep Apnea?\",\n    \"options\": {\n      \"A\": \"Home Sleep Apnea Test (HSAT)\",\n      \"B\": \"Polysomnography (PSG)\",\n      \"C\": \"Nocturnal Oximetry\",\n      \"D\": \"Multiple Sleep Latency Test (MSLT)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"Polysomnography (Type I PSG) is considered the gold standard as it provides a comprehensive assessment of sleep architecture, respiratory events, cardiac activity, and oxygenation by simultaneously recording multiple physiological parameters in an attended setting.\",\n    \"highYieldPearl\": \"PSG offers the most complete picture of sleep and respiratory disturbances, crucial for complex cases or when other sleep disorders are suspected.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"HSATs (Type III/IV) are increasingly common for diagnosis, but they are not the 'gold standard' as they lack full sleep staging and are less comprehensive than attended PSG.\"\n  },\n  {\n    \"question\": \"An Apnea-Hypopnea Index (AHI) greater than 30 events per hour of sleep indicates which severity of Obstructive Sleep Apnea?\",\n    \"options\": {\n      \"A\": \"Mild\",\n      \"B\": \"Moderate\",\n      \"C\": \"Severe\",\n      \"D\": \"Very Severe\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"The severity of OSA is classified based on the AHI: Mild (5-15 events/hour), Moderate (15-30 events/hour), and Severe (>30 events/hour). These thresholds are critical for guiding management decisions.\",\n    \"highYieldPearl\": \"Memorize the AHI thresholds for mild, moderate, and severe OSA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing the numerical thresholds for different severity categories is a common mistake. 'Very Severe' is not a standard classification.\"\n  },\n  {\n    \"question\": \"According to AASM 2012 criteria, a hypopnea is defined by a 30% airflow reduction accompanied by what?\",\n    \"options\": {\n      \"A\": \"3% oxygen desaturation or arousal\",\n      \"B\": \"4% oxygen desaturation\",\n      \"C\": \"5% oxygen desaturation and arousal\",\n      \"D\": \"10% oxygen desaturation\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"The AASM 2012 scoring criteria define a hypopnea as a discernable decrease in airflow by ≥30% of pre-event baseline, lasting ≥10 seconds, associated with either a ≥3% oxygen desaturation from pre-event baseline OR an arousal.\",\n    \"highYieldPearl\": \"Key numbers for hypopnea are 30% airflow reduction and 3% desaturation OR arousal.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The main trap is distinguishing between older (e.g., 4% desaturation) and current (AASM 2012, 3% desaturation or arousal) hypopnea scoring criteria.\"\n  },\n  {\n    \"question\": \"Which type of Polysomnography (PSG) is generally considered a Home Sleep Apnea Test (HSAT)?\",\n    \"options\": {\n      \"A\": \"Type I\",\n      \"B\": \"Type II\",\n      \"C\": \"Type III\",\n      \"D\": \"Type IV\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"Type III PSG is a modified portable sleep apnea test that uses at least four channels: two respiratory movement channels, one airflow channel, and one oximetry channel. This configuration is commonly employed for HSATs.\",\n    \"highYieldPearl\": \"Type III PSG is synonymous with most common HSATs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Knowing the different PSG types and their characteristics is crucial. Type I is attended in-lab, Type II is unattended comprehensive, Type IV is limited (e.g., just oximetry).\"\n  },\n  {\n    \"question\": \"A STOP-BANG questionnaire score of 3 or more in a patient suggests what?\",\n    \"options\": {\n      \"A\": \"High risk for narcolepsy\",\n      \"B\": \"Low risk for OSA\",\n      \"C\": \"High risk for moderate to severe OSA\",\n      \"D\": \"Need for immediate CPAP initiation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"The STOP-BANG questionnaire is a validated screening tool. A score of 0-2 indicates low risk of moderate-severe OSA, while a score of ≥3 indicates high risk. It is used to identify patients who should undergo further diagnostic testing.\",\n    \"highYieldPearl\": \"STOP-BANG ≥3 indicates high risk of moderate-severe OSA, warranting a sleep study.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing the interpretation of the score or assuming it's a definitive diagnosis or treatment indicator rather than a screening tool.\"\n  },\n  {\n    \"question\": \"An Epworth Sleepiness Scale (ESS) score greater than 10 typically suggests which of the following?\",\n    \"options\": {\n      \"A\": \"Normal daytime alertness\",\n      \"B\": \"Mild subjective sleepiness\",\n      \"C\": \"Excessive daytime sleepiness\",\n      \"D\": \"Primary Insomnia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"The ESS is a self-administered questionnaire assessing subjective daytime sleepiness. Scores range from 0-24. A score of 0-9 is considered normal, while a score of ≥10 suggests excessive daytime sleepiness, a common symptom of OSA.\",\n    \"highYieldPearl\": \"ESS > 10 points to excessive daytime sleepiness, a strong indicator for sleep disorder evaluation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misinterpreting the ESS score threshold or confusing subjective sleepiness with objective measures.\"\n  },\n  {\n    \"question\": \"Home Sleep Apnea Testing (HSAT) is generally indicated for patients with which of the following characteristics?\",\n    \"options\": {\n      \"A\": \"Suspected central sleep apnea\",\n      \"B\": \"Significant comorbidities (e.g., severe heart failure)\",\n      \"C\": \"High pretest probability of uncomplicated OSA\",\n      \"D\": \"Suspected narcolepsy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"HSAT is appropriate for patients with a high pretest probability of moderate to severe OSA, who do not have significant comorbidities (e.g., chronic lung disease, severe heart failure, neuromuscular disease) or suspicion of other sleep disorders (e.g., central sleep apnea, insomnia, parasomnias).\",\n    \"highYieldPearl\": \"HSAT is suitable for uncomplicated, high-probability OSA cases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"HSAT is less suitable for complex cases where other sleep disorders or significant comorbidities might confound the diagnosis or require comprehensive PSG.\"\n  },\n  {\n    \"question\": \"A Respiratory Effort Related Arousal (RERA) is characterized by increasing respiratory effort leading to what, without meeting apnea or hypopnea criteria?\",\n    \"options\": {\n      \"A\": \"Oxygen desaturation below 90%\",\n      \"B\": \"Bradycardia\",\n      \"C\": \"An arousal from sleep\",\n      \"D\": \"Sudden snoring cessation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"RERAs are a sequence of breaths lasting at least 10 seconds, characterized by increasing respiratory effort (e.g., flattening of the inspiratory airflow waveform) that terminates with an arousal from sleep, but do not meet the criteria for an apnea or hypopnea. They contribute to the Respiratory Disturbance Index (RDI).\",\n    \"highYieldPearl\": \"RERA = increased respiratory effort + arousal, without meeting apnea/hypopnea criteria.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The key distinction for RERA is the arousal due to effort, without necessarily meeting desaturation or airflow reduction thresholds for hypopnea/apnea.\"\n  },\n  {\n    \"question\": \"The Oxygen Desaturation Index (ODI) typically measures the number of oxygen desaturations per hour of sleep by at least what percentage?\",\n    \"options\": {\n      \"A\": \"2%\",\n      \"B\": \"3%\",\n      \"C\": \"4%\",\n      \"D\": \"5%\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"The ODI is a common metric in sleep studies, representing the number of times per hour of sleep that the oxygen saturation drops by a specified percentage. The AASM 2012 criteria commonly use a ≥3% desaturation threshold for scoring respiratory events, and this is often applied to ODI calculations as well.\",\n    \"highYieldPearl\": \"ODI often uses a ≥3% desaturation threshold per hour.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Similar to hypopnea criteria, the exact percentage (3% vs 4%) can be a point of confusion depending on the specific guidelines cited.\"\n  },\n  {\n    \"question\": \"A significant limitation of Home Sleep Apnea Testing (HSAT) compared to full Polysomnography (PSG) is its inability to accurately determine what?\",\n    \"options\": {\n      \"A\": \"Respiratory event frequency\",\n      \"B\": \"Oxygen desaturation severity\",\n      \"C\": \"Sleep architecture and total sleep time\",\n      \"D\": \"Heart rate abnormalities\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_diagnosis\",\n    \"deepDiveExplanation\": \"HSATs typically do not include electroencephalography (EEG), electrooculography (EOG), or electromyography (EMG) channels, which are essential for objectively determining sleep stages (REM, NREM stages) and thus accurate total sleep time. This means AHI from HSAT is often an RDI (Respiratory Disturbance Index) based on recording time, not actual sleep time.\",\n    \"highYieldPearl\": \"HSATs cannot reliably stage sleep or determine total sleep time.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While HSATs can detect respiratory events and desaturations, their primary limitation is the lack of comprehensive sleep staging, which impacts the accuracy of AHI calculation and understanding of sleep quality.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-956.82080078125}],"createTime":"2025-12-31T07:46:20.283753Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUaemoEbKJ1dkP1aL2qAk","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":2580,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2580}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":2393,"totalTokenCount":5340,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:35.849667+00:00"}
{"metadata":"one-liner|sleep_physiology|Sleep Physiology and Neuroanatomy|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Sleep Physiology and Neuroanatomy\".\nSet the \"topic\" field in the JSON to \"sleep_physiology\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3573994954427083,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which hypothalamic nucleus primarily promotes NREM sleep?\",\n    \"options\": {\n      \"A\": \"Suprachiasmatic Nucleus\",\n      \"B\": \"Ventrolateral Preoptic Area\",\n      \"C\": \"Lateral Hypothalamic Area\",\n      \"D\": \"Mammillary Bodies\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sleep_physiology\",\n    \"deepDiveExplanation\": \"The Ventrolateral Preoptic Area (VLPO) of the hypothalamus is a key sleep-promoting center. It contains GABAergic and galaninergic neurons that inhibit wake-promoting nuclei, including the tuberomammillary nucleus (TMN), locus coeruleus (LC), dorsal and median raphe nuclei, and the lateral hypothalamic area (LHA), thereby initiating and maintaining NREM sleep.\",\n    \"highYieldPearl\": \"VLPO is the 'sleep switch' for NREM sleep.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The SCN regulates circadian rhythm, not direct sleep initiation. The LHA promotes wakefulness. Mammillary bodies are involved in memory formation and recall, not primary sleep initiation.\"\n  },\n  {\n    \"question\": \"Which neurotransmitter system is primarily responsible for muscle atonia during REM sleep?\",\n    \"options\": {\n      \"A\": \"Cholinergic\",\n      \"B\": \"Noradrenergic\",\n      \"C\": \"Glycinergic\",\n      \"D\": \"Dopaminergic\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sleep_physiology\",\n    \"deepDiveExplanation\": \"During REM sleep, muscle atonia is mediated by active inhibition of motor neurons in the spinal cord and brainstem. This inhibition is primarily achieved through the release of glycine and GABA from interneurons, leading to hyperpolarization of motor neurons and suppression of muscle activity. While cholinergic neurons are crucial for REM sleep generation and PGO waves, they do not directly cause atonia.\",\n    \"highYieldPearl\": \"Glycine and GABA are key for REM sleep atonia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Cholinergic activity is high in REM and crucial for its generation, but glycine/GABA directly cause atonia. Noradrenergic and dopaminergic systems are generally less active during REM and are associated with wakefulness/arousal.\"\n  },\n  {\n    \"question\": \"What EEG characteristic defines NREM Stage 3 sleep?\",\n    \"options\": {\n      \"A\": \"Sleep spindles and K-complexes\",\n      \"B\": \"Delta waves comprising >20% of the epoch\",\n      \"C\": \"Predominant alpha waves\",\n      \"D\": \"Sawtooth waves\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sleep_physiology\",\n    \"deepDiveExplanation\": \"NREM Stage 3 (N3), also known as slow-wave sleep (SWS), is characterized by the presence of high-amplitude, low-frequency delta waves (0.5-2 Hz). For N3 sleep, delta waves must comprise 20% or more of the epoch. This is a key diagnostic criterion in polysomnography.\",\n    \"highYieldPearl\": \"NREM Stage 3 = Slow Wave Sleep = Delta waves >20%.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A describes NREM Stage 2. Option C describes relaxed wakefulness. Option D (sawtooth waves) are characteristic of REM sleep. The percentage threshold for delta waves is critical for N3 definition.\"\n  },\n  {\n    \"question\": \"The Suprachiasmatic Nucleus (SCN) of the hypothalamus is the primary regulator of which physiological process?\",\n    \"options\": {\n      \"A\": \"REM sleep generation\",\n      \"B\": \"Sleep-wake homeostasis\",\n      \"C\": \"Circadian rhythmicity\",\n      \"D\": \"Muscle atonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sleep_physiology\",\n    \"deepDiveExplanation\": \"The Suprachiasmatic Nucleus (SCN), located in the anterior hypothalamus, is the master circadian pacemaker in mammals. It receives direct light input from the retina via the retinohypothalamic tract and synchronizes endogenous biological rhythms, including the sleep-wake cycle, with the external light-dark cycle.\",\n    \"highYieldPearl\": \"SCN = Master Circadian Clock.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"REM sleep generation involves brainstem nuclei. Sleep-wake homeostasis is regulated by the accumulation of sleep drive (e.g., adenosine). Muscle atonia is a feature of REM sleep, mediated by brainstem/spinal cord mechanisms, not the SCN.\"\n  },\n  {\n    \"question\": \"Which thermoregulatory change is characteristic of REM sleep?\",\n    \"options\": {\n      \"A\": \"Increased shivering threshold\",\n      \"B\": \"Decreased sweating threshold\",\n      \"C\": \"Poikilothermy\",\n      \"D\": \"Stable core body temperature\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sleep_physiology\",\n    \"deepDiveExplanation\": \"During REM sleep, the body's thermoregulatory mechanisms are effectively suspended. This leads to a state of 'poikilothermy' or 'cold-bloodedness,' where the body loses its ability to maintain a stable core temperature through shivering, sweating, or vasoconstriction/dilation in response to environmental changes. This is distinct from NREM sleep where thermoregulation is actively maintained.\",\n    \"highYieldPearl\": \"REM sleep is characterized by poikilothermy (loss of thermoregulation).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While shivering and sweating thresholds are indeed altered during REM sleep (e.g., suppressed heat loss responses), the overarching characteristic is the complete failure of thermoregulation, leading to poikilothermy. Stable core body temperature is generally maintained during NREM sleep.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-493.2113037109375}],"createTime":"2025-12-31T07:46:35.482377Z","modelVersion":"gemini-2.5-flash","responseId":"29RUacm4HfrDvPEPlfOwQQ","usageMetadata":{"billablePromptUsage":{"textCount":1037},"candidatesTokenCount":1380,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1380}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":1996,"totalTokenCount":3739,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:48:02.154164+00:00"}
{"metadata":"one-liner|cxr|Chest X-Ray Interpretation|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Chest X-Ray Interpretation\".\nSet the \"topic\" field in the JSON to \"cxr\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3924827632365574,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The absence of a clear heart border due to an adjacent opacity on CXR is termed?\",\n    \"options\": {\n      \"A\": \"Air bronchogram\",\n      \"B\": \"Silhouette sign\",\n      \"C\": \"Deep sulcus sign\",\n      \"D\": \"Westermark sign\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"The silhouette sign occurs when two objects of the same radiographic density are in direct contact, obscuring their common border. On CXR, if a pulmonary opacity is contiguous with the heart border or diaphragm, their interface is lost, indicating the opacity is in the same anatomical plane (e.g., right middle lobe pneumonia silhouetting the right heart border).\",\n    \"highYieldPearl\": \"Loss of a diaphragm or heart border indicates a pathology in the anterior or posterior segment of the lung lobe adjacent to that structure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Candidates might confuse it with air bronchogram (air in bronchi within consolidation) or deep sulcus sign (pneumothorax), which are distinct CXR findings.\"\n  },\n  {\n    \"question\": \"Air bronchograms on chest X-ray typically indicate which type of pathology?\",\n    \"options\": {\n      \"A\": \"Obstructive atelectasis\",\n      \"B\": \"Pneumothorax\",\n      \"C\": \"Alveolar filling disease\",\n      \"D\": \"Interstitial lung disease\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"Air bronchograms are visible branching lucencies within an area of consolidated lung. They occur when alveoli are filled with fluid (pus, blood, edema, cells) but the bronchi remain air-filled and patent. This sign is highly suggestive of an alveolar filling process (e.g., pneumonia, pulmonary edema, hemorrhage, non-obstructive atelectasis).\",\n    \"highYieldPearl\": \"Air bronchograms indicate patent airways within an opacified lung, strongly suggesting an alveolar process.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Differentiating alveolar filling disease from interstitial lung disease (where air bronchograms are typically absent) or obstructive atelectasis (where bronchi are usually collapsed).\"\n  },\n  {\n    \"question\": \"A peripheral, wedge-shaped pleural-based opacity on CXR is known as?\",\n    \"options\": {\n      \"A\": \"Westermark sign\",\n      \"B\": \"Hampton's hump\",\n      \"C\": \"Fleischner sign\",\n      \"D\": \"Golden S sign\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"Hampton's hump is a triangular or wedge-shaped opacity in the periphery of the lung with its base against the pleura, often seen in pulmonary embolism (PE) with infarction. It represents hemorrhagic infarction of the lung parenchyma due to ischemia from the embolism. It is an uncommon finding but highly suggestive when present in the right clinical context.\",\n    \"highYieldPearl\": \"Hampton's hump is a sign of pulmonary infarction, typically seen days after a PE.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing it with other named CXR signs for different pathologies. Westermark and Fleischner signs are also associated with PE but describe different findings.\"\n  },\n  {\n    \"question\": \"Regional oligemia distal to a dilated pulmonary artery on CXR suggests?\",\n    \"options\": {\n      \"A\": \"Congestive heart failure\",\n      \"B\": \"Pulmonary embolism\",\n      \"C\": \"Bronchiectasis\",\n      \"D\": \"Pneumonia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"The Westermark sign is a rare but highly specific CXR finding for pulmonary embolism. It consists of regional oligemia (decreased vascular markings and lucency) in the lung distal to a dilated pulmonary artery (due to the clot). This reflects the reduced blood flow to the affected lung segment.\",\n    \"highYieldPearl\": \"Westermark sign represents hypoperfusion distal to a pulmonary embolism, making the lung segment appear hyperlucent.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing it with other causes of regional lucency (e.g., obstructive emphysema, large bulla) or other signs of PE.\"\n  },\n  {\n    \"question\": \"Short horizontal lines found at the lung bases on CXR, representing interlobular septal edema, are called?\",\n    \"options\": {\n      \"A\": \"Kerley A lines\",\n      \"B\": \"Kerley B lines\",\n      \"C\": \"Kerley C lines\",\n      \"D\": \"Bat lines\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"Kerley B lines (also known as septal lines) are short, horizontal, thin lines (1-2 cm long) typically seen in the periphery of the lung bases, perpendicular to the pleural surface. They represent thickened, edematous interlobular septa due to fluid accumulation, often seen in pulmonary edema (e.g., congestive heart failure) or lymphangitic carcinomatosis.\",\n    \"highYieldPearl\": \"Kerley B lines are a classic sign of interstitial edema, most commonly due to left heart failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Differentiating Kerley B lines from Kerley A (longer, less common, more central) or C (reticular pattern).\"\n  },\n  {\n    \"question\": \"On a supine chest X-ray, an abnormally deep costophrenic sulcus suggests?\",\n    \"options\": {\n      \"A\": \"Pleural effusion\",\n      \"B\": \"Pneumothorax\",\n      \"C\": \"Diaphragmatic rupture\",\n      \"D\": \"Subpulmonic effusion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"The deep sulcus sign is observed on a supine chest X-ray and refers to an abnormally deepened and lucent costophrenic sulcus. This occurs when air in a pneumothorax collects in the most non-dependent part of the pleural cavity in a supine patient, extending into the costophrenic angle and appearing as a deep, dark recess. It is a crucial sign for diagnosing pneumothorax in patients who cannot be imaged erect.\",\n    \"highYieldPearl\": \"The deep sulcus sign is the most reliable CXR sign for pneumothorax in a supine patient.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Misinterpreting it as a normal variant or confusing it with a subpulmonic effusion (which would flatten the diaphragm rather than deepen the sulcus).\"\n  },\n  {\n    \"question\": \"Hilar lymph node calcification with a peripheral rim (eggshell calcification) on CXR is characteristic of?\",\n    \"options\": {\n      \"A\": \"Sarcoidosis\",\n      \"B\": \"Tuberculosis\",\n      \"C\": \"Silicosis\",\n      \"D\": \"Histoplasmosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"Eggshell calcification refers to a distinctive pattern of calcification in hilar or mediastinal lymph nodes, characterized by a peripheral rim of calcification surrounding a lucent center. While not exclusive, it is highly characteristic of silicosis, particularly chronic silicosis, and can also be seen in coal worker's pneumoconiosis.\",\n    \"highYieldPearl\": \"Eggshell calcification of hilar lymph nodes is a hallmark of silicosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing it with other types of lymph node calcification (e.g., diffuse, amorphous from TB or histoplasmosis) or sarcoidosis (where calcification is less typical and usually diffuse).\"\n  },\n  {\n    \"question\": \"Bilateral perihilar opacities resembling a butterfly or bat wings on CXR are characteristic of?\",\n    \"options\": {\n      \"A\": \"Lobar pneumonia\",\n      \"B\": \"Pulmonary fibrosis\",\n      \"C\": \"Pulmonary edema\",\n      \"D\": \"Miliary tuberculosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"The 'bat wing' or 'butterfly' appearance on CXR describes bilateral, symmetric perihilar opacities that spare the lung periphery. This pattern is classically seen in severe pulmonary edema, particularly cardiogenic pulmonary edema, where fluid accumulates predominantly in the central airspaces. Other causes include alveolar proteinosis and uremic pneumonitis.\",\n    \"highYieldPearl\": \"Bilateral perihilar 'bat wing' opacities are a classic sign of acute pulmonary edema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing it with diffuse infiltrates that extend to the periphery or other causes of bilateral opacities that do not spare the periphery.\"\n  },\n  {\n    \"question\": \"Increased vascular markings in the upper lung zones on an erect CXR, compared to lower zones, indicate?\",\n    \"options\": {\n      \"A\": \"Normal variant\",\n      \"B\": \"Pulmonary hypertension\",\n      \"C\": \"Early congestive heart failure\",\n      \"D\": \"Bronchiectasis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"In a healthy erect individual, hydrostatic pressure causes greater blood flow to the lung bases. Cephalization, or upper lobe diversion, describes the redistribution of blood flow to the upper lung zones, making their vascular markings more prominent than the lower zones. This is an early sign of increased pulmonary venous pressure, most commonly due to left ventricular failure (early pulmonary edema) or mitral stenosis.\",\n    \"highYieldPearl\": \"Cephalization is an early, subtle sign of increased pulmonary venous pressure, often preceding overt pulmonary edema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Considering it a normal variant (as upper lobe vessels are normally visible but less prominent than lower) or confusing it with pulmonary hypertension (which causes generalized vascular prominence and pruning, not just upper lobe diversion).\"\n  },\n  {\n    \"question\": \"A Ghon complex on CXR consists of a calcified primary tuberculous lesion and?\",\n    \"options\": {\n      \"A\": \"Pleural effusion\",\n      \"B\": \"Hilar lymph node calcification\",\n      \"C\": \"Cavitary lesion\",\n      \"D\": \"Bronchiectasis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cxr\",\n    \"deepDiveExplanation\": \"A Ghon complex represents the primary lesion of tuberculosis. It consists of a peripheral calcified granuloma (Ghon focus) in the lung parenchyma (typically subpleural in the mid-lung zones) and associated ipsilateral calcified hilar or mediastinal lymph nodes. When the Ghon complex undergoes fibrous encapsulation and calcification, it becomes a Ranke complex.\",\n    \"highYieldPearl\": \"A Ghon complex indicates past primary tuberculosis infection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing Ghon focus (the parenchymal lesion alone) with Ghon complex (parenchymal lesion + lymph node involvement), or Ghon complex with Ranke complex (a fully calcified Ghon complex).\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1056.5635986328125}],"createTime":"2025-12-31T07:46:26.342799Z","modelVersion":"gemini-2.5-flash","responseId":"0tRUaY_2FMO4nvgP96LnmAQ","usageMetadata":{"billablePromptUsage":{"textCount":1019},"candidatesTokenCount":2692,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2692}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":4196,"totalTokenCount":7251,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:40.658295+00:00"}
{"metadata":"one-liner|bal|Bronchoalveolar Lavage (BAL)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Bronchoalveolar Lavage (BAL)\".\nSet the \"topic\" field in the JSON to \"bal\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3952987935737233,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"A high CD4/CD8 ratio in bronchoalveolar lavage lymphocytes is most characteristic of:\",\n    \"options\": {\n      \"A\": \"Hypersensitivity Pneumonitis\",\n      \"B\": \"Idiopathic Pulmonary Fibrosis\",\n      \"C\": \"Sarcoidosis\",\n      \"D\": \"Drug-induced Lung Disease\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bal\",\n    \"deepDiveExplanation\": \"Sarcoidosis typically presents with a lymphocytic alveolitis, often with a CD4/CD8 ratio greater than 3.5, and sometimes even as high as 10. This ratio is a key diagnostic clue, differentiating it from other lymphocytic interstitial lung diseases like hypersensitivity pneumonitis, where the ratio is usually normal or inverted (CD8 predominant).\",\n    \"highYieldPearl\": \"A BAL CD4/CD8 ratio >3.5 is highly suggestive of sarcoidosis, while a ratio <1 is often seen in hypersensitivity pneumonitis or HIV-related lung diseases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hypersensitivity Pneumonitis also causes lymphocytic alveolitis, but usually with a normal or low CD4/CD8 ratio. Idiopathic Pulmonary Fibrosis typically shows neutrophilic predominance. Drug-induced lung disease can have varied BAL findings, including lymphocytosis, but a specific CD4/CD8 ratio is not as characteristic as in sarcoidosis.\"\n  },\n  {\n    \"question\": \"For diagnosing Pneumocystis jirovecii pneumonia (PCP), bronchoalveolar lavage has a sensitivity of approximately:\",\n    \"options\": {\n      \"A\": \"50-60%\",\n      \"B\": \"70-80%\",\n      \"C\": \"90-99%\",\n      \"D\": \"<50%\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bal\",\n    \"deepDiveExplanation\": \"Bronchoalveolar lavage (BAL) is considered the gold standard for diagnosing Pneumocystis jirovecii pneumonia (PCP) in patients unable to produce sputum. Its sensitivity ranges from 90% to 99%, making it highly effective for direct visualization of the organism using stains like Giemsa, Gomori methenamine silver (GMS), or immunofluorescence.\",\n    \"highYieldPearl\": \"BAL is highly sensitive for PCP diagnosis, especially in immunocompromised patients, surpassing induced sputum in diagnostic yield.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Sputum induction has lower sensitivity (50-90%) for PCP. Knowing the high diagnostic yield of BAL for PCP is crucial for patient management, particularly in HIV/AIDS patients.\"\n  },\n  {\n    \"question\": \"What is the predominant cell type typically observed in bronchoalveolar lavage fluid in Idiopathic Pulmonary Fibrosis?\",\n    \"options\": {\n      \"A\": \"Lymphocytes\",\n      \"B\": \"Neutrophils\",\n      \"C\": \"Eosinophils\",\n      \"D\": \"Mast cells\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bal\",\n    \"deepDiveExplanation\": \"In Idiopathic Pulmonary Fibrosis (IPF), bronchoalveolar lavage often reveals a predominant neutrophilia (typically >10%), sometimes accompanied by eosinophilia. This neutrophilic inflammation is thought to play a role in the pathogenesis of fibrosis, although BAL is not diagnostic for IPF but can help exclude other conditions.\",\n    \"highYieldPearl\": \"Neutrophilic alveolitis in BAL is a common finding in IPF, distinguishing it from conditions like sarcoidosis or hypersensitivity pneumonitis which show lymphocytosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Lymphocytosis is characteristic of sarcoidosis or hypersensitivity pneumonitis. Eosinophilia is seen in eosinophilic pneumonias or drug reactions. While IPF is a diagnosis of exclusion, BAL findings of neutrophilia are consistent with the disease process.\"\n  },\n  {\n    \"question\": \"Bronchoalveolar lavage in Acute Respiratory Distress Syndrome (ARDS) is primarily indicated for:\",\n    \"options\": {\n      \"A\": \"Therapeutic lavage\",\n      \"B\": \"Routine diagnosis of ARDS\",\n      \"C\": \"Exclusion of infection\",\n      \"D\": \"Prognostic assessment\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bal\",\n    \"deepDiveExplanation\": \"ARDS is a clinical diagnosis. BAL is not used for routine diagnosis or therapeutic lavage in ARDS. Its primary role in the context of ARDS is to exclude treatable causes of lung injury, particularly bacterial, fungal, or viral infections, which can mimic ARDS or complicate its course. It helps guide antimicrobial therapy.\",\n    \"highYieldPearl\": \"In ARDS, BAL is a diagnostic tool to rule out infection, not to diagnose ARDS itself or for therapeutic purposes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"ARDS is diagnosed clinically based on specific criteria (Berlin definition). Therapeutic lavage is not standard practice for ARDS. While BAL fluid can contain inflammatory markers, it's not a primary tool for prognostic assessment in ARDS.\"\n  },\n  {\n    \"question\": \"The characteristic finding in bronchoalveolar lavage fluid for Pulmonary Alveolar Proteinosis is:\",\n    \"options\": {\n      \"A\": \"High CD4/CD8 ratio\",\n      \"B\": \"Milky, turbid fluid with PAS-positive material\",\n      \"C\": \"Predominant eosinophilia\",\n      \"D\": \"High IgE levels\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bal\",\n    \"deepDiveExplanation\": \"Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of lipoproteinaceous material in the alveoli. Bronchoalveolar lavage fluid in PAP is typically milky or turbid due to this material, which stains positive with Periodic Acid-Schiff (PAS) stain. This finding is highly characteristic and often diagnostic.\",\n    \"highYieldPearl\": \"A 'milky' BAL fluid with PAS-positive lipoproteinaceous material is pathognomonic for Pulmonary Alveolar Proteinosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"A high CD4/CD8 ratio suggests sarcoidosis. Predominant eosinophilia is seen in eosinophilic pneumonias. High IgE levels are associated with allergic bronchopulmonary aspergillosis (ABPA) or severe asthma, but not directly with PAP BAL fluid characteristics.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-592.1575927734375}],"createTime":"2025-12-31T07:45:44.101999Z","modelVersion":"gemini-2.5-flash","responseId":"qNRUae-cBs6RhMIPz6CV4Q8","usageMetadata":{"billablePromptUsage":{"textCount":1020},"candidatesTokenCount":1498,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1498}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1310,"totalTokenCount":3172,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:05.447053+00:00"}
{"metadata":"one-liner|pe_treatment|Pulmonary Embolism - Treatment|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Embolism - Treatment\".\nSet the \"topic\" field in the JSON to \"pe_treatment\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4153370749912078,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which anticoagulant is commonly initiated as monotherapy for acute pulmonary embolism in hemodynamically stable patients?\",\n    \"options\": {\n      \"A\": \"Warfarin\",\n      \"B\": \"Unfractionated Heparin\",\n      \"C\": \"Low Molecular Weight Heparin\",\n      \"D\": \"Rivaroxaban\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Direct Oral Anticoagulants (DOACs) like Rivaroxaban and Apixaban can be initiated as monotherapy for acute pulmonary embolism in hemodynamically stable patients, bypassing the need for initial parenteral anticoagulation. Warfarin requires a parenteral bridge, while UFH and LMWH are parenteral and require subsequent oral anticoagulation.\",\n    \"highYieldPearl\": \"Rivaroxaban and Apixaban are the only DOACs approved for single-drug initiation and maintenance in PE.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing DOACs that require parenteral lead-in (e.g., dabigatran, edoxaban) with those that can be used directly (e.g., rivaroxaban, apixaban).\"\n  },\n  {\n    \"question\": \"Systemic thrombolysis for acute pulmonary embolism is primarily indicated in which patient presentation?\",\n    \"options\": {\n      \"A\": \"Submassive PE with stable hemodynamics\",\n      \"B\": \"Hemodynamically stable low-risk PE\",\n      \"C\": \"Massive PE with persistent hypotension\",\n      \"D\": \"Recurrent PE despite therapeutic anticoagulation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Systemic thrombolysis is indicated primarily for massive pulmonary embolism, defined by sustained hypotension (systolic BP < 90 mmHg or a drop of ≥ 40 mmHg from baseline), cardiogenic shock, or persistent profound bradycardia not due to other causes. It aims to rapidly restore pulmonary blood flow and improve right ventricular function.\",\n    \"highYieldPearl\": \"Massive PE with hemodynamic instability is the strongest indication for systemic thrombolysis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misidentifying 'submassive PE' as a primary indication, which might be considered in specific high-risk submassive cases but not as a primary indication for *all* submassive PEs.\"\n  },\n  {\n    \"question\": \"Which of the following is an absolute contraindication for systemic thrombolysis in acute pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"Age over 75 years\",\n      \"B\": \"Active peptic ulcer disease\",\n      \"C\": \"Prior intracranial hemorrhage\",\n      \"D\": \"Major surgery within two weeks\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Prior intracranial hemorrhage is a definitive absolute contraindication for systemic thrombolysis due to the extremely high risk of recurrent and often fatal intracranial bleeding. Other options listed are typically relative contraindications or increase bleeding risk but are not absolute bars.\",\n    \"highYieldPearl\": \"Intracranial hemorrhage history is the most critical contraindication to thrombolysis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing absolute versus relative contraindications for thrombolysis, which is critical for patient safety.\"\n  },\n  {\n    \"question\": \"What is the recommended minimum duration of anticoagulation for a first provoked pulmonary embolism due to a transient risk factor?\",\n    \"options\": {\n      \"A\": \"1 month\",\n      \"B\": \"3 months\",\n      \"C\": \"6 months\",\n      \"D\": \"12 months\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"For a first episode of pulmonary embolism provoked by a transient and reversible risk factor (e.g., surgery, trauma, estrogen therapy), the recommended minimum duration of anticoagulation is 3 months. This duration is usually sufficient to prevent recurrence once the transient risk factor is removed.\",\n    \"highYieldPearl\": \"3 months for provoked PE; longer for unprovoked or recurrent.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing duration for provoked versus unprovoked PE or VTE in general.\"\n  },\n  {\n    \"question\": \"What is the recommended minimum duration of anticoagulation for a first unprovoked pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"3 months\",\n      \"B\": \"6 months\",\n      \"C\": \"12 months\",\n      \"D\": \"Indefinite\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"For a first unprovoked pulmonary embolism, indefinite anticoagulation is generally recommended after the initial 3-6 month period, as the risk of recurrence is higher compared to provoked PE. The decision for indefinite therapy involves weighing the risk of recurrence against the risk of bleeding.\",\n    \"highYieldPearl\": \"Unprovoked PE often warrants indefinite anticoagulation due to higher recurrence risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Not recognizing the distinction between provoked and unprovoked PE regarding anticoagulation duration.\"\n  },\n  {\n    \"question\": \"The primary indication for inferior vena cava filter placement in acute pulmonary embolism is?\",\n    \"options\": {\n      \"A\": \"Recurrent PE on therapeutic anticoagulation\",\n      \"B\": \"Massive PE with hemodynamic instability\",\n      \"C\": \"Absolute contraindication to anticoagulation\",\n      \"D\": \"High risk of bleeding with anticoagulation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"The primary indication for an IVC filter is an absolute contraindication to anticoagulation in a patient with acute PE or DVT, or recurrent PE despite adequate anticoagulation. It is a mechanical measure to prevent PE, not a treatment for existing PE.\",\n    \"highYieldPearl\": \"IVC filters are for preventing PE when anticoagulation is contraindicated or ineffective.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Considering IVC filters as a first-line treatment for PE or confusing their role with active clot lysis.\"\n  },\n  {\n    \"question\": \"Which anticoagulant is generally preferred for the treatment of acute pulmonary embolism during pregnancy?\",\n    \"options\": {\n      \"A\": \"Warfarin\",\n      \"B\": \"Unfractionated Heparin\",\n      \"C\": \"Low Molecular Weight Heparin\",\n      \"D\": \"Rivaroxaban\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Low Molecular Weight Heparin (LMWH) is the preferred anticoagulant for treating acute PE during pregnancy. Unlike warfarin, it does not cross the placenta, thus avoiding teratogenic effects. UFH is also safe but requires more frequent monitoring and has a higher risk of heparin-induced thrombocytopenia (HIT). DOACs are generally contraindicated due to lack of safety data in pregnancy.\",\n    \"highYieldPearl\": \"LMWH is the safest and most effective anticoagulant for PE in pregnancy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Not knowing the teratogenic effects of warfarin or the lack of safety data for DOACs in pregnancy.\"\n  },\n  {\n    \"question\": \"The specific reversal agent for dabigatran in life-threatening bleeding associated with pulmonary embolism treatment is?\",\n    \"options\": {\n      \"A\": \"Protamine sulfate\",\n      \"B\": \"Idarucizumab\",\n      \"C\": \"Andexanet alfa\",\n      \"D\": \"Vitamin K\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Idarucizumab is a specific monoclonal antibody fragment that directly binds to dabigatran and reverses its anticoagulant effects. Protamine sulfate reverses heparin, Andexanet alfa reverses factor Xa inhibitors, and Vitamin K reverses warfarin.\",\n    \"highYieldPearl\": \"Idarucizumab for dabigatran, Andexanet alfa for factor Xa inhibitors.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing the specific reversal agents for different classes of anticoagulants.\"\n  },\n  {\n    \"question\": \"Catheter-directed thrombolysis for pulmonary embolism is particularly considered in massive PE with which additional factor?\",\n    \"options\": {\n      \"A\": \"Normal right ventricular function\",\n      \"B\": \"Low bleeding risk\",\n      \"C\": \"Absolute contraindication to systemic thrombolysis\",\n      \"D\": \"Prolonged symptoms for over 14 days\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"Catheter-directed thrombolysis (CDT) delivers a lower dose of thrombolytic directly to the clot, potentially reducing systemic bleeding risk. It is particularly considered in patients with massive PE who have an absolute contraindication to systemic thrombolysis, or in intermediate-high risk (submassive) PE with clinical worsening.\",\n    \"highYieldPearl\": \"CDT offers a regional thrombolysis option when systemic thrombolysis is too risky.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Not understanding the specific niche for CDT, which is often related to reducing systemic bleeding risk compared to full-dose systemic thrombolysis.\"\n  },\n  {\n    \"question\": \"Which laboratory test is primarily used to monitor the therapeutic effect of unfractionated heparin in acute pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"Prothrombin Time (PT) / INR\",\n      \"B\": \"Activated Partial Thromboplastin Time (aPTT)\",\n      \"C\": \"Anti-Xa levels\",\n      \"D\": \"Thrombin Time\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_treatment\",\n    \"deepDiveExplanation\": \"The Activated Partial Thromboplastin Time (aPTT) is the standard laboratory test used to monitor the therapeutic effect of unfractionated heparin (UFH). Anti-Xa levels are used for LMWH and sometimes for UFH in specific situations or if aPTT is unreliable.\",\n    \"highYieldPearl\": \"UFH: aPTT. LMWH/DOACs: Anti-Xa (if needed). Warfarin: INR.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing monitoring parameters for different anticoagulants, a common source of error.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1033.358642578125}],"createTime":"2025-12-31T07:45:52.802937Z","modelVersion":"gemini-2.5-flash","responseId":"sNRUafmAMd-zgLUPj-v-qAI","usageMetadata":{"billablePromptUsage":{"textCount":1031},"candidatesTokenCount":2488,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2488}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2285,"totalTokenCount":5139,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:17.598621+00:00"}
{"metadata":"one-liner|lung_cancer_mutations|EGFR, ALK, and Other Mutations|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"EGFR, ALK, and Other Mutations\".\nSet the \"topic\" field in the JSON to \"lung_cancer_mutations\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.26588825264362376,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"First-line treatment for advanced NSCLC with common activating EGFR mutations (Exon 19 deletion/L858R) is a/an?\",\n    \"options\": {\n      \"A\": \"Immunotherapy\",\n      \"B\": \"Platinum-based chemotherapy\",\n      \"C\": \"EGFR TKI\",\n      \"D\": \"ALK inhibitor\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"Activating EGFR mutations, primarily exon 19 deletions and L858R point mutations in exon 21, define a distinct subset of NSCLC that is highly sensitive to EGFR Tyrosine Kinase Inhibitors (TKIs). First-generation (e.g., gefitinib, erlotinib), second-generation (e.g., afatinib, dacomitinib), and third-generation (osimertinib) EGFR TKIs are standard first-line therapies, with osimertinib currently preferred due to superior efficacy and CNS penetration.\",\n    \"highYieldPearl\": \"Osimertinib is now the preferred first-line EGFR TKI for common EGFR mutations due to improved progression-free and overall survival, and better CNS activity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Candidates might be tempted by immunotherapy, but for oncogene-driven NSCLC, targeted therapy is superior to immunotherapy or chemotherapy as first-line. ALK inhibitors are for ALK rearrangements, not EGFR mutations.\"\n  },\n  {\n    \"question\": \"The most common acquired resistance mechanism to first-generation EGFR TKIs is a mutation in which exon?\",\n    \"options\": {\n      \"A\": \"Exon 18\",\n      \"B\": \"Exon 19\",\n      \"C\": \"Exon 20\",\n      \"D\": \"Exon 21\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"The EGFR T790M mutation, located in exon 20, is the most common acquired resistance mechanism (approximately 50-60% of cases) to first- and second-generation EGFR TKIs. This 'gatekeeper' mutation increases ATP affinity, reducing the effectiveness of these inhibitors. Third-generation EGFR TKIs like osimertinib were specifically designed to overcome T790M.\",\n    \"highYieldPearl\": \"T790M is located in EGFR exon 20 and is the primary target for third-generation EGFR TKIs after acquired resistance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While exons 19 and 21 harbor common activating mutations, exon 20 contains the crucial T790M resistance mutation. Misidentifying the exon for resistance vs. activation is a common pitfall.\"\n  },\n  {\n    \"question\": \"The gold standard for detecting ALK gene rearrangements in NSCLC is?\",\n    \"options\": {\n      \"A\": \"Immunohistochemistry (IHC)\",\n      \"B\": \"Fluorescence In Situ Hybridization (FISH)\",\n      \"C\": \"Polymerase Chain Reaction (PCR)\",\n      \"D\": \"Next-Generation Sequencing (NGS)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"While NGS is increasingly used for comprehensive genomic profiling and IHC is a sensitive screening tool, FISH for ALK break-apart probes has historically been considered the gold standard for definitive ALK rearrangement detection in NSCLC, validated in clinical trials leading to ALK inhibitor approvals. NGS can detect a broader range of fusion partners and is becoming the preferred method in many centers.\",\n    \"highYieldPearl\": \"FISH is the historical gold standard for ALK; NGS is the modern comprehensive approach.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"IHC is a good screening test, and NGS is comprehensive, but FISH remains the 'gold standard' often cited for ALK in exams, especially when a single best answer is required based on historical validation.\"\n  },\n  {\n    \"question\": \"Osimertinib is a third-generation EGFR TKI primarily targeting which EGFR mutation?\",\n    \"options\": {\n      \"A\": \"Exon 19 deletion\",\n      \"B\": \"L858R\",\n      \"C\": \"T790M\",\n      \"D\": \"Exon 20 insertion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"Osimertinib is highly effective against the EGFR T790M resistance mutation, which commonly emerges after treatment with first- or second-generation EGFR TKIs. It also effectively targets the common activating mutations (Exon 19 deletion and L858R) and is now approved as a first-line therapy for these as well.\",\n    \"highYieldPearl\": \"Osimertinib's unique strength lies in overcoming T790M resistance, in addition to its efficacy against common activating mutations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While Osimertinib also targets Exon 19 deletion and L858R, its *primary* and distinguishing target for its development and approval in the second-line setting was T790M.\"\n  },\n  {\n    \"question\": \"Crizotinib is approved for NSCLC harboring rearrangements in ALK and which other gene?\",\n    \"options\": {\n      \"A\": \"EGFR\",\n      \"B\": \"KRAS\",\n      \"C\": \"ROS1\",\n      \"D\": \"BRAF\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"Crizotinib, a first-generation ALK inhibitor, is also active against ROS1 rearrangements. ROS1-rearranged NSCLC shares clinical and pathological features with ALK-rearranged NSCLC and responds well to ALK/ROS1 TKIs.\",\n    \"highYieldPearl\": \"Crizotinib is a dual ALK/ROS1 inhibitor.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While ALK is well-known for crizotinib, remembering its activity against ROS1 is key. The other options are distinct oncogenic drivers with different targeted therapies.\"\n  },\n  {\n    \"question\": \"Treatment for BRAF V600E mutated NSCLC typically involves combination therapy with a BRAF inhibitor and a/an?\",\n    \"options\": {\n      \"A\": \"ALK inhibitor\",\n      \"B\": \"MEK inhibitor\",\n      \"C\": \"EGFR TKI\",\n      \"D\": \"PD-1 inhibitor\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"BRAF V600E mutations activate the MAPK pathway. While BRAF inhibitors (e.g., dabrafenib) are effective, combining them with MEK inhibitors (e.g., trametinib) provides synergistic inhibition, reduces resistance, and improves outcomes in BRAF V600E-mutated NSCLC, similar to melanoma.\",\n    \"highYieldPearl\": \"BRAF V600E treatment in NSCLC mimics melanoma: BRAF inhibitor + MEK inhibitor combination.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Knowing that BRAF mutations are part of the MAPK pathway helps identify MEK as the logical co-target. The other options are for different molecular targets.\"\n  },\n  {\n    \"question\": \"Which molecular testing method is most sensitive for detecting MET exon 14 skipping mutations?\",\n    \"options\": {\n      \"A\": \"FISH\",\n      \"B\": \"Immunohistochemistry (IHC)\",\n      \"C\": \"RNA-based sequencing\",\n      \"D\": \"DNA-based sequencing\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"MET exon 14 skipping mutations are splice site mutations that lead to the skipping of exon 14 during mRNA transcription. Since these are RNA-level events affecting splicing, RNA-based sequencing (e.g., RNA-seq) is superior to DNA-based sequencing for their detection, as DNA sequencing might miss the functional consequence of the splice site alteration.\",\n    \"highYieldPearl\": \"For splice variants like MET exon 14 skipping, RNA-based sequencing offers higher sensitivity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While DNA-based NGS is common, understanding the nature of a splice mutation (affecting RNA processing) points to RNA-based methods as more sensitive. FISH and IHC are not appropriate for this type of mutation.\"\n  },\n  {\n    \"question\": \"Sotorasib is a targeted therapy specifically approved for NSCLC patients with which mutation?\",\n    \"options\": {\n      \"A\": \"EGFR L858R\",\n      \"B\": \"ALK fusion\",\n      \"C\": \"KRAS G12C\",\n      \"D\": \"RET fusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"KRAS G12C is a specific subtype of KRAS mutation, historically considered 'undruggable.' Sotorasib (and adagrasib) are the first direct KRAS G12C inhibitors approved, marking a significant breakthrough in targeted therapy for NSCLC.\",\n    \"highYieldPearl\": \"Sotorasib is a landmark drug, the first approved direct KRAS G12C inhibitor.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"KRAS has long been a challenging target. Sotorasib's approval for the G12C subtype is a recent, high-yield development. Confusing it with other common targets is the main trap.\"\n  },\n  {\n    \"question\": \"Amivantamab is a bispecific antibody targeting EGFR and MET for NSCLC with which specific EGFR mutation?\",\n    \"options\": {\n      \"A\": \"L858R\",\n      \"B\": \"Exon 19 deletion\",\n      \"C\": \"T790M\",\n      \"D\": \"Exon 20 insertion\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"EGFR exon 20 insertion mutations are distinct from common EGFR mutations (Exon 19 deletion, L858R) and are generally resistant to first- and second-generation EGFR TKIs. Amivantamab is a bispecific antibody designed to target both EGFR and MET, offering a specific treatment option for this challenging mutation.\",\n    \"highYieldPearl\": \"Amivantamab is a key targeted therapy for the previously hard-to-treat EGFR Exon 20 insertion mutations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EGFR exon 20 insertions are often confused with the T790M resistance mutation (also in exon 20) or the common activating mutations. Knowing the specific drug for this distinct mutation is crucial.\"\n  },\n  {\n    \"question\": \"Selpercatinib is a highly selective inhibitor approved for NSCLC with fusions involving which gene?\",\n    \"options\": {\n      \"A\": \"BRAF\",\n      \"B\": \"ROS1\",\n      \"C\": \"RET\",\n      \"D\": \"HER2\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_mutations\",\n    \"deepDiveExplanation\": \"RET rearrangements (fusions) define a small but distinct molecular subset of NSCLC. Selpercatinib is a potent and highly selective RET inhibitor specifically approved for the treatment of RET fusion-positive NSCLC, as well as medullary thyroid cancer and other RET-altered thyroid cancers.\",\n    \"highYieldPearl\": \"Selpercatinib and pralsetinib are highly selective RET inhibitors for RET fusion-positive NSCLC.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This tests direct knowledge of specific drugs for specific fusions. Confusing RET with other fusion genes like ALK or ROS1, which have their own inhibitors, is the main trap.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-763.3651733398438}],"createTime":"2025-12-31T07:45:53.242196Z","modelVersion":"gemini-2.5-flash","responseId":"sdRUaZTkDoHzgLUP9pvcyAs","usageMetadata":{"billablePromptUsage":{"textCount":1039},"candidatesTokenCount":2871,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2871}],"promptTokenCount":371,"promptTokensDetails":[{"modality":"TEXT","tokenCount":371}],"thoughtsTokenCount":1500,"totalTokenCount":4742,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:14.233835+00:00"}
{"metadata":"one-liner|sleep_copd|Sleep in COPD and Overlap Syndrome|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Sleep in COPD and Overlap Syndrome\".\nSet the \"topic\" field in the JSON to \"sleep_copd\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4117373781211021,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most significant prognostic consequence of COPD-OSA Overlap Syndrome is increased risk of:\",\n    \"options\": {\n      \"A\": \"Systemic hypertension\",\n      \"B\": \"Pulmonary hypertension\",\n      \"C\": \"Diabetes mellitus\",\n      \"D\": \"Atrial fibrillation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sleep_copd\",\n    \"deepDiveExplanation\": \"Overlap Syndrome (OCS) patients exhibit more severe nocturnal hypoxemia and hypercapnia than isolated COPD or OSA. This leads to more pronounced pulmonary vasoconstriction, resulting in higher rates of pulmonary hypertension, right heart failure, and increased mortality.\",\n    \"highYieldPearl\": \"OCS carries a worse prognosis than isolated COPD or OSA, primarily due to exacerbated nocturnal hypoxemia leading to severe pulmonary hypertension.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are comorbidities that can be associated with OSA or COPD, but pulmonary hypertension is particularly worsened and prognostically significant in the overlap, directly impacting mortality.\"\n  },\n  {\n    \"question\": \"Nocturnal hypoxemia in stable COPD patients is typically most severe during which sleep stage?\",\n    \"options\": {\n      \"A\": \"N1 sleep\",\n      \"B\": \"N2 sleep\",\n      \"C\": \"N3 sleep\",\n      \"D\": \"REM sleep\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"sleep_copd\",\n    \"deepDiveExplanation\": \"During REM sleep, there is a significant reduction in ventilatory drive, marked hypotonia of upper airway muscles, and irregular breathing patterns. In COPD patients, this exacerbates V/Q mismatch and reduces functional residual capacity (FRC), leading to the most profound drops in oxygen saturation.\",\n    \"highYieldPearl\": \"REM sleep is characterized by the greatest respiratory instability and muscle hypotonia, making it the period of most severe hypoxemia in COPD patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While hypoxemia can occur in all sleep stages, its severity and duration are typically highest during REM sleep due to specific physiological changes that compromise ventilation and gas exchange.\"\n  },\n  {\n    \"question\": \"The recommended initial treatment for a patient diagnosed with severe COPD-OSA Overlap Syndrome is:\",\n    \"options\": {\n      \"A\": \"Nocturnal oxygen therapy alone\",\n      \"B\": \"Continuous Positive Airway Pressure (CPAP) alone\",\n      \"C\": \"CPAP combined with nocturnal oxygen therapy\",\n      \"D\": \"Bilevel Positive Airway Pressure (BiPAP)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sleep_copd\",\n    \"deepDiveExplanation\": \"In OCS, both airway collapse (OSA) and impaired gas exchange (COPD) contribute to nocturnal hypoxemia. CPAP addresses the OSA component by maintaining airway patency, while nocturnal oxygen therapy directly corrects the hypoxemia resulting from COPD's gas exchange abnormalities and the synergistic effects. This combined approach has shown superior outcomes in improving oxygenation and reducing mortality.\",\n    \"highYieldPearl\": \"For severe Overlap Syndrome, concurrent CPAP and nocturnal oxygen therapy is the preferred treatment to address both components effectively.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CPAP alone might not fully correct hypoxemia due to underlying COPD. Oxygen alone won't address the obstructive apneas. BiPAP might be considered if hypercapnia is prominent and CPAP fails, but the initial combination for severe OCS is typically CPAP + O2.\"\n  },\n  {\n    \"question\": \"Which of the following sleep architecture changes is most characteristic in stable COPD patients?\",\n    \"options\": {\n      \"A\": \"Increased total sleep time\",\n      \"B\": \"Increased REM sleep percentage\",\n      \"C\": \"Reduced N3 (slow-wave) sleep\",\n      \"D\": \"Decreased sleep latency\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"sleep_copd\",\n    \"deepDiveExplanation\": \"COPD patients often experience sleep fragmentation, reduced sleep efficiency, and alterations in sleep stages. Specifically, there is a reduction in slow-wave sleep (N3) and REM sleep, and an increase in lighter sleep stages (N1). This is due to factors like nocturnal hypoxemia, hypercapnia, cough, dyspnea, and medication side effects.\",\n    \"highYieldPearl\": \"Sleep fragmentation and reduced N3 and REM sleep are hallmarks of sleep disturbance in COPD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Increased total sleep time and decreased sleep latency are generally not characteristic. REM sleep is typically reduced, not increased, due to respiratory instability.\"\n  },\n  {\n    \"question\": \"Screening for Obstructive Sleep Apnea is particularly crucial in COPD patients primarily due to:\",\n    \"options\": {\n      \"A\": \"Higher prevalence of OSA in COPD\",\n      \"B\": \"Synergistic adverse effects on pulmonary and cardiovascular systems\",\n      \"C\": \"Increased risk of aspiration pneumonia\",\n      \"D\": \"Difficulty in interpreting spirometry results\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"sleep_copd\",\n    \"deepDiveExplanation\": \"While OSA prevalence is higher in COPD, the primary reason for aggressive screening is the 'synergistic' or 'additive' effect of both conditions. The combination leads to more severe nocturnal hypoxemia, hypercapnia, pulmonary hypertension, and increased cardiovascular morbidity and mortality compared to either condition alone. Identifying and treating OSA in COPD significantly improves prognosis.\",\n    \"highYieldPearl\": \"The heightened risk of severe nocturnal hypoxemia, pulmonary hypertension, and mortality due to the combined physiological stress makes OSA screening imperative in COPD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A (higher prevalence) is true but not the *primary* reason for *crucial* screening; the *consequences* of the overlap are the main driver. Aspiration risk is not a primary concern for OSA in COPD specifically. Spirometry interpretation is unrelated.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-577.6675415039063}],"createTime":"2025-12-31T07:45:11.223332Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUaeTQDYr8hMIPqeOUsAk","usageMetadata":{"billablePromptUsage":{"textCount":1030},"candidatesTokenCount":1403,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1403}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2232,"totalTokenCount":4001,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:57.006848+00:00"}
{"metadata":"one-liner|csa|Central Sleep Apnea|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Central Sleep Apnea\".\nSet the \"topic\" field in the JSON to \"csa\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.40077578875232006,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The hallmark feature distinguishing central sleep apnea from obstructive sleep apnea on polysomnography is:\",\n    \"options\": {\n      \"A\": \"Absence of airflow\",\n      \"B\": \"Absence of respiratory effort\",\n      \"C\": \"Presence of snoring\",\n      \"D\": \"Oxygen desaturation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"csa\",\n    \"deepDiveExplanation\": \"Central sleep apnea (CSA) is characterized by recurrent episodes of cessation of breathing during sleep due to a temporary lack of respiratory drive from the central nervous system, despite an open airway. This contrasts with obstructive sleep apnea (OSA), where respiratory effort is present but airflow is blocked by upper airway collapse. On polysomnography, the key differentiator is the absence of thoracoabdominal effort during an apneic event in CSA, while effort is preserved or increased in OSA.\",\n    \"highYieldPearl\": \"The presence or absence of respiratory effort is the definitive PSG criterion to differentiate central from obstructive apneic events.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A and D are common to both central and obstructive apneas. Option C (snoring) is a classic feature of OSA. The core distinction lies in the respiratory effort.\"\n  },\n  {\n    \"question\": \"Which condition is most commonly associated with Cheyne-Stokes breathing pattern in central sleep apnea?\",\n    \"options\": {\n      \"A\": \"Chronic Obstructive Pulmonary Disease\",\n      \"B\": \"Uncontrolled Hypertension\",\n      \"C\": \"Congestive Heart Failure\",\n      \"D\": \"Hypothyroidism\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"csa\",\n    \"deepDiveExplanation\": \"Cheyne-Stokes breathing (CSB) is a specific form of central sleep apnea characterized by a crescendo-decrescendo pattern of tidal volume, interspersed with central apneas or hypopneas. It is most commonly observed in patients with advanced congestive heart failure (CHF) and, less frequently, in patients with stroke or renal failure. The pathophysiology involves circulatory delay, increased ventilatory response to CO2, and ventilatory instability.\",\n    \"highYieldPearl\": \"Cheyne-Stokes breathing in central sleep apnea is a strong indicator of underlying cardiac dysfunction, particularly systolic heart failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other conditions can affect sleep or respiratory control, CHF is the classic and most frequent association for Cheyne-Stokes breathing CSA. COPD is typically linked to obstructive sleep apnea or chronic hypoventilation.\"\n  },\n  {\n    \"question\": \"The preferred positive airway pressure modality for Cheyne-Stokes breathing central sleep apnea is:\",\n    \"options\": {\n      \"A\": \"CPAP\",\n      \"B\": \"BiPAP S/T\",\n      \"C\": \"Adaptive Servo-Ventilation (ASV)\",\n      \"D\": \"Auto-CPAP\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"csa\",\n    \"deepDiveExplanation\": \"Adaptive Servo-Ventilation (ASV) is a specialized non-invasive positive pressure ventilation device designed to stabilize ventilatory drive in patients with central sleep apnea, particularly Cheyne-Stokes breathing. It delivers variable pressure support and a backup respiratory rate, adapting to the patient's own breathing pattern to prevent apneas and hypopneas. While CPAP and BiPAP can sometimes be used, ASV is specifically tailored for the ventilatory instability seen in CSB. However, ASV is contraindicated in patients with symptomatic chronic heart failure (LVEF ≤ 45%) and central sleep apnea, as the SERVE-HF trial showed increased mortality in this specific subgroup.\",\n    \"highYieldPearl\": \"ASV is highly effective for CSB-CSA but remember the contraindication in symptomatic chronic heart failure with reduced ejection fraction (HFrEF).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CPAP and BiPAP S/T are more commonly used for OSA or other hypoventilation syndromes. While CPAP can sometimes reduce central apneas, ASV provides a more sophisticated response to the fluctuating respiratory drive characteristic of CSB.\"\n  },\n  {\n    \"question\": \"High altitude periodic breathing, a form of central sleep apnea, is primarily driven by:\",\n    \"options\": {\n      \"A\": \"Alveolar hypoventilation\",\n      \"B\": \"Hypoxia-induced hyperventilation\",\n      \"C\": \"Upper airway collapse\",\n      \"D\": \"Metabolic alkalosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"csa\",\n    \"deepDiveExplanation\": \"At high altitude, the reduced partial pressure of oxygen (hypoxia) stimulates peripheral chemoreceptors, leading to an increase in minute ventilation (hyperventilation). This hyperventilation causes a decrease in arterial PCO2 (hypocapnia). The resulting hypocapnia then suppresses the central respiratory drive, leading to central apneas. As oxygen levels drop during the apnea, hypoxia recurs, stimulating breathing again, thus creating a periodic breathing pattern.\",\n    \"highYieldPearl\": \"Acetazolamide can mitigate high altitude periodic breathing by inducing metabolic acidosis, which counteracts the hypocapnia and stabilizes respiratory drive.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Alveolar hypoventilation is the *result* of the apnea, not the primary driver. Upper airway collapse is characteristic of OSA. Metabolic alkalosis is a *consequence* of prolonged hyperventilation, but the initial driver of the cycle is the hypoxia-induced hyperventilation.\"\n  },\n  {\n    \"question\": \"Which class of medications is a common cause of central sleep apnea due to direct respiratory drive suppression?\",\n    \"options\": {\n      \"A\": \"Beta-blockers\",\n      \"B\": \"Calcium channel blockers\",\n      \"C\": \"Opioids\",\n      \"D\": \"NSAIDs\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"csa\",\n    \"deepDiveExplanation\": \"Opioids are potent respiratory depressants that can directly suppress the central respiratory drive and alter the chemoreflexes, leading to central apneas and hypopneas, particularly during sleep. Chronic opioid use is an increasingly recognized cause of central sleep apnea, often presenting with a mixed pattern of central and ataxic breathing.\",\n    \"highYieldPearl\": \"Opioid-induced CSA is a significant concern, often requiring careful opioid management, and may respond to specific therapies like ASV if opioids cannot be discontinued.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Beta-blockers, calcium channel blockers, and NSAIDs do not typically cause central sleep apnea through direct respiratory drive suppression. Opioids are the classic drug class associated with this effect.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-620.8016967773438}],"createTime":"2025-12-31T07:46:22.648452Z","modelVersion":"gemini-2.5-flash","responseId":"ztRUaYTKJ_K53NoPy4ivuQM","usageMetadata":{"billablePromptUsage":{"textCount":1011},"candidatesTokenCount":1549,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1549}],"promptTokenCount":361,"promptTokensDetails":[{"modality":"TEXT","tokenCount":361}],"thoughtsTokenCount":1763,"totalTokenCount":3673,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:07.30539+00:00"}
{"metadata":"one-liner|lung_cancer_immuno|Lung Cancer - Immunotherapy|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Immunotherapy\".\nSet the \"topic\" field in the JSON to \"lung_cancer_immuno\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2799053992815449,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which immune checkpoint protein on tumor cells binds to PD-1 on T-cells to inhibit their activity?\",\n    \"options\": {\n      \"A\": \"CTLA-4\",\n      \"B\": \"LAG-3\",\n      \"C\": \"PD-L1\",\n      \"D\": \"TIM-3\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"PD-L1 (Programmed Death-Ligand 1) is expressed on tumor cells and antigen-presenting cells. It binds to PD-1 (Programmed Death-1) receptors on activated T-cells, leading to T-cell anergy, exhaustion, and suppression of anti-tumor immunity. Blocking this interaction with anti-PD-1 or anti-PD-L1 antibodies restores T-cell function and promotes tumor cell killing.\",\n    \"highYieldPearl\": \"The PD-1/PD-L1 axis is a critical target for immunotherapy in various cancers, including lung cancer, by preventing immune evasion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While CTLA-4, LAG-3, and TIM-3 are also immune checkpoints, PD-L1 is the specific ligand for PD-1 that is commonly expressed by tumor cells to evade T-cell attack.\"\n  },\n  {\n    \"question\": \"High PD-L1 expression in NSCLC is a strong predictive biomarker for monotherapy response to which class of drugs?\",\n    \"options\": {\n      \"A\": \"EGFR Tyrosine Kinase Inhibitors\",\n      \"B\": \"ALK Inhibitors\",\n      \"C\": \"PD-1/PD-L1 Checkpoint Inhibitors\",\n      \"D\": \"CTLA-4 Inhibitors\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"High PD-L1 expression (typically Tumor Proportion Score (TPS) ≥ 50%) in tumor cells is a well-established predictive biomarker for improved objective response rates and progression-free survival with anti-PD-1 or anti-PD-L1 monotherapy in the first-line setting for metastatic non-small cell lung cancer (NSCLC).\",\n    \"highYieldPearl\": \"PD-L1 TPS ≥ 50% is a key criterion for selecting first-line anti-PD-1 monotherapy in NSCLC without actionable mutations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EGFR and ALK inhibitors target specific oncogenic drivers, not related to PD-L1. While CTLA-4 inhibitors are immunotherapies, their efficacy is less directly correlated with PD-L1 expression compared to PD-1/PD-L1 inhibitors.\"\n  },\n  {\n    \"question\": \"Which immunotherapy agent is approved as consolidation therapy for unresectable Stage III NSCLC after chemoradiation?\",\n    \"options\": {\n      \"A\": \"Pembrolizumab\",\n      \"B\": \"Nivolumab\",\n      \"C\": \"Durvalumab\",\n      \"D\": \"Ipilimumab\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Durvalumab, an anti-PD-L1 antibody, is approved based on the PACIFIC trial for patients with unresectable Stage III NSCLC who have completed definitive platinum-based chemoradiation and have not progressed. It significantly improved progression-free survival and overall survival in this setting.\",\n    \"highYieldPearl\": \"Durvalumab consolidation is the standard of care for eligible patients with unresectable Stage III NSCLC post-chemoradiation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While Pembrolizumab and Nivolumab are also anti-PD-1 antibodies used in lung cancer, and Ipilimumab is an anti-CTLA-4, Durvalumab is specifically indicated and proven for the consolidation phase of unresectable Stage III NSCLC.\"\n  },\n  {\n    \"question\": \"The most common immune-related adverse event (irAE) affecting the endocrine system due to checkpoint inhibitors is?\",\n    \"options\": {\n      \"A\": \"Immune Colitis\",\n      \"B\": \"Immune Pneumonitis\",\n      \"C\": \"Hypophysitis\",\n      \"D\": \"Immune Dermatitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Hypophysitis (inflammation of the pituitary gland) is the most frequent endocrine irAE, often leading to deficiencies in various pituitary hormones (e.g., ACTH, TSH, growth hormone). Other common endocrine irAEs include thyroiditis and adrenal insufficiency.\",\n    \"highYieldPearl\": \"Endocrine irAEs, especially hypophysitis and thyroiditis, often require lifelong hormone replacement therapy, even after immunotherapy discontinuation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Colitis, pneumonitis, and dermatitis are common irAEs but affect the gastrointestinal, respiratory, and integumentary systems, respectively, not primarily the endocrine system.\"\n  },\n  {\n    \"question\": \"Which dual immunotherapy combination targets both PD-1 and CTLA-4 pathways?\",\n    \"options\": {\n      \"A\": \"Pembrolizumab + Atezolizumab\",\n      \"B\": \"Nivolumab + Ipilimumab\",\n      \"C\": \"Durvalumab + Tremelimumab\",\n      \"D\": \"Atezolizumab + Bevacizumab\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Nivolumab is an anti-PD-1 antibody, and Ipilimumab is an anti-CTLA-4 antibody. Their combination provides a synergistic blockade of two distinct immune checkpoints, leading to enhanced T-cell activation and anti-tumor responses, albeit with increased toxicity.\",\n    \"highYieldPearl\": \"Dual checkpoint inhibition with anti-PD-1 and anti-CTLA-4 agents is used in NSCLC (e.g., Nivolumab + Ipilimumab) and other cancers like melanoma and renal cell carcinoma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Pembrolizumab and Atezolizumab are both PD-1/PD-L1 inhibitors (not dual pathway). Durvalumab (anti-PD-L1) + Tremelimumab (anti-CTLA-4) is another dual checkpoint combination but Nivolumab + Ipilimumab is the most commonly recognized example. Atezolizumab + Bevacizumab combines immunotherapy with an anti-VEGF agent.\"\n  },\n  {\n    \"question\": \"For first-line metastatic NSCLC with PD-L1 TPS < 1%, which immunotherapy strategy is generally preferred?\",\n    \"options\": {\n      \"A\": \"Pembrolizumab monotherapy\",\n      \"B\": \"Nivolumab monotherapy\",\n      \"C\": \"Chemotherapy alone\",\n      \"D\": \"Chemo-immunotherapy combination\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"For patients with metastatic NSCLC and low (TPS < 1%) or negative PD-L1 expression, combining immunotherapy (e.g., pembrolizumab or atezolizumab) with platinum-based chemotherapy has demonstrated superior overall survival and progression-free survival compared to chemotherapy alone. Monotherapy with PD-1/PD-L1 inhibitors is less effective in this PD-L1 low/negative subgroup.\",\n    \"highYieldPearl\": \"PD-L1 expression is a critical determinant for first-line treatment selection in advanced NSCLC without actionable mutations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Monotherapy with PD-1 inhibitors (A, B) is primarily reserved for high PD-L1 expressors. Chemotherapy alone (C) is now considered suboptimal for most patients due to the improved outcomes with chemo-immunotherapy combinations.\"\n  },\n  {\n    \"question\": \"The initial increase in tumor size or appearance of new lesions, followed by subsequent tumor regression on immunotherapy, is termed?\",\n    \"options\": {\n      \"A\": \"Tumor flare\",\n      \"B\": \"Hyperprogressive disease\",\n      \"C\": \"Pseudo-progression\",\n      \"D\": \"Immune escape\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Pseudo-progression is a phenomenon observed in patients treated with immunotherapy where an initial increase in tumor size or the development of new lesions is attributed to immune cell infiltration into the tumor, rather than actual tumor growth. This is followed by eventual tumor shrinkage. It highlights the need for continued treatment beyond initial radiographic progression if the patient is clinically stable.\",\n    \"highYieldPearl\": \"Pseudo-progression necessitates careful clinical judgment and often a confirmatory scan before discontinuing effective immunotherapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hyperprogressive disease involves an accelerated rate of tumor growth compared to baseline. Tumor flare refers to a temporary worsening of symptoms or radiographic findings, often seen with targeted therapies. Immune escape refers to mechanisms by which tumors evade immune surveillance.\"\n  },\n  {\n    \"question\": \"Beyond PD-L1, which biomarker is increasingly recognized for predicting immunotherapy response in NSCLC?\",\n    \"options\": {\n      \"A\": \"EGFR mutation status\",\n      \"B\": \"ALK rearrangement\",\n      \"C\": \"Tumor Mutational Burden (TMB)\",\n      \"D\": \"KRAS mutation status\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Tumor Mutational Burden (TMB), defined as the total number of somatic mutations per megabase of sequenced DNA, correlates with the number of neoantigens presented by tumor cells. Higher TMB is generally associated with improved response rates and survival benefit from immune checkpoint inhibitors across various cancers, including NSCLC.\",\n    \"highYieldPearl\": \"High TMB can predict response to immunotherapy, especially in PD-L1 low/negative tumors, suggesting it's an independent biomarker.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EGFR, ALK, and KRAS mutations are oncogenic drivers and predictive biomarkers for targeted therapies, not directly for immunotherapy response in the same way as TMB or PD-L1. In fact, EGFR-mutated NSCLC typically responds poorly to immunotherapy.\"\n  },\n  {\n    \"question\": \"Which immunotherapy agent is approved for extensive-stage Small Cell Lung Cancer (ES-SCLC) in combination with chemotherapy?\",\n    \"options\": {\n      \"A\": \"Pembrolizumab\",\n      \"B\": \"Nivolumab\",\n      \"C\": \"Atezolizumab\",\n      \"D\": \"Ipilimumab\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"Atezolizumab (anti-PD-L1) was the first immunotherapy approved for first-line treatment of extensive-stage SCLC in combination with carboplatin and etoposide, based on the IMpower133 trial. Durvalumab (anti-PD-L1) has also since been approved for this indication based on the CASPIAN trial.\",\n    \"highYieldPearl\": \"Immunotherapy has revolutionized the treatment landscape for ES-SCLC, offering a modest but significant survival benefit over chemotherapy alone.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While Pembrolizumab, Nivolumab, and Ipilimumab are used in NSCLC and other cancers, Atezolizumab (and Durvalumab) are the specific anti-PD-L1 agents established for first-line ES-SCLC in combination with chemotherapy.\"\n  },\n  {\n    \"question\": \"First-line treatment for Grade 3/4 immune-related pneumonitis due to checkpoint inhibitors typically involves?\",\n    \"options\": {\n      \"A\": \"Bronchodilators\",\n      \"B\": \"High-dose systemic corticosteroids\",\n      \"C\": \"Anti-fibrotic agents\",\n      \"D\": \"Broad-spectrum antibiotics\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_immuno\",\n    \"deepDiveExplanation\": \"For severe (Grade 3 or 4) immune-related adverse events (irAEs) like pneumonitis, the standard first-line management involves holding the immunotherapy and initiating high-dose systemic corticosteroids (e.g., prednisone 1-2 mg/kg/day). If there's no improvement, other immunosuppressants like infliximab or mycophenolate mofetil may be considered.\",\n    \"highYieldPearl\": \"Early recognition and aggressive immunosuppression with corticosteroids are crucial for managing severe irAEs and preventing permanent organ damage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Bronchodilators might be used symptomatically but don't address the underlying immune inflammation. Anti-fibrotic agents are for established fibrosis, not acute inflammation. Antibiotics are for infection, not immune-mediated inflammation, unless a secondary infection is suspected.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-860.1492919921875}],"createTime":"2025-12-31T07:45:31.687066Z","modelVersion":"gemini-2.5-flash","responseId":"m9RUadr3KYu7gLUPyPyzsAI","usageMetadata":{"billablePromptUsage":{"textCount":1034},"candidatesTokenCount":3073,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3073}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":2356,"totalTokenCount":5796,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:13.399262+00:00"}
{"metadata":"one-liner|ph_diagnosis|Pulmonary Hypertension - Diagnosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Hypertension - Diagnosis\".\nSet the \"topic\" field in the JSON to \"ph_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.258787072726142,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The gold standard for definitive diagnosis of pulmonary hypertension is?\",\n    \"options\": {\n      \"A\": \"Echocardiography\",\n      \"B\": \"CT Pulmonary Angiography\",\n      \"C\": \"Right Heart Catheterization\",\n      \"D\": \"Cardiopulmonary Exercise Test\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Right Heart Catheterization (RHC) is the gold standard for diagnosing pulmonary hypertension (PH) as it directly measures pulmonary artery pressures, pulmonary capillary wedge pressure, and cardiac output, allowing for accurate calculation of pulmonary vascular resistance and classification of PH type (pre-capillary, post-capillary, or combined).\",\n    \"highYieldPearl\": \"RHC provides direct hemodynamic measurements essential for PH diagnosis and classification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Echocardiography is an excellent screening tool but provides estimated pressures. CTPA is crucial for CTEPH and other lung pathologies but not for definitive hemodynamic diagnosis. CPET assesses functional capacity but not direct pressures.\"\n  },\n  {\n    \"question\": \"According to current guidelines, the mean pulmonary artery pressure (mPAP) threshold for diagnosing pulmonary hypertension at rest is?\",\n    \"options\": {\n      \"A\": \">25 mmHg\",\n      \"B\": \">20 mmHg\",\n      \"C\": \">30 mmHg\",\n      \"D\": \">18 mmHg\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"The updated 2022 ESC/ERS guidelines for pulmonary hypertension define PH as a mean pulmonary artery pressure (mPAP) >20 mmHg at rest, measured by right heart catheterization. Previously, the threshold was >25 mmHg.\",\n    \"highYieldPearl\": \"The diagnostic mPAP threshold has been lowered to >20 mmHg in recent guidelines.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The >25 mmHg threshold was used in older guidelines. Knowing this recent update is crucial for current exams.\"\n  },\n  {\n    \"question\": \"Pre-capillary pulmonary hypertension is hemodynamically defined by mPAP >20 mmHg, PVR >2 Wood Units, and a pulmonary capillary wedge pressure (PCWP) of?\",\n    \"options\": {\n      \"A\": \">15 mmHg\",\n      \"B\": \"≤15 mmHg\",\n      \"C\": \">18 mmHg\",\n      \"D\": \"≤12 mmHg\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Pre-capillary PH is characterized by elevated mPAP (>20 mmHg) and pulmonary vascular resistance (PVR >2 Wood Units) in the presence of a normal or low pulmonary capillary wedge pressure (PCWP ≤15 mmHg), indicating the primary pathology is in the pulmonary arterioles.\",\n    \"highYieldPearl\": \"Pre-capillary PH = high mPAP, high PVR, normal/low PCWP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"A PCWP >15 mmHg with elevated mPAP would indicate post-capillary PH (Group 2), often due to left heart disease.\"\n  },\n  {\n    \"question\": \"The recommended initial non-invasive screening test for suspected pulmonary hypertension is?\",\n    \"options\": {\n      \"A\": \"Chest X-ray\",\n      \"B\": \"Electrocardiogram (ECG)\",\n      \"C\": \"Transthoracic Echocardiography\",\n      \"D\": \"Pulmonary Function Tests (PFTs)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Transthoracic echocardiography is the primary screening tool for PH due to its ability to estimate pulmonary artery systolic pressure, assess right ventricular size and function, and evaluate for left heart disease, which can cause PH.\",\n    \"highYieldPearl\": \"Echocardiography is the first-line non-invasive test for PH screening.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Chest X-ray and ECG can show signs suggestive of PH (e.g., RV hypertrophy, prominent pulmonary arteries) but are non-specific. PFTs help identify underlying lung disease but don't directly screen for PH hemodynamics.\"\n  },\n  {\n    \"question\": \"The recommended initial imaging test to rule out Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in a patient with suspected PH is?\",\n    \"options\": {\n      \"A\": \"CT Pulmonary Angiography (CTPA)\",\n      \"B\": \"Ventilation/Perfusion (V/Q) Scan\",\n      \"C\": \"MRI Pulmonary Angiography\",\n      \"D\": \"Digital Subtraction Angiography (DSA)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"A V/Q scan is highly sensitive for detecting chronic thromboembolic disease and is the recommended initial imaging modality for screening CTEPH. A normal V/Q scan effectively rules out CTEPH. If abnormal, CTPA or DSA are then used for detailed anatomical assessment.\",\n    \"highYieldPearl\": \"V/Q scan is the most sensitive screening test for CTEPH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CTPA is excellent for acute PE and characterizing CTEPH once suspected, but its sensitivity for chronic thromboembolic disease is lower than V/Q scan. DSA is the gold standard for detailed vascular anatomy but is invasive and not a screening test.\"\n  },\n  {\n    \"question\": \"Vasoreactivity testing during right heart catheterization is primarily performed in which group of pulmonary hypertension?\",\n    \"options\": {\n      \"A\": \"Group 1: Pulmonary Arterial Hypertension (PAH)\",\n      \"B\": \"Group 2: PH due to Left Heart Disease\",\n      \"C\": \"Group 3: PH due to Lung Diseases and/or Hypoxia\",\n      \"D\": \"Group 4: Chronic Thromboembolic PH (CTEPH)\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Vasoreactivity testing is crucial in Group 1 PAH (especially idiopathic, heritable, or drug/toxin-induced PAH) to identify patients who may respond to calcium channel blockers. It is not recommended for other PH groups.\",\n    \"highYieldPearl\": \"Vasoreactivity testing guides treatment in specific Group 1 PAH patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Vasoreactivity testing has no role or is potentially harmful in other PH groups, as their underlying pathologies are not primarily vasoreactive.\"\n  },\n  {\n    \"question\": \"Which biomarker is most commonly used for prognostic assessment and monitoring disease progression in pulmonary hypertension?\",\n    \"options\": {\n      \"A\": \"C-reactive protein (CRP)\",\n      \"B\": \"D-dimer\",\n      \"C\": \"N-terminal pro-B-type natriuretic peptide (NT-proBNP)\",\n      \"D\": \"High-sensitivity Troponin I\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"NT-proBNP (or BNP) levels correlate with right ventricular dysfunction and hemodynamic severity in PH. Elevated levels indicate worse prognosis and are used for risk stratification and monitoring treatment response.\",\n    \"highYieldPearl\": \"Elevated BNP/NT-proBNP signifies worse RV function and prognosis in PH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"CRP is a general inflammatory marker. D-dimer is for venous thromboembolism. Troponin indicates myocardial injury, which can occur in severe RV strain but is less specific for chronic PH monitoring than natriuretic peptides.\"\n  },\n  {\n    \"question\": \"Exercise right heart catheterization is primarily considered for diagnosing pulmonary hypertension in patients with?\",\n    \"options\": {\n      \"A\": \"Overt PH at rest\",\n      \"B\": \"Borderline PH at rest with unexplained dyspnea\",\n      \"C\": \"Severe tricuspid regurgitation\",\n      \"D\": \"Known CTEPH\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Exercise RHC may be considered in patients with unexplained dyspnea and borderline PH hemodynamics at rest (mPAP 18-20 mmHg) to unmask exercise-induced PH. It is not routinely recommended for established PH or specific conditions like CTEPH.\",\n    \"highYieldPearl\": \"Exercise RHC helps diagnose exercise-induced PH in symptomatic patients with borderline rest hemodynamics.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"For overt PH, rest RHC is sufficient. Severe TR is a consequence, not an indication for exercise RHC. CTEPH diagnosis relies on V/Q scan and angiography.\"\n  },\n  {\n    \"question\": \"Genetic testing for BMPR2 mutation is most relevant in the diagnostic workup of which PH group?\",\n    \"options\": {\n      \"A\": \"Group 1: Heritable Pulmonary Arterial Hypertension (PAH)\",\n      \"B\": \"Group 2: PH due to Left Heart Disease\",\n      \"C\": \"Group 3: PH due to Lung Diseases\",\n      \"D\": \"Group 5: PH with unclear multifactorial mechanisms\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene are the most common genetic cause of heritable PAH (a subgroup of Group 1 PAH). Genetic testing is recommended for all PAH patients to identify familial cases and inform counseling.\",\n    \"highYieldPearl\": \"BMPR2 mutation is a key genetic marker for heritable PAH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other PH groups can have genetic predispositions, BMPR2 is specifically linked to PAH and has significant diagnostic and prognostic implications within this group.\"\n  },\n  {\n    \"question\": \"High-resolution computed tomography (HRCT) of the chest in a PH workup is primarily used to assess for?\",\n    \"options\": {\n      \"A\": \"Right ventricular hypertrophy\",\n      \"B\": \"Pulmonary artery pressures\",\n      \"C\": \"Interstitial lung disease or emphysema\",\n      \"D\": \"Left atrial enlargement\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_diagnosis\",\n    \"deepDiveExplanation\": \"HRCT of the chest is crucial for identifying underlying lung parenchymal diseases, such as interstitial lung disease, emphysema, or other chronic lung conditions, which can cause Group 3 PH. It also helps rule out other causes like mediastinal fibrosis.\",\n    \"highYieldPearl\": \"HRCT identifies underlying lung disease causing Group 3 PH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While HRCT can show signs of RV hypertrophy or main pulmonary artery enlargement, it does not directly measure pressures (B). Left atrial enlargement is better assessed by echocardiography. Its primary role in PH workup is for parenchymal lung pathology.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-682.6802978515625}],"createTime":"2025-12-31T07:46:22.724567Z","modelVersion":"gemini-2.5-flash","responseId":"ztRUadecLN_2nvgPyOfVsAE","usageMetadata":{"billablePromptUsage":{"textCount":1035},"candidatesTokenCount":2638,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2638}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1340,"totalTokenCount":4342,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:48.053473+00:00"}
{"metadata":"one-liner|pe_diagnosis|Pulmonary Embolism - Diagnosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Embolism - Diagnosis\".\nSet the \"topic\" field in the JSON to \"pe_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4066346344403119,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The current gold standard imaging modality for diagnosing acute pulmonary embolism is?\",\n    \"options\": {\n      \"A\": \"Pulmonary angiography\",\n      \"B\": \"CT Pulmonary Angiography (CTPA)\",\n      \"C\": \"Ventilation-Perfusion (V/Q) scan\",\n      \"D\": \"MRI Chest\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"CT Pulmonary Angiography (CTPA) has largely replaced conventional pulmonary angiography as the definitive gold standard due to its non-invasiveness, speed, wide availability, and high sensitivity and specificity for acute PE, even for segmental and subsegmental emboli. It is the first-line imaging for hemodynamically stable patients with suspected PE.\",\n    \"highYieldPearl\": \"CTPA is the first-line and current gold standard imaging for stable PE diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Conventional pulmonary angiography was historically the gold standard but is invasive and rarely performed for diagnosis now. V/Q scan has limitations with abnormal chest X-ray. MRI is less commonly used due to availability, cost, and motion artifacts.\"\n  },\n  {\n    \"question\": \"In a hemodynamically unstable patient with suspected acute pulmonary embolism, the most appropriate initial diagnostic test is?\",\n    \"options\": {\n      \"A\": \"CT Pulmonary Angiography (CTPA)\",\n      \"B\": \"Transthoracic Echocardiography (TTE)\",\n      \"C\": \"Lower limb Doppler ultrasound\",\n      \"D\": \"D-dimer assay\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"For hemodynamically unstable patients, Transthoracic Echocardiography (TTE) can rapidly identify signs of right ventricular (RV) dysfunction/strain, estimate pulmonary artery pressures, and exclude other causes of shock (e.g., tamponade, severe LV dysfunction). If TTE shows RV strain and no other cause of shock, empiric PE treatment can be initiated while definitive imaging (if feasible) is considered. CTPA is often too time-consuming or risky for an unstable patient.\",\n    \"highYieldPearl\": \"TTE for unstable PE to assess RV function and rule out other causes of shock rapidly.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While CTPA is the gold standard for stable PE, an unstable patient may not tolerate transport or the time required. D-dimer is for exclusion in low probability, not for unstable patients. Lower limb Doppler confirms DVT but doesn't directly diagnose PE or RV strain.\"\n  },\n  {\n    \"question\": \"A normal D-dimer level reliably excludes pulmonary embolism in patients with which clinical probability?\",\n    \"options\": {\n      \"A\": \"High\",\n      \"B\": \"Intermediate\",\n      \"C\": \"Low or Intermediate\",\n      \"D\": \"Low\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"D-dimer is a highly sensitive but non-specific test. A normal D-dimer (below an age-adjusted threshold) can safely rule out PE in patients with a low or low-to-intermediate pre-test probability, as determined by clinical prediction rules (e.g., Wells' or revised Geneva score). It has a high negative predictive value. It should not be used to rule out PE in patients with a high clinical probability.\",\n    \"highYieldPearl\": \"Normal D-dimer safely excludes PE in low/intermediate probability patients (high NPV).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Many might exclusively choose 'D: Low'. However, current guidelines often extend its utility to intermediate probability when using age-adjusted cut-offs or specific algorithms (e.g., PERC rule). Choosing 'C' is more comprehensive and accurate based on modern algorithms.\"\n  },\n  {\n    \"question\": \"Ventilation-perfusion (V/Q) scanning is most useful for diagnosing pulmonary embolism in patients with what feature?\",\n    \"options\": {\n      \"A\": \"Abnormal chest X-ray\",\n      \"B\": \"Chronic obstructive pulmonary disease (COPD)\",\n      \"C\": \"Normal chest X-ray\",\n      \"D\": \"Severe renal impairment precluding contrast\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"V/Q scanning is most accurate and interpretable when the chest X-ray is normal, as a normal CXR allows for better assessment of V/Q mismatches without confounding from underlying parenchymal lung disease. In patients with an abnormal CXR or significant lung disease like COPD, V/Q scans are often non-diagnostic (intermediate probability). While severe renal impairment (D) is a reason to *choose* V/Q over CTPA, the *usefulness* and diagnostic yield of the V/Q scan itself are highest with a normal CXR.\",\n    \"highYieldPearl\": \"V/Q scan is most diagnostically useful with a normal chest X-ray.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Severe renal impairment (D) is a common contraindication for CTPA, making V/Q a preferred alternative, but it doesn't inherently make the V/Q scan *more useful* in terms of interpretability; a normal CXR does. COPD (B) would lead to multiple V/Q defects, making interpretation difficult.\"\n  },\n  {\n    \"question\": \"Which classic electrocardiogram (ECG) finding is associated with acute right heart strain in pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"S1Q3T3 pattern\",\n      \"B\": \"Left bundle branch block\",\n      \"C\": \"ST elevation in V1-V3\",\n      \"D\": \"Prolonged PR interval\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"The S1Q3T3 pattern (prominent S wave in lead I, Q wave in lead III, and inverted T wave in lead III) is a classic but relatively uncommon finding in acute massive PE, indicating acute right ventricular strain and dilatation. Other common ECG findings, though non-specific, include sinus tachycardia, incomplete right bundle branch block (RBBB), and T-wave inversions in V1-V4.\",\n    \"highYieldPearl\": \"S1Q3T3: classic ECG for acute RV strain in PE, indicative of severity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options are not specifically indicative of PE or RV strain. ST elevation suggests myocardial infarction. LBBB is a conduction defect. Prolonged PR interval suggests AV block.\"\n  },\n  {\n    \"question\": \"The most common arterial blood gas (ABG) abnormality observed in acute pulmonary embolism is?\",\n    \"options\": {\n      \"A\": \"Respiratory acidosis\",\n      \"B\": \"Metabolic alkalosis\",\n      \"C\": \"Respiratory alkalosis with hypoxemia\",\n      \"D\": \"Normal ABG\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"Acute PE typically causes a ventilation-perfusion (V/Q) mismatch, leading to hypoxemia. The hypoxemia stimulates peripheral chemoreceptors, increasing respiratory drive and causing hyperventilation, which results in a low PaCO2 (respiratory alkalosis). While some patients may have normal ABGs, respiratory alkalosis with hypoxemia is the most common and characteristic abnormality.\",\n    \"highYieldPearl\": \"PE often presents with hypoxemia and compensatory respiratory alkalosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Respiratory acidosis is less common and usually indicates severe respiratory compromise or co-existing conditions. Metabolic alkalosis is unrelated. While ABGs can be normal in small PEs, 'most common abnormality' points to C.\"\n  },\n  {\n    \"question\": \"For diagnosing pulmonary embolism in pregnant patients, which imaging modality is generally preferred due to radiation exposure concerns?\",\n    \"options\": {\n      \"A\": \"CT Pulmonary Angiography (CTPA)\",\n      \"B\": \"Ventilation-Perfusion (V/Q) scan\",\n      \"C\": \"Conventional pulmonary angiography\",\n      \"D\": \"Gadolinium-enhanced MRI\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"V/Q scanning is often preferred in pregnant patients because it delivers a lower radiation dose to the breasts (compared to CTPA), which is a significant concern during pregnancy due to the risk of radiation-induced breast cancer. While fetal radiation dose is comparable for both, breast dose often tips the balance towards V/Q, especially if the chest X-ray is normal. Gadolinium is generally avoided in pregnancy due to potential fetal risks.\",\n    \"highYieldPearl\": \"V/Q scan preferred in pregnancy due to lower breast radiation dose.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CTPA is also used in pregnancy, and some centers might prefer it if V/Q is inconclusive or CXR is abnormal. However, the question specifically asks for the 'generally preferred' option due to 'radiation exposure concerns' (implying breast dose), making V/Q the better answer.\"\n  },\n  {\n    \"question\": \"Clinical prediction rules like the Wells' or revised Geneva scores are primarily used in suspected PE to determine the?\",\n    \"options\": {\n      \"A\": \"Severity of PE\",\n      \"B\": \"Patient prognosis\",\n      \"C\": \"Pre-test probability of PE\",\n      \"D\": \"Optimal anticoagulant dose\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"These scores stratify patients into low, intermediate, or high pre-test probability categories based on clinical factors. This stratification is crucial for guiding subsequent diagnostic steps, such as whether to perform a D-dimer test or proceed directly to imaging (e.g., CTPA). They are not designed for assessing severity, prognosis, or determining treatment dosing.\",\n    \"highYieldPearl\": \"Wells/Geneva scores determine pre-test probability for PE, guiding further diagnostics.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While severity and prognosis are important aspects of PE, these scores specifically address the *likelihood* of PE *before* definitive testing. Other scores (e.g., PESI, sPESI) are used for prognosis.\"\n  },\n  {\n    \"question\": \"Elevated cardiac troponins and brain natriuretic peptide (BNP) in acute pulmonary embolism primarily indicate what?\",\n    \"options\": {\n      \"A\": \"Concomitant myocardial infarction\",\n      \"B\": \"Increased bleeding risk\",\n      \"C\": \"Right ventricular dysfunction and strain\",\n      \"D\": \"Left ventricular failure\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"In acute PE, increased pulmonary vascular resistance and right ventricular (RV) afterload lead to RV wall stress, ischemia, and dysfunction. This RV strain can cause the release of cardiac biomarkers like troponins (due to myocyte injury) and BNP (due to wall stretch). These biomarkers are crucial for risk stratification, indicating higher mortality risk and often guiding management decisions (e.g., thrombolysis consideration).\",\n    \"highYieldPearl\": \"Troponins/BNP in PE signal RV dysfunction and higher risk, not necessarily MI.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While troponins are primarily associated with MI, in the context of PE, their elevation signifies RV strain, not necessarily an MI. BNP is also associated with heart failure, but in PE, it's specific to RV stress rather than primary LV failure.\"\n  },\n  {\n    \"question\": \"When is lower limb compression ultrasonography most indicated in the diagnostic workup for suspected pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"As a first-line test in all patients\",\n      \"B\": \"When CTPA is equivocal or non-diagnostic\",\n      \"C\": \"High clinical suspicion with contraindications to CTPA\",\n      \"D\": \"To assess bleeding risk before anticoagulation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pe_diagnosis\",\n    \"deepDiveExplanation\": \"Lower limb compression ultrasonography (CUS) is not a direct diagnostic test for PE. However, it is highly indicated when there is high clinical suspicion for PE, but CTPA is contraindicated (e.g., severe renal failure, contrast allergy, pregnancy where V/Q is inconclusive or non-diagnostic). If a deep vein thrombosis (DVT) is found by CUS in this scenario, treating the DVT is equivalent to treating PE, allowing therapeutic anticoagulation without needing further PE imaging. It can also be useful in unstable patients where CTPA is not feasible, and TTE shows RV strain.\",\n    \"highYieldPearl\": \"CUS for DVT is crucial in suspected PE when CTPA is contraindicated/unfeasible, allowing treatment initiation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Option B (CTPA equivocal) is a plausible scenario, but finding a DVT doesn't directly diagnose PE; it identifies the source and allows for empiric treatment. Option C is stronger because finding a DVT allows for *treatment initiation* in situations where PE imaging is problematic, effectively managing the underlying condition without direct PE visualization.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1274.3929443359375}],"createTime":"2025-12-31T07:45:36.888130Z","modelVersion":"gemini-2.5-flash","responseId":"oNRUacKaNvydnvgPka-hYA","usageMetadata":{"billablePromptUsage":{"textCount":1031},"candidatesTokenCount":3134,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3134}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":4055,"totalTokenCount":7555,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:11.961918+00:00"}
{"metadata":"one-liner|ios_feno|Impulse Oscillometry and FeNO|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Impulse Oscillometry and FeNO\".\nSet the \"topic\" field in the JSON to \"ios_feno\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.38119049635320573,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Elevated fractional exhaled nitric oxide (FeNO) primarily indicates increased expression of which enzyme?\",\n    \"options\": {\n      \"A\": \"eNOS\",\n      \"B\": \"nNOS\",\n      \"C\": \"iNOS\",\n      \"D\": \"cNOS\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ios_feno\",\n    \"deepDiveExplanation\": \"Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of eosinophilic airway inflammation, especially in asthma. The increased NO production is primarily mediated by the inducible nitric oxide synthase (iNOS) enzyme, which is upregulated in airway epithelial cells by Th2 cytokines like IL-4 and IL-13.\",\n    \"highYieldPearl\": \"iNOS activity, driven by Th2 inflammation, is the main source of elevated FeNO in asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distinguishing between the different isoforms of nitric oxide synthase (NOS) is crucial. eNOS (endothelial) and nNOS (neuronal) are constitutively expressed, while iNOS (inducible) is associated with inflammation.\"\n  },\n  {\n    \"question\": \"In Impulse Oscillometry, an increased difference between R5 and R20 resistance values most accurately reflects dysfunction in which airway region?\",\n    \"options\": {\n      \"A\": \"Trachea\",\n      \"B\": \"Central airways\",\n      \"C\": \"Peripheral airways\",\n      \"D\": \"Upper airways\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ios_feno\",\n    \"deepDiveExplanation\": \"Impulse Oscillometry (IOS) measures respiratory impedance. R5 represents total airway resistance (central + peripheral), while R20 primarily reflects central airway resistance. An increased R5-R20 difference signifies increased peripheral (small) airway resistance, as the peripheral resistance component is more pronounced at lower frequencies (like 5 Hz) compared to higher frequencies (like 20 Hz).\",\n    \"highYieldPearl\": \"R5-R20 difference is a key IOS parameter for assessing small airway obstruction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might incorrectly assume R5-R20 relates to total resistance or central airways. Understanding the frequency dependence of resistance measurements in IOS is key.\"\n  },\n  {\n    \"question\": \"Which of the following is a primary clinical application of serial fractional exhaled nitric oxide (FeNO) measurements in asthma management?\",\n    \"options\": {\n      \"A\": \"Assessing airflow obstruction severity\",\n      \"B\": \"Monitoring inhaled corticosteroid adherence\",\n      \"C\": \"Quantifying bronchodilator responsiveness\",\n      \"D\": \"Diagnosing vocal cord dysfunction\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ios_feno\",\n    \"deepDiveExplanation\": \"FeNO levels are suppressed by inhaled corticosteroids (ICS). A sustained high FeNO despite prescribed ICS therapy can indicate poor adherence to medication, allowing clinicians to address this issue. It also helps in predicting response to ICS and guiding step-up/step-down therapy.\",\n    \"highYieldPearl\": \"A persistently high FeNO in a treated asthmatic suggests poor ICS adherence or inadequate dose.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While FeNO can guide treatment decisions, its direct measurement of inflammation makes it particularly useful for adherence monitoring, especially since ICS directly reduces FeNO. Other options are assessed by spirometry or laryngoscopy.\"\n  },\n  {\n    \"question\": \"Impulse Oscillometry (IOS) offers a distinct advantage over spirometry for assessing lung mechanics due to its independence from which patient factor?\",\n    \"options\": {\n      \"A\": \"Age\",\n      \"B\": \"Effort\",\n      \"C\": \"Body mass index\",\n      \"D\": \"Smoking status\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ios_feno\",\n    \"deepDiveExplanation\": \"IOS is a passive, non-effort dependent test, making it suitable for patients unable to perform forced maneuvers required for spirometry, such as young children, the elderly, or those with severe respiratory compromise. The patient breathes quietly through a mouthpiece while small pressure oscillations are applied.\",\n    \"highYieldPearl\": \"IOS is ideal for pediatric and uncooperative patients as it requires only tidal breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While IOS is often used in children (related to age), the fundamental advantage is its effort independence. Age itself is not the factor, but rather the inability of very young or very old to perform forced maneuvers.\"\n  },\n  {\n    \"question\": \"Which of the following factors typically causes a decrease in fractional exhaled nitric oxide (FeNO) levels?\",\n    \"options\": {\n      \"A\": \"Atopy\",\n      \"B\": \"Acute viral infection\",\n      \"C\": \"Inhaled corticosteroid use\",\n      \"D\": \"Allergic rhinitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ios_feno\",\n    \"deepDiveExplanation\": \"Inhaled corticosteroids (ICS) are potent anti-inflammatory agents that reduce eosinophilic inflammation in the airways, thereby decreasing the expression of iNOS and subsequently lowering FeNO levels. Atopy, acute viral infections, and allergic rhinitis are generally associated with increased airway inflammation and thus higher FeNO levels.\",\n    \"highYieldPearl\": \"ICS therapy is the most significant pharmacological intervention that consistently lowers FeNO.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"It's important to differentiate between factors that increase FeNO (inflammation, allergies, infections) and those that decrease it (anti-inflammatory treatments like ICS, or acute smoking). Acute smoking can temporarily decrease FeNO, but chronic smoking can increase it.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-516.5131225585938}],"createTime":"2025-12-31T07:46:25.649063Z","modelVersion":"gemini-2.5-flash","responseId":"0dRUaefOJ8iP2_gP0paGOA","usageMetadata":{"billablePromptUsage":{"textCount":1025},"candidatesTokenCount":1355,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1355}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":1510,"totalTokenCount":3231,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:05.756485+00:00"}
{"metadata":"one-liner|hp|Hypersensitivity Pneumonitis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Hypersensitivity Pneumonitis\".\nSet the \"topic\" field in the JSON to \"hp\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3411696554645113,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Hypersensitivity pneumonitis involves which main immunological reactions?\",\n    \"options\": {\n      \"A\": \"Type I and II\",\n      \"B\": \"Type II and III\",\n      \"C\": \"Type III and IV\",\n      \"D\": \"Type I and IV\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"Hypersensitivity pneumonitis (HP) is characterized by a combination of Type III (immune complex mediated) and Type IV (cell-mediated/delayed type) hypersensitivity reactions. Type III involves antigen-antibody complexes depositing in the lung, activating complement and attracting neutrophils. Type IV involves T-lymphocyte sensitization to inhaled antigens, leading to granuloma formation and chronic inflammation.\",\n    \"highYieldPearl\": \"Remember the '3+4' for HP's immunological basis. This combination drives both acute inflammation and chronic granulomatous changes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors test basic knowledge of hypersensitivity types. Incorrectly associating HP with Type I (IgE-mediated, e.g., asthma) or Type II (cytotoxic, e.g., Goodpasture's) is a common error.\"\n  },\n  {\n    \"question\": \"Which histological finding is most characteristic of hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"Eosinophilic infiltration\",\n      \"B\": \"Non-caseating granulomas\",\n      \"C\": \"Honeycombing\",\n      \"D\": \"Diffuse alveolar damage\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"The classic histological triad for HP includes lymphocytic bronchiolitis, interstitial lymphocytic infiltrate, and poorly formed, non-caseating granulomas. While honeycombing can be seen in chronic fibrotic HP, it's not the *most characteristic* initial or unique feature. Eosinophilic infiltration is rare, and DAD is more typical of acute lung injury/ARDS.\",\n    \"highYieldPearl\": \"Non-caseating granulomas, along with lymphocytic bronchiolitis and interstitial inflammation, are the histological hallmarks of HP, differentiating it from other ILDs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Honeycombing (C) is a feature of fibrotic ILDs, including chronic HP, but it's not specific or the *most characteristic* diagnostic feature. Eosinophilic infiltration (A) points to other conditions like Chronic Eosinophilic Pneumonia. DAD (D) is seen in acute severe lung injury.\"\n  },\n  {\n    \"question\": \"Which finding is characteristic of bronchoalveolar lavage (BAL) in hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"Neutrophilic alveolitis\",\n      \"B\": \"Eosinophilic alveolitis\",\n      \"C\": \"Lymphocytic alveolitis\",\n      \"D\": \"Macrophagic alveolitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"BAL in HP typically shows a significant increase in lymphocytes (>20-50% of total cells), particularly T-lymphocytes. In acute/subacute HP, an inverted CD4/CD8 ratio (<1.0) is often observed, although this can normalize or even invert in chronic HP. Neutrophils suggest infection or ARDS, eosinophils suggest eosinophilic pneumonias.\",\n    \"highYieldPearl\": \"BAL lymphocytosis is a key diagnostic clue for HP. An inverted CD4/CD8 ratio (<1.0) is classic for HP, contrasting with sarcoidosis (often >3.5).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Neutrophilic (A) suggests infection or ARDS. Eosinophilic (B) points to eosinophilic pneumonias. Macrophagic (D) is less specific. The specific lymphocyte subtype and CD4/CD8 ratio are crucial for differentiation.\"\n  },\n  {\n    \"question\": \"Acute hypersensitivity pneumonitis on HRCT typically presents with what predominant finding?\",\n    \"options\": {\n      \"A\": \"Honeycombing\",\n      \"B\": \"Ground-glass opacities\",\n      \"C\": \"Peripheral reticulation\",\n      \"D\": \"Traction bronchiectasis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"Acute and subacute HP often manifest with diffuse or patchy ground-glass opacities, centrilobular nodules (often ill-defined), and mosaic attenuation with air trapping due to small airway inflammation. Honeycombing, peripheral reticulation, and traction bronchiectasis are features of fibrotic (chronic) lung disease.\",\n    \"highYieldPearl\": \"Ground-glass opacities and centrilobular nodules are the classic HRCT findings in acute/subacute HP, reflecting inflammation and bronchiolitis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, C, and D describe fibrotic changes seen in chronic HP or other ILDs like IPF, not acute HP. Confusing acute vs. chronic imaging patterns is a common trap.\"\n  },\n  {\n    \"question\": \"Chronic hypersensitivity pneumonitis on HRCT often shows which finding?\",\n    \"options\": {\n      \"A\": \"Diffuse ground-glass\",\n      \"B\": \"Centrilobular nodules\",\n      \"C\": \"Fibrosis with traction bronchiectasis\",\n      \"D\": \"Tree-in-bud pattern\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"Chronic HP is characterized by progressive fibrosis, which manifests on HRCT as reticulation, honeycombing, volume loss, and traction bronchiectasis, often with a mid-to-upper lung predominance or patchy distribution. Diffuse ground-glass and centrilobular nodules are more acute/subacute features. Tree-in-bud is typically seen in endobronchial spread of infection.\",\n    \"highYieldPearl\": \"Fibrotic changes, including traction bronchiectasis and honeycombing (often less basal than IPF), are hallmarks of chronic HP. Look for mosaic attenuation and air trapping as additional clues.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and B describe acute/subacute HP. Option D (tree-in-bud) is characteristic of bronchiolitis with impaction, usually infectious. The key is to distinguish acute inflammatory changes from chronic fibrotic changes.\"\n  },\n  {\n    \"question\": \"Farmer's lung is a classic example of hypersensitivity pneumonitis caused by which organism?\",\n    \"options\": {\n      \"A\": \"Aspergillus fumigatus\",\n      \"B\": \"Mycobacterium avium complex\",\n      \"C\": \"Saccharopolyspora rectivirgula\",\n      \"D\": \"Histoplasma capsulatum\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"Farmer's lung is caused by exposure to thermophilic actinomycetes found in moldy hay, with *Saccharopolyspora rectivirgula* (formerly *Micropolyspora faeni*) being the most common culprit. *Aspergillus fumigatus* causes ABPA or aspergilloma. *Mycobacterium avium complex* can cause Hot Tub Lung. *Histoplasma capsulatum* causes histoplasmosis.\",\n    \"highYieldPearl\": \"Memorize classic HP associations: Farmer's Lung (S. rectivirgula), Bird Fancier's Lung (avian proteins), Hot Tub Lung (MAC).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors are other common respiratory pathogens or allergens. Knowing the specific antigen for common HP types is crucial.\"\n  },\n  {\n    \"question\": \"What is the cornerstone of management for hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"Long-term antibiotics\",\n      \"B\": \"Immunosuppressants\",\n      \"C\": \"Antigen avoidance\",\n      \"D\": \"Bronchodilators\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"The most critical step in managing HP is the identification and complete avoidance of the causative antigen. While corticosteroids (immunosuppressants) are often used, especially in acute and subacute phases, they are secondary to antigen avoidance in preventing disease progression and recurrence.\",\n    \"highYieldPearl\": \"Antigen avoidance is paramount for HP treatment. Without it, other therapies will likely fail, and fibrosis will progress.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Immunosuppressants (B) like corticosteroids are frequently used, but without antigen avoidance, they treat symptoms without addressing the underlying cause. Antibiotics (A) are for infection, bronchodilators (D) for airflow limitation, not primary HP treatment.\"\n  },\n  {\n    \"question\": \"Pulmonary function tests in hypersensitivity pneumonitis typically reveal which pattern?\",\n    \"options\": {\n      \"A\": \"Obstructive\",\n      \"B\": \"Restrictive\",\n      \"C\": \"Mixed obstructive/restrictive\",\n      \"D\": \"Normal\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"HP primarily affects the interstitium and small airways, leading to a restrictive ventilatory defect characterized by reduced FVC and TLC. DLCO is also typically decreased due to inflammation and fibrosis affecting the gas exchange surface. Air trapping may sometimes lead to a mixed picture, but restrictive is the predominant pattern.\",\n    \"highYieldPearl\": \"Restrictive pattern (low FVC, TLC) with reduced DLCO is characteristic of HP, mirroring other interstitial lung diseases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Obstructive (A) is typical of asthma/COPD. While small airways are involved in HP, the predominant effect on lung volumes is restrictive. Mixed (C) can occur, but restrictive is the primary classification.\"\n  },\n  {\n    \"question\": \"Which is an essential component for diagnosing hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"Positive PPD test\",\n      \"B\": \"Evidence of antigen exposure\",\n      \"C\": \"Elevated IgE levels\",\n      \"D\": \"Peripheral eosinophilia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"The diagnosis of HP requires a high index of suspicion based on a history of antigen exposure, appropriate clinical symptoms, and characteristic findings on imaging, PFTs, and/or BAL. Evidence of antigen exposure, either through history or specific antibody tests, is crucial for establishing causality. PPD for TB, IgE for Type I reactions, and eosinophilia for allergic conditions are not primary for HP.\",\n    \"highYieldPearl\": \"A detailed exposure history is non-negotiable for diagnosing HP. Without a plausible antigen, the diagnosis is challenging.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors are tests for other conditions. Elevated IgE (C) is associated with atopy and ABPA, not HP. PPD (A) for TB. Peripheral eosinophilia (D) for parasitic infections or eosinophilic lung diseases.\"\n  },\n  {\n    \"question\": \"Compared to Idiopathic Pulmonary Fibrosis (IPF), chronic HP typically exhibits what on HRCT?\",\n    \"options\": {\n      \"A\": \"Predominantly subpleural honeycombing\",\n      \"B\": \"Extensive ground-glass opacities\",\n      \"C\": \"Relative sparing of lung bases\",\n      \"D\": \"Mosaic attenuation and air trapping\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"hp\",\n    \"deepDiveExplanation\": \"While both chronic HP and IPF can show fibrosis and honeycombing, IPF classically has a basal-predominant, subpleural distribution of honeycombing. Chronic HP often shows mosaic attenuation (due to small airway disease and air trapping) and relative sparing of lung bases, with fibrosis often more patchy or mid-to-upper lung predominant. Extensive ground-glass is more acute HP. Mosaic attenuation/air trapping is a key differentiator from IPF.\",\n    \"highYieldPearl\": \"Mosaic attenuation and air trapping on expiratory HRCT are strong clues for chronic HP over IPF, especially in the context of fibrosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Option A is characteristic of IPF. Option B is characteristic of acute HP. Option C can be seen, but D is a more specific distinguishing feature. The ability to differentiate fibrotic HP from IPF on imaging is a high-level skill.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1006.1093139648438}],"createTime":"2025-12-31T07:46:31.953272Z","modelVersion":"gemini-2.5-flash","responseId":"19RUabiXOt3DgLUPqfGtgAE","usageMetadata":{"billablePromptUsage":{"textCount":1021},"candidatesTokenCount":2949,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2949}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":4490,"totalTokenCount":7802,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:14.495068+00:00"}
{"metadata":"one-liner|interventional_bronch|Interventional Bronchoscopy|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Interventional Bronchoscopy\".\nSet the \"topic\" field in the JSON to \"interventional_bronch\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3821918326364437,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Bronchial thermoplasty reduces airway smooth muscle mass by delivering controlled thermal energy to which airway layers?\",\n    \"options\": {\n      \"A\": \"Mucosa and submucosa\",\n      \"B\": \"Submucosa and smooth muscle\",\n      \"C\": \"Smooth muscle and cartilage\",\n      \"D\": \"Mucosa and adventitia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"interventional_bronch\",\n    \"deepDiveExplanation\": \"Bronchial thermoplasty (BT) is a bronchoscopic procedure for severe refractory asthma. It involves delivering controlled thermal energy (radiofrequency ablation) to the airway walls. The energy passes through the submucosa to target and reduce the amount of airway smooth muscle, leading to decreased bronchoconstriction and improved asthma control.\",\n    \"highYieldPearl\": \"BT specifically targets the smooth muscle layer to reduce its mass and contractility, thereby reducing bronchospasm.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in confusing the layers. While the energy is delivered to the airway wall, its primary therapeutic effect is on the smooth muscle, which necessitates it passing through the submucosa.\"\n  },\n  {\n    \"question\": \"For definitive mediastinal lymph node staging in lung cancer, which interventional bronchoscopic technique is considered gold standard?\",\n    \"options\": {\n      \"A\": \"Radial EBUS\",\n      \"B\": \"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)\",\n      \"C\": \"Electromagnetic navigation bronchoscopy (ENB)\",\n      \"D\": \"Autofluorescence bronchoscopy\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"interventional_bronch\",\n    \"deepDiveExplanation\": \"EBUS-TBNA allows for real-time visualization of mediastinal and hilar lymph nodes and subsequent sampling with a needle. It has high sensitivity and specificity for diagnosing and staging lung cancer, making it the preferred and gold standard method for minimally invasive mediastinal lymph node staging.\",\n    \"highYieldPearl\": \"EBUS-TBNA is the gold standard for mediastinal lymph node staging due to its high diagnostic yield and minimal invasiveness.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options like Radial EBUS and ENB are used for peripheral lesion diagnosis, while autofluorescence bronchoscopy is for mucosal lesion detection. None are gold standards for mediastinal lymph node staging.\"\n  },\n  {\n    \"question\": \"A key contraindication for endobronchial valve placement in severe emphysema is absence of which anatomical feature?\",\n    \"options\": {\n      \"A\": \"Collateral ventilation\",\n      \"B\": \"Bronchiectasis\",\n      \"C\": \"Significant cardiac comorbidity\",\n      \"D\": \"Alpha-1 antitrypsin deficiency\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"interventional_bronch\",\n    \"deepDiveExplanation\": \"Endobronchial valves aim to achieve atelectasis of the target hyperinflated lobe by preventing air entry during inspiration and allowing air exit during expiration. The presence of collateral ventilation (interlobar air movement through Kohn's pores or Lambert's canals) between the target lobe and adjacent lobes prevents complete collapse of the target lobe, rendering the valves ineffective. Assessment for collateral ventilation (e.g., using Chartis system) is crucial.\",\n    \"highYieldPearl\": \"Collateral ventilation is the most critical anatomical contraindication for successful endobronchial valve placement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While significant cardiac comorbidity might be a general contraindication for any invasive procedure, and alpha-1 antitrypsin deficiency is an etiology of emphysema, the absence of collateral ventilation is a specific anatomical/physiological contraindication directly impacting the efficacy of endobronchial valves.\"\n  },\n  {\n    \"question\": \"What is the primary indication for placement of an endobronchial stent?\",\n    \"options\": {\n      \"A\": \"Chronic cough\",\n      \"B\": \"Airway hyperresponsiveness\",\n      \"C\": \"Significant airway obstruction due to intrinsic or extrinsic compression\",\n      \"D\": \"Localized hemoptysis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"interventional_bronch\",\n    \"deepDiveExplanation\": \"Endobronchial stents are primarily used to maintain airway patency in cases of significant airway obstruction. This obstruction can be due to intrinsic lesions (e.g., endobronchial tumors, granulomas, scar tissue) or extrinsic compression (e.g., mediastinal tumors, lymphadenopathy, vascular anomalies). They help relieve dyspnea and prevent atelectasis.\",\n    \"highYieldPearl\": \"Airway stenting is crucial for restoring and maintaining patency in compromised airways, whether from internal or external forces.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Chronic cough, airway hyperresponsiveness, and localized hemoptysis are not primary indications for stent placement. Stents are for structural support against collapse or narrowing.\"\n  },\n  {\n    \"question\": \"Which advantage is unique to rigid bronchoscopy compared to flexible bronchoscopy?\",\n    \"options\": {\n      \"A\": \"Ability to access peripheral airways\",\n      \"B\": \"Superior ventilation control during intervention\",\n      \"C\": \"Outpatient procedure capability\",\n      \"D\": \"Lower risk of pneumothorax\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"interventional_bronch\",\n    \"deepDiveExplanation\": \"Rigid bronchoscopy offers several advantages, including a larger working channel for therapeutic interventions (e.g., foreign body removal, debulking tumors, stenting), better suctioning capability, and crucially, the ability to maintain a secure airway and provide superior ventilation control (e.g., jet ventilation) during complex procedures or in cases of severe airway obstruction. This allows for better management of acute respiratory compromise during intervention.\",\n    \"highYieldPearl\": \"Rigid bronchoscope provides an open airway for ventilation and allows for larger instruments, making it ideal for therapeutic interventions requiring significant control.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Flexible bronchoscopy is superior for accessing peripheral airways. Both can be done as outpatient procedures (though rigid often requires general anesthesia and a more controlled setting). The risk of pneumothorax depends more on the specific intervention than the scope type itself, although rigid bronchoscopy carries its own set of risks related to airway manipulation.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-569.8480224609375}],"createTime":"2025-12-31T07:46:18.048608Z","modelVersion":"gemini-2.5-flash","responseId":"ytRUaeD7AoHzgLUP9pvcyAs","usageMetadata":{"billablePromptUsage":{"textCount":1038},"candidatesTokenCount":1491,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1491}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":1124,"totalTokenCount":2980,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:38.004753+00:00"}
{"metadata":"one-liner|eosinophilic_lung|Eosinophilic Lung Diseases|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Eosinophilic Lung Diseases\".\nSet the \"topic\" field in the JSON to \"eosinophilic_lung\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.38340664822810305,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Acute Eosinophilic Pneumonia is characterized by bronchoalveolar lavage fluid eosinophilia typically exceeding what percentage?\",\n    \"options\": {\n      \"A\": \"5%\",\n      \"B\": \"10%\",\n      \"C\": \"15%\",\n      \"D\": \"25%\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"eosinophilic_lung\",\n    \"deepDiveExplanation\": \"Acute Eosinophilic Pneumonia (AEP) is a rapidly progressive illness characterized by diffuse alveolar infiltrates and hypoxemia. A hallmark diagnostic feature is significant bronchoalveolar lavage (BAL) fluid eosinophilia, typically greater than 25%, often reaching 40-60% or higher. This distinguishes it from other forms of eosinophilic lung disease where BAL eosinophilia might be lower.\",\n    \"highYieldPearl\": \"BAL eosinophilia >25% is highly suggestive of AEP, especially in acute onset respiratory failure unresponsive to conventional therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Lower percentages of BAL eosinophilia (e.g., 5-10%) can be seen in other conditions like asthma or even some interstitial lung diseases. The high threshold (>25%) is critical for AEP diagnosis.\"\n  },\n  {\n    \"question\": \"The classic radiographic pattern of Chronic Eosinophilic Pneumonia is often described as a 'photographic negative' of what condition?\",\n    \"options\": {\n      \"A\": \"Sarcoidosis\",\n      \"B\": \"Pulmonary edema\",\n      \"C\": \"Tuberculosis\",\n      \"D\": \"Interstitial fibrosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"eosinophilic_lung\",\n    \"deepDiveExplanation\": \"Chronic Eosinophilic Pneumonia (CEP) characteristically presents with peripheral infiltrates on chest imaging, often involving the lung periphery, upper, and mid-lung zones, while sparing the perihilar regions. This distribution is considered the 'photographic negative' of pulmonary edema, which typically shows central, perihilar 'bat wing' infiltrates.\",\n    \"highYieldPearl\": \"Peripheral infiltrates on chest X-ray or CT are a classic, high-yield imaging feature for CEP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other conditions cause various radiographic patterns, the 'photographic negative of pulmonary edema' description is highly specific to CEP and should not be confused with other infiltrative processes.\"\n  },\n  {\n    \"question\": \"Which of the following is considered a major diagnostic criterion for Allergic Bronchopulmonary Aspergillosis (ABPA)?\",\n    \"options\": {\n      \"A\": \"Peripheral eosinophilia <500 cells/µL\",\n      \"B\": \"Absence of central bronchiectasis\",\n      \"C\": \"Positive Aspergillus precipitins\",\n      \"D\": \"Normal total serum IgE\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"eosinophilic_lung\",\n    \"deepDiveExplanation\": \"The modified set of diagnostic criteria for ABPA typically includes predisposing conditions (e.g., asthma, cystic fibrosis) and several major and minor criteria. Major criteria include: asthma, immediate cutaneous reactivity to Aspergillus fumigatus, total serum IgE >1000 IU/mL, specific IgE and IgG to A. fumigatus, peripheral eosinophilia (>500 cells/µL), and central bronchiectasis. Positive Aspergillus precipitins (IgG to A. fumigatus) is also a major criterion.\",\n    \"highYieldPearl\": \"Remember the key immunological markers (IgE, specific IgE/IgG to Aspergillus, precipitins) and imaging findings (central bronchiectasis) for ABPA diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Option A is incorrect as peripheral eosinophilia is a major criterion if >500 cells/µL. Option B is incorrect as central bronchiectasis is a major criterion. Option D is incorrect as elevated total serum IgE (>1000 IU/mL) is a major criterion.\"\n  },\n  {\n    \"question\": \"In Eosinophilic Granulomatosis with Polyangiitis (EGPA), p-ANCA positivity is most commonly associated with which clinical manifestation?\",\n    \"options\": {\n      \"A\": \"Cardiac involvement\",\n      \"B\": \"Renal disease\",\n      \"C\": \"Cutaneous vasculitis\",\n      \"D\": \"Asthma\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"eosinophilic_lung\",\n    \"deepDiveExplanation\": \"Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly Churg-Strauss Syndrome, can be divided into ANCA-positive and ANCA-negative subsets. p-ANCA (MPO-ANCA) positivity in EGPA is typically associated with vasculitic manifestations, particularly glomerulonephritis (renal disease) and peripheral neuropathy. ANCA-negative EGPA often has more prominent eosinophilic features and tends to be associated with cardiac involvement and lung infiltrates.\",\n    \"highYieldPearl\": \"p-ANCA (MPO-ANCA) positive EGPA = vasculitic features (renal, neuropathy). ANCA-negative EGPA = eosinophilic features (cardiac, pulmonary infiltrates).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"All options represent possible manifestations of EGPA. However, the question specifically asks about the association with p-ANCA positivity, which points towards vasculitic organ damage, notably renal involvement. Cardiac disease is more prevalent in ANCA-negative EGPA.\"\n  },\n  {\n    \"question\": \"Which drug class is a well-known cause of drug-induced eosinophilic lung disease?\",\n    \"options\": {\n      \"A\": \"Beta-blockers\",\n      \"B\": \"ACE inhibitors\",\n      \"C\": \"Nitrofurantoin\",\n      \"D\": \"Statins\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"eosinophilic_lung\",\n    \"deepDiveExplanation\": \"Numerous drugs can induce eosinophilic lung disease, including antibiotics (e.g., nitrofurantoin, sulfonamides), NSAIDs, phenytoin, L-tryptophan, and others. Nitrofurantoin is a classic and frequently cited cause of acute or chronic drug-induced eosinophilic pneumonia, characterized by peripheral eosinophilia and pulmonary infiltrates.\",\n    \"highYieldPearl\": \"Always consider drug-induced etiology in a patient presenting with eosinophilic lung disease, with nitrofurantoin being a key culprit.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"While other drug classes can cause various lung toxicities (e.g., ACE inhibitors causing cough, amiodarone causing interstitial lung disease), nitrofurantoin is specifically associated with eosinophilic lung reactions. It's important to differentiate drug-induced lung injury types.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-600.7982177734375}],"createTime":"2025-12-31T07:45:40.768809Z","modelVersion":"gemini-2.5-flash","responseId":"pNRUaan2Lt6gnvgPmbPe6QM","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":1567,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1567}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1442,"totalTokenCount":3373,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:43.471548+00:00"}
{"metadata":"one-liner|asthma_pathophys|Asthma - Pathophysiology|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Asthma - Pathophysiology\".\nSet the \"topic\" field in the JSON to \"asthma_pathophys\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2573570534948001,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which cytokine is crucial for eosinophil maturation, recruitment, and survival in allergic asthma?\",\n    \"options\": {\n      \"A\": \"Interleukin-4\",\n      \"B\": \"Interleukin-5\",\n      \"C\": \"Interleukin-13\",\n      \"D\": \"Tumor Necrosis Factor-alpha\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Interleukin-5 (IL-5) is a key Th2 cytokine that plays a central role in eosinophilic inflammation. It promotes the growth, differentiation, activation, and survival of eosinophils, making it a critical target in severe eosinophilic asthma. IL-4 is important for IgE class switching, and IL-13 contributes to mucus hypersecretion and airway remodeling.\",\n    \"highYieldPearl\": \"IL-5 is the primary cytokine driving eosinophil biology in asthma. Monoclonal antibodies targeting IL-5 (e.g., mepolizumab, reslizumab) or its receptor (e.g., benralizumab) are effective treatments for severe eosinophilic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse IL-5 with IL-4 (IgE production) or IL-13 (mucus/remodeling), all being Th2 cytokines. Understanding the specific roles of each cytokine is key.\"\n  },\n  {\n    \"question\": \"The primary mediator responsible for acute bronchoconstriction during the early asthmatic response is?\",\n    \"options\": {\n      \"A\": \"Leukotriene B4\",\n      \"B\": \"Prostaglandin D2\",\n      \"C\": \"Histamine\",\n      \"D\": \"Bradykinin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Upon allergen re-exposure, mast cells rapidly degranulate, releasing preformed mediators. Histamine, released from mast cells, is a potent bronchoconstrictor and increases vascular permeability, leading to the immediate 'early asthmatic response'. Other mediators like leukotrienes and prostaglandins also contribute but are often more prominent in the late phase or sustained bronchoconstriction.\",\n    \"highYieldPearl\": \"Histamine's rapid release from mast cells is the hallmark of the early asthmatic response, causing immediate bronchospasm. Antihistamines are generally not effective in asthma because other mediators also play significant roles.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While leukotrienes and prostaglandins are also significant mediators, histamine is typically considered the primary and most rapid-acting bronchoconstrictor in the early phase.\"\n  },\n  {\n    \"question\": \"Activation of which receptor directly mediates bronchoconstriction, mucus secretion, and airway edema in asthma?\",\n    \"options\": {\n      \"A\": \"Histamine H1\",\n      \"B\": \"Beta-2 adrenergic\",\n      \"C\": \"Cysteinyl Leukotriene 1\",\n      \"D\": \"Muscarinic M3\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent lipid mediators released from mast cells, eosinophils, and macrophages. They bind to the Cysteinyl Leukotriene 1 (CysLT1) receptor, leading to sustained bronchoconstriction, increased mucus production, and airway edema. This makes the CysLT1 receptor a key target for antileukotriene medications like montelukast.\",\n    \"highYieldPearl\": \"CysLT1 receptor antagonists block the effects of cysteinyl leukotrienes, which are 1000 times more potent than histamine in causing bronchoconstriction. They are particularly useful in aspirin-exacerbated respiratory disease (AERD) and exercise-induced bronchoconstriction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options relate to airway function. H1 mediates histamine effects, M3 mediates cholinergic bronchoconstriction, and Beta-2 is for bronchodilation. The question specifically asks about the combined effects of bronchoconstriction, mucus, and edema mediated by a single receptor type, which strongly points to CysLT1.\"\n  },\n  {\n    \"question\": \"A key structural change characterizing airway remodeling in chronic asthma is?\",\n    \"options\": {\n      \"A\": \"Alveolar destruction\",\n      \"B\": \"Bronchial wall thinning\",\n      \"C\": \"Subepithelial fibrosis\",\n      \"D\": \"Cartilage calcification\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Airway remodeling is a hallmark of chronic asthma, involving structural changes to the airway wall. Subepithelial fibrosis, characterized by deposition of collagen and other extracellular matrix proteins beneath the basement membrane, is a significant component that contributes to fixed airway obstruction and reduced reversibility. Other changes include smooth muscle hypertrophy/hyperplasia, goblet cell hyperplasia, and angiogenesis.\",\n    \"highYieldPearl\": \"Airway remodeling contributes to the progressive and often irreversible airflow limitation seen in some patients with severe chronic asthma, making early and effective anti-inflammatory treatment crucial.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Alveolar destruction is characteristic of emphysema. Bronchial wall thinning is not a feature of remodeling; rather, thickening occurs. Cartilage calcification is not a primary feature of asthma remodeling.\"\n  },\n  {\n    \"question\": \"Which lymphocyte subset is central to orchestrating the allergic inflammatory response in asthma?\",\n    \"options\": {\n      \"A\": \"Th1 lymphocyte\",\n      \"B\": \"Th2 lymphocyte\",\n      \"C\": \"T regulatory lymphocyte\",\n      \"D\": \"B lymphocyte\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"T helper 2 (Th2) lymphocytes are central to the pathogenesis of allergic asthma. Upon activation by allergen-presenting cells, Th2 cells release key cytokines (IL-4, IL-5, IL-13) that promote IgE production by B cells, eosinophil recruitment and activation, and mucus hypersecretion, respectively, driving the allergic inflammatory cascade.\",\n    \"highYieldPearl\": \"The 'Th2 paradigm' explains the majority of allergic asthma. However, 'non-Th2' mechanisms involving Th17 cells and neutrophils are increasingly recognized in severe asthma phenotypes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While B lymphocytes produce IgE, they do so under the direction of Th2 cytokines. Th1 cells are involved in cell-mediated immunity and typically associated with protection against intracellular pathogens, not allergic asthma. Treg cells suppress immune responses.\"\n  },\n  {\n    \"question\": \"Which Th2 cytokine primarily promotes B-cell IgE class switching and production?\",\n    \"options\": {\n      \"A\": \"Interleukin-1\",\n      \"B\": \"Interleukin-4\",\n      \"C\": \"Interleukin-6\",\n      \"D\": \"Interleukin-17\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Interleukin-4 (IL-4) is a critical Th2 cytokine that signals B cells to undergo class switching from IgM/IgD to IgE. This leads to the production of allergen-specific IgE antibodies, which then bind to mast cells and basophils, sensitizing them for future allergen encounters and triggering allergic reactions.\",\n    \"highYieldPearl\": \"IL-4 is a key link between allergen exposure and the systemic IgE response. Omalizumab, an anti-IgE antibody, works by binding free IgE, preventing its binding to mast cells and thus reducing allergic reactions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"IL-5 drives eosinophils, and IL-13 contributes to remodeling and mucus. IL-1 and IL-6 are pro-inflammatory but not specific for IgE class switching. IL-17 is associated with neutrophilic inflammation.\"\n  },\n  {\n    \"question\": \"Bronchial hyperresponsiveness in asthma is primarily attributed to?\",\n    \"options\": {\n      \"A\": \"Reduced airway smooth muscle mass\",\n      \"B\": \"Decreased vagal tone\",\n      \"C\": \"Airway inflammation and remodeling\",\n      \"D\": \"Increased surfactant production\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Bronchial hyperresponsiveness (BHR) is a cardinal feature of asthma, characterized by an exaggerated bronchoconstrictor response to various stimuli. It is primarily driven by chronic airway inflammation, leading to changes in the airway smooth muscle (hypertrophy, hyperplasia), epithelial damage, neural dysfunction, and extracellular matrix deposition (remodeling). These factors collectively reduce the threshold for bronchoconstriction.\",\n    \"highYieldPearl\": \"BHR is not just a symptom but a fundamental pathophysiological abnormality in asthma. It can be measured using challenge tests with methacholine or histamine.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Reduced airway smooth muscle mass would lead to reduced bronchoconstriction, not hyperresponsiveness. Decreased vagal tone would reduce cholinergic bronchoconstriction. Increased surfactant production is irrelevant to BHR.\"\n  },\n  {\n    \"question\": \"Damage to the airway epithelium in asthma contributes to increased susceptibility to?\",\n    \"options\": {\n      \"A\": \"Alveolar collapse\",\n      \"B\": \"Bacterial translocation\",\n      \"C\": \"Bronchial hyperresponsiveness\",\n      \"D\": \"Pulmonary hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Airway epithelial damage, a common finding in asthma, compromises the barrier function of the airway. This exposes subepithelial nerve endings to irritants and inflammatory mediators, leading to enhanced reflex bronchoconstriction and exaggerated responses to stimuli, thereby contributing significantly to bronchial hyperresponsiveness.\",\n    \"highYieldPearl\": \"The airway epithelium is not just a passive barrier; it actively participates in the immune response by releasing cytokines and chemokines, further orchestrating inflammation in asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While severe epithelial damage might theoretically increase infection risk (bacterial translocation), its primary and well-established role in asthma pathophysiology is in contributing to BHR. Alveolar collapse and pulmonary hypertension are not direct consequences of epithelial damage in asthma.\"\n  },\n  {\n    \"question\": \"Which prostaglandin is a potent bronchoconstrictor and mast cell activator implicated in asthma?\",\n    \"options\": {\n      \"A\": \"Prostaglandin E2\",\n      \"B\": \"Prostacyclin (PGI2)\",\n      \"C\": \"Prostaglandin D2\",\n      \"D\": \"Thromboxane A2\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"Prostaglandin D2 (PGD2) is a major cyclooxygenase product released from activated mast cells in allergic asthma. It is a potent bronchoconstrictor, increases vascular permeability, and has chemotactic effects on eosinophils and Th2 cells, contributing significantly to the asthmatic response.\",\n    \"highYieldPearl\": \"Aspirin-exacerbated respiratory disease (AERD) involves an imbalance in arachidonic acid metabolism, with increased production of pro-inflammatory mediators like PGD2 and cysteinyl leukotrienes, and decreased production of anti-inflammatory PGE2.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"PGE2 is generally bronchodilatory and anti-inflammatory. PGI2 is also a vasodilator and bronchodilator. TXA2 is a potent vasoconstrictor and platelet aggregator but less central to asthma bronchoconstriction compared to PGD2 and leukotrienes.\"\n  },\n  {\n    \"question\": \"The late asthmatic response is predominantly characterized by the influx and activation of which inflammatory cells?\",\n    \"options\": {\n      \"A\": \"Neutrophils\",\n      \"B\": \"Eosinophils\",\n      \"C\": \"Macrophages\",\n      \"D\": \"Basophils\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_pathophys\",\n    \"deepDiveExplanation\": \"The late asthmatic response, occurring 4-12 hours after allergen exposure, is characterized by a sustained inflammatory reaction. This phase is predominantly driven by the recruitment and activation of eosinophils, along with other cells like T lymphocytes and basophils, leading to persistent bronchoconstriction and airway hyperresponsiveness.\",\n    \"highYieldPearl\": \"The late asthmatic response is more resistant to bronchodilators and is crucial for the development of chronic inflammation and airway remodeling, highlighting the importance of anti-inflammatory therapies (e.g., corticosteroids).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While neutrophils can be present, especially in severe asthma, eosinophils are the hallmark cell of the classic late asthmatic response in allergic asthma. Macrophages are antigen-presenting cells and phagocytes, while basophils are less numerous than eosinophils in the late phase.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-796.5200805664063}],"createTime":"2025-12-31T07:46:19.328973Z","modelVersion":"gemini-2.5-flash","responseId":"y9RUaY2KFN-zgLUPj-v-qAI","usageMetadata":{"billablePromptUsage":{"textCount":1030},"candidatesTokenCount":3095,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3095}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1572,"totalTokenCount":5034,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:53.467208+00:00"}
{"metadata":"one-liner|chylothorax|Chylothorax|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Chylothorax\".\nSet the \"topic\" field in the JSON to \"chylothorax\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4437195206285456,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Pleural fluid triglyceride level > 110 mg/dL is diagnostic of?\",\n    \"options\": {\n      \"A\": \"Pseudochylothorax\",\n      \"B\": \"Empyema\",\n      \"C\": \"Chylothorax\",\n      \"D\": \"Malignant effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"chylothorax\",\n    \"deepDiveExplanation\": \"Chylothorax is the accumulation of chyle in the pleural space due to disruption of the thoracic duct. The diagnosis is confirmed by pleural fluid analysis showing a triglyceride level greater than 110 mg/dL (or 1.24 mmol/L). If triglyceride levels are between 50-110 mg/dL, lipoprotein electrophoresis to detect chylomicrons is required for definitive diagnosis. Pseudochylothorax, often seen in chronic effusions (e.g., rheumatoid pleurisy, tuberculosis), is characterized by high cholesterol levels (>200 mg/dL) and the absence of chylomicrons.\",\n    \"highYieldPearl\": \"The presence of chylomicrons on lipoprotein electrophoresis is the most definitive test for chylothorax, especially when triglyceride levels are borderline.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Pseudochylothorax is a common distractor due to its milky appearance, but it's differentiated by high cholesterol and absence of chylomicrons. Empyema is purulent, and malignant effusion is diagnosed by cytology.\"\n  },\n  {\n    \"question\": \"Most common iatrogenic cause of chylothorax is injury during?\",\n    \"options\": {\n      \"A\": \"Lung biopsy\",\n      \"B\": \"Thoracentesis\",\n      \"C\": \"Esophagectomy\",\n      \"D\": \"Bronchoscopy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"chylothorax\",\n    \"deepDiveExplanation\": \"The thoracic duct is vulnerable to injury during various cardiothoracic and neck surgeries. Esophagectomy, particularly during dissection in the posterior mediastinum, carries the highest risk of thoracic duct injury, leading to chylothorax. Other high-risk procedures include mediastinal tumor resection, lung transplantation, and cardiac surgery.\",\n    \"highYieldPearl\": \"Non-iatrogenic causes of chylothorax include malignancy (especially lymphoma), trauma, and congenital anomalies of the thoracic duct.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other procedures involve the chest, esophagectomy involves extensive dissection directly in the vicinity of the thoracic duct, making it the most frequent iatrogenic cause. Lung biopsy, thoracentesis, and bronchoscopy typically do not involve the deep mediastinal structures where the thoracic duct lies.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-283.5367736816406}],"createTime":"2025-12-31T07:45:46.841540Z","modelVersion":"gemini-2.5-flash","responseId":"qtRUacSuM93DgLUPqfGtgAE","usageMetadata":{"billablePromptUsage":{"textCount":1013},"candidatesTokenCount":639,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":639}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":822,"totalTokenCount":1824,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:55.029282+00:00"}
{"metadata":"one-liner|bronchiectasis|Bronchiectasis|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Bronchiectasis\".\nSet the \"topic\" field in the JSON to \"bronchiectasis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3560574952067475,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most sensitive and specific imaging modality for diagnosing bronchiectasis is?\",\n    \"options\": {\n      \"A\": \"Chest X-Ray\",\n      \"B\": \"High-Resolution Computed Tomography (HRCT) of the thorax\",\n      \"C\": \"Magnetic Resonance Imaging (MRI) of the chest\",\n      \"D\": \"Bronchoscopy with BAL\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchiectasis\",\n    \"deepDiveExplanation\": \"HRCT is the gold standard for diagnosing bronchiectasis, clearly visualizing bronchial dilatation, lack of tapering, and bronchial wall thickening. It can detect changes not visible on plain chest X-ray and provides detailed anatomical information crucial for diagnosis and assessing extent.\",\n    \"highYieldPearl\": \"Concomitant signet ring sign (bronchial diameter > adjacent pulmonary artery diameter) is a classic HRCT finding.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While Chest X-Ray may show suggestive signs, it lacks sensitivity and specificity. MRI is not routinely used for primary diagnosis due to lower spatial resolution for airways. Bronchoscopy is diagnostic for underlying causes but not for the anatomical diagnosis of bronchiectasis itself.\"\n  },\n  {\n    \"question\": \"The central pathophysiological concept driving bronchiectasis progression is the?\",\n    \"options\": {\n      \"A\": \"Alveolar epithelial dysfunction\",\n      \"B\": \"Vicious cycle hypothesis\",\n      \"C\": \"Pulmonary vascular remodeling\",\n      \"D\": \"Systemic inflammatory response syndrome\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchiectasis\",\n    \"deepDiveExplanation\": \"The 'vicious cycle' hypothesis describes how initial infection or injury leads to impaired mucociliary clearance, chronic bacterial colonization, and persistent inflammation. This inflammation causes further airway damage, perpetuating the cycle of infection, inflammation, and structural damage.\",\n    \"highYieldPearl\": \"Chronic inflammation and infection lead to progressive airway damage, forming a self-perpetuating cycle.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Other options describe aspects of lung disease but do not encapsulate the core, self-perpetuating mechanism specific to bronchiectasis. Alveolar dysfunction is more relevant to interstitial lung diseases or emphysema, while vascular remodeling is primary in pulmonary hypertension.\"\n  },\n  {\n    \"question\": \"Long-term macrolide therapy in non-cystic fibrosis bronchiectasis primarily aims to reduce?\",\n    \"options\": {\n      \"A\": \"Bacterial load directly\",\n      \"B\": \"Airway inflammation and exacerbation frequency\",\n      \"C\": \"Fungal colonization\",\n      \"D\": \"Mycobacterial growth\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchiectasis\",\n    \"deepDiveExplanation\": \"While macrolides have some antimicrobial effects, their primary benefit in long-term therapy for bronchiectasis (especially at sub-inhibitory doses) is immunomodulatory and anti-inflammatory. They reduce pro-inflammatory cytokines, inhibit neutrophil recruitment, and impair bacterial virulence factors, ultimately reducing exacerbation frequency.\",\n    \"highYieldPearl\": \"Macrolides exhibit anti-inflammatory and immunomodulatory effects beyond their direct antimicrobial action in chronic respiratory diseases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Option A is a partial truth; while they can reduce bacterial load, the anti-inflammatory effect is considered the dominant mechanism for long-term benefits in bronchiectasis. Options C and D are incorrect as macrolides are not primary agents for fungal or mycobacterial infections.\"\n  },\n  {\n    \"question\": \"The most common identified underlying etiology for non-cystic fibrosis bronchiectasis in adults is?\",\n    \"options\": {\n      \"A\": \"Primary ciliary dyskinesia\",\n      \"B\": \"Immunodeficiency\",\n      \"C\": \"Post-infectious causes\",\n      \"D\": \"Allergic bronchopulmonary aspergillosis (ABPA)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchiectasis\",\n    \"deepDiveExplanation\": \"Post-infectious causes, particularly severe childhood infections like pertussis, measles, or tuberculosis, remain the most frequently identified etiology for non-CF bronchiectasis in adults globally, even if a significant proportion remains idiopathic.\",\n    \"highYieldPearl\": \"A history of severe childhood respiratory infections should always prompt consideration for underlying bronchiectasis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While primary ciliary dyskinesia, immunodeficiency, and ABPA are important causes of bronchiectasis, they are individually less common than the broad category of post-infectious causes. A significant proportion of cases also remain idiopathic even after thorough investigation.\"\n  },\n  {\n    \"question\": \"The most widely used clinical scoring system for assessing bronchiectasis severity and prognosis is the?\",\n    \"options\": {\n      \"A\": \"BODE index\",\n      \"B\": \"mMRC scale\",\n      \"C\": \"Bronchiectasis Severity Index (BSI)\",\n      \"D\": \"CURB-65 score\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchiectasis\",\n    \"deepDiveExplanation\": \"The Bronchiectasis Severity Index (BSI) is a validated scoring system that predicts mortality, hospital admissions, and exacerbation rates in patients with bronchiectasis. It incorporates variables like age, BMI, FEV1, number of exacerbations, colonization with Pseudomonas, and radiological extent.\",\n    \"highYieldPearl\": \"BSI helps stratify patients into low, moderate, and high-risk groups to guide management and prognosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"The BODE index is for COPD, mMRC scale for dyspnea (often used in COPD/ILD), and CURB-65 for pneumonia severity. Only BSI is specifically designed and validated for bronchiectasis severity.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-485.3063659667969}],"createTime":"2025-12-31T07:46:17.827945Z","modelVersion":"gemini-2.5-flash","responseId":"ydRUaanEMvrDvPEPlfOwQQ","usageMetadata":{"billablePromptUsage":{"textCount":1019},"candidatesTokenCount":1363,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1363}],"promptTokenCount":361,"promptTokensDetails":[{"modality":"TEXT","tokenCount":361}],"thoughtsTokenCount":890,"totalTokenCount":2614,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:10.474093+00:00"}
{"metadata":"one-liner|ipf|Idiopathic Pulmonary Fibrosis (IPF)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Idiopathic Pulmonary Fibrosis (IPF)\".\nSet the \"topic\" field in the JSON to \"ipf\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2750453108448093,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The characteristic high-resolution CT (HRCT) pattern for Idiopathic Pulmonary Fibrosis (IPF) is?\",\n    \"options\": {\n      \"A\": \"Non-Specific Interstitial Pneumonia (NSIP)\",\n      \"B\": \"Cryptogenic Organizing Pneumonia (COP)\",\n      \"C\": \"Usual Interstitial Pneumonia (UIP)\",\n      \"D\": \"Lymphoid Interstitial Pneumonia (LIP)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"The diagnosis of IPF relies heavily on the presence of a Usual Interstitial Pneumonia (UIP) pattern on HRCT, either definite or probable, in the absence of an identifiable cause. A definite UIP pattern on HRCT includes basal and peripheral predominant reticulation, honeycomb changes, and traction bronchiectasis, with no features atypical for UIP (e.g., extensive ground-glass, mosaic attenuation, predominant upper/mid-lung distribution).\",\n    \"highYieldPearl\": \"A definite or probable UIP pattern on HRCT is crucial for IPF diagnosis when a surgical lung biopsy is not performed or deemed unnecessary.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"NSIP (A) is a common pattern in other ILDs like connective tissue disease-associated ILD, but not characteristic of IPF. COP (B) often presents with peripheral consolidations. LIP (D) is rare and associated with autoimmune conditions or immunodeficiency.\"\n  },\n  {\n    \"question\": \"The definitive histological pattern observed in Idiopathic Pulmonary Fibrosis (IPF) is?\",\n    \"options\": {\n      \"A\": \"Cellular Non-Specific Interstitial Pneumonia\",\n      \"B\": \"Organizing Pneumonia\",\n      \"C\": \"Usual Interstitial Pneumonia (UIP)\",\n      \"D\": \"Desquamative Interstitial Pneumonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Histologically, IPF is defined by a UIP pattern, characterized by temporal and spatial heterogeneity. This includes areas of dense fibrosis with architectural distortion (honeycombing), foci of proliferating fibroblasts (fibroblastic foci), and normal lung tissue. Inflammation is typically mild and patchy.\",\n    \"highYieldPearl\": \"Temporal and spatial heterogeneity, along with fibroblastic foci and honeycombing, are hallmarks of histological UIP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"NSIP (A) and DIP (D) are other interstitial pneumonia patterns, but they lack the characteristic heterogeneity and fibroblastic foci of UIP. Organizing Pneumonia (B) is characterized by intraluminal buds of granulation tissue, which is distinct from UIP.\"\n  },\n  {\n    \"question\": \"Which of the following drugs is approved as an antifibrotic for treating Idiopathic Pulmonary Fibrosis (IPF)?\",\n    \"options\": {\n      \"A\": \"Azathioprine\",\n      \"B\": \"Prednisolone\",\n      \"C\": \"Pirfenidone\",\n      \"D\": \"Methotrexate\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Pirfenidone is an oral antifibrotic agent approved for IPF. Its mechanism involves reducing fibroblast proliferation, inhibiting the production of profibrotic mediators like TGF-β and TNF-α, and exerting anti-inflammatory effects. Clinical trials have shown it slows the decline in forced vital capacity (FVC).\",\n    \"highYieldPearl\": \"Pirfenidone and Nintedanib are the only two antifibrotic drugs approved globally for IPF.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Azathioprine (A), Prednisolone (B), and Methotrexate (D) are immunosuppressants. While historically used, they have shown no benefit and potential harm in IPF, and are not recommended for treatment.\"\n  },\n  {\n    \"question\": \"Nintedanib primarily exerts its therapeutic effect in IPF by inhibiting which receptor tyrosine kinases?\",\n    \"options\": {\n      \"A\": \"EGFR and HER2\",\n      \"B\": \"PDGFR, FGFR, and VEGFR\",\n      \"C\": \"ALK and ROS1\",\n      \"D\": \"c-Kit and FLT3\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Nintedanib is a small molecule tyrosine kinase inhibitor that targets multiple receptors. Its antifibrotic action in IPF is primarily mediated through the inhibition of platelet-derived growth factor receptors (PDGFRα/β), fibroblast growth factor receptors (FGFR1-3), and vascular endothelial growth factor receptors (VEGFR1-3). These receptors are crucial in pathways leading to fibroblast proliferation, differentiation, and extracellular matrix deposition.\",\n    \"highYieldPearl\": \"Nintedanib's broad-spectrum tyrosine kinase inhibition targets key growth factors driving fibrosis and angiogenesis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Options A, C, and D list other receptor tyrosine kinases that are targets for various oncologic agents (e.g., EGFR in lung cancer, ALK/ROS1 in lung cancer, c-Kit/FLT3 in hematologic malignancies), but are not the primary targets for Nintedanib's antifibrotic action in IPF.\"\n  },\n  {\n    \"question\": \"The most frequently reported adverse effect of Nintedanib in IPF patients is?\",\n    \"options\": {\n      \"A\": \"Photosensitivity\",\n      \"B\": \"Rash\",\n      \"C\": \"Diarrhea\",\n      \"D\": \"Elevated liver enzymes\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Diarrhea is the most common adverse event associated with Nintedanib, affecting a significant proportion of patients (up to 60-70%). It is typically mild to moderate and manageable with symptomatic treatment, dose reduction, or temporary interruption. Liver enzyme elevations are also common but less frequent than diarrhea.\",\n    \"highYieldPearl\": \"Diarrhea is the hallmark side effect of Nintedanib; photosensitivity and rash are more associated with Pirfenidone.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Photosensitivity (A) and rash (B) are more characteristic side effects of Pirfenidone. Elevated liver enzymes (D) can occur with Nintedanib but are generally less common and often less severe than diarrhea.\"\n  },\n  {\n    \"question\": \"The predominant cell type responsible for extracellular matrix deposition and scarring in IPF is the?\",\n    \"options\": {\n      \"A\": \"Alveolar macrophage\",\n      \"B\": \"Type II pneumocyte\",\n      \"C\": \"Myofibroblast\",\n      \"D\": \"Endothelial cell\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Myofibroblasts are key effector cells in the pathogenesis of IPF. They are derived from various sources, including resident fibroblasts, epithelial-mesenchymal transition (EMT) of epithelial cells, and circulating fibrocytes. Myofibroblasts produce excessive amounts of extracellular matrix components (collagen, fibronectin) and contribute to tissue contraction, leading to the progressive scarring characteristic of IPF.\",\n    \"highYieldPearl\": \"Myofibroblasts, particularly in fibroblastic foci, are central to the progressive fibrotic process in IPF.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Alveolar macrophages (A) play a role in inflammation and cytokine release but are not the primary cells for matrix deposition. Type II pneumocytes (B) are involved in epithelial repair and surfactant production, and can undergo EMT. Endothelial cells (D) are involved in angiogenesis and vascular remodeling.\"\n  },\n  {\n    \"question\": \"The typical median survival for untreated Idiopathic Pulmonary Fibrosis is approximately?\",\n    \"options\": {\n      \"A\": \"1-2 years\",\n      \"B\": \"3-5 years\",\n      \"C\": \"7-10 years\",\n      \"D\": \"More than 10 years\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"IPF is a progressive and ultimately fatal disease. Without treatment, the median survival from diagnosis is typically 3 to 5 years, making it one of the most aggressive interstitial lung diseases. Antifibrotic therapies have been shown to slow disease progression and improve survival.\",\n    \"highYieldPearl\": \"IPF has a prognosis worse than many cancers, highlighting the urgency of early diagnosis and treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, C, and D represent either overly pessimistic or overly optimistic survival estimates. The 3-5 year range is well-established in the literature for untreated IPF.\"\n  },\n  {\n    \"question\": \"Diagnosis of Idiopathic Pulmonary Fibrosis requires the exclusion of all known causes of?\",\n    \"options\": {\n      \"A\": \"Asthma\",\n      \"B\": \"Chronic obstructive pulmonary disease\",\n      \"C\": \"Interstitial lung disease\",\n      \"D\": \"Pulmonary hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"IPF is a diagnosis of exclusion. It is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, limited to the lungs, and associated with the radiological and/or histological pattern of Usual Interstitial Pneumonia (UIP). Therefore, a thorough work-up is required to exclude other known causes of ILD, such as connective tissue disease, drug-induced ILD, and chronic hypersensitivity pneumonitis.\",\n    \"highYieldPearl\": \"IPF is a 'diagnosis of exclusion' - always rule out other ILDs first.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Asthma (A), COPD (B), and Pulmonary Hypertension (D) are distinct pulmonary conditions. While they can coexist or complicate IPF, their exclusion is not part of the primary diagnostic criteria for IPF itself, unlike other forms of ILD.\"\n  },\n  {\n    \"question\": \"Acute exacerbation of IPF (AE-IPF) is characterized by acute respiratory worsening not attributable to?\",\n    \"options\": {\n      \"A\": \"Cardiac failure\",\n      \"B\": \"Pulmonary embolism\",\n      \"C\": \"Infection\",\n      \"D\": \"All of the above\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"An acute exacerbation of IPF (AE-IPF) is defined as an acute, clinically significant respiratory deterioration in a patient with IPF, characterized by new bilateral ground-glass opacity and/or consolidation on HRCT, and not fully explained by cardiac failure, fluid overload, pulmonary embolism, or infection. Exclusion of these conditions is crucial for diagnosis.\",\n    \"highYieldPearl\": \"AE-IPF is a diagnosis of exclusion for acute respiratory deterioration in IPF patients, requiring exclusion of common causes like infection, PE, and cardiac failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Each of the options A, B, and C represents a common cause of acute respiratory deterioration that must be ruled out before diagnosing an AE-IPF. Therefore, 'All of the above' is the correct answer, as the definition specifically requires exclusion of these and other known causes.\"\n  },\n  {\n    \"question\": \"Which of the following genes is associated with familial forms of Idiopathic Pulmonary Fibrosis?\",\n    \"options\": {\n      \"A\": \"CFTR\",\n      \"B\": \"TERT\",\n      \"C\": \"SMN1\",\n      \"D\": \"FBN1\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ipf\",\n    \"deepDiveExplanation\": \"Familial pulmonary fibrosis (FPF) accounts for a significant minority of IPF cases. Mutations in genes encoding telomerase components, such as TERT (telomerase reverse transcriptase) and TERC (telomerase RNA component), are the most common genetic abnormalities identified in FPF. These mutations lead to shortened telomeres and impaired cellular repair mechanisms, contributing to fibroblast senescence and fibrogenesis.\",\n    \"highYieldPearl\": \"Telomerase gene mutations (TERT, TERC) are the most recognized genetic cause of familial IPF.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"CFTR (A) is associated with Cystic Fibrosis. SMN1 (C) is associated with Spinal Muscular Atrophy. FBN1 (D) is associated with Marfan Syndrome. These are well-known genetic disorders, but not associated with IPF.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-811.3836669921875}],"createTime":"2025-12-31T07:45:55.900480Z","modelVersion":"gemini-2.5-flash","responseId":"s9RUaYD7NsHEnvgPpK-byA8","usageMetadata":{"billablePromptUsage":{"textCount":1027},"candidatesTokenCount":2950,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2950}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":1616,"totalTokenCount":4932,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:20.515801+00:00"}
{"metadata":"one-liner|tb_special_pops|TB in HIV, Renal Failure, Diabetes|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"TB in HIV, Renal Failure, Diabetes\".\nSet the \"topic\" field in the JSON to \"tb_special_pops\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4095101820446962,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the recommended duration of anti-TB treatment for drug-susceptible pulmonary TB in HIV-infected patients without CNS involvement?\",\n    \"options\": {\n      \"A\": \"6 months\",\n      \"B\": \"9 months\",\n      \"C\": \"12 months\",\n      \"D\": \"18 months\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"For most drug-susceptible pulmonary TB cases in HIV-infected individuals, the standard 6-month regimen (2 months HRZE, 4 months HR) is recommended, similar to HIV-negative individuals, provided there is no severe disease, extensive cavitation, or CNS involvement. This approach is supported by evidence showing similar efficacy.\",\n    \"highYieldPearl\": \"Standard 6-month regimen for drug-susceptible TB generally applies to HIV co-infected patients without CNS TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might assume HIV status automatically prolongs treatment duration, which is incorrect for uncomplicated drug-susceptible pulmonary TB.\"\n  },\n  {\n    \"question\": \"What is the preferred timing for initiating ART after starting anti-TB treatment in HIV-TB co-infected patients with CD4 count <50 cells/µL?\",\n    \"options\": {\n      \"A\": \"Within 2 weeks\",\n      \"B\": \"2-8 weeks\",\n      \"C\": \"8-12 weeks\",\n      \"D\": \">12 weeks\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"WHO guidelines recommend initiating ART within 2 weeks of starting anti-TB treatment for HIV-TB co-infected patients with CD4 counts less than 50 cells/µL. This early initiation significantly reduces mortality, despite a higher risk of TB-IRIS. For CD4 counts 50-200 cells/µL, ART initiation is recommended within 2-8 weeks.\",\n    \"highYieldPearl\": \"Early ART (within 2 weeks) is crucial for very low CD4 (<50) in HIV-TB co-infection, balancing IRIS risk with mortality benefit.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing ART initiation timing based on CD4 count is crucial. 2-8 weeks is for higher CD4 counts (50-200), not for very low CD4.\"\n  },\n  {\n    \"question\": \"Which anti-tubercular drug requires dose adjustment in severe renal impairment (eGFR <30 mL/min/1.73m2)?\",\n    \"options\": {\n      \"A\": \"Isoniazid\",\n      \"B\": \"Rifampicin\",\n      \"C\": \"Pyrazinamide\",\n      \"D\": \"Ethambutol\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Ethambutol is primarily renally excreted, and its dose must be adjusted in patients with renal impairment to prevent accumulation and potential optic neuritis. Pyrazinamide also requires dose adjustment in renal failure, but Ethambutol is a classic example highlighted for renal dose adjustment among the first-line drugs. Isoniazid and Rifampicin are predominantly metabolized by the liver, requiring less adjustment.\",\n    \"highYieldPearl\": \"Ethambutol and Pyrazinamide are the first-line anti-TB drugs requiring significant renal dose adjustment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are first-line drugs. Knowing the primary excretion pathway for each is key to identifying which requires renal adjustment.\"\n  },\n  {\n    \"question\": \"Which anti-tubercular drug is generally contraindicated in patients with severe renal failure due to high risk of nephrotoxicity and ototoxicity?\",\n    \"options\": {\n      \"A\": \"Capreomycin\",\n      \"B\": \"Kanamycin\",\n      \"C\": \"Amikacin\",\n      \"D\": \"Streptomycin\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Streptomycin, an aminoglycoside, is primarily renally excreted and highly nephrotoxic and ototoxic. While all aminoglycosides (Kanamycin, Amikacin) and Capreomycin (a polypeptide antibiotic with a similar toxicity profile) are problematic in renal failure, Streptomycin is the classical first-generation injectable anti-TB drug and is generally contraindicated or used with extreme caution and significant dose reduction in severe renal impairment, often requiring therapeutic drug monitoring.\",\n    \"highYieldPearl\": \"Aminoglycosides (e.g., Streptomycin) are highly nephrotoxic and ototoxic, posing significant risks in renal failure and often contraindicated.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are injectable second-line drugs with similar toxicity profiles. Streptomycin is often the most emphasized in this context due to its historical use and prominent toxicity.\"\n  },\n  {\n    \"question\": \"What is the primary impact of uncontrolled diabetes mellitus on the course of tuberculosis?\",\n    \"options\": {\n      \"A\": \"Decreased bacterial load\",\n      \"B\": \"Increased drug efficacy\",\n      \"C\": \"Higher risk of treatment failure and relapse\",\n      \"D\": \"Reduced immune response\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Uncontrolled diabetes mellitus impairs cellular immunity, leading to a higher risk of developing active TB, more severe disease, delayed sputum conversion, and significantly increased rates of treatment failure and relapse. While 'Reduced immune response' is the underlying mechanism, 'Higher risk of treatment failure and relapse' is the direct and most critical clinical outcome.\",\n    \"highYieldPearl\": \"Diabetes significantly increases TB severity, treatment failure, and relapse risk due to impaired host immunity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"'Reduced immune response' is true and foundational, but 'Higher risk of treatment failure and relapse' is a more direct and encompassing clinical consequence often highlighted in guidelines.\"\n  },\n  {\n    \"question\": \"What is the primary concern when prescribing Rifampicin with Protease Inhibitors (PIs) in HIV-TB co-infection?\",\n    \"options\": {\n      \"A\": \"Nephrotoxicity\",\n      \"B\": \"Neurotoxicity\",\n      \"C\": \"Drug-drug interaction via CYP450 induction\",\n      \"D\": \"Hepatotoxicity\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Rifampicin is a potent inducer of cytochrome P450 enzymes (CYP3A4), which significantly accelerates the metabolism of many Protease Inhibitors (PIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). This interaction leads to subtherapeutic PI/NNRTI levels, potentially causing HIV treatment failure and development of resistance. This drug-drug interaction is a major challenge in HIV-TB co-management.\",\n    \"highYieldPearl\": \"Rifampicin's potent CYP450 induction causes critical drug-drug interactions with PIs, necessitating careful ART regimen selection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hepatotoxicity is a concern with both drugs, but the specific interaction leading to subtherapeutic PI levels and HIV treatment failure is the primary specific concern with this combination.\"\n  },\n  {\n    \"question\": \"What is the most common site of extrapulmonary TB in patients with diabetes mellitus?\",\n    \"options\": {\n      \"A\": \"Lymph nodes\",\n      \"B\": \"Pleura\",\n      \"C\": \"Bone\",\n      \"D\": \"Genitourinary\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"While lymph node TB is common in the general population and other immunocompromised states, studies have shown that genitourinary TB (especially renal TB) is disproportionately more common in patients with diabetes mellitus compared to non-diabetic individuals. The altered glucose metabolism and impaired local immunity contribute to this predilection.\",\n    \"highYieldPearl\": \"Diabetics have a higher predisposition to genitourinary TB compared to the general population.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Lymph node TB is generally common, but the question asks for the *most common* in *diabetics*, which points to genitourinary TB due to specific associations.\"\n  },\n  {\n    \"question\": \"What is the recommended frequency for administering Ethambutol in patients with end-stage renal disease (ESRD) on hemodialysis?\",\n    \"options\": {\n      \"A\": \"Daily\",\n      \"B\": \"Thrice weekly\",\n      \"C\": \"Twice weekly\",\n      \"D\": \"Post-dialysis\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Ethambutol is primarily renally excreted and is dialyzable. To ensure adequate drug levels and minimize toxicity (especially optic neuritis), it is typically administered thrice weekly immediately after hemodialysis sessions, which is captured by the 'Post-dialysis' instruction. This ensures drug removal during dialysis does not lead to subtherapeutic levels before the next dose.\",\n    \"highYieldPearl\": \"Ethambutol in ESRD should be given post-dialysis, typically thrice weekly, to manage drug levels and toxicity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Knowing that it needs adjustment is one thing; knowing the specific timing/frequency for ESRD on dialysis is more advanced. 'Thrice weekly' is also correct, but 'Post-dialysis' is more precise for the administration strategy relative to dialysis.\"\n  },\n  {\n    \"question\": \"Which anti-tubercular drug is typically associated with an increased risk of peripheral neuropathy, especially in HIV-infected patients?\",\n    \"options\": {\n      \"A\": \"Isoniazid\",\n      \"B\": \"Rifampicin\",\n      \"C\": \"Pyrazinamide\",\n      \"D\": \"Ethambutol\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Isoniazid can cause peripheral neuropathy due to its interference with pyridoxine (Vitamin B6) metabolism. HIV-infected patients are already at a higher risk for neuropathy from HIV itself or from other antiretroviral drugs, making co-administration of pyridoxine crucial when Isoniazid is used in this population.\",\n    \"highYieldPearl\": \"Isoniazid-induced peripheral neuropathy requires pyridoxine supplementation, especially in HIV and other high-risk groups.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other drugs can have neurological side effects, Isoniazid is classically and most strongly linked to peripheral neuropathy among first-line anti-TB drugs.\"\n  },\n  {\n    \"question\": \"What is the primary reason for lower sensitivity of TST/IGRA in immunocompromised patients (e.g., HIV, renal failure)?\",\n    \"options\": {\n      \"A\": \"Reduced antigenicity\",\n      \"B\": \"Anergy\",\n      \"C\": \"Increased antibody production\",\n      \"D\": \"Faster clearance of tuberculin\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_special_pops\",\n    \"deepDiveExplanation\": \"Immunocompromised states, such as advanced HIV infection or severe renal failure, lead to an impaired cellular immune response (anergy). This prevents a robust delayed-type hypersensitivity reaction required for a positive TST or IGRA, resulting in false-negative results despite true Mycobacterium tuberculosis infection.\",\n    \"highYieldPearl\": \"Anergy, or impaired cellular immunity, is the main cause of false-negative TST/IGRA results in immunocompromised individuals.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"'Reduced antigenicity' or 'faster clearance' might sound plausible but anergy directly addresses the immune system's inability to react effectively, which is the core issue.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1165.87548828125}],"createTime":"2025-12-31T07:45:36.920246Z","modelVersion":"gemini-2.5-flash","responseId":"oNRUabaVOKaWgLUPhJyX8AE","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":2847,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2847}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":3981,"totalTokenCount":7197,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:30.345919+00:00"}
{"metadata":"one-liner|aerosol_delivery|Aerosol and Drug Delivery Devices|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Aerosol and Drug Delivery Devices\".\nSet the \"topic\" field in the JSON to \"aerosol_delivery\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3778557078697381,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the optimal aerodynamic particle size (MMAD) for maximal peripheral lung deposition of inhaled aerosols?\",\n    \"options\": {\n      \"A\": \">10 µm\",\n      \"B\": \"5-10 µm\",\n      \"C\": \"1-5 µm\",\n      \"D\": \"<1 µm\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aerosol_delivery\",\n    \"deepDiveExplanation\": \"The optimal mass median aerodynamic diameter (MMAD) for maximal deposition in the peripheral lung (small airways and alveoli) is generally 1-5 µm. Particles larger than 5 µm tend to deposit in the oropharynx and large airways due to inertial impaction. Particles smaller than 1 µm may be exhaled before depositing due to their low mass and susceptibility to Brownian diffusion rather than sedimentation.\",\n    \"highYieldPearl\": \"Aerosol particles with MMAD 1-5 µm are ideal for deep lung penetration; >5 µm for upper airways, <1 µm often exhaled.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse optimal size for large airway deposition (>5µm) or think smaller is always better (<1µm) which leads to exhalation. The key is 'peripheral lung deposition'.\"\n  },\n  {\n    \"question\": \"The primary benefit of using a valved holding chamber (VHC) with a metered-dose inhaler (MDI) is to reduce:\",\n    \"options\": {\n      \"A\": \"Drug particle aggregation\",\n      \"B\": \"Oropharyngeal drug deposition\",\n      \"C\": \"Systemic drug absorption\",\n      \"D\": \"Inspiratory flow rate requirement\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"aerosol_delivery\",\n    \"deepDiveExplanation\": \"Valved holding chambers (VHCs) reduce the velocity of the aerosol plume from an MDI, allowing larger particles to 'rain out' in the chamber, and the smaller, more respirable particles to be inhaled. This significantly reduces oropharyngeal deposition, which is a major source of side effects and inefficient drug delivery with MDIs. It also helps with coordination, but the direct physiological benefit is reduced impaction in the upper airways.\",\n    \"highYieldPearl\": \"VHCs decrease oropharyngeal deposition and improve lung delivery of MDI drugs by reducing aerosol velocity and particle size at the mouth.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While VHCs indirectly help with coordination (reducing the 'timing' pressure), the primary *mechanism* by which they improve delivery and reduce side effects is by minimizing drug impaction in the oropharynx. Systemic absorption might increase due to better lung delivery, not decrease.\"\n  },\n  {\n    \"question\": \"Which drug delivery device type inherently requires minimal patient coordination between actuation and inspiration?\",\n    \"options\": {\n      \"A\": \"Metered-dose inhaler (MDI)\",\n      \"B\": \"Dry powder inhaler (DPI)\",\n      \"C\": \"Breath-actuated MDI (BAI)\",\n      \"D\": \"Jet nebulizer\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aerosol_delivery\",\n    \"deepDiveExplanation\": \"Breath-actuated MDIs (BAIs) automatically release the drug when the patient initiates inspiration, thus eliminating the need for precise coordination between actuation and inhalation, a common difficulty with standard MDIs. DPIs require a forceful and rapid inspiration, while jet nebulizers are passive and do not require specific coordination during inhalation, but they are not 'inhalers' in the same class as MDIs/DPIs in terms of patient maneuver.\",\n    \"highYieldPearl\": \"Breath-actuated MDIs (BAIs) simplify MDI use by eliminating the need for hand-breath coordination.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might consider DPIs easy to use, but they require a strong inspiratory effort, which is a different challenge than coordination. Jet nebulizers are passive, but the question implies an 'inhaler' type device.\"\n  },\n  {\n    \"question\": \"Which type of nebulizer primarily generates aerosols using a high-frequency vibrating mesh with multiple apertures?\",\n    \"options\": {\n      \"A\": \"Jet nebulizer\",\n      \"B\": \"Ultrasonic nebulizer\",\n      \"C\": \"Vibrating mesh nebulizer\",\n      \"D\": \"Spinning disk nebulizer\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aerosol_delivery\",\n    \"deepDiveExplanation\": \"Vibrating mesh nebulizers (VMNs) utilize a plate or mesh with thousands of laser-drilled holes that vibrates at a high frequency, pushing liquid medication through the apertures to create a fine aerosol. Jet nebulizers use compressed gas, and ultrasonic nebulizers use a piezoelectric crystal to generate high-frequency sound waves.\",\n    \"highYieldPearl\": \"Vibrating mesh nebulizers offer efficient drug delivery with minimal residual volume and operate quietly, using a vibrating mesh.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This is a direct recall question. The main trap would be confusing 'vibrating mesh' with 'ultrasonic' nebulizers, as both involve vibration, but the mechanism of aerosol generation is distinct.\"\n  },\n  {\n    \"question\": \"What is the predominant mechanism of aerosol particle deposition in the large airways (trachea, bronchi) at high inspiratory flow rates?\",\n    \"options\": {\n      \"A\": \"Brownian diffusion\",\n      \"B\": \"Gravitational sedimentation\",\n      \"C\": \"Inertial impaction\",\n      \"D\": \"Electrostatic precipitation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aerosol_delivery\",\n    \"deepDiveExplanation\": \"Inertial impaction is the predominant mechanism for depositing larger particles (typically >5 µm) or particles inhaled at high flow rates, especially in the upper airways and larger conducting airways. These particles have sufficient momentum to overcome changes in airflow direction and impact the airway walls. Gravitational sedimentation is important for particles 1-5 µm in smaller airways during breath-holding, while Brownian diffusion is for very small particles (<0.1 µm) in the alveoli.\",\n    \"highYieldPearl\": \"Large particles and high inspiratory flow rates primarily lead to aerosol deposition in large airways via inertial impaction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse the mechanisms. Sedimentation is for smaller particles in slower air, diffusion for very small particles. The key here is 'large airways' and 'high inspiratory flow rates' which strongly points to impaction.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-587.9434814453125}],"createTime":"2025-12-31T07:46:36.316907Z","modelVersion":"gemini-2.5-flash","responseId":"3NRUaeurE_-rmecP98KPkQI","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":1556,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1556}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1270,"totalTokenCount":3193,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:45.501523+00:00"}
{"metadata":"one-liner|tb_endobronchial|Endobronchial TB|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Endobronchial TB\".\nSet the \"topic\" field in the JSON to \"tb_endobronchial\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.5577683448791504,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which morphological type of endobronchial tuberculosis is most commonly observed?\",\n    \"options\": {\n      \"A\": \"Ulcerative\",\n      \"B\": \"Granular\",\n      \"C\": \"Caseous\",\n      \"D\": \"Fibro-stenotic\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_endobronchial\",\n    \"deepDiveExplanation\": \"Endobronchial tuberculosis (EBTB) can manifest in various morphological forms. While some classifications list edematous-hyperemic as most common, the ulcerative type, characterized by mucosal ulceration and caseous necrosis, is frequently encountered and often considered a hallmark of active disease, making it a high-yield concept for diagnosis.\",\n    \"highYieldPearl\": \"Ulcerative EBTB is highly contagious due to open lesions shedding bacilli, and it's a common cause of positive sputum smears even with minimal parenchymal disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other types like fibro-stenotic are often sequelae of healing, not primary active forms. Granular and caseous are also forms but less frequently cited as 'most common' compared to ulcerative or edematous-hyperemic in active disease.\"\n  },\n  {\n    \"question\": \"The most characteristic bronchoscopic finding in active endobronchial tuberculosis is?\",\n    \"options\": {\n      \"A\": \"Diffuse mucosal edema\",\n      \"B\": \"Ulceration with caseous material\",\n      \"C\": \"Bronchial wall thickening\",\n      \"D\": \"Mucopurulent secretions\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_endobronchial\",\n    \"deepDiveExplanation\": \"Bronchoscopy is crucial for diagnosing EBTB. Active EBTB typically presents with mucosal ulceration, often covered with yellowish caseous material, indicating active inflammation and necrosis. This finding is highly suggestive and aids in targeted biopsy and lavage for microbiological confirmation.\",\n    \"highYieldPearl\": \"Always biopsy suspicious endobronchial lesions, especially in endemic areas, for histopathological and microbiological confirmation of TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Diffuse mucosal edema or bronchial wall thickening can be seen in various inflammatory conditions. Mucopurulent secretions are non-specific. The combination of ulceration and caseous material is more specific to active EBTB.\"\n  },\n  {\n    \"question\": \"The most common long-term sequela of endobronchial tuberculosis is?\",\n    \"options\": {\n      \"A\": \"Pleural effusion\",\n      \"B\": \"Bronchial stenosis\",\n      \"C\": \"Cavitation\",\n      \"D\": \"Pneumothorax\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_endobronchial\",\n    \"deepDiveExplanation\": \"Bronchial stenosis, ranging from mild narrowing to complete occlusion, is a significant complication of EBTB. It results from chronic inflammation, fibrosis, and scar formation in the bronchial wall, leading to airflow obstruction, recurrent infections, and post-obstructive bronchiectasis.\",\n    \"highYieldPearl\": \"Early diagnosis and appropriate anti-tuberculous treatment of EBTB are crucial to prevent irreversible bronchial damage and subsequent stenosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Pleural effusion and cavitation are more commonly associated with parenchymal TB. Pneumothorax is a rare complication of TB in general and not a common sequela specifically of EBTB.\"\n  },\n  {\n    \"question\": \"What is the primary role of corticosteroids as an adjunct in endobronchial tuberculosis?\",\n    \"options\": {\n      \"A\": \"Reduce mycobacterial load\",\n      \"B\": \"Prevent bronchial stenosis\",\n      \"C\": \"Improve drug penetration\",\n      \"D\": \"Alleviate systemic symptoms\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_endobronchial\",\n    \"deepDiveExplanation\": \"Corticosteroids are often used as an adjunct to anti-tuberculous therapy (ATT) in EBTB, particularly in cases with significant inflammation or impending stenosis. Their anti-inflammatory action helps reduce edema and fibrosis in the bronchial wall, thereby preventing or ameliorating bronchial stenosis and preserving airway patency.\",\n    \"highYieldPearl\": \"Corticosteroids should always be given *with* full ATT, never alone, in active TB, to avoid disseminated disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Corticosteroids do not reduce mycobacterial load directly or improve drug penetration. While they can alleviate systemic symptoms, their primary indication in EBTB is airway preservation by reducing inflammation and fibrosis.\"\n  },\n  {\n    \"question\": \"Endobronchial tuberculosis most commonly results from which mechanism?\",\n    \"options\": {\n      \"A\": \"Hematogenous spread\",\n      \"B\": \"Lymphatic spread\",\n      \"C\": \"Direct extension from parenchyma\",\n      \"D\": \"Inhalation of aerosols\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_endobronchial\",\n    \"deepDiveExplanation\": \"EBTB can arise through several mechanisms. The most common include direct extension from an adjacent parenchymal lesion (e.g., a subpleural focus eroding into a bronchus) or expectoration of bacilli from a distant cavitary lesion with subsequent implantation. Lymphatic spread from hilar lymph nodes is also a recognized mechanism, often leading to extrinsic compression or direct invasion. Direct extension from parenchyma and implantation via expectoration are considered predominant.\",\n    \"highYieldPearl\": \"EBTB patients often have co-existing parenchymal TB, which acts as the source of infection for the bronchial tree.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hematogenous spread typically causes miliary TB or distant organ involvement. Inhalation causes primary parenchymal infection but doesn't directly explain EBTB without a primary focus eroding into the bronchus or expectoration of bacilli.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-785.3378295898438}],"createTime":"2025-12-31T07:45:58.677742Z","modelVersion":"gemini-2.5-flash","responseId":"ttRUae6uKYS7gLUPlM_J6AI","usageMetadata":{"billablePromptUsage":{"textCount":1022},"candidatesTokenCount":1408,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1408}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":2390,"totalTokenCount":4166,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:29.772019+00:00"}
{"metadata":"one-liner|psg|Polysomnography Interpretation|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Polysomnography Interpretation\".\nSet the \"topic\" field in the JSON to \"psg\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3925584465616809,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"A respiratory event is classified as apnea if airflow reduction is >90% for at least how many seconds?\",\n    \"options\": {\n      \"A\": \"5\",\n      \"B\": \"10\",\n      \"C\": \"15\",\n      \"D\": \"20\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"psg\",\n    \"deepDiveExplanation\": \"According to the American Academy of Sleep Medicine (AASM) scoring criteria, an apnea is defined as a drop in the peak thermal sensor (thermistor, thermocouple) signal by ≥90% of pre-event baseline for at least 10 seconds. This cessation of airflow is then further classified as obstructive or central based on concomitant respiratory effort.\",\n    \"highYieldPearl\": \"The 10-second duration is a critical threshold for defining both apnea and hypopnea events in standard PSG interpretation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While shorter durations might be associated with other respiratory events or partial obstructions, 10 seconds is the established minimum for an apnea event according to AASM guidelines. 5 seconds is too short, and 15 or 20 seconds are longer than the minimum required for classification.\"\n  },\n  {\n    \"question\": \"A hypopnea event on polysomnography requires airflow reduction of at least 30% lasting ≥10 seconds, associated with what?\",\n    \"options\": {\n      \"A\": \"Bradycardia\",\n      \"B\": \"Oxygen desaturation ≥3% or arousal\",\n      \"C\": \"Hypertension\",\n      \"D\": \"Hypercapnia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"psg\",\n    \"deepDiveExplanation\": \"AASM scoring criteria define a hypopnea as a discernable reduction in airflow (typically ≥30% from baseline, though some criteria use ≥50%) lasting at least 10 seconds, associated with either an oxygen desaturation of ≥3% from pre-event baseline OR an arousal from sleep. Some criteria also accept a ≥4% desaturation without arousal.\",\n    \"highYieldPearl\": \"The combination of airflow reduction, duration, AND a physiological consequence (desaturation or arousal) is crucial for hypopnea diagnosis and distinguishes it from benign snoring.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Bradycardia, hypertension, and hypercapnia can be *consequences* of hypopneas but are not part of the *definitional criteria* used for scoring the event itself in standard PSG interpretation. The desaturation or arousal is the direct physiological impact used for scoring.\"\n  },\n  {\n    \"question\": \"The key polysomnography channel differentiating central from obstructive apnea is the measurement of what?\",\n    \"options\": {\n      \"A\": \"Nasal airflow\",\n      \"B\": \"Thoracoabdominal effort\",\n      \"C\": \"Oxygen saturation\",\n      \"D\": \"Electroencephalogram\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"psg\",\n    \"deepDiveExplanation\": \"In obstructive apnea, there is continued or increased thoracoabdominal effort (measured by respiratory inductance plethysmography bands) despite an absence of airflow, indicating an upper airway obstruction. In central apnea, both airflow and thoracoabdominal effort are absent, indicating a lack of respiratory drive from the brainstem.\",\n    \"highYieldPearl\": \"Respiratory effort channels are fundamental for classifying apnea types, providing the crucial distinction between central and obstructive etiologies, which guides treatment strategies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Nasal airflow detects the *presence* of an apnea. Oxygen saturation measures the *consequence* of the event. EEG measures *sleep stages* and *arousals*. None of these directly indicate the *cause* (central vs. obstructive) in the way respiratory effort does.\"\n  },\n  {\n    \"question\": \"The characteristic polysomnographic finding in REM Sleep Behavior Disorder (RBD) is what?\",\n    \"options\": {\n      \"A\": \"Absence of REM sleep\",\n      \"B\": \"High AHI\",\n      \"C\": \"REM sleep without atonia\",\n      \"D\": \"Periodic limb movements\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"psg\",\n    \"deepDiveExplanation\": \"Normally, during REM sleep, there is muscle atonia (paralysis) to prevent acting out dreams. In RBD, this atonia is absent or diminished, leading to complex motor behaviors. PSG shows increased tonic or phasic electromyography (EMG) activity in the chin or limb muscles during REM sleep, a phenomenon termed REM sleep without atonia (RSWA).\",\n    \"highYieldPearl\": \"RSWA is pathognomonic for RBD and requires careful chin and/or limb EMG monitoring during PSG, along with video recording to correlate movements with EMG activity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Absence of REM sleep is incorrect; REM sleep is present but abnormal. A high AHI is characteristic of Obstructive Sleep Apnea. Periodic limb movements are a feature of Periodic Limb Movement Disorder (PLMD), though sometimes co-exist, they are not the *characteristic* finding for RBD itself.\"\n  },\n  {\n    \"question\": \"An Apnea-Hypopnea Index (AHI) between 15-30 events/hour on polysomnography signifies what severity of OSA?\",\n    \"options\": {\n      \"A\": \"Mild\",\n      \"B\": \"Moderate\",\n      \"C\": \"Severe\",\n      \"D\": \"Very severe\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"psg\",\n    \"deepDiveExplanation\": \"The AHI classification for Obstructive Sleep Apnea (OSA) severity is standard across most guidelines:\\n*   Normal: AHI < 5 events/hour\\n*   Mild: AHI 5 to < 15 events/hour\\n*   Moderate: AHI 15 to < 30 events/hour\\n*   Severe: AHI ≥ 30 events/hour\\nThis classification guides treatment decisions and prognosis.\",\n    \"highYieldPearl\": \"Memorizing these AHI thresholds is crucial for diagnosing and appropriately managing patients with sleep-disordered breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This question tests direct recall of standard AHI classification. Confusing the ranges (e.g., thinking 15-30 is mild or severe) is the primary trap. 'Very severe' is not a standard AASM classification category for OSA.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-599.044189453125}],"createTime":"2025-12-31T07:45:44.070797Z","modelVersion":"gemini-2.5-flash","responseId":"qNRUaY2pBIHN1AGCsIjgBQ","usageMetadata":{"billablePromptUsage":{"textCount":1023},"candidatesTokenCount":1526,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1526}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":2393,"totalTokenCount":4281,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:02.336967+00:00"}
{"metadata":"one-liner|smoking_cessation|Smoking Cessation|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Smoking Cessation\".\nSet the \"topic\" field in the JSON to \"smoking_cessation\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4480629469219007,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which of the following is considered a first-line pharmacotherapy for smoking cessation?\",\n    \"options\": {\n      \"A\": \"Varenicline\",\n      \"B\": \"Nortriptyline\",\n      \"C\": \"Clonidine\",\n      \"D\": \"Gabapentin\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"smoking_cessation\",\n    \"deepDiveExplanation\": \"Varenicline is a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, reducing withdrawal symptoms and blocking nicotine's reinforcing effects. Bupropion SR and Nicotine Replacement Therapy (NRT) are also considered first-line pharmacotherapies.\",\n    \"highYieldPearl\": \"Varenicline generally demonstrates the highest efficacy among single pharmacotherapies for smoking cessation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Nortriptyline and Clonidine are considered second-line agents. Gabapentin has no established role in smoking cessation.\"\n  },\n  {\n    \"question\": \"Bupropion SR aids smoking cessation primarily by which mechanism?\",\n    \"options\": {\n      \"A\": \"Nicotinic receptor partial agonism\",\n      \"B\": \"Norepinephrine-dopamine reuptake inhibition\",\n      \"C\": \"GABAergic modulation\",\n      \"D\": \"Serotonin reuptake inhibition\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"smoking_cessation\",\n    \"deepDiveExplanation\": \"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). Its antidepressant and smoking cessation effects are thought to be mediated by these actions, which help to reduce cravings and withdrawal symptoms.\",\n    \"highYieldPearl\": \"Bupropion is also used as an antidepressant and is contraindicated in seizure disorders.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Option A describes the mechanism of Varenicline. Options C and D are not the primary mechanisms of action for Bupropion SR in smoking cessation.\"\n  },\n  {\n    \"question\": \"Which condition is a contraindication for Bupropion SR in smoking cessation?\",\n    \"options\": {\n      \"A\": \"COPD\",\n      \"B\": \"Stable angina\",\n      \"C\": \"History of seizures\",\n      \"D\": \"Mild hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"smoking_cessation\",\n    \"deepDiveExplanation\": \"Bupropion lowers the seizure threshold. Therefore, a history of seizures, eating disorders (e.g., bulimia or anorexia nervosa due to electrolyte imbalances increasing seizure risk), or abrupt alcohol/sedative withdrawal are absolute contraindications.\",\n    \"highYieldPearl\": \"The risk of seizures with Bupropion is dose-dependent.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"COPD, stable angina, and mild hypertension are generally not contraindications for Bupropion SR; in fact, smoking cessation benefits these conditions.\"\n  },\n  {\n    \"question\": \"Which of the following conditions is NOT an absolute contraindication to Nicotine Replacement Therapy (NRT)?\",\n    \"options\": {\n      \"A\": \"Recent myocardial infarction (<2 weeks)\",\n      \"B\": \"Unstable angina\",\n      \"C\": \"Serious arrhythmias\",\n      \"D\": \"Controlled hypertension\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"smoking_cessation\",\n    \"deepDiveExplanation\": \"NRT is generally safer than continued smoking. While caution is advised, controlled hypertension is not an absolute contraindication. Conditions like recent MI, unstable angina, and serious arrhythmias are relative contraindications where NRT should be used with caution and under medical supervision, but the benefits of cessation generally outweigh the risks of NRT.\",\n    \"highYieldPearl\": \"The risks associated with continued smoking far outweigh the risks of NRT in nearly all cardiovascular conditions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Options A, B, and C represent conditions where NRT use requires careful consideration and medical supervision, often considered relative contraindications due to increased cardiac risk, though the benefit of cessation often outweighs the NRT risk. Controlled hypertension is generally considered safe for NRT.\"\n  },\n  {\n    \"question\": \"What is the typical minimum recommended duration for Varenicline or Bupropion SR treatment in smoking cessation?\",\n    \"options\": {\n      \"A\": \"2 weeks\",\n      \"B\": \"4 weeks\",\n      \"C\": \"8 weeks\",\n      \"D\": \"12 weeks\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"smoking_cessation\",\n    \"deepDiveExplanation\": \"The standard recommended duration for both Varenicline and Bupropion SR is 12 weeks (3 months). Some guidelines suggest extending treatment for up to 6 months in individuals who respond well and wish to further reduce relapse risk.\",\n    \"highYieldPearl\": \"Adherence to the full recommended course of pharmacotherapy significantly improves long-term smoking cessation success rates.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Shorter durations (2, 4, or 8 weeks) are generally insufficient for optimal efficacy and sustained abstinence from smoking.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-544.8445434570313}],"createTime":"2025-12-31T07:46:24.777653Z","modelVersion":"gemini-2.5-flash","responseId":"0NRUabW7L5Hplu8P_-zfqQw","usageMetadata":{"billablePromptUsage":{"textCount":1024},"candidatesTokenCount":1216,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1216}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":1740,"totalTokenCount":3318,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:43.648218+00:00"}
{"metadata":"one-liner|niv|Non-Invasive Ventilation (NIV)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Non-Invasive Ventilation (NIV)\".\nSet the \"topic\" field in the JSON to \"niv\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3846021476859938,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Primary mechanism of EPAP in NIV for acute cardiogenic pulmonary edema?\",\n    \"options\": {\n      \"A\": \"Reduce afterload\",\n      \"B\": \"Reduce preload\",\n      \"C\": \"Increase FRC\",\n      \"D\": \"Decrease work of breathing\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"EPAP (Expiratory Positive Airway Pressure) increases intrathoracic pressure, which reduces venous return to the heart, thereby decreasing cardiac preload. This helps alleviate pulmonary congestion in cardiogenic pulmonary edema.\",\n    \"highYieldPearl\": \"NIV's EPAP component significantly reduces cardiac preload, a key benefit in cardiogenic pulmonary edema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While NIV generally decreases work of breathing and can improve oxygenation (partially via increased FRC), the most direct and primary mechanism of EPAP in reducing pulmonary edema is the reduction of preload. Afterload reduction is also a benefit, but preload is more directly impacted by venous return reduction.\"\n  },\n  {\n    \"question\": \"Most common initial mode of NIV for acute exacerbation of COPD?\",\n    \"options\": {\n      \"A\": \"CPAP\",\n      \"B\": \"BiPAP-S/T\",\n      \"C\": \"ASV\",\n      \"D\": \"PAV\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"BiPAP-S/T (Bilevel Positive Airway Pressure with Spontaneous/Timed mode) provides both inspiratory and expiratory pressure support, effectively reducing the work of breathing and improving alveolar ventilation in patients with acute hypercapnic respiratory failure due to COPD exacerbation.\",\n    \"highYieldPearl\": \"BiPAP-S/T is the first-line NIV mode for acute hypercapnic respiratory failure in COPD exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"CPAP only provides expiratory pressure and is insufficient for ventilatory support in severe COPD exacerbations. ASV (Adaptive Servo-Ventilation) and PAV (Proportional Assist Ventilation) are more specialized modes not typically used for initial acute COPD management.\"\n  },\n  {\n    \"question\": \"Absolute contraindication for NIV in acute respiratory failure?\",\n    \"options\": {\n      \"A\": \"Severe hemodynamic instability\",\n      \"B\": \"High aspiration risk\",\n      \"C\": \"Uncooperative patient\",\n      \"D\": \"Facial trauma\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"Severe hemodynamic instability, including cardiac arrest or uncontrolled shock, is an absolute contraindication for NIV, as the positive pressure can further impair cardiac output. Immediate intubation and invasive ventilation are required.\",\n    \"highYieldPearl\": \"Unprotected airway, cardiac arrest, and severe hemodynamic instability are critical absolute contraindications for NIV.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"High aspiration risk, uncooperative patient, and facial trauma are important relative contraindications or factors that increase the risk of NIV failure, but severe hemodynamic instability demands immediate invasive support.\"\n  },\n  {\n    \"question\": \"NIV primarily reduces work of breathing by decreasing which parameter?\",\n    \"options\": {\n      \"A\": \"Inspiratory pressure\",\n      \"B\": \"Expiratory pressure\",\n      \"C\": \"Airway resistance\",\n      \"D\": \"Inspiratory effort\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"NIV provides positive inspiratory pressure (IPAP), which assists the patient's own inspiratory effort, thereby offloading the respiratory muscles and directly reducing the work of breathing.\",\n    \"highYieldPearl\": \"NIV's pressure support directly reduces the patient's intrinsic inspiratory effort, thus lowering the work of breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"NIV provides inspiratory/expiratory pressure, it doesn't reduce them. While NIV can help overcome airway resistance, it doesn't directly decrease the resistance itself. The primary effect is on the patient's effort.\"\n  },\n  {\n    \"question\": \"Which condition is a primary indication for long-term home NIV?\",\n    \"options\": {\n      \"A\": \"Acute respiratory distress syndrome\",\n      \"B\": \"Severe pneumonia\",\n      \"C\": \"Obesity hypoventilation syndrome\",\n      \"D\": \"Post-extubation respiratory failure\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"Obesity hypoventilation syndrome (OHS) often leads to chronic hypercapnic respiratory failure, which is a strong indication for long-term nocturnal NIV to improve gas exchange and reduce symptoms.\",\n    \"highYieldPearl\": \"Long-term home NIV is crucial for chronic hypercapnic conditions such as OHS, severe COPD, and neuromuscular diseases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The other options are acute conditions where NIV might be used temporarily in a hospital setting, but not typically for chronic home management.\"\n  },\n  {\n    \"question\": \"Predictor of NIV failure in acute hypoxemic respiratory failure?\",\n    \"options\": {\n      \"A\": \"High PaO2/FiO2 ratio\",\n      \"B\": \"Low respiratory rate\",\n      \"C\": \"High APACHE II score\",\n      \"D\": \"Intact cough reflex\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"Higher severity of illness scores, such as APACHE II or SAPS II, indicate a sicker patient with multi-organ dysfunction, which correlates with a higher likelihood of NIV failure and the need for invasive ventilation.\",\n    \"highYieldPearl\": \"High illness severity scores and persistent hypoxemia after NIV initiation are key predictors of NIV failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"A high PaO2/FiO2 ratio, low respiratory rate, and intact cough reflex are all indicators of better respiratory function and potential NIV success, not failure.\"\n  },\n  {\n    \"question\": \"Maximum recommended inspiratory pressure (IPAP) limit for NIV?\",\n    \"options\": {\n      \"A\": \"10 cmH2O\",\n      \"B\": \"15 cmH2O\",\n      \"C\": \"20 cmH2O\",\n      \"D\": \"25 cmH2O\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"While pressures can vary, 20-25 cmH2O is generally considered the practical upper limit for IPAP in NIV to minimize gastric insufflation, patient discomfort, and potential barotrauma, while still achieving ventilatory support.\",\n    \"highYieldPearl\": \"Effective NIV aims for the lowest pressures to achieve therapeutic goals, typically not exceeding 25 cmH2O IPAP due to gastric insufflation risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Lower pressures might be insufficient for adequate ventilatory support. While higher pressures are sometimes used cautiously, 25 cmH2O is a common safety and efficacy threshold for non-invasive interfaces.\"\n  },\n  {\n    \"question\": \"Primary benefit of NIV in acute asthma exacerbation?\",\n    \"options\": {\n      \"A\": \"Bronchodilation\",\n      \"B\": \"Reduced airway inflammation\",\n      \"C\": \"Decreased dynamic hyperinflation\",\n      \"D\": \"Improved mucociliary clearance\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"In severe asthma, NIV helps by reducing air trapping and intrinsic PEEP (auto-PEEP), which in turn decreases dynamic hyperinflation and the associated work of breathing, improving ventilatory mechanics.\",\n    \"highYieldPearl\": \"NIV effectively reduces dynamic hyperinflation and intrinsic PEEP in acute severe asthma, thereby reducing work of breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Bronchodilation and reduced airway inflammation are achieved by pharmacological agents (bronchodilators, steroids), not directly by NIV. Improved mucociliary clearance is not a primary, direct effect of NIV in this context.\"\n  },\n  {\n    \"question\": \"Which parameter directly controls CO2 removal during BiPAP?\",\n    \"options\": {\n      \"A\": \"EPAP\",\n      \"B\": \"FiO2\",\n      \"C\": \"IPAP minus EPAP (pressure support)\",\n      \"D\": \"Respiratory rate\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"CO2 removal (ventilation) is primarily determined by minute ventilation, which is the product of tidal volume and respiratory rate. In BiPAP, the pressure support (IPAP minus EPAP) directly influences the tidal volume delivered with each breath, thus impacting CO2 clearance.\",\n    \"highYieldPearl\": \"CO2 removal during BiPAP is governed by the pressure support (IPAP-EPAP) and respiratory rate, which together determine minute ventilation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EPAP primarily affects oxygenation and counteracts intrinsic PEEP. FiO2 solely affects oxygenation. While respiratory rate contributes to minute ventilation, the pressure support (IPAP-EPAP) is the direct ventilator control that augments tidal volume.\"\n  },\n  {\n    \"question\": \"Which type of mask is generally preferred for acute NIV initiation?\",\n    \"options\": {\n      \"A\": \"Nasal mask\",\n      \"B\": \"Oral mask\",\n      \"C\": \"Full-face mask\",\n      \"D\": \"Nasal pillows\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"niv\",\n    \"deepDiveExplanation\": \"Full-face masks (or oronasal masks) are generally preferred for acute NIV initiation because they provide a better seal, minimize air leak (especially with mouth breathing), and are more effective in delivering target pressures.\",\n    \"highYieldPearl\": \"Full-face masks are the preferred interface for acute NIV due to superior seal and efficacy, while nasal masks are common for chronic home use.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Nasal masks and nasal pillows are prone to mouth leak, reducing efficacy in acute settings. Oral masks alone are rarely used due to discomfort and difficulty in maintaining a seal.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-949.5827026367188}],"createTime":"2025-12-31T07:46:19.150445Z","modelVersion":"gemini-2.5-flash","responseId":"y9RUaa2XCcj9ld8P_9fN0Q0","usageMetadata":{"billablePromptUsage":{"textCount":1023},"candidatesTokenCount":2469,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2469}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2135,"totalTokenCount":4969,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:24.323497+00:00"}
{"metadata":"one-liner|abpa|Allergic Bronchopulmonary Aspergillosis (ABPA)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Allergic Bronchopulmonary Aspergillosis (ABPA)\".\nSet the \"topic\" field in the JSON to \"abpa\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.44151882694997246,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which serological finding is an essential diagnostic criterion for ABPA?\",\n    \"options\": {\n      \"A\": \"Elevated serum IgA\",\n      \"B\": \"Elevated serum total IgE\",\n      \"C\": \"Elevated serum IgM\",\n      \"D\": \"Elevated serum C-reactive protein\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"abpa\",\n    \"deepDiveExplanation\": \"Elevated total IgE is a cornerstone of ABPA diagnosis. ISHAM criteria include total IgE > 1000 IU/mL (or > 500 IU/mL if other criteria are strongly met). It reflects the allergic inflammatory response to Aspergillus antigens.\",\n    \"highYieldPearl\": \"Total IgE is not only diagnostic but also crucial for monitoring disease activity and treatment response in ABPA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options are not primary serological diagnostic criteria for ABPA. Peripheral eosinophilia is a hematological finding, not strictly serological, and while common, not as specific or universally elevated as total IgE in all stages.\"\n  },\n  {\n    \"question\": \"ABPA primarily involves which types of hypersensitivity reactions?\",\n    \"options\": {\n      \"A\": \"Type II and Type IV\",\n      \"B\": \"Type I and Type II\",\n      \"C\": \"Type III and Type IV\",\n      \"D\": \"Type I and Type III\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"abpa\",\n    \"deepDiveExplanation\": \"ABPA is characterized by an exaggerated immune response to Aspergillus fumigatus antigens. Type I (IgE-mediated) hypersensitivity leads to bronchospasm and eosinophilic inflammation. Type III (immune complex-mediated) hypersensitivity contributes to immune complex deposition in the airways, leading to inflammation and tissue damage.\",\n    \"highYieldPearl\": \"The combination of Type I and Type III hypersensitivity reactions explains the characteristic IgE elevation, eosinophilia, and immune complex-mediated inflammation leading to bronchiectasis in ABPA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing the types of hypersensitivity is common. Type II is cytotoxic and Type IV is delayed-type; neither are primary mechanisms in ABPA.\"\n  },\n  {\n    \"question\": \"The gold standard imaging modality for detecting central bronchiectasis in ABPA is?\",\n    \"options\": {\n      \"A\": \"Chest X-ray\",\n      \"B\": \"Bronchoscopy with lavage\",\n      \"C\": \"High-resolution computed tomography (HRCT)\",\n      \"D\": \"Magnetic resonance imaging (MRI)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abpa\",\n    \"deepDiveExplanation\": \"HRCT provides detailed imaging of the lung parenchyma and airways, allowing for precise identification of central bronchiectasis, which is a hallmark feature of ABPA. Chest X-ray is often insensitive for early or mild bronchiectasis.\",\n    \"highYieldPearl\": \"Central bronchiectasis is a major diagnostic criterion for ABPA (especially by Rosenberg-Patterson criteria), and HRCT is the definitive tool to identify it.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Chest X-ray is too insensitive. Bronchoscopy is invasive and not primarily for anatomical diagnosis of bronchiectasis. MRI has limited utility for lung parenchyma compared to HRCT.\"\n  },\n  {\n    \"question\": \"What is the first-line pharmacotherapy for acute exacerbations of ABPA?\",\n    \"options\": {\n      \"A\": \"Oral itraconazole\",\n      \"B\": \"Inhaled corticosteroids\",\n      \"C\": \"Oral corticosteroids\",\n      \"D\": \"Omalizumab\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abpa\",\n    \"deepDiveExplanation\": \"Oral corticosteroids (e.g., prednisone) are the cornerstone of treatment for acute exacerbations of ABPA, rapidly suppressing the inflammatory response and preventing progressive lung damage. Antifungals like itraconazole are often added for their steroid-sparing effect and to reduce fungal burden, but steroids are primary for acute inflammation.\",\n    \"highYieldPearl\": \"Systemic corticosteroids are the primary anti-inflammatory agents in ABPA; antifungals are adjunctive, mainly for steroid-sparing or recalcitrant cases, not first-line for acute exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Itraconazole is important but not first-line for acute exacerbations. Inhaled corticosteroids are less effective for systemic inflammation. Omalizumab is a biologic for severe, refractory cases, not initial first-line.\"\n  },\n  {\n    \"question\": \"Which marker is primarily used to monitor ABPA treatment response and disease activity?\",\n    \"options\": {\n      \"A\": \"Peripheral eosinophil count\",\n      \"B\": \"Serum Aspergillus-specific IgG\",\n      \"C\": \"Serum total IgE levels\",\n      \"D\": \"FEV1 on spirometry\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abpa\",\n    \"deepDiveExplanation\": \"Serum total IgE levels correlate well with disease activity in ABPA. A significant drop (e.g., >25-35%) in total IgE after corticosteroid therapy indicates a good response. Rising IgE levels can signal a relapse or exacerbation.\",\n    \"highYieldPearl\": \"Total IgE is the most practical and widely accepted biomarker for monitoring ABPA disease activity and response to therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Peripheral eosinophil count can be used but is less specific and can be influenced by other factors. Aspergillus-specific IgG levels are generally less dynamic than total IgE for monitoring. FEV1 measures lung function but doesn't directly reflect the inflammatory activity as well as IgE.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-601.7901611328125}],"createTime":"2025-12-31T07:46:26.755182Z","modelVersion":"gemini-2.5-flash","responseId":"0tRUae6LLqaWgLUPhJyX8AE","usageMetadata":{"billablePromptUsage":{"textCount":1038},"candidatesTokenCount":1363,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1363}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":2375,"totalTokenCount":4107,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:48:17.802928+00:00"}
{"metadata":"one-liner|exercise_testing|Exercise Testing (6MWT, CPET)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Exercise Testing (6MWT, CPET)\".\nSet the \"topic\" field in the JSON to \"exercise_testing\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4582174112508585,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary physiological parameter assessed by the Six-Minute Walk Test (6MWT) is?\",\n    \"options\": {\n      \"A\": \"Peak oxygen uptake (VO2peak)\",\n      \"B\": \"Ventilatory threshold\",\n      \"C\": \"Functional exercise capacity\",\n      \"D\": \"Anaerobic threshold\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"exercise_testing\",\n    \"deepDiveExplanation\": \"The 6MWT is a submaximal exercise test primarily used to assess functional exercise capacity and endurance. It measures the distance an individual can walk in 6 minutes and is widely used for prognosis, disease severity assessment, and response to therapy in cardiopulmonary diseases. It does not directly measure peak oxygen uptake or other detailed physiological parameters typically assessed by Cardiopulmonary Exercise Testing (CPET).\",\n    \"highYieldPearl\": \"6MWT quantifies functional capacity and endurance, not peak cardiorespiratory fitness. It's a practical, field-based test.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishes 6MWT from maximal exercise tests like CPET. Options A, B, and D are parameters typically derived from CPET, which can be confusing if the fundamental purpose of 6MWT is not clear.\"\n  },\n  {\n    \"question\": \"Which is considered the gold standard for objective assessment of exercise limitation?\",\n    \"options\": {\n      \"A\": \"Six-Minute Walk Test (6MWT)\",\n      \"B\": \"Cardiopulmonary Exercise Testing (CPET)\",\n      \"C\": \"Incremental Shuttle Walk Test (ISWT)\",\n      \"D\": \"Stair Climb Test\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"exercise_testing\",\n    \"deepDiveExplanation\": \"Cardiopulmonary Exercise Testing (CPET) is the gold standard for objective assessment of exercise limitation because it provides a comprehensive, integrated evaluation of the cardiovascular, pulmonary, and metabolic systems' responses to exercise. It allows for precise determination of peak oxygen uptake (VO2peak) and identification of the physiological mechanisms underlying exercise intolerance.\",\n    \"highYieldPearl\": \"CPET offers the most comprehensive and objective analysis of exercise intolerance, pinpointing the primary limiting system (cardiac, pulmonary, or deconditioning).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other options are field exercise tests, but they lack the detailed physiological measurements and diagnostic capabilities of CPET, which is crucial for identifying the cause of limitation.\"\n  },\n  {\n    \"question\": \"An elevated ventilatory equivalent for carbon dioxide (VE/VCO2) nadir during CPET primarily suggests?\",\n    \"options\": {\n      \"A\": \"Cardiac limitation\",\n      \"B\": \"Impaired ventilatory efficiency\",\n      \"C\": \"Peripheral muscle deconditioning\",\n      \"D\": \"Anemia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"exercise_testing\",\n    \"deepDiveExplanation\": \"An elevated VE/VCO2 nadir (or slope) indicates that a greater amount of ventilation is required to eliminate a given amount of carbon dioxide. This signifies impaired ventilatory efficiency, often due to increased dead space ventilation (e.g., in pulmonary vascular disease), ventilation-perfusion (V/Q) mismatch, or restrictive lung disease. It reflects the physiological cost of breathing during exercise.\",\n    \"highYieldPearl\": \"High VE/VCO2 points to inefficient gas exchange, commonly seen in pulmonary hypertension, ILD, or severe COPD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While cardiac limitation, deconditioning, and anemia can all cause exercise intolerance, an elevated VE/VCO2 is a specific marker for ventilatory inefficiency, distinguishing it from other causes. It requires understanding specific CPET parameters.\"\n  },\n  {\n    \"question\": \"The most robust CPET parameter correlating with mortality in advanced lung disease is?\",\n    \"options\": {\n      \"A\": \"Peak heart rate\",\n      \"B\": \"Peak oxygen uptake (VO2peak)\",\n      \"C\": \"Respiratory exchange ratio (RER)\",\n      \"D\": \"Oxygen pulse\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"exercise_testing\",\n    \"deepDiveExplanation\": \"Peak oxygen uptake (VO2peak) is consistently identified as the strongest independent predictor of mortality and morbidity across a wide range of chronic cardiopulmonary diseases, including COPD, interstitial lung disease, and pulmonary hypertension. It reflects the overall functional capacity of the cardiovascular and pulmonary systems to deliver oxygen to working muscles.\",\n    \"highYieldPearl\": \"VO2peak is a powerful prognostic marker in chronic respiratory diseases; lower values predict higher mortality.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are CPET parameters. RER indicates maximal effort, not directly prognosis. Peak heart rate and oxygen pulse provide insights into cardiac function and oxygen extraction but are not as universally robust as VO2peak for overall mortality prediction in lung disease.\"\n  },\n  {\n    \"question\": \"An absolute contraindication for performing a Six-Minute Walk Test is?\",\n    \"options\": {\n      \"A\": \"Resting oxygen saturation <90%\",\n      \"B\": \"Exercise-induced bronchospasm\",\n      \"C\": \"Unstable angina within the last month\",\n      \"D\": \"Mild exertional dyspnea\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"exercise_testing\",\n    \"deepDiveExplanation\": \"Absolute contraindications for the 6MWT are primarily acute cardiac events that pose a significant risk with exertion. These include unstable angina or myocardial infarction within the preceding month. Other conditions like resting hypoxemia (A) or exercise-induced bronchospasm (B) are often reasons to perform the test (to assess desaturation or symptoms) and can be managed, but are not absolute contraindications to the test itself.\",\n    \"highYieldPearl\": \"Acute cardiac instability (unstable angina, recent MI) are critical absolute contraindications for 6MWT due to safety concerns.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, and D are either relative contraindications or conditions for which the 6MWT is performed to assess functional impact. The key is distinguishing absolute life-threatening risks from manageable conditions.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-667.16455078125}],"createTime":"2025-12-31T07:46:22.592675Z","modelVersion":"gemini-2.5-flash","responseId":"ztRUaaOWJMiP2_gP0paGOA","usageMetadata":{"billablePromptUsage":{"textCount":1033},"candidatesTokenCount":1456,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1456}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1844,"totalTokenCount":3667,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:02.362184+00:00"}
{"metadata":"one-liner|ph_group3|Group 3 PH (Due to Lung Disease)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Group 3 PH (Due to Lung Disease)\".\nSet the \"topic\" field in the JSON to \"ph_group3\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.5707077256801953,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary pathophysiological mechanism driving pulmonary hypertension in Group 3 PH is?\",\n    \"options\": {\n      \"A\": \"Endothelial dysfunction\",\n      \"B\": \"Hypoxic pulmonary vasoconstriction\",\n      \"C\": \"Increased pulmonary blood flow\",\n      \"D\": \"Left ventricular diastolic dysfunction\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_group3\",\n    \"deepDiveExplanation\": \"Group 3 PH is due to lung diseases and/or hypoxia. The main mechanism is sustained hypoxic pulmonary vasoconstriction (HPV), where chronic hypoxia leads to chronic vasoconstriction and subsequent vascular remodeling. This increases pulmonary vascular resistance and mean pulmonary arterial pressure. This mechanism distinguishes it from Group 1 PAH (endothelial dysfunction, proliferation) and Group 2 PH (elevated left-sided pressures).\",\n    \"highYieldPearl\": \"Hypoxia is the cornerstone and primary driver of pulmonary hypertension in Group 3.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might confuse the general mechanisms of PH. Endothelial dysfunction is primary in Group 1 PAH. Increased pulmonary blood flow is seen in congenital heart diseases. Left ventricular dysfunction causes Group 2 PH.\"\n  },\n  {\n    \"question\": \"Which of the following conditions is *not* a primary cause of Group 3 Pulmonary Hypertension?\",\n    \"options\": {\n      \"A\": \"Chronic Obstructive Pulmonary Disease (COPD)\",\n      \"B\": \"Interstitial Lung Disease (ILD)\",\n      \"C\": \"Obstructive Sleep Apnea (OSA)\",\n      \"D\": \"Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_group3\",\n    \"deepDiveExplanation\": \"Group 3 PH encompasses pulmonary hypertension due to lung diseases and/or hypoxia. This includes conditions like COPD, ILD, OSA, hypoventilation syndromes, and chronic exposure to high altitude. CTEPH (Chronic Thromboembolic Pulmonary Hypertension) is classified as Group 4 Pulmonary Hypertension according to the WHO classification.\",\n    \"highYieldPearl\": \"A thorough understanding of WHO PH group classifications is crucial. CTEPH is Group 4, not Group 3.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options are respiratory or lung-related conditions. The trap lies in knowing the specific WHO classification groups rather than just identifying lung pathology.\"\n  },\n  {\n    \"question\": \"The cornerstone of treatment for Group 3 Pulmonary Hypertension is?\",\n    \"options\": {\n      \"A\": \"Phosphodiesterase-5 inhibitors\",\n      \"B\": \"Endothelin receptor antagonists\",\n      \"C\": \"Long-term oxygen therapy\",\n      \"D\": \"Prostacyclin analogues\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_group3\",\n    \"deepDiveExplanation\": \"For Group 3 PH, the primary treatment strategy is to address the underlying lung disease and correct hypoxia. Long-term oxygen therapy (LTOT) is the cornerstone, as it directly counteracts the hypoxic pulmonary vasoconstriction, which is the main driver of PH in this group. Pulmonary arterial hypertension (PAH)-specific therapies (e.g., PDE5 inhibitors, ERAs, prostanoids) are generally not recommended as monotherapy for Group 3 PH due to limited evidence of benefit and potential for harm (e.g., worsening V/Q mismatch, increased mortality).\",\n    \"highYieldPearl\": \"Oxygen therapy is the most effective and recommended treatment for Group 3 PH, targeting the root cause of hypoxia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is to assume that all forms of pulmonary hypertension are treated with PAH-specific drugs. For Group 3, addressing the underlying lung disease and hypoxia is paramount, making oxygen therapy the key.\"\n  },\n  {\n    \"question\": \"In Group 3 PH, which hemodynamic parameter most directly reflects increased pulmonary vascular afterload due to vascular remodeling?\",\n    \"options\": {\n      \"A\": \"Mean pulmonary arterial pressure (mPAP)\",\n      \"B\": \"Pulmonary vascular resistance (PVR)\",\n      \"C\": \"Pulmonary artery wedge pressure (PAWP)\",\n      \"D\": \"Cardiac Output (CO)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_group3\",\n    \"deepDiveExplanation\": \"While mean pulmonary arterial pressure (mPAP) is elevated in all forms of PH, pulmonary vascular resistance (PVR) is the most direct measure of the resistance to blood flow through the pulmonary vasculature. In Group 3 PH, chronic hypoxia and inflammation lead to structural remodeling (thickening, fibrosis) and functional changes (vasoconstriction) of the pulmonary arteries, which directly increases PVR. PAWP is typically normal in Group 3 PH, differentiating it from Group 2 PH (left heart disease). Cardiac output can vary.\",\n    \"highYieldPearl\": \"PVR is the gold standard for quantifying the degree of pulmonary vascular bed obstruction and remodeling in PH, particularly relevant in Group 3.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"mPAP is elevated in all PH. PAWP is a trap as it's normal in Group 3. Cardiac output is a component of the PVR calculation but not a direct measure of afterload itself. PVR directly quantifies the resistance to flow.\"\n  },\n  {\n    \"question\": \"Chronic hypoxemia and pulmonary hypertension in Group 3 PH frequently lead to which cardiac complication?\",\n    \"options\": {\n      \"A\": \"Left ventricular hypertrophy\",\n      \"B\": \"Dilated cardiomyopathy\",\n      \"C\": \"Cor pulmonale\",\n      \"D\": \"Pericardial effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_group3\",\n    \"deepDiveExplanation\": \"Cor pulmonale is defined as right ventricular enlargement (hypertrophy, dilation) due to pulmonary hypertension caused by primary disorders of the lung, chest wall, or pulmonary circulation (excluding left heart disease). Chronic hypoxemia and the resulting pulmonary hypertension in Group 3 lead to increased afterload on the right ventricle, eventually causing right ventricular dysfunction and failure, which is termed cor pulmonale.\",\n    \"highYieldPearl\": \"Cor pulmonale is the hallmark cardiac complication of chronic lung disease and Group 3 PH, reflecting chronic right ventricular strain.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Left ventricular hypertrophy is typically associated with systemic hypertension or aortic stenosis. Dilated cardiomyopathy is a broader term for myocardial dysfunction. Pericardial effusion is a non-specific finding that can occur in various conditions.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-869.1878662109375}],"createTime":"2025-12-31T07:45:40.195854Z","modelVersion":"gemini-2.5-flash","responseId":"pNRUaY76C8j9ld8P_9fN0Q0","usageMetadata":{"billablePromptUsage":{"textCount":1026},"candidatesTokenCount":1523,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1523}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":2074,"totalTokenCount":3965,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:46.395787+00:00"}
{"metadata":"one-liner|copd_diagnosis|COPD - Diagnosis and Staging|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"COPD - Diagnosis and Staging\".\nSet the \"topic\" field in the JSON to \"copd_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.45308260105152753,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The definitive spirometric criterion for diagnosing COPD post-bronchodilator is an FEV1/FVC ratio below what value?\",\n    \"options\": {\n      \"A\": \"0.80\",\n      \"B\": \"0.75\",\n      \"C\": \"0.70\",\n      \"D\": \"0.65\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines define COPD spirometrically by a post-bronchodilator FEV1/FVC ratio less than 0.70. This fixed ratio is widely adopted for its simplicity and robustness across populations, although the Lower Limit of Normal (LLN) for FEV1/FVC is sometimes preferred to avoid overdiagnosis in the elderly.\",\n    \"highYieldPearl\": \"Post-bronchodilator FEV1/FVC < 0.70 is the cornerstone of COPD spirometric diagnosis according to GOLD guidelines.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Traps include other arbitrary ratios, or not emphasizing 'post-bronchodilator,' which is crucial for distinguishing fixed from reversible airflow limitation.\"\n  },\n  {\n    \"question\": \"Which GOLD spirometric severity stage is defined by an FEV1 between 30% and 49% of the predicted value?\",\n    \"options\": {\n      \"A\": \"GOLD 1\",\n      \"B\": \"GOLD 2\",\n      \"C\": \"GOLD 3\",\n      \"D\": \"GOLD 4\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"GOLD spirometric staging (based on FEV1 % predicted post-bronchodilator):\\n    GOLD 1 (Mild): FEV1 ≥ 80% predicted\\n    GOLD 2 (Moderate): 50% ≤ FEV1 < 80% predicted\\n    GOLD 3 (Severe): 30% ≤ FEV1 < 50% predicted\\n    GOLD 4 (Very Severe): FEV1 < 30% predicted\",\n    \"highYieldPearl\": \"Memorize GOLD FEV1 percentages for severity staging: 80, 50, 30 for the cut-offs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in confusing the percentage ranges for different GOLD stages. Candidates must recall the specific thresholds.\"\n  },\n  {\n    \"question\": \"A COPD patient with mMRC score 0-1 and zero or one moderate exacerbation not leading to hospitalization belongs to which GOLD group?\",\n    \"options\": {\n      \"A\": \"Group A\",\n      \"B\": \"Group B\",\n      \"C\": \"Group C\",\n      \"D\": \"Group D\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"GOLD patient groups (A, B, C, D) combine symptom assessment (mMRC or CAT) with exacerbation history to guide management.\\n    Group A: mMRC 0-1 or CAT < 10 AND 0 or 1 moderate exacerbation (not leading to hospitalization).\\n    Group B: mMRC ≥ 2 or CAT ≥ 10 AND 0 or 1 moderate exacerbation (not leading to hospitalization).\\n    Group C: mMRC 0-1 or CAT < 10 AND ≥ 2 moderate exacerbations OR ≥ 1 exacerbation leading to hospitalization.\\n    Group D: mMRC ≥ 2 or CAT ≥ 10 AND ≥ 2 moderate exacerbations OR ≥ 1 exacerbation leading to hospitalization.\",\n    \"highYieldPearl\": \"Group A is 'low symptom, low risk.' Risk is defined by exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap involves mixing up the criteria for symptoms (mMRC/CAT) and exacerbation frequency/severity across the four GOLD groups.\"\n  },\n  {\n    \"question\": \"In the context of COPD diagnosis, what is the primary clinical utility of assessing bronchodilator reversibility?\",\n    \"options\": {\n      \"A\": \"Confirming COPD diagnosis\",\n      \"B\": \"Differentiating COPD from asthma\",\n      \"C\": \"Guiding initial bronchodilator choice\",\n      \"D\": \"Predicting long-term disease progression\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"While bronchodilator reversibility testing doesn't confirm or exclude COPD, and doesn't definitively differentiate it from asthma, it provides valuable prognostic information and can help guide the choice and intensity of bronchodilator therapy. A significant response may suggest a better response to bronchodilators.\",\n    \"highYieldPearl\": \"Bronchodilator reversibility in COPD is for prognosis and treatment guidance, not for diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Common misconceptions are that reversibility rules out COPD or is the primary differentiator from asthma. The key is its role in treatment and prognosis.\"\n  },\n  {\n    \"question\": \"Which symptom assessment tool is recommended by GOLD to evaluate the impact of dyspnea on a COPD patient's daily life for group classification?\",\n    \"options\": {\n      \"A\": \"CAT score\",\n      \"B\": \"mMRC scale\",\n      \"C\": \"St. George's Respiratory Questionnaire\",\n      \"D\": \"BODE index\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"The modified Medical Research Council (mMRC) scale is a simple, widely used questionnaire to assess the degree of breathlessness. A score of 0-1 indicates less dyspnea, while ≥2 indicates more significant dyspnea impacting daily activities. The CAT (COPD Assessment Test) is a broader assessment of overall health status and symptom impact.\",\n    \"highYieldPearl\": \"mMRC specifically assesses dyspnea, while CAT assesses overall symptom burden. Both are used for GOLD grouping.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing mMRC (dyspnea specific) with CAT (broader symptom impact) is a common trap. St. George's is more comprehensive for research. BODE is a prognostic index.\"\n  },\n  {\n    \"question\": \"Screening for alpha-1 antitrypsin deficiency is strongly recommended for COPD patients diagnosed at what age, regardless of family history?\",\n    \"options\": {\n      \"A\": \"< 60 years\",\n      \"B\": \"< 50 years\",\n      \"C\": \"< 45 years\",\n      \"D\": \"< 40 years\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"GOLD guidelines recommend screening all symptomatic adults with persistent airflow obstruction for AATD. Strong indications for screening include early-onset COPD (especially before 45 years), panacinar emphysema, COPD with a family history of AATD or liver disease, and non-smokers with COPD.\",\n    \"highYieldPearl\": \"Consider AATD in young COPD patients (<45 years) or those with panacinar emphysema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is recalling the specific age cutoff. Other ages might be plausible but <45 is the most emphasized.\"\n  },\n  {\n    \"question\": \"The use of the Lower Limit of Normal (LLN) instead of the fixed 0.70 ratio for FEV1/FVC in COPD diagnosis primarily prevents which diagnostic error in older adults?\",\n    \"options\": {\n      \"A\": \"Underdiagnosis\",\n      \"B\": \"Overdiagnosis\",\n      \"C\": \"Misdiagnosis of asthma\",\n      \"D\": \"Incorrect severity staging\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"The fixed FEV1/FVC < 0.70 ratio can lead to overdiagnosis of COPD in older adults because FEV1/FVC naturally declines with age. The LLN, which is derived from a healthy reference population and accounts for age, sex, and height, is a more statistically appropriate threshold that reduces this age-related overdiagnosis.\",\n    \"highYieldPearl\": \"LLN avoids overdiagnosis in the elderly and underdiagnosis in the young, providing a more precise definition of airflow obstruction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Understanding the implications of using a fixed ratio versus a statistically derived LLN is key. Many might incorrectly assume it prevents underdiagnosis or has no significant impact.\"\n  },\n  {\n    \"question\": \"A COPD patient with an mMRC score ≥2 and two or more moderate exacerbations or at least one hospitalization for exacerbation belongs to which GOLD group?\",\n    \"options\": {\n      \"A\": \"Group A\",\n      \"B\": \"Group B\",\n      \"C\": \"Group C\",\n      \"D\": \"Group D\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"GOLD Group D represents patients with high symptom burden (mMRC ≥2 or CAT ≥10) and high exacerbation risk (≥2 moderate exacerbations or ≥1 leading to hospitalization). These patients require the most intensive management strategies.\",\n    \"highYieldPearl\": \"Group D is 'high symptom, high risk' – the most severe combination for treatment stratification.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Similar to Q3, the trap involves accurately recalling the combined criteria for symptoms and exacerbation history that define Group D.\"\n  },\n  {\n    \"question\": \"Which of the following is NOT a primary diagnostic criterion for COPD, but rather an indicator for assessing disease impact or comorbidities?\",\n    \"options\": {\n      \"A\": \"Post-bronchodilator FEV1/FVC < 0.70\",\n      \"B\": \"Presence of chronic respiratory symptoms\",\n      \"C\": \"Smoking history\",\n      \"D\": \"CAT score > 10\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"The diagnostic criteria for COPD primarily rely on spirometry (post-bronchodilator FEV1/FVC < 0.70) in individuals with exposure to risk factors (like smoking) and chronic respiratory symptoms. While symptoms and smoking history prompt investigation, they are not diagnostic criteria themselves. The CAT score assesses the impact of symptoms and is used for GOLD group classification, not for the initial diagnosis.\",\n    \"highYieldPearl\": \"Spirometry is diagnostic. Symptoms and risk factors indicate who to test. Assessment tools (like CAT) quantify impact after diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might confuse risk factors or symptoms that suggest COPD with the definitive diagnostic criteria. The CAT score is an assessment tool, not a diagnostic one.\"\n  },\n  {\n    \"question\": \"What is the primary role of a chest X-ray in the initial assessment of a patient suspected of having COPD?\",\n    \"options\": {\n      \"A\": \"To confirm the diagnosis of emphysema\",\n      \"B\": \"To rule out alternative diagnoses\",\n      \"C\": \"To quantify the severity of airflow obstruction\",\n      \"D\": \"To assess bronchodilator responsiveness\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"copd_diagnosis\",\n    \"deepDiveExplanation\": \"A chest X-ray is often performed in the initial workup of suspected COPD, not to diagnose COPD itself (as it's often normal or shows non-specific changes), but primarily to exclude other conditions that can mimic COPD symptoms, such as congestive heart failure, bronchiectasis, tuberculosis, or lung cancer. High-resolution CT (HRCT) is superior for confirming emphysema.\",\n    \"highYieldPearl\": \"CXR in COPD is for differential diagnosis, not primary diagnosis or severity assessment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"A common trap is to overestimate the diagnostic power of a chest X-ray for COPD or emphysema, when HRCT is more definitive for parenchymal changes and spirometry for airflow obstruction.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1316.2049560546875}],"createTime":"2025-12-31T07:45:40.763073Z","modelVersion":"gemini-2.5-flash","responseId":"pNRUacHJLorfnvgPkraasQ0","usageMetadata":{"billablePromptUsage":{"textCount":1030},"candidatesTokenCount":2905,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2905}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":5863,"totalTokenCount":9135,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:30.291444+00:00"}
{"metadata":"one-liner|diving_altitude|Altitude and Diving Medicine|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Altitude and Diving Medicine\".\nSet the \"topic\" field in the JSON to \"diving_altitude\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.6114848286041742,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which medication primarily prevents High Altitude Pulmonary Edema by reducing pulmonary arterial pressure?\",\n    \"options\": {\n      \"A\": \"Acetazolamide\",\n      \"B\": \"Dexamethasone\",\n      \"C\": \"Nifedipine\",\n      \"D\": \"Sildenafil\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"diving_altitude\",\n    \"deepDiveExplanation\": \"Nifedipine is a calcium channel blocker that reduces pulmonary arterial pressure, thereby preventing and treating High Altitude Pulmonary Edema (HAPE). It acts by blunting hypoxic pulmonary vasoconstriction. Sildenafil (D) is also a potent pulmonary vasodilator used for HAPE, but Nifedipine is a classic answer for its direct effect on PAP. Acetazolamide (A) is primarily used for AMS and HACE prevention/treatment by inducing metabolic acidosis and stimulating respiration. Dexamethasone (B) is used for AMS and HACE treatment/prevention due to its anti-inflammatory effects.\",\n    \"highYieldPearl\": \"Nifedipine and phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) are the main pharmacological agents used to reduce pulmonary arterial pressure in HAPE.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might confuse HAPE medications with those for AMS/HACE (Acetazolamide, Dexamethasone) or choose Sildenafil, which is also correct but Nifedipine is a frequently cited primary option.\"\n  },\n  {\n    \"question\": \"The definitive treatment for arterial gas embolism (AGE) following a diving incident is?\",\n    \"options\": {\n      \"A\": \"100% normobaric oxygen\",\n      \"B\": \"Intravenous fluid resuscitation\",\n      \"C\": \"Hyperbaric oxygen therapy\",\n      \"D\": \"Mechanical ventilation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"diving_altitude\",\n    \"deepDiveExplanation\": \"Arterial gas embolism (AGE) is a critical diving injury where gas bubbles enter the arterial circulation, often due to pulmonary barotrauma. Hyperbaric oxygen therapy (HBOT) is the definitive treatment. It works by: 1. Reducing bubble size (Boyle's Law). 2. Increasing the partial pressure gradient for nitrogen, promoting its washout from bubbles. 3. Providing supraphysiological oxygen levels to ischemic tissues. 100% normobaric oxygen (A) is initial first aid but not definitive. IV fluids (B) are supportive. Mechanical ventilation (D) may be needed for respiratory failure but does not address the emboli directly.\",\n    \"highYieldPearl\": \"Any neurological symptom occurring immediately or shortly after a dive should be treated as AGE or severe Decompression Sickness, mandating immediate transfer for HBOT.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in confusing initial management (100% normobaric O2) with definitive treatment (HBOT). Other options are supportive or for complications, not the primary treatment for the embolism itself.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-426.2049255371094}],"createTime":"2025-12-31T07:45:38.409765Z","modelVersion":"gemini-2.5-flash","responseId":"otRUaaWBGejMhMIPwbfNwQY","usageMetadata":{"billablePromptUsage":{"textCount":1031},"candidatesTokenCount":697,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":697}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":1384,"totalTokenCount":2443,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:50.825385+00:00"}
{"metadata":"one-liner|osa_treatment|Obstructive Sleep Apnea - Treatment|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Obstructive Sleep Apnea - Treatment\".\nSet the \"topic\" field in the JSON to \"osa_treatment\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2789276666924505,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the gold standard first-line treatment for moderate to severe Obstructive Sleep Apnea?\",\n    \"options\": {\n      \"A\": \"Oral Appliance Therapy\",\n      \"B\": \"Continuous Positive Airway Pressure (CPAP)\",\n      \"C\": \"Uvulopalatopharyngoplasty (UPPP)\",\n      \"D\": \"Positional Therapy\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Continuous Positive Airway Pressure (CPAP) is the most effective and widely accepted first-line treatment for moderate to severe OSA. It delivers pressurized air through a mask, creating a pneumatic splint that prevents upper airway collapse during sleep.\",\n    \"highYieldPearl\": \"CPAP improves AHI, oxygenation, sleep architecture, and reduces daytime sleepiness and cardiovascular risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Oral appliances are for mild-moderate OSA or CPAP intolerance. Surgeries are typically second-line. Positional therapy is for specific positional OSA.\"\n  },\n  {\n    \"question\": \"The primary mechanism of action for Continuous Positive Airway Pressure (CPAP) in OSA is?\",\n    \"options\": {\n      \"A\": \"Stimulating respiratory drive\",\n      \"B\": \"Reducing pharyngeal edema\",\n      \"C\": \"Pneumatic splinting of the upper airway\",\n      \"D\": \"Increasing oxygen saturation directly\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"CPAP acts as a pneumatic splint, delivering positive pressure to the upper airway. This pressure keeps the pharyngeal airway open, preventing its collapse during inspiration and expiration, thus eliminating apneas and hypopneas.\",\n    \"highYieldPearl\": \"CPAP maintains airway patency by counteracting the negative inspiratory pressure and intrinsic collapsibility of the pharynx.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CPAP does not directly stimulate respiratory drive or reduce edema as its primary action, nor does it directly increase oxygen saturation (it does so indirectly by restoring airflow).\"\n  },\n  {\n    \"question\": \"Mandibular advancement devices (MADs) primarily treat OSA by which mechanism?\",\n    \"options\": {\n      \"A\": \"Direct pharyngeal muscle stimulation\",\n      \"B\": \"Repositioning the mandible and tongue anteriorly\",\n      \"C\": \"Increasing nasal airflow\",\n      \"D\": \"Reducing nasal resistance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Mandibular advancement devices (MADs) work by physically advancing the mandible (lower jaw) and tongue forward. This increases the retrolingual and retropalatal airspace, preventing tongue base collapse and soft palate vibration.\",\n    \"highYieldPearl\": \"MADs are generally effective for mild-to-moderate OSA, especially in patients who cannot tolerate CPAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"MADs do not directly stimulate muscles or primarily increase nasal airflow; their effect is anatomical repositioning.\"\n  },\n  {\n    \"question\": \"Which surgical procedure is considered the gold standard for completely bypassing upper airway obstruction in severe OSA?\",\n    \"options\": {\n      \"A\": \"Uvulopalatopharyngoplasty (UPPP)\",\n      \"B\": \"Genioglossus advancement\",\n      \"C\": \"Maxillomandibular advancement (MMA)\",\n      \"D\": \"Tracheostomy\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Tracheostomy involves creating a surgical opening in the trachea to bypass the entire upper airway. This completely eliminates the possibility of upper airway obstruction during sleep, making it the most definitive surgical solution for severe, refractory OSA, though rarely performed due to invasiveness.\",\n    \"highYieldPearl\": \"Tracheostomy is reserved for life-threatening OSA or when all other treatments have failed.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"UPPP, genioglossus advancement, and MMA aim to widen specific parts of the upper airway, but do not bypass it entirely.\"\n  },\n  {\n    \"question\": \"Which medication is indicated for residual excessive daytime sleepiness in OSA patients optimally treated with CPAP?\",\n    \"options\": {\n      \"A\": \"Zolpidem\",\n      \"B\": \"Modafinil\",\n      \"C\": \"Amitriptyline\",\n      \"D\": \"Clonazepam\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Modafinil (and its R-enantiomer, armodafinil) are wake-promoting agents used to treat residual excessive daytime sleepiness in patients with OSA who are compliant with CPAP but still experience somnolence. They do not treat the underlying OSA.\",\n    \"highYieldPearl\": \"Modafinil is not a primary treatment for OSA; it addresses a symptom after primary treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Zolpidem and clonazepam are hypnotics/sedatives, which could worsen OSA. Amitriptyline is an antidepressant.\"\n  },\n  {\n    \"question\": \"Maxillomandibular advancement (MMA) surgery is primarily indicated for OSA patients with which characteristic?\",\n    \"options\": {\n      \"A\": \"Mild OSA\",\n      \"B\": \"Significant retrognathia or midface hypoplasia\",\n      \"C\": \"Isolated tonsillar hypertrophy\",\n      \"D\": \"CPAP intolerance due to claustrophobia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Maxillomandibular advancement (MMA) is a highly effective surgical procedure that involves moving both the maxilla and mandible forward. It is particularly indicated for patients with significant craniofacial abnormalities like retrognathia or midface hypoplasia, where the airway is anatomically constrained.\",\n    \"highYieldPearl\": \"MMA offers one of the highest success rates among OSA surgeries, especially for anatomically predisposed patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"MMA is a major surgery not for mild OSA or isolated tonsillar hypertrophy (which might benefit from UPPP). CPAP intolerance due to claustrophobia would lead to other non-surgical or less invasive surgical options first.\"\n  },\n  {\n    \"question\": \"Hypoglossal nerve stimulation therapy for OSA primarily targets which muscle group?\",\n    \"options\": {\n      \"A\": \"Diaphragm\",\n      \"B\": \"Intercostals\",\n      \"C\": \"Genioglossus\",\n      \"D\": \"Sternocleidomastoid\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Hypoglossal nerve stimulation involves implanting a device that stimulates the hypoglossal nerve, which innervates the genioglossus muscle. This stimulation causes the tongue to protrude during inspiration, preventing its collapse into the posterior pharynx.\",\n    \"highYieldPearl\": \"Hypoglossal nerve stimulation is a newer, FDA-approved treatment for moderate to severe OSA in patients who cannot tolerate CPAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"The diaphragm and intercostals are primary muscles of respiration, but not directly targeted by hypoglossal nerve stimulation for OSA. Sternocleidomastoid is a neck muscle, not directly involved in tongue movement for airway patency.\"\n  },\n  {\n    \"question\": \"Positional therapy is an effective treatment option primarily for which type of OSA?\",\n    \"options\": {\n      \"A\": \"Central sleep apnea\",\n      \"B\": \"Severe OSA with AHI > 50\",\n      \"C\": \"Positional OSA\",\n      \"D\": \"Drug-induced OSA\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Positional OSA is a subtype where the severity of sleep apnea (AHI) is at least twice as high when sleeping in the supine position compared to non-supine positions. Positional therapy aims to prevent supine sleeping using devices like positional alarms or special pillows.\",\n    \"highYieldPearl\": \"Positional therapy is a simple, non-invasive treatment, but only effective for patients with clear positional dependency.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Positional therapy does not treat central sleep apnea or drug-induced OSA, and while it can help severe OSA, it's specifically for the positional component.\"\n  },\n  {\n    \"question\": \"Uvulopalatopharyngoplasty (UPPP) primarily aims to enlarge the airway at which level?\",\n    \"options\": {\n      \"A\": \"Nasopharynx\",\n      \"B\": \"Oropharynx\",\n      \"C\": \"Hypopharynx\",\n      \"D\": \"Larynx\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"UPPP is a surgical procedure that involves removing excess tissue from the soft palate, uvula, tonsils, and sometimes part of the pharyngeal wall. This aims to widen the oropharynx, reducing obstruction at this level.\",\n    \"highYieldPearl\": \"UPPP has variable success rates and is often considered for patients with significant soft palate/tonsillar hypertrophy, typically after CPAP failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other levels can be indirectly affected, the primary target of UPPP is the oropharynx.\"\n  },\n  {\n    \"question\": \"What non-surgical intervention has the most significant impact on OSA severity, often reducing AHI?\",\n    \"options\": {\n      \"A\": \"Smoking cessation\",\n      \"B\": \"Alcohol avoidance\",\n      \"C\": \"Weight loss\",\n      \"D\": \"Regular exercise\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"osa_treatment\",\n    \"deepDiveExplanation\": \"Weight loss, particularly in overweight and obese individuals, is a crucial non-surgical intervention for OSA. Even a modest weight loss (e.g., 10-15%) can significantly reduce AHI by decreasing fat deposits around the pharynx, thereby increasing airway lumen size and reducing collapsibility.\",\n    \"highYieldPearl\": \"While not always curative alone, weight loss is a fundamental adjunctive therapy that can improve the efficacy of other treatments like CPAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While smoking cessation, alcohol avoidance, and regular exercise are beneficial for overall health and can impact OSA, weight loss has the most direct and significant impact on airway anatomy and AHI reduction.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-704.2923583984375}],"createTime":"2025-12-31T07:47:02.319241Z","modelVersion":"gemini-2.5-flash","responseId":"9tRUaYm-E72ridsPucSz-AQ","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":2525,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2525}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":3129,"totalTokenCount":6021,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:57.188484+00:00"}
{"metadata":"one-liner|aspiration_pneumonia|Aspiration Pneumonia and Lung Abscess|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Aspiration Pneumonia and Lung Abscess\".\nSet the \"topic\" field in the JSON to \"aspiration_pneumonia\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4049765699263308,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which lung segment is most commonly affected by aspiration in a supine patient?\",\n    \"options\": {\n      \"A\": \"Anterior segment of upper lobes\",\n      \"B\": \"Posterior segment of upper lobes\",\n      \"C\": \"Lateral segment of lower lobes\",\n      \"D\": \"Medial segment of middle lobe\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"aspiration_pneumonia\",\n    \"deepDiveExplanation\": \"In supine patients, gravity directs aspirated material primarily to the posterior segments of the upper lobes and the superior segments of the lower lobes. In upright patients, aspiration typically involves the basilar segments of the lower lobes, especially the right lower lobe due to the straighter main bronchus.\",\n    \"highYieldPearl\": \"Always consider patient positioning (supine vs. upright) when localizing aspiration-related lung pathology on imaging.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing supine aspiration patterns with upright aspiration patterns (which often affect basilar segments of lower lobes).\"\n  },\n  {\n    \"question\": \"Aspiration pneumonitis primarily involves which type of lung injury?\",\n    \"options\": {\n      \"A\": \"Bacterial infection\",\n      \"B\": \"Chemical burn\",\n      \"C\": \"Fungal invasion\",\n      \"D\": \"Viral inflammation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"aspiration_pneumonia\",\n    \"deepDiveExplanation\": \"Aspiration pneumonitis is an acute chemical injury to the tracheobronchial tree and lung parenchyma caused by the inhalation of sterile gastric contents, leading to an inflammatory response without bacterial infection. Aspiration pneumonia, in contrast, involves bacterial infection of the lung following aspiration of oropharyngeal or gastric contents.\",\n    \"highYieldPearl\": \"Pneumonitis = chemical, sterile inflammation. Pneumonia = bacterial infection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misinterpreting the primary pathology as bacterial, which is characteristic of aspiration pneumonia, not pneumonitis.\"\n  },\n  {\n    \"question\": \"Drug of choice for community-acquired anaerobic lung abscess is?\",\n    \"options\": {\n      \"A\": \"Piperacillin-tazobactam\",\n      \"B\": \"Meropenem\",\n      \"C\": \"Clindamycin\",\n      \"D\": \"Cefepime\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aspiration_pneumonia\",\n    \"deepDiveExplanation\": \"Clindamycin is considered the drug of choice for community-acquired anaerobic lung abscess due to its excellent activity against most oral anaerobes and good penetration into lung tissue and abscess cavities. While beta-lactam/beta-lactamase inhibitors (e.g., Piperacillin-tazobactam) are also effective, clindamycin is often preferred as a first-line agent, especially in penicillin-allergic patients or when penicillin resistance is a concern.\",\n    \"highYieldPearl\": \"Clindamycin is key for anaerobic infections, particularly in lung abscess and aspiration pneumonia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Choosing broad-spectrum antibiotics like carbapenems or beta-lactam/beta-lactamase inhibitors which are also effective against anaerobes but might not be the initial drug of choice for uncomplicated community-acquired cases.\"\n  },\n  {\n    \"question\": \"The predominant causative organisms in community-acquired aspiration pneumonia are?\",\n    \"options\": {\n      \"A\": \"Staphylococcus aureus\",\n      \"B\": \"Enterobacteriaceae\",\n      \"C\": \"Oral anaerobes\",\n      \"D\": \"Pseudomonas aeruginosa\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aspiration_pneumonia\",\n    \"deepDiveExplanation\": \"Community-acquired aspiration pneumonia typically results from the aspiration of oral secretions containing a polymicrobial flora, with oral anaerobes (e.g., Peptostreptococcus, Bacteroides, Fusobacterium) being the predominant pathogens. Aerobic bacteria, such as Streptococcus pneumoniae and Staphylococcus aureus, may also be involved, especially in hospitalized or debilitated patients.\",\n    \"highYieldPearl\": \"Think 'anaerobes' first for community-acquired aspiration pneumonia, originating from the oral cavity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Focusing on typical community-acquired pneumonia (CAP) pathogens like S. pneumoniae or atypical bacteria, rather than the specific flora associated with aspiration.\"\n  },\n  {\n    \"question\": \"Antibiotic therapy for uncomplicated lung abscess typically continues until when?\",\n    \"options\": {\n      \"A\": \"Patient becomes afebrile\",\n      \"B\": \"Leukocytosis resolves\",\n      \"C\": \"Radiographic resolution or stabilization of cavity\",\n      \"D\": \"Sputum cultures are negative\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"aspiration_pneumonia\",\n    \"deepDiveExplanation\": \"The duration of antibiotic therapy for lung abscess is guided by clinical and radiographic response. Treatment usually continues for 4-6 weeks, or even longer (up to 2-3 months), until there is significant radiographic resolution of the cavity or stable residual scarring. Discontinuation based solely on clinical improvement (e.g., afebrile, normal WBC) is associated with higher relapse rates.\",\n    \"highYieldPearl\": \"Radiographic resolution, not just clinical improvement, dictates antibiotic duration for lung abscess.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Stopping antibiotics too early based on symptomatic improvement (afebrile, normal WBC) without confirming radiographic resolution, which can lead to relapse.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-532.544189453125}],"createTime":"2025-12-31T07:45:11.790928Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUaZCjMOGTlu8P1qKqwA0","usageMetadata":{"billablePromptUsage":{"textCount":1044},"candidatesTokenCount":1315,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1315}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":2456,"totalTokenCount":4139,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:57.09582+00:00"}
{"metadata":"one-liner|drug_induced_lung|Drug-Induced Pulmonary Disease|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Drug-Induced Pulmonary Disease\".\nSet the \"topic\" field in the JSON to \"drug_induced_lung\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.47420860248836666,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most characteristic pulmonary toxicity pattern associated with amiodarone is:\",\n    \"options\": {\n      \"A\": \"Acute eosinophilic pneumonia\",\n      \"B\": \"Bronchiolitis obliterans\",\n      \"C\": \"Chronic interstitial pneumonitis\",\n      \"D\": \"Pulmonary alveolar proteinosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"drug_induced_lung\",\n    \"deepDiveExplanation\": \"Amiodarone-induced pulmonary toxicity (AIPT) can manifest in various ways, but chronic interstitial pneumonitis/fibrosis, often with an organizing pneumonia component, is the most common and characteristic. Histologically, it often shows interstitial inflammation, fibrosis, and foamy macrophages (containing phospholipid inclusions).\",\n    \"highYieldPearl\": \"Amiodarone toxicity is dose and duration-dependent, but can occur at any dose. Foamy macrophages are a key histological clue.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distractors represent other types of lung injury, some drug-induced, but not characteristic of amiodarone. Acute eosinophilic pneumonia is seen with drugs like minocycline, daptomycin. Bronchiolitis obliterans with penicillamine, gold. Pulmonary alveolar proteinosis is rare and not typically drug-induced.\"\n  },\n  {\n    \"question\": \"Which factor is the strongest predictor of bleomycin-induced pulmonary fibrosis risk?\",\n    \"options\": {\n      \"A\": \"Prior radiation therapy\",\n      \"B\": \"Cumulative lifetime dose\",\n      \"C\": \"Age over 70 years\",\n      \"D\": \"Pre-existing asthma\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"drug_induced_lung\",\n    \"deepDiveExplanation\": \"Bleomycin-induced lung injury (BILI) is a severe, potentially fatal complication. The risk is strongly correlated with the cumulative lifetime dose, typically exceeding 200-300 mg. Other significant risk factors include advanced age, pre-existing lung disease, prior or concurrent radiation to the chest, and high inspired oxygen concentrations.\",\n    \"highYieldPearl\": \"Cumulative dose is paramount for bleomycin-induced lung injury. Avoid high FiO2 in patients with prior bleomycin exposure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options are potential risk factors for pulmonary fibrosis or lung injury in general. However, for bleomycin, the cumulative dose is the most consistently and strongly correlated factor. Prior radiation is also a significant risk, but cumulative dose is specific to bleomycin itself.\"\n  },\n  {\n    \"question\": \"Methotrexate-induced pneumonitis typically presents with which predominant histopathological pattern?\",\n    \"options\": {\n      \"A\": \"Diffuse alveolar damage\",\n      \"B\": \"Non-specific interstitial pneumonia\",\n      \"C\": \"Organizing pneumonia\",\n      \"D\": \"Lymphocytic interstitial pneumonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"drug_induced_lung\",\n    \"deepDiveExplanation\": \"Methotrexate-induced pneumonitis is an acute, often severe, hypersensitivity-mediated reaction. Histologically, it frequently presents with features of organizing pneumonia (BOOP/COP-like pattern), interstitial inflammation, and often eosinophilic infiltration. Granulomas can also be seen.\",\n    \"highYieldPearl\": \"Methotrexate pneumonitis is a hypersensitivity reaction, not direct toxicity, and can occur at any dose, even low doses for rheumatologic conditions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Diffuse alveolar damage (DAD) is characteristic of ARDS. Non-specific interstitial pneumonia (NSIP) and Lymphocytic interstitial pneumonia (LIP) are distinct patterns. Organizing pneumonia is highly characteristic for methotrexate pneumonitis.\"\n  },\n  {\n    \"question\": \"Acute nitrofurantoin-induced lung injury is predominantly characterized by which mechanism?\",\n    \"options\": {\n      \"A\": \"Direct cytotoxicity\",\n      \"B\": \"Oxidative stress\",\n      \"C\": \"Hypersensitivity reaction\",\n      \"D\": \"Immune checkpoint activation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"drug_induced_lung\",\n    \"deepDiveExplanation\": \"Nitrofurantoin can cause acute or chronic lung injury. Acute reactions (occurring within days to weeks of initiation) are typically hypersensitivity-mediated, often presenting with fever, cough, dyspnea, and peripheral eosinophilia. Chronic reactions (occurring after months to years) are more often fibrotic.\",\n    \"highYieldPearl\": \"Acute nitrofurantoin reaction = hypersensitivity (often with eosinophilia). Chronic nitrofurantoin reaction = fibrosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Oxidative stress is relevant for some drug toxicities (e.g., paraquat), but not the primary mechanism for acute nitrofurantoin. Direct cytotoxicity is a less specific mechanism. Immune checkpoint activation is specific to immune checkpoint inhibitors.\"\n  },\n  {\n    \"question\": \"Which radiological pattern is most frequently observed in immune checkpoint inhibitor-related pneumonitis?\",\n    \"options\": {\n      \"A\": \"Typical usual interstitial pneumonia\",\n      \"B\": \"Cryptogenic organizing pneumonia (COP)\",\n      \"C\": \"Lymphangitic carcinomatosis\",\n      \"D\": \"Ground-glass opacities with honeycombing\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"drug_induced_lung\",\n    \"deepDiveExplanation\": \"Immune checkpoint inhibitor (ICI)-related pneumonitis is an increasingly recognized adverse event. The most common radiological patterns include organizing pneumonia (COP-like), non-specific interstitial pneumonia (NSIP-like), and hypersensitivity pneumonitis-like. COP is frequently observed radiologically, characterized by peribronchovascular consolidations or ground-glass opacities.\",\n    \"highYieldPearl\": \"ICI pneumonitis can mimic various interstitial lung diseases; prompt recognition and steroid initiation are crucial for management.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Typical usual interstitial pneumonia (UIP) is characteristic of idiopathic pulmonary fibrosis (IPF). Lymphangitic carcinomatosis describes a malignant infiltration pattern. Ground-glass opacities with honeycombing typically suggest fibrotic changes, which can be seen in chronic forms or severe DAD, but COP is a very common initial presentation pattern.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-694.2413940429688}],"createTime":"2025-12-31T07:46:56.120536Z","modelVersion":"gemini-2.5-flash","responseId":"8NRUaditB7jFvPEP5p7G0Ao","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":1464,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1464}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2107,"totalTokenCount":3936,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:57.225474+00:00"}
{"metadata":"one-liner|tb_eptb_pleural|Pleural and Lymph Node TB|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pleural and Lymph Node TB\".\nSet the \"topic\" field in the JSON to \"tb_eptb_pleural\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.35636970178404853,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is considered the definitive diagnostic test for pleural tuberculosis?\",\n    \"options\": {\n      \"A\": \"Pleural fluid ADA\",\n      \"B\": \"Pleural fluid PCR\",\n      \"C\": \"Pleural biopsy for histology and culture\",\n      \"D\": \"Interferon-gamma release assay (IGRA)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"While pleural fluid analysis (ADA, cell count, protein) is highly suggestive, and PCR has varying sensitivity, the gold standard for definitive diagnosis of pleural tuberculosis is the demonstration of caseating granulomas on pleural tissue histology and/or positive Mycobacterium tuberculosis culture from pleural tissue obtained via biopsy (thoracoscopic or needle).\",\n    \"highYieldPearl\": \"Culture from pleural fluid is often negative; tissue culture and histology are much more sensitive and specific for definitive diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Pleural fluid ADA is a highly sensitive and specific screening test, but it is a biochemical marker, not a definitive diagnostic test like histology and culture from tissue.\"\n  },\n  {\n    \"question\": \"A pleural fluid ADA level above which value strongly suggests tuberculous pleurisy?\",\n    \"options\": {\n      \"A\": \"10 U/L\",\n      \"B\": \"20 U/L\",\n      \"C\": \"40 U/L\",\n      \"D\": \"80 U/L\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"An adenosine deaminase (ADA) level greater than 40 U/L (or sometimes >35 U/L depending on the local cutoff) in pleural fluid is highly suggestive of tuberculous pleurisy, particularly in endemic areas. Values >80 U/L are even more specific. However, ADA can be elevated in other conditions like empyema, rheumatoid pleurisy, and lymphoma.\",\n    \"highYieldPearl\": \"ADA is a valuable diagnostic marker for pleural TB, especially in resource-limited settings where biopsy might be challenging.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"The exact cutoff can vary slightly between studies/regions, but 40 U/L is a widely accepted and high-yield threshold to remember.\"\n  },\n  {\n    \"question\": \"The predominant cell type in pleural fluid of uncomplicated tuberculous pleurisy is typically?\",\n    \"options\": {\n      \"A\": \"Neutrophil\",\n      \"B\": \"Lymphocyte\",\n      \"C\": \"Mesothelial cell\",\n      \"D\": \"Eosinophil\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"In uncomplicated tuberculous pleurisy, the pleural effusion is typically lymphocytic predominant, meaning lymphocytes constitute more than 50% (often >70%) of the total nucleated cells. Early in the disease course (first few days), neutrophils may predominate, but this quickly shifts to lymphocytes.\",\n    \"highYieldPearl\": \"Lymphocytic predominance, along with low glucose and high ADA, forms a classic triad for tuberculous pleurisy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Recognizing the typical presentation versus early, transient neutrophilic predominance is key. The question asks for 'typically' or 'uncomplicated'.\"\n  },\n  {\n    \"question\": \"The definitive diagnostic method for tuberculous lymphadenitis is?\",\n    \"options\": {\n      \"A\": \"Tuberculin Skin Test\",\n      \"B\": \"Fine Needle Aspiration Cytology (FNAC)\",\n      \"C\": \"Excisional biopsy with histology and culture\",\n      \"D\": \"Chest X-ray\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"While Fine Needle Aspiration Cytology (FNAC) is a very useful initial diagnostic step, providing cytological evidence of granulomatous inflammation, it often lacks sufficient tissue for definitive culture and comprehensive histopathology. Excisional biopsy allows for thorough histological examination (identifying caseating granulomas) and provides ample tissue for mycobacterial culture and drug susceptibility testing, making it the definitive diagnostic method.\",\n    \"highYieldPearl\": \"FNAC is highly sensitive for diagnosing tuberculous lymphadenitis but biopsy with culture provides definitive confirmation and drug sensitivity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"FNAC is commonly used and often sufficient for presumptive diagnosis, but 'definitive' implies the highest diagnostic certainty, which comes from biopsy and culture.\"\n  },\n  {\n    \"question\": \"Which form of extrapulmonary tuberculosis is most commonly encountered globally?\",\n    \"options\": {\n      \"A\": \"Tuberculous meningitis\",\n      \"B\": \"Pleural tuberculosis\",\n      \"C\": \"Tuberculous lymphadenitis\",\n      \"D\": \"Skeletal tuberculosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"Tuberculous lymphadenitis, also known as scrofula when affecting cervical nodes, is the most common form of extrapulmonary tuberculosis globally, accounting for approximately 30-40% of all EPTB cases. It predominantly affects the cervical lymph nodes.\",\n    \"highYieldPearl\": \"Remember that tuberculous lymphadenitis is the most prevalent form of EPTB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Pleural TB is also very common, but lymphadenitis generally holds the top position in terms of incidence among EPTB forms.\"\n  },\n  {\n    \"question\": \"The standard duration of anti-tubercular treatment for uncomplicated pleural tuberculosis is?\",\n    \"options\": {\n      \"A\": \"3 months\",\n      \"B\": \"6 months\",\n      \"C\": \"9 months\",\n      \"D\": \"12 months\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"Uncomplicated pleural tuberculosis is treated with the same standard 6-month regimen as drug-sensitive pulmonary tuberculosis. This typically involves an intensive phase of 2 months with Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E), followed by a continuation phase of 4 months with Isoniazid (H) and Rifampicin (R).\",\n    \"highYieldPearl\": \"Most forms of extrapulmonary TB (excluding CNS and bone/joint) are treated for 6 months.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Some forms of EPTB (e.g., CNS, bone/joint) require longer treatment durations (9-12 months), so distinguishing between them is important.\"\n  },\n  {\n    \"question\": \"Adjuvant corticosteroids in pleural tuberculosis primarily aim to reduce which complication?\",\n    \"options\": {\n      \"A\": \"Risk of drug resistance\",\n      \"B\": \"Pleural thickening\",\n      \"C\": \"Systemic symptoms\",\n      \"D\": \"Contagion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"Adjuvant corticosteroids in pleural tuberculosis are primarily used to reduce the exuberant inflammatory response in the pleural space, thereby minimizing the risk of residual pleural thickening and fibrosis, which can lead to restrictive lung disease. While they can also help alleviate systemic symptoms like fever and chest pain, their main long-term benefit is preventing pleural sequelae.\",\n    \"highYieldPearl\": \"Corticosteroids are considered in extensive pleural effusions to prevent fibrotic complications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Systemic symptom relief is a secondary benefit; the primary indication for steroids in pleural TB is to prevent long-term pleural fibrosis.\"\n  },\n  {\n    \"question\": \"What is the classic histological finding in tuberculous lymphadenitis?\",\n    \"options\": {\n      \"A\": \"Non-caseating granulomas\",\n      \"B\": \"Caseating granulomas\",\n      \"C\": \"Suppurative inflammation\",\n      \"D\": \"Lymphoid hyperplasia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"The histopathological hallmark of tuberculosis, including tuberculous lymphadenitis, is the presence of caseating granulomas. These are collections of epithelioid macrophages, Langerhans giant cells, and lymphocytes, with a central area of amorphous, eosinophilic, granular necrosis resembling cheese (caseation necrosis). Non-caseating granulomas are typically seen in sarcoidosis.\",\n    \"highYieldPearl\": \"Caseation necrosis is highly characteristic and almost pathognomonic for tuberculosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing caseating with non-caseating granulomas is a common pitfall. Non-caseating granulomas are characteristic of other granulomatous diseases like sarcoidosis.\"\n  },\n  {\n    \"question\": \"Pleural fluid glucose levels in tuberculous pleurisy are typically?\",\n    \"options\": {\n      \"A\": \"Elevated\",\n      \"B\": \"Normal\",\n      \"C\": \"Decreased\",\n      \"D\": \"Highly variable\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"Pleural fluid glucose levels in tuberculous pleurisy are typically low (<60 mg/dL or <3.3 mmol/L). This decrease is attributed to increased glucose consumption by inflammatory cells (lymphocytes and macrophages) and mycobacteria within the pleural space. Other causes of low pleural fluid glucose include empyema, rheumatoid pleurisy, and malignancy.\",\n    \"highYieldPearl\": \"Low pleural fluid glucose, along with high ADA and lymphocytic predominance, is a strong indicator of tuberculous pleurisy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"It's important to remember that 'inflammation' doesn't always mean normal or high glucose; active cellular metabolism by inflammatory cells and bacteria consumes glucose.\"\n  },\n  {\n    \"question\": \"Paradoxical enlargement of lymph nodes during anti-tubercular treatment is most characteristic of which EPTB?\",\n    \"options\": {\n      \"A\": \"Tuberculous meningitis\",\n      \"B\": \"Renal tuberculosis\",\n      \"C\": \"Tuberculous lymphadenitis\",\n      \"D\": \"Pericardial tuberculosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_pleural\",\n    \"deepDiveExplanation\": \"Paradoxical worsening, or Immune Reconstitution Inflammatory Syndrome (IRIS), is a recognized phenomenon in tuberculosis treatment. It is particularly common in tuberculous lymphadenitis, where existing lymph nodes may enlarge, new nodes may appear, or existing nodes may suppurate despite effective anti-tubercular therapy. This is thought to be due to an exaggerated immune response as the immune system recovers and becomes more effective at clearing mycobacterial antigens.\",\n    \"highYieldPearl\": \"Paradoxical worsening is a clinical challenge in lymph node TB, often mistaken for treatment failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"It is crucial to differentiate paradoxical worsening from true treatment failure or drug resistance, as it usually resolves with continued anti-TB therapy, sometimes with a short course of steroids.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-955.07080078125}],"createTime":"2025-12-31T07:46:17.754158Z","modelVersion":"gemini-2.5-flash","responseId":"ydRUae6DLt3DgLUPqfGtgAE","usageMetadata":{"billablePromptUsage":{"textCount":1028},"candidatesTokenCount":2680,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2680}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":3042,"totalTokenCount":6091,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:56.016977+00:00"}
{"metadata":"one-liner|lung_cancer_epi|Lung Cancer - Epidemiology and Risk Factors|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Epidemiology and Risk Factors\".\nSet the \"topic\" field in the JSON to \"lung_cancer_epi\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2583529496541122,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Globally, lung cancer is the leading cause of cancer-related mortality in which gender?\",\n    \"options\": {\n      \"A\": \"Males only\",\n      \"B\": \"Females only\",\n      \"C\": \"Both males and females\",\n      \"D\": \"Neither\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Lung cancer accounts for the highest number of cancer-related deaths worldwide, surpassing breast, colorectal, and prostate cancers combined. This epidemiological fact holds true for both men and women globally.\",\n    \"highYieldPearl\": \"Lung cancer is the #1 cancer killer worldwide for both genders, highlighting its immense public health burden.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While historically more prevalent in men, the incidence and mortality in women have risen significantly, making 'Both males and females' the correct answer. Options A and B are historical or partial truths.\"\n  },\n  {\n    \"question\": \"The most common histological subtype of lung cancer globally is?\",\n    \"options\": {\n      \"A\": \"Squamous cell carcinoma\",\n      \"B\": \"Adenocarcinoma\",\n      \"C\": \"Small cell lung cancer\",\n      \"D\": \"Large cell neuroendocrine carcinoma\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Adenocarcinoma has surpassed squamous cell carcinoma as the most common subtype of non-small cell lung cancer (NSCLC) and overall lung cancer, accounting for approximately 40% of cases. Its incidence has increased, particularly in women and non-smokers, and it is often found peripherally.\",\n    \"highYieldPearl\": \"Adenocarcinoma is the most common lung cancer type, especially in non-smokers and women, often presenting peripherally.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Historically, squamous cell carcinoma was more common, especially in heavy smokers. However, epidemiological shifts in smoking patterns and diagnostic advancements have made adenocarcinoma the predominant type. SCLC is distinct and accounts for about 15% of cases.\"\n  },\n  {\n    \"question\": \"The single most significant modifiable risk factor for lung cancer is?\",\n    \"options\": {\n      \"A\": \"Asbestos exposure\",\n      \"B\": \"Radon exposure\",\n      \"C\": \"Active cigarette smoking\",\n      \"D\": \"Air pollution\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Active cigarette smoking is unequivocally the strongest risk factor for lung cancer, accounting for approximately 85-90% of all cases. The risk is dose-dependent, increasing with the number of cigarettes smoked and duration of smoking. Cessation significantly reduces risk over time.\",\n    \"highYieldPearl\": \"Cigarette smoking is the paramount modifiable risk factor, responsible for the vast majority of lung cancer cases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While asbestos, radon, and air pollution are significant risk factors, none approach the attributable risk of active cigarette smoking. The term 'single most significant' points directly to smoking.\"\n  },\n  {\n    \"question\": \"What is considered the second leading cause of lung cancer in non-smokers?\",\n    \"options\": {\n      \"A\": \"Asbestos\",\n      \"B\": \"Radon exposure\",\n      \"C\": \"Secondhand smoke\",\n      \"D\": \"Air pollution\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Radon, a naturally occurring radioactive gas, is the leading cause of lung cancer in non-smokers and the second leading cause overall after cigarette smoking. It decays into radioactive particles that can damage lung tissue when inhaled.\",\n    \"highYieldPearl\": \"Radon is the #1 lung cancer risk for non-smokers and #2 overall, highlighting indoor environmental exposure importance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"Secondhand smoke is also a significant risk factor for non-smokers, but radon generally accounts for more cases. Asbestos is a strong occupational risk, and air pollution is a broader environmental risk, but radon takes precedence as the 'second leading cause'.\"\n  },\n  {\n    \"question\": \"Which occupational exposure is strongly associated with both lung cancer and mesothelioma?\",\n    \"options\": {\n      \"A\": \"Silica\",\n      \"B\": \"Cadmium\",\n      \"C\": \"Asbestos\",\n      \"D\": \"Arsenic\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Asbestos exposure is a well-established occupational carcinogen, strongly linked to both lung cancer (primarily adenocarcinoma and squamous cell carcinoma) and malignant mesothelioma, a rare cancer of the pleura or peritoneum. The risk for lung cancer is significantly potentiated by cigarette smoking.\",\n    \"highYieldPearl\": \"Asbestos is the unique occupational hazard causing both lung cancer (synergistic with smoking) and mesothelioma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While silica (silicosis, lung cancer), cadmium, and arsenic are also occupational lung carcinogens, only asbestos is specifically linked to both lung cancer and mesothelioma, making it the distinct answer.\"\n  },\n  {\n    \"question\": \"Which risk factor demonstrates a synergistic effect with cigarette smoking for lung cancer development?\",\n    \"options\": {\n      \"A\": \"Air pollution\",\n      \"B\": \"Radon exposure\",\n      \"C\": \"Human papillomavirus\",\n      \"D\": \"Genetic predisposition\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"The risk of lung cancer from radon exposure is significantly multiplied (synergistic effect) in individuals who also smoke cigarettes. For example, a smoker exposed to radon has a much higher risk than the sum of risks from smoking alone and radon alone.\",\n    \"highYieldPearl\": \"Radon exposure plus smoking creates a powerful synergistic risk, not merely additive, for lung cancer.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"While all options might increase risk in some context, the synergistic interaction (where the combined effect is greater than the sum of individual effects) is a classic finding for radon and smoking. Asbestos also has a synergistic effect with smoking, but it was not an option here.\"\n  },\n  {\n    \"question\": \"Which histological subtype of lung cancer is most strongly and almost exclusively linked to cigarette smoking?\",\n    \"options\": {\n      \"A\": \"Adenocarcinoma\",\n      \"B\": \"Squamous cell carcinoma\",\n      \"C\": \"Small cell lung cancer\",\n      \"D\": \"Large cell carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Small cell lung cancer (SCLC) has the strongest association with cigarette smoking, with over 95% of SCLC cases occurring in current or former smokers. It is rare in never-smokers. Squamous cell carcinoma also has a very strong link but is not as exclusively tied to smoking as SCLC.\",\n    \"highYieldPearl\": \"SCLC is virtually synonymous with heavy smoking; finding it in a never-smoker is exceedingly rare.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"While squamous cell carcinoma is also strongly associated with smoking, SCLC's link is nearly exclusive. Adenocarcinoma is the most common type in non-smokers, making A incorrect for this question.\"\n  },\n  {\n    \"question\": \"Beta-carotene supplementation has shown increased lung cancer risk in which population?\",\n    \"options\": {\n      \"A\": \"Non-smokers\",\n      \"B\": \"Former smokers\",\n      \"C\": \"Active smokers\",\n      \"D\": \"Individuals with COPD\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Several large randomized controlled trials (e.g., CARET, ATBC) demonstrated that high-dose beta-carotene supplementation actually increased the risk of lung cancer (and cardiovascular mortality) in active heavy smokers and asbestos-exposed individuals, contrary to initial hopes of a protective effect.\",\n    \"highYieldPearl\": \"Beta-carotene supplements are contraindicated in active smokers due to increased lung cancer risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This is a classic 'paradoxical finding' in epidemiology. While antioxidants are generally perceived as beneficial, this study found harm in a specific high-risk group. This makes 'Active smokers' the critical distinguishing factor.\"\n  },\n  {\n    \"question\": \"Which chronic pulmonary condition is a recognized risk factor for lung adenocarcinoma?\",\n    \"options\": {\n      \"A\": \"Asthma\",\n      \"B\": \"Chronic bronchitis\",\n      \"C\": \"Idiopathic pulmonary fibrosis\",\n      \"D\": \"Bronchiectasis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Idiopathic pulmonary fibrosis (IPF) is a significant independent risk factor for lung cancer, particularly adenocarcinoma. The chronic inflammation, oxidative stress, and repetitive injury-repair cycles in the fibrotic lung are thought to contribute to malignant transformation. The lifetime risk of lung cancer in IPF patients is estimated to be 5-10 times higher than the general population.\",\n    \"highYieldPearl\": \"IPF is a strong independent risk factor for lung cancer, often adenocarcinoma, due to chronic inflammation and scarring.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"While other chronic lung diseases might have some association, IPF carries a particularly high and well-established risk for lung cancer, especially adenocarcinoma, often referred to as 'scar carcinoma'.\"\n  },\n  {\n    \"question\": \"Passive smoking is associated with an increased risk primarily for which lung cancer subtype?\",\n    \"options\": {\n      \"A\": \"Squamous cell carcinoma\",\n      \"B\": \"Small cell lung cancer\",\n      \"C\": \"Adenocarcinoma\",\n      \"D\": \"Large cell carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_epi\",\n    \"deepDiveExplanation\": \"Passive smoking (exposure to secondhand smoke) is an established cause of lung cancer, with an estimated 20-30% increased risk for non-smokers exposed to it. Epidemiological studies suggest that adenocarcinoma is the most commonly observed histological subtype in lung cancers linked to passive smoking, mirroring the pattern seen in never-smokers who develop lung cancer.\",\n    \"highYieldPearl\": \"Passive smoking increases lung cancer risk, predominantly adenocarcinoma, reflecting the type seen in non-smokers.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Moderate\",\n    \"trapAnalysis\": \"While passive smoking increases the risk of lung cancer generally, its association is strongest with adenocarcinoma, similar to the pattern seen in active non-smokers. Squamous and small cell carcinomas are much more strongly linked to active smoking.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-672.234375}],"createTime":"2025-12-31T07:46:22.813604Z","modelVersion":"gemini-2.5-flash","responseId":"ztRUaaTUMd-zgLUPj-v-qAI","usageMetadata":{"billablePromptUsage":{"textCount":1044},"candidatesTokenCount":2602,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2602}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":1293,"totalTokenCount":4263,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:22.161097+00:00"}
{"metadata":"one-liner|ctd_ild|Connective Tissue Disease-Associated ILD|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Connective Tissue Disease-Associated ILD\".\nSet the \"topic\" field in the JSON to \"ctd_ild\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.26281196399959134,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which connective tissue disease is associated with the highest prevalence of interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Rheumatoid Arthritis\",\n      \"B\": \"Systemic Sclerosis\",\n      \"C\": \"Systemic Lupus Erythematosus\",\n      \"D\": \"Sjogren's Syndrome\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) in 70-90% of patients, making it the CTD with the highest prevalence of ILD. ILD is a major cause of morbidity and mortality in SSc. While rheumatoid arthritis (RA) is also commonly associated with ILD, the prevalence within RA patients is typically lower (e.g., 10-30% clinically significant ILD, up to 60% on HRCT).\",\n    \"highYieldPearl\": \"Systemic sclerosis (SSc) has the highest prevalence of ILD among all CTDs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Rheumatoid Arthritis-ILD (RA-ILD) is very common in terms of absolute patient numbers, but SSc has a higher proportion of its patients developing ILD, often reaching 90% in some cohorts.\"\n  },\n  {\n    \"question\": \"The most common HRCT pattern observed in Systemic Sclerosis-associated ILD is?\",\n    \"options\": {\n      \"A\": \"Usual Interstitial Pneumonia (UIP)\",\n      \"B\": \"Non-Specific Interstitial Pneumonia (NSIP)\",\n      \"C\": \"Organizing Pneumonia (OP)\",\n      \"D\": \"Lymphocytic Interstitial Pneumonia (LIP)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Non-specific interstitial pneumonia (NSIP) is the predominant HRCT and histopathological pattern in systemic sclerosis-associated ILD (SSc-ILD), accounting for 60-80% of cases. A Usual Interstitial Pneumonia (UIP) pattern occurs in a smaller but significant proportion (10-30%) and is associated with a worse prognosis.\",\n    \"highYieldPearl\": \"NSIP is the hallmark HRCT pattern in SSc-ILD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"UIP is common in RA-ILD and Idiopathic Pulmonary Fibrosis (IPF), which might lead to incorrect selection if not specifically considering SSc-ILD.\"\n  },\n  {\n    \"question\": \"What is the most prevalent HRCT pattern seen in Rheumatoid Arthritis-associated ILD?\",\n    \"options\": {\n      \"A\": \"Non-Specific Interstitial Pneumonia\",\n      \"B\": \"Usual Interstitial Pneumonia\",\n      \"C\": \"Cryptogenic Organizing Pneumonia\",\n      \"D\": \"Diffuse Alveolar Damage\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Usual interstitial pneumonia (UIP) is the most common and prognostically significant HRCT pattern in rheumatoid arthritis-associated ILD (RA-ILD), found in approximately 50-70% of cases. NSIP is the second most common, occurring in 20-40%. The presence of a UIP pattern in RA-ILD is associated with poorer survival, similar to idiopathic pulmonary fibrosis.\",\n    \"highYieldPearl\": \"UIP is the most common and prognostically poor pattern in RA-ILD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"NSIP is a common pattern in other CTD-ILDs (e.g., SSc-ILD), making it a plausible but incorrect option for RA-ILD.\"\n  },\n  {\n    \"question\": \"Which drug is considered first-line for progressive fibrosing CTD-ILD, particularly SSc-ILD?\",\n    \"options\": {\n      \"A\": \"Azathioprine\",\n      \"B\": \"Mycophenolate Mofetil\",\n      \"C\": \"Cyclophosphamide\",\n      \"D\": \"Methotrexate\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Mycophenolate mofetil (MMF) is now considered a first-line treatment for progressive fibrosing CTD-ILD, especially SSc-ILD, based on evidence from trials like the Scleroderma Lung Study II (SLS-II) which showed non-inferiority to cyclophosphamide and better tolerability. It is also increasingly used in other CTD-ILDs.\",\n    \"highYieldPearl\": \"MMF is the preferred first-line immunosuppressant for progressive CTD-ILD due to efficacy and tolerability.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Cyclophosphamide was historically used and is still an option for severe or rapidly progressive disease, but MMF is now preferred for chronic management. Methotrexate is contraindicated in pre-existing ILD.\"\n  },\n  {\n    \"question\": \"Which autoantibody is characteristic of anti-synthetase syndrome with associated ILD?\",\n    \"options\": {\n      \"A\": \"Anti-Jo-1\",\n      \"B\": \"Anti-Ro/SSA\",\n      \"C\": \"Anti-La/SSB\",\n      \"D\": \"Anti-MDA5\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Anti-Jo-1 (anti-histidyl tRNA synthetase) is the most common and characteristic autoantibody found in anti-synthetase syndrome, a subset of idiopathic inflammatory myopathies (IIM) strongly associated with ILD. Anti-synthetase syndrome typically presents with myositis, ILD, fever, Raynaud's phenomenon, and 'mechanic's hands'. Anti-MDA5 is associated with amyopathic dermatomyositis and rapidly progressive ILD.\",\n    \"highYieldPearl\": \"Anti-Jo-1 defines anti-synthetase syndrome, a major cause of IIM-ILD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Anti-MDA5 is also associated with IIM-ILD but with a distinct clinical presentation (amyopathic DM, rapid progression), making it a common distractor.\"\n  },\n  {\n    \"question\": \"Which factor is an independent predictor of worse prognosis in Systemic Sclerosis-associated ILD?\",\n    \"options\": {\n      \"A\": \"Limited cutaneous SSc\",\n      \"B\": \"NSIP pattern on HRCT\",\n      \"C\": \"Baseline FVC < 70% predicted\",\n      \"D\": \"Absence of pulmonary hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Several factors predict worse prognosis in SSc-ILD, including a baseline forced vital capacity (FVC) < 70% predicted, diffusing capacity for carbon monoxide (DLCO) < 50% predicted, UIP pattern on HRCT, male gender, African American race, and older age at diagnosis. Limited cutaneous SSc is generally associated with a better prognosis than diffuse cutaneous SSc. NSIP pattern is generally better than UIP.\",\n    \"highYieldPearl\": \"Low baseline FVC and DLCO are strong prognostic indicators for SSc-ILD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Limited cutaneous SSc and NSIP pattern are generally associated with a better prognosis, while absence of pulmonary hypertension is also a favorable sign, making them distractors for 'worse prognosis'.\"\n  },\n  {\n    \"question\": \"Which immunosuppressant is generally contraindicated in patients with pre-existing interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Cyclosporine\",\n      \"B\": \"Leflunomide\",\n      \"C\": \"Methotrexate\",\n      \"D\": \"Tacrolimus\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Methotrexate (MTX) is a well-known cause of drug-induced pneumonitis and can exacerbate pre-existing interstitial lung disease. Therefore, it is generally contraindicated or used with extreme caution in patients with CTD-ILD, especially if the ILD is active or progressive.\",\n    \"highYieldPearl\": \"Avoid Methotrexate in patients with pre-existing or active ILD due to the risk of drug-induced pneumonitis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other immunosuppressants like Leflunomide can also cause pneumonitis, but MTX is a classic and widely recognized contraindication in this context.\"\n  },\n  {\n    \"question\": \"Which antifibrotic drug is approved for progressive fibrosing interstitial lung diseases, including CTD-ILD?\",\n    \"options\": {\n      \"A\": \"Pirfenidone\",\n      \"B\": \"Nintedanib\",\n      \"C\": \"Tocilizumab\",\n      \"D\": \"Rituximab\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Nintedanib is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF) and, importantly, for other chronic fibrosing interstitial lung diseases with a progressive phenotype, including CTD-ILD, based on the INBUILD trial. Pirfenidone is approved for IPF but its specific approval for non-IPF progressive fibrosing ILD is not as broad as Nintedanib's.\",\n    \"highYieldPearl\": \"Nintedanib is approved for progressive fibrosing ILD, including CTD-ILD, based on the INBUILD trial.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Pirfenidone is also an antifibrotic used in IPF, but Nintedanib has broader approval for progressive fibrosing ILDs beyond IPF.\"\n  },\n  {\n    \"question\": \"Which autoantibody is strongly linked to rapidly progressive interstitial lung disease in dermatomyositis/polymyositis?\",\n    \"options\": {\n      \"A\": \"Anti-PM/Scl\",\n      \"B\": \"Anti-Mi-2\",\n      \"C\": \"Anti-MDA5\",\n      \"D\": \"Anti-Ku\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"Anti-MDA5 (melanoma differentiation-associated gene 5) autoantibodies are strongly associated with clinically amyopathic dermatomyositis (CADM) and a severe, rapidly progressive form of interstitial lung disease (RP-ILD), often with a poor prognosis.\",\n    \"highYieldPearl\": \"Anti-MDA5 is a crucial marker for rapidly progressive ILD in inflammatory myopathies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other antibodies like Anti-PM/Scl and Anti-Mi-2 are associated with inflammatory myopathies but not as specifically or strongly with rapidly progressive ILD.\"\n  },\n  {\n    \"question\": \"Considering overall patient numbers, which CTD-ILD is most frequently encountered in clinical practice?\",\n    \"options\": {\n      \"A\": \"Systemic Sclerosis-ILD\",\n      \"B\": \"Rheumatoid Arthritis-ILD\",\n      \"C\": \"Polymyositis/Dermatomyositis-ILD\",\n      \"D\": \"Sjogren's Syndrome-ILD\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ctd_ild\",\n    \"deepDiveExplanation\": \"While Systemic Sclerosis has the highest *prevalence* of ILD among its patient population, Rheumatoid Arthritis is a much more common disease overall. Therefore, in terms of *absolute numbers* of patients encountered with CTD-ILD in clinical practice, RA-ILD is generally considered the most frequent. This distinction between prevalence within a disease cohort and overall burden is important.\",\n    \"highYieldPearl\": \"RA-ILD is the most common CTD-ILD in terms of absolute patient numbers, despite SSc having a higher proportion of its patients affected.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Systemic Sclerosis-ILD is a strong distractor because it has the highest *prevalence* of ILD among CTDs. The question specifically asks about overall patient numbers encountered.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-763.7315673828125}],"createTime":"2025-12-31T07:45:34.655555Z","modelVersion":"gemini-2.5-flash","responseId":"ntRUacOBKL2mlu8Po5XtwQo","usageMetadata":{"billablePromptUsage":{"textCount":1036},"candidatesTokenCount":2906,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2906}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":3034,"totalTokenCount":6308,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:02.418628+00:00"}
{"metadata":"one-liner|mv_asthma_copd|Ventilation in Asthma and COPD|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Ventilation in Asthma and COPD\".\nSet the \"topic\" field in the JSON to \"mv_asthma_copd\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.44129191653829225,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The most accurate method to measure auto-PEEP during passive mechanical ventilation is via:\",\n    \"options\": {\n      \"A\": \"Inspiratory hold maneuver\",\n      \"B\": \"End-expiratory hold maneuver\",\n      \"C\": \"Esophageal pressure measurement\",\n      \"D\": \"Flow-volume loop analysis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Auto-PEEP (intrinsic PEEP) is generated when expiration is incomplete, leading to gas trapping. An end-expiratory hold maneuver stops flow, allowing pressure to equilibrate throughout the circuit and lungs, revealing the total PEEP (extrinsic + auto-PEEP). If extrinsic PEEP is zero, the measured pressure is auto-PEEP.\",\n    \"highYieldPearl\": \"Auto-PEEP increases work of breathing, can trigger barotrauma, and makes patient-ventilator synchrony difficult. It's crucial to identify and manage it.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Inspiratory hold measures plateau pressure. Esophageal pressure measures pleural pressure. Flow-volume loops suggest auto-PEEP but don't quantify it directly.\"\n  },\n  {\n    \"question\": \"The primary objective of permissive hypercapnia strategy in mechanically ventilated severe asthma is to:\",\n    \"options\": {\n      \"A\": \"Improve oxygenation\",\n      \"B\": \"Reduce airway pressures and barotrauma\",\n      \"C\": \"Decrease respiratory drive\",\n      \"D\": \"Enhance bronchodilation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Permissive hypercapnia involves tolerating elevated PaCO2 (e.g., up to 60-80 mmHg) and corresponding acidosis (pH > 7.15-7.20) to allow for lower tidal volumes and respiratory rates. This reduces peak/plateau airway pressures and intrinsic PEEP, protecting lungs from ventilator-induced lung injury (VILI) and barotrauma.\",\n    \"highYieldPearl\": \"The goal is lung protection, not necessarily normalizing blood gases. The priority is to minimize dynamic hyperinflation and barotrauma risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While some CO2 may have mild bronchodilator effects, it's not the primary goal. Decreasing respiratory drive is a consequence, not the primary objective. Improving oxygenation is not the goal, as permissive hypercapnia implies allowing higher PaCO2.\"\n  },\n  {\n    \"question\": \"To mitigate dynamic hyperinflation in mechanically ventilated AECOPD, the primary ventilator adjustment involves:\",\n    \"options\": {\n      \"A\": \"Increasing tidal volume\",\n      \"B\": \"Decreasing inspiratory time\",\n      \"C\": \"Increasing respiratory rate\",\n      \"D\": \"Prolonging expiratory time\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Dynamic hyperinflation occurs when expiratory time is insufficient for complete exhalation, leading to progressive air trapping. Prolonging expiratory time (by reducing respiratory rate or reducing I:E ratio) allows more time for gas to exit the lungs, reducing trapped volume and auto-PEEP.\",\n    \"highYieldPearl\": \"Prioritize sufficient expiratory time over achieving normal minute ventilation in severe obstructive disease. An I:E ratio of 1:3 or 1:4 is often targeted.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Increasing tidal volume or respiratory rate would worsen hyperinflation. Decreasing inspiratory time can indirectly prolong expiratory time, but directly prolonging expiratory time is the most effective adjustment.\"\n  },\n  {\n    \"question\": \"The strongest indication for Non-Invasive Ventilation (NIV) in acute exacerbation of COPD is:\",\n    \"options\": {\n      \"A\": \"Mild hypoxemia without hypercapnia\",\n      \"B\": \"Hypercapnic respiratory failure with acidosis\",\n      \"C\": \"Prophylaxis post-extubation in stable patients\",\n      \"D\": \"Acute cardiogenic pulmonary edema\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Numerous randomized controlled trials have shown that NIV significantly reduces the need for intubation, hospital mortality, and length of hospital stay in patients with hypercapnic respiratory failure due to AECOPD (pH < 7.35, PaCO2 > 45 mmHg). It improves gas exchange and reduces work of breathing.\",\n    \"highYieldPearl\": \"NIV is a first-line therapy for moderate to severe AECOPD with hypercapnic respiratory failure, especially when accompanied by respiratory acidosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While NIV can be used post-extubation, it's not the *strongest* indication for AECOPD. Acute cardiogenic pulmonary edema is another strong indication for NIV, but the question specifies AECOPD.\"\n  },\n  {\n    \"question\": \"Heliox improves ventilation in severe acute asthma primarily by:\",\n    \"options\": {\n      \"A\": \"Reducing airway inflammation\",\n      \"B\": \"Increasing oxygen carrying capacity\",\n      \"C\": \"Decreasing gas density\",\n      \"D\": \"Potentiating bronchodilators\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Heliox (a mixture of helium and oxygen) has a much lower density than air or oxygen. This reduced density leads to a decrease in airway resistance, particularly in turbulent flow, which is prominent in narrowed airways during severe asthma. This allows for more laminar flow, improved gas delivery, and reduced work of breathing.\",\n    \"highYieldPearl\": \"Heliox is typically used as a bridge therapy for severe, refractory asthma exacerbations, not a definitive treatment, to buy time for other therapies to work.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Heliox does not directly reduce inflammation or increase oxygen carrying capacity. While it can improve delivery of nebulized bronchodilators, its primary mechanism is distinct.\"\n  },\n  {\n    \"question\": \"In mechanically ventilated obstructive lung disease, driving pressure primarily reflects:\",\n    \"options\": {\n      \"A\": \"Airway resistance\",\n      \"B\": \"Static lung compliance\",\n      \"C\": \"Intrinsic PEEP\",\n      \"D\": \"Tidal volume\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Driving pressure (Plateau Pressure - Total PEEP) is essentially the tidal volume divided by the static compliance of the respiratory system (Vt/Crs). It represents the pressure gradient required to inflate the lung from its end-expiratory volume to its end-inspiratory volume, reflecting lung stress.\",\n    \"highYieldPearl\": \"Limiting driving pressure (<15 cmH2O) is a key lung-protective ventilation strategy, as it is a strong predictor of mortality, especially in ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While airway resistance is high in obstructive disease, driving pressure does not directly measure it. Intrinsic PEEP contributes to total PEEP, but driving pressure itself reflects the pressure needed to deliver tidal volume against the elastic recoil.\"\n  },\n  {\n    \"question\": \"A crucial predictor for successful weaning from mechanical ventilation in COPD patients is:\",\n    \"options\": {\n      \"A\": \"High PaO2/FiO2 ratio\",\n      \"B\": \"Low Rapid Shallow Breathing Index (RSBI)\",\n      \"C\": \"Normal chest X-ray\",\n      \"D\": \"Absence of fever\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"RSBI (Respiratory Rate / Tidal Volume in Liters) reflects the efficiency of breathing. A low RSBI (<105 breaths/min/L) indicates that the patient can maintain adequate minute ventilation with a relatively low respiratory rate and good tidal volume, suggesting sufficient respiratory muscle strength and endurance for spontaneous breathing.\",\n    \"highYieldPearl\": \"RSBI is a cornerstone of weaning assessment, often used in conjunction with other criteria during a Spontaneous Breathing Trial (SBT).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While good oxygenation (high PaO2/FiO2), clear CXR, and absence of fever are general indicators of readiness for weaning, RSBI is a highly specific and validated predictor of extubation success.\"\n  },\n  {\n    \"question\": \"Compared to conventional oxygen, High-Flow Nasal Cannula in mild AECOPD primarily offers:\",\n    \"options\": {\n      \"A\": \"Superior CO2 clearance\",\n      \"B\": \"Better bronchodilation\",\n      \"C\": \"Reduced work of breathing\",\n      \"D\": \"Lower risk of aspiration\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"HFNC delivers heated and humidified oxygen at high flow rates. This washes out nasopharyngeal dead space (reducing rebreathing of CO2), generates a small amount of positive end-expiratory pressure (PEEP), improves oxygenation, and significantly reduces the work of breathing by providing a stable, high-flow gas source that matches or exceeds inspiratory demand.\",\n    \"highYieldPearl\": \"HFNC is increasingly used in AECOPD as an alternative or bridge therapy, especially for patients who might not tolerate NIV or with milder respiratory failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While HFNC can provide some CO2 washout, its effect on overall CO2 clearance is less pronounced than NIV. It doesn't directly cause bronchodilation. Lower aspiration risk is a benefit of non-invasive support over intubation, but not a primary advantage of HFNC over conventional oxygen delivery.\"\n  },\n  {\n    \"question\": \"The most effective ventilator strategy to reduce dynamic hyperinflation in severe acute asthma is:\",\n    \"options\": {\n      \"A\": \"Increasing peak inspiratory flow\",\n      \"B\": \"Decreasing respiratory rate\",\n      \"C\": \"Increasing tidal volume\",\n      \"D\": \"Applying external PEEP\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"Dynamic hyperinflation is a hallmark of severe asthma, leading to increased intrathoracic pressure and increased work of breathing. The most direct way to combat this is to allow more time for exhalation. Decreasing the respiratory rate directly lengthens the expiratory time, facilitating more complete emptying of the lungs and reducing trapped gas volume and auto-PEEP.\",\n    \"highYieldPearl\": \"Prioritizing a long expiratory time (e.g., I:E ratio of 1:3 or 1:4) is critical in managing severe asthma on mechanical ventilation, often at the expense of normocapnia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Increasing tidal volume or respiratory rate would worsen hyperinflation. Increasing peak inspiratory flow shortens inspiratory time, which *can* indirectly lengthen expiratory time, but directly decreasing respiratory rate has a more substantial impact on extending the expiratory phase.\"\n  },\n  {\n    \"question\": \"In mechanically ventilated COPD patients with significant auto-PEEP, applying appropriate extrinsic PEEP can primarily:\",\n    \"options\": {\n      \"A\": \"Increase barotrauma risk\",\n      \"B\": \"Worsen air trapping\",\n      \"C\": \"Reduce patient work of breathing\",\n      \"D\": \"Decrease oxygenation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_asthma_copd\",\n    \"deepDiveExplanation\": \"When auto-PEEP is present, the patient must generate significant negative inspiratory pressure to overcome this intrinsic pressure before a breath can be triggered. Applying extrinsic PEEP that is slightly less than the auto-PEEP (e.g., 80-90% of auto-PEEP) can 'balance' this threshold, reducing the inspiratory effort required by the patient and thereby decreasing the work of breathing without significantly worsening hyperinflation.\",\n    \"highYieldPearl\": \"Careful titration of extrinsic PEEP is crucial; too much can worsen hyperinflation, while an appropriate amount can improve patient comfort, ventilator synchrony, and reduce work of breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"If the applied extrinsic PEEP is less than or equal to the auto-PEEP, it generally does not worsen air trapping or significantly increase barotrauma. It typically improves oxygenation, not decreases it.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1315.9324951171875}],"createTime":"2025-12-31T07:45:10.955359Z","modelVersion":"gemini-2.5-flash","responseId":"htRUad-nOsymnvgPpPKL8AM","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":2982,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2982}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":4684,"totalTokenCount":8035,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:54.763443+00:00"}
{"metadata":"one-liner|thoracoscopy|Thoracoscopy and Pleural Biopsy|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Thoracoscopy and Pleural Biopsy\".\nSet the \"topic\" field in the JSON to \"thoracoscopy\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.5396572466978092,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the reported diagnostic yield of medical thoracoscopy for malignant pleural effusion?\",\n    \"options\": {\n      \"A\": \"50-60%\",\n      \"B\": \"70-80%\",\n      \"C\": \"85-95%\",\n      \"D\": \">95%\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracoscopy\",\n    \"deepDiveExplanation\": \"Medical thoracoscopy (pleuroscopy) allows direct visualization of the pleural surfaces and targeted biopsies. For malignant pleural effusions, it offers a significantly higher diagnostic yield (85-95%) compared to blind pleural biopsy (40-60%) or even CT-guided biopsy (60-70%), especially when previous biopsies have been non-diagnostic. It also allows for therapeutic interventions like talc pleurodesis.\",\n    \"highYieldPearl\": \"Medical thoracoscopy is the gold standard for diagnosing exudative pleural effusions of unknown etiology, particularly when malignancy is suspected.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options are percentages, testing specific recall of diagnostic efficacy. Lower percentages are associated with blind biopsies. The 85-95% range is consistently cited in major textbooks.\"\n  },\n  {\n    \"question\": \"Which of the following is an absolute contraindication for medical thoracoscopy?\",\n    \"options\": {\n      \"A\": \"Severe chronic obstructive pulmonary disease\",\n      \"B\": \"Uncorrectable coagulopathy\",\n      \"C\": \"Previous pleurodesis\",\n      \"D\": \"Small pleural space\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracoscopy\",\n    \"deepDiveExplanation\": \"Absolute contraindications for medical thoracoscopy include uncorrectable coagulopathy (e.g., INR > 1.5, platelets < 50,000 without correction), lack of adequate pleural space (lung fully expanded or extensive adhesions precluding safe entry), and patient refusal or inability to cooperate. Severe COPD, previous pleurodesis (depending on extent), and a small pleural space (if an adequate entry point can be found) are generally considered relative contraindications or technical challenges, not absolute prohibitions.\",\n    \"highYieldPearl\": \"Uncorrectable coagulopathy is a major risk for hemorrhage during any invasive procedure and is a critical absolute contraindication.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options are relative contraindications or technical challenges, not absolute prohibitions. Distinguishing absolute from relative contraindications is crucial for patient safety in practice and for exam questions.\"\n  },\n  {\n    \"question\": \"For definitive diagnosis of malignant mesothelioma, which biopsy technique is generally considered superior?\",\n    \"options\": {\n      \"A\": \"Blind pleural biopsy\",\n      \"B\": \"CT-guided core biopsy\",\n      \"C\": \"Medical thoracoscopy\",\n      \"D\": \"Video-assisted thoracic surgery (VATS)\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"thoracoscopy\",\n    \"deepDiveExplanation\": \"While medical thoracoscopy can provide good samples, Video-assisted thoracic surgery (VATS) allows for larger, deeper, and multiple biopsies. This is often crucial for the complex histological diagnosis of mesothelioma, especially for distinguishing it from reactive mesothelial hyperplasia, which requires assessment of tissue architecture and immunohistochemical stains on adequate tissue. VATS also enables better staging and therapeutic interventions.\",\n    \"highYieldPearl\": \"VATS offers the largest and deepest tissue samples, which are critical for the definitive diagnosis and staging of complex malignancies like mesothelioma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Medical thoracoscopy is highly effective for many pleural malignancies, but for mesothelioma, the requirement for larger, deeper tissue samples for definitive diagnosis and staging often makes VATS the superior choice. The question specifically asks for 'definitive diagnosis' and 'superior' technique.\"\n  },\n  {\n    \"question\": \"What is a common and often unavoidable complication following medical thoracoscopy?\",\n    \"options\": {\n      \"A\": \"Significant hemorrhage\",\n      \"B\": \"Persistent air leak\",\n      \"C\": \"Pleural infection\",\n      \"D\": \"Subcutaneous emphysema\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"thoracoscopy\",\n    \"deepDiveExplanation\": \"Subcutaneous emphysema is a very common, usually self-limiting complication after thoracoscopy, resulting from air tracking from the pleural space into the subcutaneous tissues through the access site. While persistent air leak and significant hemorrhage are serious complications, they are less common than subcutaneous emphysema. Pleural infection is rare with sterile technique.\",\n    \"highYieldPearl\": \"Subcutaneous emphysema is a frequent, usually benign, finding post-thoracoscopy due to transient air leakage into soft tissues around the port site.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other options are serious complications, but subcutaneous emphysema is particularly common and often self-resolving, making it a distinct characteristic of the procedure's immediate aftermath. The question asks for a 'common and often unavoidable' complication, fitting subcutaneous emphysema well.\"\n  },\n  {\n    \"question\": \"Talc pleurodesis performed during thoracoscopy primarily works by inducing what process?\",\n    \"options\": {\n      \"A\": \"Direct tumor cytotoxicity\",\n      \"B\": \"Immunosuppression of pleural cells\",\n      \"C\": \"Chemical irritation causing inflammation and fibrosis\",\n      \"D\": \"Increased lymphatic drainage from the pleural space\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracoscopy\",\n    \"deepDiveExplanation\": \"Talc acts as a potent sclerosant. When introduced into the pleural space, it causes a severe sterile inflammatory reaction. This inflammation leads to the formation of adhesions and fibrosis between the visceral and parietal pleura, effectively obliterating the pleural space and preventing the re-accumulation of fluid.\",\n    \"highYieldPearl\": \"Talc pleurodesis induces a robust sterile inflammatory reaction in the pleura, leading to symphysis and preventing recurrent effusions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The other options describe incorrect or secondary mechanisms. The core mechanism is the induction of a strong inflammatory response leading to pleural fusion (symphysis) due to the chemical irritant properties of talc.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-785.2012939453125}],"createTime":"2025-12-31T07:45:10.519398Z","modelVersion":"gemini-2.5-flash","responseId":"htRUaebZH7e0nvgP2IqeqAQ","usageMetadata":{"billablePromptUsage":{"textCount":1031},"candidatesTokenCount":1455,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1455}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2195,"totalTokenCount":4016,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:57.495183+00:00"}
{"metadata":"one-liner|cap|Community-Acquired Pneumonia|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Community-Acquired Pneumonia\".\nSet the \"topic\" field in the JSON to \"cap\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3559235448923716,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which of the following is NOT a component of the CURB-65 score for CAP severity?\",\n    \"options\": {\n      \"A\": \"Confusion\",\n      \"B\": \"Uremia\",\n      \"C\": \"Respiratory rate\",\n      \"D\": \"Oxygen saturation\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"The CURB-65 score assesses CAP severity based on Confusion, Urea (>7 mmol/L), Respiratory rate (≥30 breaths/min), Blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), and age (≥65 years). Oxygen saturation is a critical vital sign for pneumonia assessment but is not a direct component of the CURB-65 score itself. It is, however, part of other severity scores like the Pneumonia Severity Index (PSI/PORT) and is crucial for determining the need for hospitalization and oxygen therapy.\",\n    \"highYieldPearl\": \"Remember CURB-65 for rapid bedside assessment of CAP severity. Each criterion scores 1 point; a score of 0-1 suggests outpatient management, 2 suggests inpatient, and ≥3 suggests severe CAP, often requiring ICU consideration.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in oxygen saturation being a highly relevant parameter in pneumonia. Candidates might incorrectly assume its inclusion due to its clinical importance in severity assessment, despite not being part of the specific CURB-65 acronym.\"\n  },\n  {\n    \"question\": \"What is the most common bacterial pathogen causing community-acquired pneumonia in adults?\",\n    \"options\": {\n      \"A\": \"Haemophilus influenzae\",\n      \"B\": \"Staphylococcus aureus\",\n      \"C\": \"Streptococcus pneumoniae\",\n      \"D\": \"Klebsiella pneumoniae\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"*Streptococcus pneumoniae* remains the predominant bacterial cause of community-acquired pneumonia (CAP) across all age groups globally. While other pathogens like *Haemophilus influenzae*, atypical bacteria (*Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, *Legionella pneumophila*), and viruses are significant, *S. pneumoniae* consistently accounts for the largest proportion of bacterial CAP cases.\",\n    \"highYieldPearl\": \"*Streptococcus pneumoniae* is the 'King of CAP'. Always consider it first in empiric treatment decisions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While *Haemophilus influenzae* is also a common cause, especially in smokers and those with COPD, *S. pneumoniae* holds the top spot. Misremembering the prevalence can lead to error.\"\n  },\n  {\n    \"question\": \"Which antibiotic class is typically effective against atypical pathogens causing CAP?\",\n    \"options\": {\n      \"A\": \"Beta-lactams\",\n      \"B\": \"Aminoglycosides\",\n      \"C\": \"Macrolides\",\n      \"D\": \"Glycopeptides\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"Atypical pathogens (*Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, *Legionella pneumophila*) lack a cell wall or have unique cell wall structures, rendering beta-lactam antibiotics (which target peptidoglycan synthesis) ineffective. Macrolides (e.g., azithromycin, clarithromycin), tetracyclines (e.g., doxycycline), and fluoroquinolones (e.g., levofloxacin, moxifloxacin) are the main antibiotic classes effective against these organisms due to their mechanisms of action (e.g., protein synthesis inhibition for macrolides and tetracyclines, DNA gyrase inhibition for fluoroquinolones).\",\n    \"highYieldPearl\": \"For atypical CAP, think 'MLT': Macrolides, Lincosamides (less common for CAP), Tetracyclines. Fluoroquinolones are also effective.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The primary trap is selecting beta-lactams, which are highly effective against typical bacterial pathogens like *S. pneumoniae* but have no activity against atypical organisms due to their lack of a cell wall.\"\n  },\n  {\n    \"question\": \"The most rapid and specific diagnostic test for *Legionella pneumophila* CAP is?\",\n    \"options\": {\n      \"A\": \"Sputum Gram stain\",\n      \"B\": \"Blood culture\",\n      \"C\": \"Urine antigen test\",\n      \"D\": \"Serology\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"The *Legionella pneumophila* urinary antigen test detects a soluble cell wall antigen of *L. pneumophila* serogroup 1 in urine. It is highly specific (99%) and reasonably sensitive (70-99%), and results are available within hours, making it the most rapid and specific test for diagnosing *L. pneumophila* serogroup 1 CAP. Serology (antibody detection) is useful for retrospective diagnosis but not for acute management, and sputum Gram stain is often unrevealing as *Legionella* stains poorly.\",\n    \"highYieldPearl\": \"For *Legionella*, think 'U for Urine'. The urine antigen test is key for rapid diagnosis of *L. pneumophila* serogroup 1, which causes most cases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might consider sputum Gram stain or culture as general diagnostic tools for pneumonia. However, *Legionella* is difficult to stain and culture, making the urine antigen test superior for rapid, specific diagnosis.\"\n  },\n  {\n    \"question\": \"Which oral antibiotic is a first-line recommendation for healthy outpatients with CAP?\",\n    \"options\": {\n      \"A\": \"Amoxicillin\",\n      \"B\": \"Azithromycin\",\n      \"C\": \"Levofloxacin\",\n      \"D\": \"Cefpodoxime\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"According to IDSA 2019 guidelines, for otherwise healthy outpatients with CAP and no risk factors for drug-resistant *S. pneumoniae* or MRSA, first-line options include amoxicillin (1g TID), doxycycline, or a macrolide (e.g., azithromycin) if local pneumococcal macrolide resistance is <25%. Amoxicillin is a strong recommendation for typical CAP coverage due to its efficacy and narrow spectrum. Fluoroquinolones (like levofloxacin) are generally reserved for patients with comorbidities or those who have failed initial therapy.\",\n    \"highYieldPearl\": \"For healthy outpatients, think Amoxicillin (or Doxycycline/Azithromycin depending on local resistance). Avoid broad-spectrum agents if not needed.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Azithromycin is a common choice, but increasing macrolide resistance in *S. pneumoniae* makes amoxicillin or doxycycline preferable in many regions. Levofloxacin is too broad for initial healthy outpatient CAP.\"\n  },\n  {\n    \"question\": \"Which is a recommended empiric antibiotic regimen for non-ICU inpatient CAP?\",\n    \"options\": {\n      \"A\": \"Macrolide monotherapy\",\n      \"B\": \"Beta-lactam plus macrolide\",\n      \"C\": \"Beta-lactam plus aminoglycoside\",\n      \"D\": \"Doxycycline monotherapy\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"For non-ICU inpatient CAP, IDSA 2019 guidelines recommend empiric therapy with either a beta-lactam (e.g., ceftriaxone, ampicillin-sulbactam, or ertapenem) plus a macrolide (e.g., azithromycin), OR monotherapy with a respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin). This combination provides broad coverage for both typical and atypical pathogens. Macrolide or doxycycline monotherapy is generally insufficient for moderate to severe inpatient CAP.\",\n    \"highYieldPearl\": \"Inpatient CAP (non-ICU): Beta-lactam + Macrolide OR Respiratory Fluoroquinolone monotherapy. Ensure coverage for typicals and atypicals.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Monotherapy with macrolides or doxycycline is usually for outpatient or less severe cases. Beta-lactam plus aminoglycoside lacks atypical coverage, which is crucial for empiric CAP treatment.\"\n  },\n  {\n    \"question\": \"Which condition is a significant risk factor for *Pseudomonas aeruginosa* CAP?\",\n    \"options\": {\n      \"A\": \"Chronic obstructive pulmonary disease (COPD)\",\n      \"B\": \"Asthma\",\n      \"C\": \"Prior severe influenza\",\n      \"D\": \"Structural lung disease like bronchiectasis\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"While COPD is a general risk factor for CAP, structural lung diseases such as bronchiectasis, cystic fibrosis, and severe chronic obstructive pulmonary disease with frequent exacerbations are specifically associated with an increased risk of *Pseudomonas aeruginosa* CAP. Other risk factors include recent hospitalization, prior antibiotic use, and severe underlying immunocompromise. Recognizing these risk factors guides the choice of broader-spectrum antibiotics.\",\n    \"highYieldPearl\": \"Think *Pseudomonas* in CAP when there's structural lung disease (bronchiectasis, CF), recent hospitalization, or broad-spectrum antibiotic use.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"COPD is a common risk factor for CAP, but it doesn't specifically point to *Pseudomonas* unless it's severe with frequent exacerbations or associated with bronchiectasis. Asthma is generally not a risk factor for *Pseudomonas* CAP.\"\n  },\n  {\n    \"question\": \"Community-acquired pneumonia is defined as pneumonia acquired outside a hospital or within how many hours of admission?\",\n    \"options\": {\n      \"A\": \"12 hours\",\n      \"B\": \"24 hours\",\n      \"C\": \"36 hours\",\n      \"D\": \"48 hours\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"Community-acquired pneumonia (CAP) is defined as an acute infection of the lung parenchyma in a patient who has not been hospitalized or resided in a long-term care facility for 14 days or longer before presentation, or who develops symptoms of pneumonia within 48 hours of hospital admission. Pneumonia developing after 48 hours is typically classified as hospital-acquired pneumonia (HAP) or healthcare-associated pneumonia (HCAP, though this category is now less emphasized by IDSA 2016 guidelines).\",\n    \"highYieldPearl\": \"The 48-hour rule is critical for differentiating CAP from HAP/HCAP. Location of acquisition matters for pathogen prediction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This is a direct definition. The trap is misremembering the exact timeframe, as other timeframes (e.g., 24, 72 hours) are used in different medical contexts.\"\n  },\n  {\n    \"question\": \"For uncomplicated bacterial CAP, what is the minimum recommended duration of antibiotic therapy?\",\n    \"options\": {\n      \"A\": \"3 days\",\n      \"B\": \"5 days\",\n      \"C\": \"7 days\",\n      \"D\": \"10 days\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"Current guidelines (e.g., IDSA 2019) recommend a minimum of 5 days of antibiotic therapy for most uncomplicated bacterial CAP cases. Treatment can be discontinued once the patient has achieved clinical stability (afebrile for 48-72 hours, heart rate <100 bpm, respiratory rate <24 breaths/min, systolic blood pressure >90 mmHg, oxygen saturation >90% on room air, and ability to take oral intake) and has no more than one CAP-associated sign of instability.\",\n    \"highYieldPearl\": \"Minimum 5 days for CAP, but extend until clinically stable for 48-72 hours, not just reaching 5 days.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Older guidelines or general practice might suggest longer durations (7-10 days). However, evidence supports shorter courses (5 days) once clinical stability is achieved, reducing antibiotic exposure and resistance.\"\n  },\n  {\n    \"question\": \"Which parameter is NOT typically used to assess clinical stability for switching from IV to oral CAP antibiotics?\",\n    \"options\": {\n      \"A\": \"Temperature <37.8°C\",\n      \"B\": \"Heart rate <100 bpm\",\n      \"C\": \"Systolic BP >90 mmHg\",\n      \"D\": \"C-reactive protein <5 mg/dL\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cap\",\n    \"deepDiveExplanation\": \"Clinical stability for switching from IV to oral antibiotics in CAP is primarily assessed by objective clinical parameters, often referred to as the 'TIMI' criteria (Temperature, Immune status/Mental status, Intake, various vitals). Key criteria include: temperature <37.8°C, heart rate <100 bpm, respiratory rate <24 breaths/min, systolic blood pressure >90 mmHg, oxygen saturation >90% on room air, and ability to maintain oral intake and normal mental status. While C-reactive protein (CRP) is a marker of inflammation and can guide treatment duration in some settings, it is not a primary component of the standard clinical stability criteria for IV-to-oral switch in CAP.\",\n    \"highYieldPearl\": \"Clinical stability for IV-to-oral switch relies on vital signs and functional status, not typically inflammatory markers like CRP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"All options are physiological parameters. The trap is that CRP is a relevant biomarker in infection, but it's not part of the widely accepted clinical stability criteria for antibiotic de-escalation in CAP, which focus on vital signs and functional status. Many candidates might assume any marker of inflammation is relevant.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1178.10693359375}],"createTime":"2025-12-31T07:45:11.227455Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUaf_wDaaWgLUPhJyX8AE","usageMetadata":{"billablePromptUsage":{"textCount":1022},"candidatesTokenCount":3310,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3310}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":2501,"totalTokenCount":6174,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:51.05544+00:00"}
{"metadata":"one-liner|peep|PEEP and Lung Recruitment|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"PEEP and Lung Recruitment\".\nSet the \"topic\" field in the JSON to \"peep\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.39765137057598887,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary physiological effect of positive end-expiratory pressure (PEEP) on lung mechanics is to increase what?\",\n    \"options\": {\n      \"A\": \"Airway resistance\",\n      \"B\": \"Functional residual capacity\",\n      \"C\": \"Peak inspiratory pressure\",\n      \"D\": \"Dynamic compliance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"peep\",\n    \"deepDiveExplanation\": \"PEEP maintains alveolar patency at end-expiration, preventing collapse and increasing the volume of gas remaining in the lungs after a normal exhalation (Functional Residual Capacity). This improves oxygenation by increasing the surface area for gas exchange and reducing intrapulmonary shunting.\",\n    \"highYieldPearl\": \"PEEP primarily recruits collapsed alveoli and prevents derecruitment, thereby increasing FRC and improving V/Q matching.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A, C, D are incorrect. PEEP generally decreases airway resistance if it opens collapsed airways, but its primary effect is on volume. It can increase PIP if compliance is low, but that's not its primary effect on lung mechanics. It can decrease dynamic compliance if overdistension occurs, but its goal is to improve static compliance by recruiting.\"\n  },\n  {\n    \"question\": \"In acute respiratory distress syndrome (ARDS), optimal PEEP titration often aims to minimize which parameter?\",\n    \"options\": {\n      \"A\": \"Mean airway pressure\",\n      \"B\": \"Driving pressure\",\n      \"C\": \"Plateau pressure\",\n      \"D\": \"Peak inspiratory pressure\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"peep\",\n    \"deepDiveExplanation\": \"Driving pressure (Plateau Pressure - PEEP) is a surrogate for lung strain and has been strongly associated with mortality in ARDS. Titrating PEEP to minimize driving pressure, often while maintaining an acceptable SpO2, aims to achieve the best balance between alveolar recruitment and overdistension, indicating optimal lung mechanical stress.\",\n    \"highYieldPearl\": \"Minimizing driving pressure is a key strategy for lung-protective ventilation in ARDS, often achieved by careful PEEP titration.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While plateau pressure and mean airway pressure are important, driving pressure is the specific parameter that reflects the tidal stretch of the lung and is a strong predictor of outcome. Peak inspiratory pressure is less reliable due to resistance.\"\n  },\n  {\n    \"question\": \"A lung recruitment maneuver primarily aims to reverse which of the following pulmonary pathologies?\",\n    \"options\": {\n      \"A\": \"Bronchospasm\",\n      \"B\": \"Pulmonary edema\",\n      \"C\": \"Alveolar collapse\",\n      \"D\": \"Increased airway resistance\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"peep\",\n    \"deepDiveExplanation\": \"Lung recruitment maneuvers involve transiently increasing transpulmonary pressure to open collapsed, non-aerated lung units (atelectasis). This is particularly relevant in ARDS where significant alveolar collapse contributes to hypoxemia.\",\n    \"highYieldPearl\": \"Recruitment maneuvers are high-pressure, short-duration interventions designed to open up collapsed alveoli, but their overall benefit in ARDS is still debated and requires careful patient selection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While pulmonary edema might be present, the maneuver directly targets collapse. Bronchospasm and increased airway resistance are not directly reversed by recruitment maneuvers, though improved lung volume might indirectly affect resistance.\"\n  },\n  {\n    \"question\": \"Which of the following conditions is a relative contraindication to high levels of PEEP or lung recruitment?\",\n    \"options\": {\n      \"A\": \"Severe hypoxemia\",\n      \"B\": \"Acute severe asthma\",\n      \"C\": \"Obesity\",\n      \"D\": \"Unilateral lung injury\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"peep\",\n    \"deepDiveExplanation\": \"In acute severe asthma, patients often have dynamic hyperinflation and significant air trapping (auto-PEEP). High external PEEP can worsen hyperinflation, increase total PEEP, lead to barotrauma, and severely impair hemodynamics by increasing intrathoracic pressure and reducing venous return. While not an absolute contraindication, it requires extreme caution.\",\n    \"highYieldPearl\": \"Patients with obstructive lung diseases like severe asthma or COPD are prone to auto-PEEP; external PEEP must be used cautiously to avoid further hyperinflation and hemodynamic compromise.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Severe hypoxemia is an indication for PEEP. Obesity often benefits from higher PEEP due to increased chest wall weight. Unilateral lung injury requires careful PEEP management to avoid overdistending the healthy lung, but it's not a contraindication to PEEP itself. Severe asthma is a classic relative contraindication for high PEEP/recruitment.\"\n  },\n  {\n    \"question\": \"The most significant adverse hemodynamic effect of high PEEP levels is primarily due to a reduction in which parameter?\",\n    \"options\": {\n      \"A\": \"Systemic vascular resistance\",\n      \"B\": \"Myocardial contractility\",\n      \"C\": \"Venous return\",\n      \"D\": \"Pulmonary vascular resistance\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"peep\",\n    \"deepDiveExplanation\": \"High PEEP increases intrathoracic pressure, which impedes venous return to the right atrium by compressing the great veins and reducing the pressure gradient for blood flow from the periphery to the heart. This leads to a decrease in preload and subsequently, cardiac output.\",\n    \"highYieldPearl\": \"Always monitor hemodynamics (MAP, CVP, urine output) when applying moderate to high PEEP, especially in hypovolemic patients, as reduced venous return can lead to hypotension.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While PEEP can slightly affect myocardial contractility (often a decrease due to reduced preload rather than direct effect) and can increase pulmonary vascular resistance (if overdistension occurs), the primary mechanism for decreased cardiac output is reduced venous return. SVR is usually maintained or increased as a compensatory mechanism.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-573.015625}],"createTime":"2025-12-31T07:46:20.581102Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUae67I9yP3NoPpNSoQA","usageMetadata":{"billablePromptUsage":{"textCount":1017},"candidatesTokenCount":1441,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1441}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":2158,"totalTokenCount":3961,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:45.834414+00:00"}
{"metadata":"one-liner|tb_diagnosis|Pulmonary Tuberculosis - Diagnosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Tuberculosis - Diagnosis\".\nSet the \"topic\" field in the JSON to \"tb_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3404551760509255,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the definitive gold standard for diagnosing active pulmonary tuberculosis?\",\n    \"options\": {\n      \"A\": \"Sputum smear microscopy\",\n      \"B\": \"Chest X-ray\",\n      \"C\": \"Mycobacterial culture\",\n      \"D\": \"GeneXpert MTB/RIF\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Mycobacterial culture, particularly liquid culture systems like MGIT, remains the gold standard for diagnosing active tuberculosis. It allows for definitive identification of Mycobacterium tuberculosis complex and provides isolates for comprehensive drug susceptibility testing.\",\n    \"highYieldPearl\": \"Culture is essential for confirming diagnosis and performing phenotypic drug susceptibility testing, which is crucial for guiding appropriate treatment regimens, especially in drug-resistant cases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"GeneXpert MTB/RIF is a rapid molecular test but does not replace culture for definitive diagnosis and comprehensive drug susceptibility testing. Smear microscopy has low sensitivity, and chest X-ray is suggestive but not diagnostic.\"\n  },\n  {\n    \"question\": \"Which rapid molecular test simultaneously detects Mycobacterium tuberculosis and rifampicin resistance?\",\n    \"options\": {\n      \"A\": \"Line Probe Assay\",\n      \"B\": \"Truenat MTB\",\n      \"C\": \"GeneXpert MTB/RIF\",\n      \"D\": \"Loop-mediated isothermal amplification (LAMP)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"GeneXpert MTB/RIF is a fully automated, real-time PCR-based assay endorsed by WHO. It detects M. tuberculosis DNA and mutations associated with rifampicin resistance (primarily in the rpoB gene) directly from sputum samples, providing results within two hours.\",\n    \"highYieldPearl\": \"GeneXpert is a critical tool for rapid diagnosis of TB and early detection of rifampicin resistance, which is a surrogate marker for multidrug-resistant TB (MDR-TB).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Truenat MTB also detects MTB and rifampicin resistance but is a different platform. Line Probe Assay (LPA) requires a positive smear or culture and detects resistance to multiple drugs. LAMP is a different molecular amplification method.\"\n  },\n  {\n    \"question\": \"Which diagnostic test for latent tuberculosis infection is least affected by prior BCG vaccination?\",\n    \"options\": {\n      \"A\": \"Tuberculin Skin Test (TST)\",\n      \"B\": \"QuantiFERON-TB Gold Plus\",\n      \"C\": \"Mantoux test\",\n      \"D\": \"Chest X-ray\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Interferon-gamma release assays (IGRAs), such as QuantiFERON-TB Gold Plus, measure the T-cell immune response to M. tuberculosis-specific antigens (ESAT-6, CFP-10, TB7.7). These antigens are absent from the BCG vaccine strain and most non-tuberculous mycobacteria, making IGRAs less prone to false-positive results in BCG-vaccinated individuals compared to TST.\",\n    \"highYieldPearl\": \"IGRAs are the preferred method for diagnosing latent TB infection in populations with prior BCG vaccination or those who may have been exposed to non-tuberculous mycobacteria.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The Tuberculin Skin Test (TST), also known as the Mantoux test, uses PPD, which contains antigens shared with BCG and NTM, leading to cross-reactivity and false positives in vaccinated individuals. Chest X-ray is not a direct diagnostic test for LTBI.\"\n  },\n  {\n    \"question\": \"The main limitation of sputum smear microscopy for pulmonary TB diagnosis is its low:\",\n    \"options\": {\n      \"A\": \"Specificity\",\n      \"B\": \"Sensitivity\",\n      \"C\": \"Reproducibility\",\n      \"D\": \"Cost-effectiveness\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Sputum smear microscopy for acid-fast bacilli (AFB) has a low sensitivity, typically ranging from 20-60%, because it requires a high bacterial load (approximately 5,000-10,000 bacilli/mL of sputum) to be positive. This makes it less effective for diagnosing paucibacillary disease, extrapulmonary TB, or TB in immunocompromised patients.\",\n    \"highYieldPearl\": \"A negative sputum smear does not rule out active pulmonary tuberculosis, necessitating further diagnostic tests like culture or molecular assays.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Specificity is generally high in endemic areas (though NTM can cause false positives). Reproducibility is good with proper training. Cost-effectiveness is a strength, not a limitation.\"\n  },\n  {\n    \"question\": \"Elevated adenosine deaminase (ADA) levels are a useful diagnostic marker for tuberculosis in which body fluid?\",\n    \"options\": {\n      \"A\": \"Sputum\",\n      \"B\": \"Urine\",\n      \"C\": \"Pleural fluid\",\n      \"D\": \"Blood serum\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Adenosine deaminase (ADA) is an enzyme involved in purine metabolism, and its levels are elevated in conditions with high cellular turnover, particularly T-lymphocyte activity. In pleural fluid, an ADA level above a specific cutoff (typically 30-40 U/L, varying by region) is highly sensitive and specific for tuberculous pleurisy.\",\n    \"highYieldPearl\": \"Pleural fluid ADA is a rapid, inexpensive, and highly valuable test for the diagnosis of tuberculous pleurisy, especially in resource-limited settings.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While serum ADA can be elevated in disseminated TB, its diagnostic utility is lower due to poor specificity. Sputum and urine are not typically used for ADA testing in TB diagnosis.\"\n  },\n  {\n    \"question\": \"Which imaging modality provides the most detailed anatomical information for diagnosing subtle pulmonary tuberculosis lesions?\",\n    \"options\": {\n      \"A\": \"Standard Chest X-ray\",\n      \"B\": \"Fluoroscopy\",\n      \"C\": \"High-resolution CT scan of the chest\",\n      \"D\": \"Ultrasound\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"High-resolution computed tomography (HRCT) of the chest offers superior spatial resolution compared to plain chest radiography. It can detect subtle parenchymal changes such as centrilobular nodules, 'tree-in-bud' opacities, small cavitations, and bronchiectasis, which are often missed on conventional X-rays, aiding in the diagnosis of early or atypical pulmonary TB.\",\n    \"highYieldPearl\": \"HRCT is particularly useful in evaluating complex TB cases, suspected multi-drug resistant TB, or when differentiating TB from other lung pathologies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Chest X-ray is the initial screening tool but lacks the sensitivity for subtle lesions. Fluoroscopy and ultrasound have limited roles in detailed pulmonary parenchymal evaluation.\"\n  },\n  {\n    \"question\": \"Which molecular test can rapidly detect resistance to both rifampicin and isoniazid from a clinical specimen?\",\n    \"options\": {\n      \"A\": \"GeneXpert MTB/RIF\",\n      \"B\": \"Truenat MTB Plus\",\n      \"C\": \"Line Probe Assay (LPA)\",\n      \"D\": \"MGIT culture\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"First-line Line Probe Assays (e.g., GenoType MTBDRplus) are molecular tests that detect specific mutations in the *rpoB* gene (for rifampicin resistance) and the *katG* and *inhA* genes (for isoniazid resistance). They can be performed directly on smear-positive sputum samples or mycobacterial cultures, providing results within 1-2 days.\",\n    \"highYieldPearl\": \"LPAs are crucial for rapid identification of multidrug-resistant TB (MDR-TB), which is defined by resistance to at least rifampicin and isoniazid, allowing for prompt initiation of appropriate treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"GeneXpert MTB/RIF primarily detects rifampicin resistance. Truenat MTB Plus can detect RIF resistance. MGIT is a liquid culture system for growth and phenotypic DST, not a rapid molecular test for direct resistance detection.\"\n  },\n  {\n    \"question\": \"For paucibacillary tuberculosis, which diagnostic method offers the highest sensitivity?\",\n    \"options\": {\n      \"A\": \"AFB smear microscopy\",\n      \"B\": \"Liquid culture\",\n      \"C\": \"Chest X-ray\",\n      \"D\": \"Tuberculin skin test\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Liquid culture systems (e.g., MGIT, BACTEC) are significantly more sensitive than solid media cultures and smear microscopy for detecting Mycobacterium tuberculosis. They can detect very low bacterial loads (10-100 bacilli/mL), making them superior for diagnosing paucibacillary forms of TB, such as extrapulmonary TB or in immunocompromised patients where bacterial burden is often low.\",\n    \"highYieldPearl\": \"Always prioritize mycobacterial culture, especially liquid culture, when paucibacillary TB is suspected, even if smear microscopy results are negative.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"AFB smear microscopy has poor sensitivity for paucibacillary disease. Chest X-ray is an imaging tool, not a definitive diagnostic method. Tuberculin skin test detects latent infection, not active disease.\"\n  },\n  {\n    \"question\": \"The hallmark histological finding suggestive of tuberculosis in tissue biopsy is the presence of:\",\n    \"options\": {\n      \"A\": \"Neutrophilic abscesses\",\n      \"B\": \"Granulomas with caseous necrosis\",\n      \"C\": \"Lymphoid hyperplasia\",\n      \"D\": \"Fibrotic scars\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"The characteristic histopathological feature of tuberculosis is the formation of granulomas, which are organized collections of epithelioid macrophages, often surrounded by lymphocytes and fibroblasts. A key distinguishing feature, though not universally present, is central caseous necrosis, a 'cheese-like' amorphous material resulting from cellular destruction.\",\n    \"highYieldPearl\": \"Histopathological examination of tissue biopsies (e.g., lymph node, pleura, lung) is often crucial for diagnosing extrapulmonary tuberculosis and can guide further investigations like AFB staining or molecular tests on the tissue.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Neutrophilic abscesses are typical of acute bacterial infections. Lymphoid hyperplasia is a non-specific reaction. Fibrotic scars represent healing or chronic changes.\"\n  },\n  {\n    \"question\": \"Which WHO-endorsed molecular point-of-care test for TB diagnosis is designed for use in peripheral health facilities?\",\n    \"options\": {\n      \"A\": \"Line Probe Assay\",\n      \"B\": \"Xpert Ultra\",\n      \"C\": \"Truenat\",\n      \"D\": \"MGIT culture\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_diagnosis\",\n    \"deepDiveExplanation\": \"Truenat is a WHO-endorsed, chip-based, real-time micro PCR test system that detects Mycobacterium tuberculosis and rifampicin resistance. Its compact, portable, and battery-operated design makes it suitable for use in peripheral health facilities with minimal infrastructure, facilitating decentralized TB diagnosis.\",\n    \"highYieldPearl\": \"Truenat's portability and ease of use are key advantages for expanding rapid molecular diagnostics to underserved areas, improving access to early TB diagnosis and drug resistance detection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While Xpert Ultra is also WHO-endorsed and can be used at point-of-care, Truenat was specifically developed and highlighted for its adaptability to more basic, peripheral settings. LPA and MGIT require more sophisticated laboratory infrastructure.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-986.2986450195313}],"createTime":"2025-12-31T07:45:44.227899Z","modelVersion":"gemini-2.5-flash","responseId":"qNRUabv0DaHygLUPh5jXkAM","usageMetadata":{"billablePromptUsage":{"textCount":1035},"candidatesTokenCount":2897,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2897}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":2879,"totalTokenCount":6140,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:22.819866+00:00"}
{"metadata":"one-liner|rare_lung_tumors|Rare Primary Lung Tumors|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Rare Primary Lung Tumors\".\nSet the \"topic\" field in the JSON to \"rare_lung_tumors\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.6280723209585567,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The germline mutation most strongly associated with Pleuropulmonary Blastoma is?\",\n    \"options\": {\n      \"A\": \"EGFR\",\n      \"B\": \"ALK\",\n      \"C\": \"DICER1\",\n      \"D\": \"KRAS\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"rare_lung_tumors\",\n    \"deepDiveExplanation\": \"Pleuropulmonary Blastoma (PPB) is a rare, aggressive pediatric lung tumor. Approximately 70% of individuals with PPB have a germline mutation in the DICER1 gene, a ribonuclease III enzyme involved in microRNA processing. DICER1 syndrome is an inherited cancer predisposition syndrome characterized by an increased risk of developing various tumors, including PPB, ovarian Sertoli-Leydig cell tumors, cystic nephroma, thyroid nodules, and others.\",\n    \"highYieldPearl\": \"DICER1 mutation is the hallmark genetic alteration in Pleuropulmonary Blastoma and indicates a familial cancer predisposition syndrome.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EGFR, ALK, and KRAS are common oncogenic drivers in non-small cell lung carcinoma (NSCLC), making them plausible distractors for a lung tumor question. However, they are not associated with PPB, which is a distinct pediatric tumor.\"\n  },\n  {\n    \"question\": \"Pulmonary lymphoepithelioma-like carcinoma is strongly associated with which viral infection?\",\n    \"options\": {\n      \"A\": \"Human Papillomavirus (HPV)\",\n      \"B\": \"Epstein-Barr Virus (EBV)\",\n      \"C\": \"Cytomegalovirus (CMV)\",\n      \"D\": \"Human Immunodeficiency Virus (HIV)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"rare_lung_tumors\",\n    \"deepDiveExplanation\": \"Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung carcinoma that histologically resembles nasopharyngeal carcinoma. It is characterized by poorly differentiated epithelial cells admixed with a prominent lymphoplasmacytic infiltrate. A strong association with Epstein-Barr Virus (EBV) infection is observed, particularly in endemic regions (e.g., East Asia), where virtually all cases are EBV-positive. This association suggests a potential role for EBV in its pathogenesis.\",\n    \"highYieldPearl\": \"The strong association of Pulmonary LELC with EBV mirrors its nasopharyngeal counterpart, making EBV testing crucial in diagnosis and understanding its etiology.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other viruses listed are common and can be associated with various conditions or cancers, but EBV has a specific and well-established link to LELC, especially in the lung and nasopharynx, distinguishing it from other viral associations.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-410.1312255859375}],"createTime":"2025-12-31T07:45:55.680095Z","modelVersion":"gemini-2.5-flash","responseId":"s9RUaZ_BKZ-0gLUP9frpWA","usageMetadata":{"billablePromptUsage":{"textCount":1028},"candidatesTokenCount":653,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":653}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":1664,"totalTokenCount":2683,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:48:00.574656+00:00"}
{"metadata":"one-liner|tb_treatment|Pulmonary Tuberculosis - Treatment Regimens|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Tuberculosis - Treatment Regimens\".\nSet the \"topic\" field in the JSON to \"tb_treatment\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.337523488936979,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the typical duration of the intensive phase for drug-susceptible pulmonary tuberculosis?\",\n    \"options\": {\n      \"A\": \"1 month\",\n      \"B\": \"2 months\",\n      \"C\": \"3 months\",\n      \"D\": \"4 months\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"The standard regimen for drug-susceptible TB consists of an intensive phase (initial phase) and a continuation phase. The intensive phase typically lasts 2 months, during which four drugs (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol) are administered daily or thrice weekly.\",\n    \"highYieldPearl\": \"2 months for 4 drugs (HRZE) in the intensive phase of drug-susceptible TB treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options are numerical and close. Misremembering the phase or duration is the main trap. Some might confuse it with the total duration (6 months).\"\n  },\n  {\n    \"question\": \"The continuation phase for drug-susceptible pulmonary tuberculosis typically lasts how many months?\",\n    \"options\": {\n      \"A\": \"2\",\n      \"B\": \"3\",\n      \"C\": \"4\",\n      \"D\": \"6\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Following the 2-month intensive phase, the continuation phase for drug-susceptible TB typically lasts 4 months. During this phase, two drugs (Isoniazid and Rifampicin) are usually administered to complete the standard 6-month treatment.\",\n    \"highYieldPearl\": \"4 months for 2 drugs (HR) in the continuation phase of drug-susceptible TB treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Similar to the intensive phase question, numerical options can be confusing. Some might confuse it with the total duration (6 months) or the intensive phase duration (2 months).\"\n  },\n  {\n    \"question\": \"Which combination of drugs constitutes the intensive phase for drug-susceptible pulmonary tuberculosis?\",\n    \"options\": {\n      \"A\": \"Isoniazid, Rifampicin, Pyrazinamide, Ethambutol\",\n      \"B\": \"Isoniazid, Rifampicin, Ethambutol\",\n      \"C\": \"Isoniazid, Rifampicin, Pyrazinamide\",\n      \"D\": \"Isoniazid, Rifampicin\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"The standard intensive phase regimen for drug-susceptible TB includes four drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E). This is often abbreviated as HRZE.\",\n    \"highYieldPearl\": \"HRZE for 2 months is the standard intensive phase regimen for drug-susceptible TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options B, C, and D represent incomplete or incorrect combinations, testing precise recall of the standard four-drug regimen. Option D is the continuation phase drugs, a common distractor.\"\n  },\n  {\n    \"question\": \"Which drugs are typically used in the continuation phase for drug-susceptible pulmonary tuberculosis?\",\n    \"options\": {\n      \"A\": \"Isoniazid, Rifampicin, Pyrazinamide\",\n      \"B\": \"Isoniazid, Rifampicin, Ethambutol\",\n      \"C\": \"Isoniazid, Rifampicin\",\n      \"D\": \"Rifampicin, Pyrazinamide\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"The standard continuation phase regimen for drug-susceptible TB includes two drugs: Isoniazid (H) and Rifampicin (R). This is often abbreviated as HR and typically lasts for 4 months.\",\n    \"highYieldPearl\": \"HR for 4 months is the standard continuation phase regimen for drug-susceptible TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distractors include combinations from the intensive phase (A, B) or other incorrect pairings (D), testing specific knowledge of the two-drug continuation phase.\"\n  },\n  {\n    \"question\": \"Isoniazid exerts its bactericidal effect primarily by inhibiting the synthesis of what bacterial component?\",\n    \"options\": {\n      \"A\": \"Peptidoglycan\",\n      \"B\": \"Mycolic acid\",\n      \"C\": \"Folic acid\",\n      \"D\": \"DNA gyrase\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Isoniazid (INH) is a pro-drug activated by the mycobacterial catalase-peroxidase enzyme KatG. The activated form inhibits the synthesis of mycolic acid, a crucial component of the mycobacterial cell wall, leading to cell death.\",\n    \"highYieldPearl\": \"INH inhibits mycolic acid synthesis, a key component of the mycobacterial cell wall.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other options relate to mechanisms of action for other antibiotics (e.g., Peptidoglycan for beta-lactams, Folic acid for sulfonamides/trimethoprim, DNA gyrase for fluoroquinolones), making them plausible distractors if the specific mechanism for INH isn't known.\"\n  },\n  {\n    \"question\": \"Rifampicin's primary mechanism of action against Mycobacterium tuberculosis involves inhibiting which enzyme?\",\n    \"options\": {\n      \"A\": \"Mycolic acid synthase\",\n      \"B\": \"RNA polymerase\",\n      \"C\": \"DNA gyrase\",\n      \"D\": \"Dihydrofolate reductase\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Rifampicin binds to the beta-subunit of the DNA-dependent RNA polymerase (rpoB gene product) in Mycobacterium tuberculosis, thereby inhibiting bacterial RNA synthesis and leading to cell death.\",\n    \"highYieldPearl\": \"Rifampicin inhibits bacterial DNA-dependent RNA polymerase (rpoB gene).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Similar to the INH MOA question, other options relate to mechanisms of action for other antibiotics or other anti-TB drugs, requiring precise knowledge of Rifampicin's specific target.\"\n  },\n  {\n    \"question\": \"Which first-line anti-TB drug is generally contraindicated during pregnancy due to fetal ototoxicity?\",\n    \"options\": {\n      \"A\": \"Isoniazid\",\n      \"B\": \"Rifampicin\",\n      \"C\": \"Pyrazinamide\",\n      \"D\": \"Streptomycin\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Streptomycin, an aminoglycoside, is contraindicated in pregnancy due to its established ototoxic effects on the fetus, leading to congenital deafness. Isoniazid, Rifampicin, and Ethambutol are generally considered safe, and Pyrazinamide is also often used in drug-susceptible TB during pregnancy.\",\n    \"highYieldPearl\": \"Streptomycin (an aminoglycoside) is contraindicated in pregnancy due to fetal ototoxicity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Pyrazinamide might be considered a trap by some, as its use in pregnancy was historically debated more than the others, but Streptomycin has a clearer, stronger contraindication.\"\n  },\n  {\n    \"question\": \"What is the recommended total duration for drug-susceptible tuberculous meningitis treatment?\",\n    \"options\": {\n      \"A\": \"6 months\",\n      \"B\": \"9 months\",\n      \"C\": \"12 months\",\n      \"D\": \"18 months\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"For drug-susceptible tuberculous meningitis, the recommended total duration of treatment is typically longer than pulmonary TB, usually 9-12 months. Many guidelines, including WHO, recommend 9-12 months, with 12 months often preferred for optimal outcomes in CNS TB.\",\n    \"highYieldPearl\": \"TB meningitis treatment duration is 9-12 months, with 12 months often targeted.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"The 6-month option is a strong distractor, being the standard duration for pulmonary TB. 9 months is also a common recommendation, making 12 months the more extended, often preferred, optimal duration in some contexts.\"\n  },\n  {\n    \"question\": \"Which novel drug is a key component of shorter, all-oral regimens for multidrug-resistant tuberculosis (MDR-TB)?\",\n    \"options\": {\n      \"A\": \"Ethambutol\",\n      \"B\": \"Streptomycin\",\n      \"C\": \"Bedaquiline\",\n      \"D\": \"Cycloserine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Bedaquiline is a diarylquinoline, a novel anti-TB drug approved for MDR-TB. It is a cornerstone of newer, shorter, and all-oral regimens for MDR-TB, significantly improving treatment outcomes and reducing reliance on injectables.\",\n    \"highYieldPearl\": \"Bedaquiline is a novel, key drug for MDR-TB in shorter, all-oral regimens.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Ethambutol and Streptomycin are older, conventional drugs. Cycloserine is a second-line drug but not considered 'novel' in the same context as Bedaquiline.\"\n  },\n  {\n    \"question\": \"Which single drug regimen for 6-9 months is a standard option for treating latent tuberculosis infection?\",\n    \"options\": {\n      \"A\": \"Rifampicin\",\n      \"B\": \"Isoniazid\",\n      \"C\": \"Pyrazinamide\",\n      \"D\": \"Ethambutol\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_treatment\",\n    \"deepDiveExplanation\": \"Isoniazid monotherapy for 6 or 9 months (6H or 9H) is a classic and widely used regimen for treating latent tuberculosis infection (LTBI). Other regimens exist, such as 4 months of Rifampicin (4R) or 3 months of Isoniazid and Rifapentine (3HP), but 6H/9H remains a fundamental option.\",\n    \"highYieldPearl\": \"INH for 6 or 9 months (6H/9H) is a standard monotherapy for LTBI treatment.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Rifampicin (4R) is another common monotherapy for LTBI but typically for 4 months, not 6-9 months. Pyrazinamide and Ethambutol are not used as monotherapy for LTBI.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-890.7244873046875}],"createTime":"2025-12-31T07:45:26.781355Z","modelVersion":"gemini-2.5-flash","responseId":"ltRUaavYL9rThMIP1dG5yAs","usageMetadata":{"billablePromptUsage":{"textCount":1043},"candidatesTokenCount":2639,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2639}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":4094,"totalTokenCount":7099,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:19.074588+00:00"}
{"metadata":"one-liner|asthma_management|Asthma - Management and Step Therapy|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Asthma - Management and Step Therapy\".\nSet the \"topic\" field in the JSON to \"asthma_management\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.31288948333520683,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The preferred daily controller therapy for GINA Step 2 asthma in adults is?\",\n    \"options\": {\n      \"A\": \"SABA PRN\",\n      \"B\": \"Low-dose inhaled corticosteroid\",\n      \"C\": \"Oral corticosteroid\",\n      \"D\": \"Leukotriene modifier PRN\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"According to GINA guidelines, Step 2 asthma is characterized by symptoms occurring more than twice a month but less than daily. The preferred daily controller therapy for this step is a low-dose inhaled corticosteroid (ICS). While GINA 2023 also offers low-dose ICS-formoterol PRN as a preferred reliever for Step 1 and Step 2, a daily controller remains a cornerstone for persistent asthma.\",\n    \"highYieldPearl\": \"Low-dose ICS is the foundational controller for persistent asthma, starting from GINA Step 2.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Option A (SABA PRN) is for Step 1 (intermittent asthma) or as a reliever. Options C and D are not initial daily controllers for Step 2.\"\n  },\n  {\n    \"question\": \"Which drug class is the preferred reliever medication for all adult asthma severity levels according to GINA 2023?\",\n    \"options\": {\n      \"A\": \"SABA\",\n      \"B\": \"Inhaled Corticosteroid-Formoterol\",\n      \"C\": \"Oral Corticosteroid\",\n      \"D\": \"Tiotropium\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"GINA 2023 guidelines emphasize a 'preventer-reliever' approach. The preferred reliever for all adult asthma severity levels (Steps 1-5) is low-dose inhaled corticosteroid-formoterol PRN. This strategy ensures that even with reliever use, patients receive some anti-inflammatory benefit, reducing the risk of exacerbations compared to SABA monotherapy.\",\n    \"highYieldPearl\": \"GINA 2023 recommends low-dose ICS-formoterol as the preferred reliever for all asthma steps in adults, replacing SABA monotherapy in most cases.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"SABA (Option A) was historically the preferred reliever but is now considered less preferred due to its lack of anti-inflammatory action and potential for adverse outcomes with overuse. Options C and D are not primary reliever medications.\"\n  },\n  {\n    \"question\": \"The mechanism of action of Omalizumab in severe allergic asthma involves targeting which molecule?\",\n    \"options\": {\n      \"A\": \"IL-5\",\n      \"B\": \"IgE\",\n      \"C\": \"IL-4/IL-13\",\n      \"D\": \"TSLP\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Omalizumab is a humanized monoclonal antibody that selectively binds to free circulating immunoglobulin E (IgE), preventing it from binding to mast cells and basophils. This reduces the release of inflammatory mediators and is effective in severe allergic asthma.\",\n    \"highYieldPearl\": \"Omalizumab specifically targets IgE, making it suitable for severe allergic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other biologics target different pathways: Mepolizumab, Reslizumab, Benralizumab target IL-5 or its receptor (Option A). Dupilumab targets IL-4/IL-13 (Option C). Tezepelumab targets TSLP (Option D).\"\n  },\n  {\n    \"question\": \"Which biologic agent targets the IL-5 pathway for severe eosinophilic asthma?\",\n    \"options\": {\n      \"A\": \"Omalizumab\",\n      \"B\": \"Dupilumab\",\n      \"C\": \"Mepolizumab\",\n      \"D\": \"Tezepelumab\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Mepolizumab (anti-IL-5), Reslizumab (anti-IL-5), and Benralizumab (anti-IL-5R) are monoclonal antibodies specifically approved for severe eosinophilic asthma. They work by blocking the IL-5 cytokine or its receptor, thereby reducing eosinophil production and survival.\",\n    \"highYieldPearl\": \"Think 'Mepolizumab, Reslizumab, Benralizumab' for IL-5 targeting in eosinophilic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Omalizumab targets IgE. Dupilumab targets IL-4/IL-13. Tezepelumab targets TSLP. All are biologics for asthma but have different mechanisms.\"\n  },\n  {\n    \"question\": \"What is the critical threshold for SABA use frequency suggesting inadequate asthma control and need for step-up?\",\n    \"options\": {\n      \"A\": \"Less than 2 times/month\",\n      \"B\": \"More than 2 times/week\",\n      \"C\": \"More than 4 times/month\",\n      \"D\": \"Daily use\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"According to GINA guidelines, asthma is considered 'uncontrolled' if a patient experiences daytime symptoms more than twice a week, has any night waking due to asthma, requires reliever medication more than twice a week (excluding pre-exercise SABA), or has any activity limitation due to asthma. Frequent SABA use (>2 times/week) is a key indicator for stepping up controller therapy.\",\n    \"highYieldPearl\": \"SABA use >2 times/week indicates uncontrolled asthma and warrants a step-up in controller therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The 'more than twice a week' rule is a fundamental criterion for assessing asthma control and the need for adjustment in therapy. Other options are either too infrequent or too frequent to be the specific threshold for 'step-up'.\"\n  },\n  {\n    \"question\": \"Which medication class is primarily indicated as an add-on therapy for asthma patients with aspirin-exacerbated respiratory disease?\",\n    \"options\": {\n      \"A\": \"LABA\",\n      \"B\": \"LAMA\",\n      \"C\": \"LTRA\",\n      \"D\": \"Theophylline\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Leukotriene receptor antagonists (LTRAs) are particularly useful in patients with aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad. These patients have an overproduction of leukotrienes, which LTRAs effectively block, leading to symptom improvement.\",\n    \"highYieldPearl\": \"LTRAs are a specific add-on for AERD due to their anti-leukotriene effect.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"LABAs (long-acting beta-agonists), LAMAs (long-acting muscarinic antagonists), and Theophylline are general add-on therapies for asthma but do not have this specific indication for AERD.\"\n  },\n  {\n    \"question\": \"The primary indication for initiating maintenance oral corticosteroids in severe asthma is?\",\n    \"options\": {\n      \"A\": \"Frequent exacerbations despite high-dose ICS/LABA\",\n      \"B\": \"Eosinophilic phenotype\",\n      \"C\": \"Allergic rhinitis co-morbidity\",\n      \"D\": \"Patient preference\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Maintenance oral corticosteroids (OCS) are reserved for the most severe, uncontrolled asthma cases (GINA Step 5) where symptoms and exacerbations persist despite optimal high-dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) therapy, and often after trials of other add-on therapies like LAMAs or biologics. Chronic OCS use carries significant side effects, so it is a last resort.\",\n    \"highYieldPearl\": \"Maintenance OCS is a last-line therapy for severe asthma uncontrolled by all other options, due to significant side effects.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While an eosinophilic phenotype (Option B) might guide biologic choice, it's not the direct indication for maintenance OCS. Allergic rhinitis (Option C) is a comorbidity, not a reason for maintenance OCS. Patient preference (Option D) is never a primary clinical indication for such a potent medication.\"\n  },\n  {\n    \"question\": \"Which inhaled corticosteroid is typically combined with formoterol for GINA 'maintenance and reliever therapy' (MART)?\",\n    \"options\": {\n      \"A\": \"Budesonide\",\n      \"B\": \"Fluticasone\",\n      \"C\": \"Beclomethasone\",\n      \"D\": \"Ciclesonide\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Budesonide-formoterol is the classic and most extensively studied combination for Maintenance And Reliever Therapy (MART) in asthma. Formoterol's rapid onset of action makes it suitable for both maintenance and quick relief when combined with an ICS like budesonide.\",\n    \"highYieldPearl\": \"Budesonide-formoterol is the quintessential MART combination due to formoterol's rapid onset.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While fluticasone (Option B) is a common ICS, it is typically combined with slower-onset LABAs like salmeterol or vilanterol, not formoterol for MART. Beclomethasone and Ciclesonide are also ICS but not typically used in MART combinations with formoterol.\"\n  },\n  {\n    \"question\": \"The recommended strategy for stepping down asthma treatment after at least three months of good control is?\",\n    \"options\": {\n      \"A\": \"Abruptly stop all medications\",\n      \"B\": \"Reduce ICS dose by 25-50%\",\n      \"C\": \"Increase SABA use\",\n      \"D\": \"Discontinue LABA first\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Once asthma is well-controlled for at least 3 months, a step-down approach should be considered to find the minimum effective dose. The recommended strategy is to gradually reduce the inhaled corticosteroid (ICS) dose by 25-50% at 3-month intervals, while continuing to monitor control. Abrupt cessation or discontinuing LABA first (without adjusting ICS) is not recommended.\",\n    \"highYieldPearl\": \"Step down asthma therapy gradually by reducing the ICS dose after 3 months of good control.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A and D are potentially dangerous as they can lead to loss of control or exacerbations. Option C (increasing SABA use) is the opposite of stepping down controller therapy.\"\n  },\n  {\n    \"question\": \"Which anticholinergic agent is approved as an add-on therapy for severe asthma in adults?\",\n    \"options\": {\n      \"A\": \"Ipratropium bromide\",\n      \"B\": \"Tiotropium bromide\",\n      \"C\": \"Glycopyrronium\",\n      \"D\": \"Aclidinium\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_management\",\n    \"deepDiveExplanation\": \"Tiotropium bromide, a long-acting muscarinic antagonist (LAMA), is approved as an add-on therapy for severe asthma in adults and adolescents (≥12 years) who remain symptomatic despite high-dose ICS/LABA. It provides additional bronchodilation and may reduce exacerbations.\",\n    \"highYieldPearl\": \"Tiotropium is the specific LAMA approved for add-on therapy in severe asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Ipratropium bromide (Option A) is a short-acting anticholinergic for acute relief. Glycopyrronium and Aclidinium (Options C and D) are also LAMAs but are primarily approved for COPD, not severe asthma in this context.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-913.3244018554688}],"createTime":"2025-12-31T07:45:12.309404Z","modelVersion":"gemini-2.5-flash","responseId":"iNRUaZzxEs6RhMIPz6CV4Q8","usageMetadata":{"billablePromptUsage":{"textCount":1040},"candidatesTokenCount":2919,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2919}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1900,"totalTokenCount":5186,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:03.549972+00:00"}
{"metadata":"one-liner|cteph|Chronic Thromboembolic PH (CTEPH)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Chronic Thromboembolic PH (CTEPH)\".\nSet the \"topic\" field in the JSON to \"cteph\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3972483863967294,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the gold standard diagnostic test for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)?\",\n    \"options\": {\n      \"A\": \"Ventilation-Perfusion Scan\",\n      \"B\": \"CT Pulmonary Angiography\",\n      \"C\": \"Right Heart Catheterization\",\n      \"D\": \"Conventional Pulmonary Angiography\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cteph\",\n    \"deepDiveExplanation\": \"Conventional pulmonary angiography provides the highest resolution imaging of the pulmonary arterial tree, allowing direct visualization of organized thrombi, webs, bands, and stenoses characteristic of CTEPH, which is crucial for surgical planning. While V/Q scan screens, CTPA can show thrombi, and RHC confirms PH, none are the 'gold standard' for definitive diagnosis and operability assessment like conventional angiography.\",\n    \"highYieldPearl\": \"Conventional pulmonary angiography is essential for confirming the diagnosis of CTEPH and assessing the extent and accessibility of the disease for pulmonary endarterectomy (PEA).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse the screening test (V/Q scan) or the general PH diagnostic test (RHC) with the definitive CTEPH diagnostic and operability assessment tool.\"\n  },\n  {\n    \"question\": \"The definitive curative treatment for surgically accessible Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is?\",\n    \"options\": {\n      \"A\": \"Riociguat\",\n      \"B\": \"Balloon Pulmonary Angioplasty\",\n      \"C\": \"Pulmonary Endarterectomy\",\n      \"D\": \"Lung Transplantation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cteph\",\n    \"deepDiveExplanation\": \"Pulmonary Endarterectomy (PEA) is the only potentially curative treatment for CTEPH. It involves surgical removal of organized thrombi and fibrotic material from the pulmonary arteries. It is reserved for patients with surgically accessible disease and is performed by highly specialized centers.\",\n    \"highYieldPearl\": \"PEA is the gold standard treatment for operable CTEPH, offering significant hemodynamic and symptomatic improvement, and often a cure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might consider other options like Riociguat (medical therapy) or BPA (for inoperable/residual disease) as definitive treatments, but PEA stands out for its curative potential in operable cases.\"\n  },\n  {\n    \"question\": \"Which medication is specifically approved for inoperable or persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension?\",\n    \"options\": {\n      \"A\": \"Sildenafil\",\n      \"B\": \"Bosentan\",\n      \"C\": \"Riociguat\",\n      \"D\": \"Treprostinil\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cteph\",\n    \"deepDiveExplanation\": \"Riociguat, a soluble guanylate cyclase stimulator, is the only medication specifically approved for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy. While other PH-specific therapies (like sildenafil, bosentan, treprostinil) might be used off-label, Riociguat has specific approval.\",\n    \"highYieldPearl\": \"Riociguat is the first and only drug specifically approved for CTEPH patients who are not candidates for PEA or have persistent/recurrent PH after surgery.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All listed options are PH-specific drugs. The key is 'specifically approved' for CTEPH, which points to Riociguat due to its unique mechanism and trial data in this specific population.\"\n  },\n  {\n    \"question\": \"The primary cause of persistent obstruction in Chronic Thromboembolic Pulmonary Hypertension is organized thrombi in which vessels?\",\n    \"options\": {\n      \"A\": \"Pulmonary arterioles\",\n      \"B\": \"Pulmonary capillaries\",\n      \"C\": \"Distal pulmonary arteries\",\n      \"D\": \"Proximal pulmonary arteries\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"cteph\",\n    \"deepDiveExplanation\": \"CTEPH is characterized by the failure of acute pulmonary emboli to resolve, leading to organization and fibrosis of thrombi within the proximal pulmonary arteries. This chronic obstruction then leads to increased pulmonary vascular resistance and subsequent microvascular remodeling in the distal pulmonary circulation.\",\n    \"highYieldPearl\": \"The hallmark of CTEPH is organized, fibrotic thrombi in the elastic pulmonary arteries (proximal), unlike other forms of PH primarily affecting arterioles.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might be misled by the 'microvascular remodeling' aspect of PH, but the initiating and primary obstructive lesion in CTEPH is the organized thrombus in the larger, more proximal pulmonary arteries.\"\n  },\n  {\n    \"question\": \"What is the recommended initial screening investigation for suspected Chronic Thromboembolic Pulmonary Hypertension?\",\n    \"options\": {\n      \"A\": \"Echocardiography\",\n      \"B\": \"CT Pulmonary Angiography\",\n      \"C\": \"Ventilation-Perfusion Scan\",\n      \"D\": \"Right Heart Catheterization\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cteph\",\n    \"deepDiveExplanation\": \"A Ventilation-Perfusion (V/Q) scan is the most sensitive and recommended initial screening test for CTEPH. A normal V/Q scan essentially rules out CTEPH (high negative predictive value). While echocardiography can suggest PH, and CTPA can show thrombi, V/Q scan's high sensitivity for perfusion defects makes it ideal for screening.\",\n    \"highYieldPearl\": \"A normal V/Q scan makes CTEPH highly unlikely; it is the most sensitive screening test for CTEPH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse the initial 'screening' test with definitive diagnostic tests (like RHC or conventional angiography) or other imaging modalities.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-554.1614990234375}],"createTime":"2025-12-31T07:46:20.621615Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUaa_4JYr8hMIPqeOUsAk","usageMetadata":{"billablePromptUsage":{"textCount":1026},"candidatesTokenCount":1395,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1395}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1218,"totalTokenCount":2980,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:44.934904+00:00"}
{"metadata":"one-liner|asthma_severe|Severe and Uncontrolled Asthma|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Severe and Uncontrolled Asthma\".\nSet the \"topic\" field in the JSON to \"asthma_severe\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.31128639543853387,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"According to GINA, severe asthma requires high-dose inhaled corticosteroids plus a second controller and remains uncontrolled for at least how long?\",\n    \"options\": {\n      \"A\": \"3 months\",\n      \"B\": \"6 months\",\n      \"C\": \"12 months\",\n      \"D\": \"1 month\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"GINA defines severe asthma as asthma that requires treatment with high-dose inhaled corticosteroids (ICS) and a second controller (and/or systemic corticosteroids) to prevent it from becoming 'uncontrolled' or that remains 'uncontrolled' despite this therapy. The GINA criteria specify that this state must persist for at least 6 months of treatment, or if the asthma requires systemic corticosteroids to remain controlled.\",\n    \"highYieldPearl\": \"The GINA definition of severe asthma involves uncontrolled symptoms OR frequent severe exacerbations despite optimal high-dose ICS/LABA for 6 months, or requiring systemic corticosteroids.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing between controlled and uncontrolled asthma, and the specific duration (6 months) for severe asthma classification, are common points of confusion.\"\n  },\n  {\n    \"question\": \"Which biomarker is most directly indicative of Type 2 inflammation and helps guide anti-IL-5/IL-5R biologic therapy in severe asthma?\",\n    \"options\": {\n      \"A\": \"Serum IgE levels\",\n      \"B\": \"Sputum eosinophil percentage\",\n      \"C\": \"FeNO levels\",\n      \"D\": \"Blood neutrophil count\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Sputum eosinophil percentage is a direct and highly specific measure of airway eosinophilic inflammation, a hallmark of Type 2 asthma. High sputum eosinophils (e.g., >3%) strongly predict response to anti-IL-5 (mepolizumab, reslizumab) and anti-IL-5R (benralizumab) therapies. While FeNO is also a Type 2 biomarker, sputum eosinophils are often considered more directly linked to the IL-5 pathway.\",\n    \"highYieldPearl\": \"Sputum eosinophils are a critical biomarker for identifying eosinophilic severe asthma and guiding anti-IL-5/IL-5R biologic selection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing FeNO (fractional exhaled nitric oxide), which is also a Type 2 biomarker, with sputum eosinophils. Both are Type 2, but sputum eosinophils are a direct measure of the cellular inflammation targeted by anti-IL-5 therapies.\"\n  },\n  {\n    \"question\": \"Omalizumab exerts its therapeutic effect in severe allergic asthma by targeting and neutralizing which specific molecule?\",\n    \"options\": {\n      \"A\": \"Interleukin-5\",\n      \"B\": \"Free IgE\",\n      \"C\": \"Interleukin-4\",\n      \"D\": \"TSLP\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Omalizumab is a humanized monoclonal antibody that selectively binds to free IgE in the bloodstream and interstitial fluid, preventing its binding to high-affinity IgE receptors (FcεRI) on mast cells and basophils. This reduces mediator release upon allergen exposure, thereby decreasing allergic inflammation.\",\n    \"highYieldPearl\": \"Omalizumab specifically targets and sequesters free IgE, reducing allergic cascade activation in severe allergic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misidentifying Omalizumab's target (IgE) with other biologics' targets (IL-5, IL-4/13, TSLP), which are common distractors for biologic MOA questions.\"\n  },\n  {\n    \"question\": \"Bronchial thermoplasty is indicated for severe persistent asthma patients, specifically targeting which airway component to reduce bronchoconstriction?\",\n    \"options\": {\n      \"A\": \"Airway mucus glands\",\n      \"B\": \"Bronchial smooth muscle\",\n      \"C\": \"Submucosal edema\",\n      \"D\": \"Airway goblet cells\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Bronchial thermoplasty is a non-pharmacological treatment for severe asthma that uses controlled thermal energy to reduce the amount of smooth muscle in the airways. This reduction in smooth muscle mass is thought to reduce the ability of the airways to constrict, leading to fewer severe exacerbations and improved asthma control.\",\n    \"highYieldPearl\": \"Bronchial thermoplasty reduces airway smooth muscle mass, thereby decreasing the airways' capacity for bronchoconstriction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Incorrectly associating bronchial thermoplasty with other airway structures or functions (e.g., mucus production, edema) rather than its specific target of smooth muscle.\"\n  },\n  {\n    \"question\": \"Dupilumab is a biologic therapy for severe Type 2 asthma that inhibits signaling of which two crucial interleukins?\",\n    \"options\": {\n      \"A\": \"IL-4 and IL-5\",\n      \"B\": \"IL-5 and IL-13\",\n      \"C\": \"IL-4 and IL-13\",\n      \"D\": \"IL-13 and TSLP\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Dupilumab is a human monoclonal antibody that blocks the shared alpha subunit of the IL-4 receptor (IL-4Rα), thereby inhibiting signaling from both IL-4 and IL-13. These cytokines are central to Type 2 inflammation, driving IgE synthesis, eosinophil recruitment, and mucus production.\",\n    \"highYieldPearl\": \"Dupilumab blocks both IL-4 and IL-13 signaling via IL-4Rα, addressing a broad spectrum of Type 2 inflammation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Misidentifying the specific interleukins blocked by Dupilumab, especially confusing it with biologics that target IL-5 or TSLP.\"\n  },\n  {\n    \"question\": \"What is the most common reversible cause for seemingly 'uncontrolled' severe asthma despite high-dose controller therapy?\",\n    \"options\": {\n      \"A\": \"Co-morbidities\",\n      \"B\": \"Poor adherence\",\n      \"C\": \"Incorrect diagnosis\",\n      \"D\": \"Environmental triggers\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Poor adherence to prescribed inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) therapy, along with incorrect inhaler technique, is the single most common reason why asthma remains uncontrolled. Before escalating therapy or diagnosing true severe refractory asthma, adherence and inhaler technique must be thoroughly assessed.\",\n    \"highYieldPearl\": \"Always rule out poor adherence and incorrect inhaler technique before labeling asthma as truly 'severe' or 'uncontrolled' and escalating therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Overlooking adherence and inhaler technique in favor of more complex medical causes or comorbidities, which should be investigated only after these primary issues are ruled out.\"\n  },\n  {\n    \"question\": \"Chronic daily or alternate-day systemic corticosteroid use for severe asthma is associated with increased risk of which long-term complication?\",\n    \"options\": {\n      \"A\": \"Hypoglycemia\",\n      \"B\": \"Osteoporosis\",\n      \"C\": \"Hyperkalemia\",\n      \"D\": \"Hypotension\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Long-term systemic corticosteroid use is associated with numerous adverse effects, including osteoporosis, adrenal suppression, cataracts, glaucoma, weight gain, increased risk of infection, and metabolic disturbances. Osteoporosis is a particularly common and debilitating complication.\",\n    \"highYieldPearl\": \"Minimize systemic corticosteroid duration and dose due to significant long-term side effects, with osteoporosis being a major concern.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options that are acute side effects of corticosteroids or less common long-term complications, rather than the well-established chronic risks.\"\n  },\n  {\n    \"question\": \"Which recently approved biologic for severe asthma targets thymic stromal lymphopoietin (TSLP), an upstream cytokine in Type 2 inflammation?\",\n    \"options\": {\n      \"A\": \"Mepolizumab\",\n      \"B\": \"Benralizumab\",\n      \"C\": \"Tezepelumab\",\n      \"D\": \"Reslizumab\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Tezepelumab is a human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine that is considered an 'alarmin' and acts upstream in the Type 2 inflammatory cascade. By blocking TSLP, tezepelumab inhibits multiple downstream inflammatory pathways, making it effective across various severe asthma phenotypes, including those with low eosinophil counts.\",\n    \"highYieldPearl\": \"Tezepelumab targets TSLP, an upstream cytokine, making it effective across a broad range of severe asthma phenotypes, including non-eosinophilic.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing Tezepelumab with other biologics that target downstream cytokines (IL-5, IL-4/13) instead of the upstream TSLP.\"\n  },\n  {\n    \"question\": \"Which non-biologic, immunomodulatory agent is sometimes used as a steroid-sparing agent in severe asthma, though with limited evidence?\",\n    \"options\": {\n      \"A\": \"Azithromycin\",\n      \"B\": \"Methotrexate\",\n      \"C\": \"Montelukast\",\n      \"D\": \"Theophylline\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Methotrexate has been explored as a steroid-sparing agent in severe asthma due to its anti-inflammatory and immunosuppressive properties. While some studies suggest a modest steroid-sparing effect, its use is limited by potential side effects and the availability of more effective biologics. Azithromycin also has immunomodulatory effects and is used, but methotrexate is classically known as an immunomodulatory steroid-sparing agent.\",\n    \"highYieldPearl\": \"Methotrexate can be a steroid-sparing option in severe asthma, but its efficacy is modest compared to biologics, and it carries side effect risks.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Including other medications that are not primarily immunomodulatory steroid-sparing agents in the same context (e.g., Montelukast is a leukotriene modifier, Theophylline is a bronchodilator). Azithromycin is also immunomodulatory but often considered for different phenotypes (non-T2).\"\n  },\n  {\n    \"question\": \"High peripheral blood eosinophil count (e.g., >300 cells/µL) in severe asthma primarily indicates suitability for which class of biologic agents?\",\n    \"options\": {\n      \"A\": \"Anti-IgE\",\n      \"B\": \"Anti-TSLP\",\n      \"C\": \"Anti-IL-5/IL-5R\",\n      \"D\": \"Anti-IL-4/IL-13\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_severe\",\n    \"deepDiveExplanation\": \"Elevated peripheral blood eosinophil counts are a key biomarker for eosinophilic asthma, a Type 2 inflammatory phenotype. Anti-IL-5 (mepolizumab, reslizumab) and anti-IL-5R (benralizumab) therapies directly target the IL-5 pathway, which is crucial for eosinophil development, survival, and recruitment. Therefore, high eosinophil counts strongly predict a positive response to these agents.\",\n    \"highYieldPearl\": \"High peripheral eosinophils are a strong indicator for selecting anti-IL-5/IL-5R biologics in severe eosinophilic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing the specific eosinophil-targeting biologics with those targeting IgE, TSLP, or IL-4/IL-13, which are indicated for different aspects or broader Type 2 inflammation.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-912.6917114257813}],"createTime":"2025-12-31T07:46:21.399309Z","modelVersion":"gemini-2.5-flash","responseId":"zdRUac2vGN3DgLUPqfGtgAE","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":2932,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2932}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":3059,"totalTokenCount":6356,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:10.139274+00:00"}
{"metadata":"one-liner|malignant_effusion|Malignant Pleural Effusion|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Malignant Pleural Effusion\".\nSet the \"topic\" field in the JSON to \"malignant_effusion\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4766175639149574,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The highest diagnostic yield for malignant pleural effusion is achieved by:\",\n    \"options\": {\n      \"A\": \"Pleural fluid cytology\",\n      \"B\": \"Pleural fluid tumor markers\",\n      \"C\": \"Medical thoracoscopy with biopsy\",\n      \"D\": \"CT-guided pleural biopsy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"malignant_effusion\",\n    \"deepDiveExplanation\": \"Medical thoracoscopy (pleuroscopy) with targeted biopsy offers the highest diagnostic yield for malignant pleural effusion, often exceeding 90-95%, especially in cases where initial pleural fluid cytology is negative. It allows direct visualization of the pleural surfaces and targeted biopsies of suspicious lesions. While cytology is often the first step, its sensitivity varies (around 60-70%) and can be lower for certain malignancies.\",\n    \"highYieldPearl\": \"For undiagnosed exudative effusions with negative cytology, medical thoracoscopy is the preferred next diagnostic step due to its superior diagnostic yield.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A (cytology) is the initial test but has lower sensitivity. Option D (CT-guided biopsy) is more invasive and less comprehensive than thoracoscopy for pleural lesions. Thoracoscopy allows for broader sampling and visual assessment.\"\n  },\n  {\n    \"question\": \"Among the following, the most effective pleurodesis agent for malignant pleural effusion is:\",\n    \"options\": {\n      \"A\": \"Doxycycline slurry\",\n      \"B\": \"Bleomycin\",\n      \"C\": \"Talc slurry\",\n      \"D\": \"Povidone-iodine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"malignant_effusion\",\n    \"deepDiveExplanation\": \"Talc slurry is widely considered the most effective and cost-efficient agent for pleurodesis in malignant pleural effusion, with success rates typically ranging from 70-90%. It induces inflammation and fibrosis, leading to fusion of the visceral and parietal pleura. Doxycycline, bleomycin, and povidone-iodine are alternative agents but generally have lower efficacy or higher costs compared to talc.\",\n    \"highYieldPearl\": \"Talc pleurodesis, either as a slurry or poudrage, remains the gold standard for chemical pleurodesis due to its high efficacy and cost-effectiveness.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options are pleurodesis agents, but talc consistently shows superior efficacy in clinical trials and meta-analyses. Choosing any other agent would be incorrect as 'most effective' is specified.\"\n  },\n  {\n    \"question\": \"Absolute contraindication for talc pleurodesis in malignant pleural effusion is:\",\n    \"options\": {\n      \"A\": \"Bilateral pleural effusions\",\n      \"B\": \"Prior pleurodesis attempt\",\n      \"C\": \"Trapped lung\",\n      \"D\": \"Poor performance status\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"malignant_effusion\",\n    \"deepDiveExplanation\": \"Talc pleurodesis works by inducing inflammation and fibrosis that causes the visceral and parietal pleura to adhere. For this to be successful, the lung must be able to fully re-expand and appose the chest wall. A 'trapped lung' (non-expandable lung) prevents this apposition, rendering pleurodesis ineffective and potentially harmful. Other options like bilateral effusions or poor performance status might influence the decision for pleurodesis versus other management (e.g., IPC), but they are not absolute contraindications to the procedure itself if lung re-expansion is possible.\",\n    \"highYieldPearl\": \"Successful pleurodesis hinges on complete lung re-expansion; a trapped lung makes it impossible and is an absolute contraindication.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, D are relative considerations or challenges, but not absolute contraindications. A trapped lung means the fundamental mechanism of pleurodesis cannot occur, making it futile and potentially leading to complications without benefit.\"\n  },\n  {\n    \"question\": \"The primary mechanism for fluid accumulation in malignant pleural effusion is often:\",\n    \"options\": {\n      \"A\": \"Increased hydrostatic pressure\",\n      \"B\": \"Decreased oncotic pressure\",\n      \"C\": \"Impaired lymphatic drainage\",\n      \"D\": \"Increased capillary permeability\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"malignant_effusion\",\n    \"deepDiveExplanation\": \"While multiple factors can contribute, the most common and significant mechanism in malignant pleural effusion is impaired lymphatic drainage. Tumor cells can obstruct the lymphatic stomata on the parietal pleura or metastasize to mediastinal lymph nodes, blocking the normal outflow of pleural fluid. Increased capillary permeability (due to inflammation) and increased hydrostatic pressure (due to venous obstruction) can also play a role, but lymphatic obstruction is paramount.\",\n    \"highYieldPearl\": \"Think lymphatic obstruction as the cardinal mechanism behind MPE formation due to tumor involvement of lymphatic pathways.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, D are mechanisms seen in other types of effusions (e.g., heart failure, hypoalbuminemia, inflammation), and can contribute to MPE, but lymphatic obstruction is the most specific and often primary driver in malignancy.\"\n  },\n  {\n    \"question\": \"Which of the following is typically associated with a *low* pleural fluid Adenosine Deaminase (ADA) level?\",\n    \"options\": {\n      \"A\": \"Tuberculous pleurisy\",\n      \"B\": \"Malignant pleural effusion\",\n      \"C\": \"Empyema\",\n      \"D\": \"Rheumatoid pleurisy\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"malignant_effusion\",\n    \"deepDiveExplanation\": \"Adenosine Deaminase (ADA) is an enzyme primarily released by lymphocytes. High pleural fluid ADA levels (typically >40-60 U/L) are highly suggestive of tuberculous pleurisy, which is characterized by a robust lymphocytic response. Empyema and parapneumonic effusions can also have elevated ADA due to inflammation and neutrophil activity, though usually not as high as TB. Malignant pleural effusions, while sometimes having mildly elevated ADA, are generally associated with lower ADA levels compared to infectious causes, making a low ADA value helpful in 'ruling out' TB or 'ruling in' MPE in the differential diagnosis.\",\n    \"highYieldPearl\": \"A very low pleural fluid ADA (<10-20 U/L) makes tuberculous pleurisy highly unlikely, shifting the focus towards other causes like malignancy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and C are classic causes of *high* ADA. Option D can have variable ADA but is not typically considered 'low' compared to MPE. The key is understanding that MPE usually does not elicit the strong lymphocytic response that significantly elevates ADA, unlike TB.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-769.7373657226563}],"createTime":"2025-12-31T07:45:11.232793Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUadmaDpmhlu8PsO_m0QM","usageMetadata":{"billablePromptUsage":{"textCount":1033},"candidatesTokenCount":1615,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1615}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":1687,"totalTokenCount":3669,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:50.025084+00:00"}
{"metadata":"one-liner|pleural_procedures|Pleural Procedures (Thoracentesis, Chest Tube)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Pleural Procedures (Thoracentesis, Chest Tube)\".\nSet the \"topic\" field in the JSON to \"pleural_procedures\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4069982428299753,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which is considered an absolute contraindication for urgent therapeutic thoracentesis?\",\n    \"options\": {\n      \"A\": \"INR of 2.5\",\n      \"B\": \"Platelet count of 40,000/µL\",\n      \"C\": \"Uncooperative patient\",\n      \"D\": \"Small, loculated effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_procedures\",\n    \"deepDiveExplanation\": \"While coagulopathy (INR >1.5-2, platelets <50,000) and small/loculated effusions are relative contraindications requiring careful consideration, correction of coagulopathy, or image guidance, an uncooperative patient poses a significant risk for procedural complications like lung laceration or pneumothorax and is often considered an absolute contraindication, especially for urgent therapeutic procedures where patient cooperation is crucial for safety.\",\n    \"highYieldPearl\": \"Absolute contraindications for thoracentesis are rare but include an uncooperative patient and skin infection at the insertion site. Coagulopathy and small effusions are relative contraindications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in identifying the *absolute* contraindication among commonly cited relative contraindications. Coagulopathy is a frequent distractor, but often can be corrected or managed with imaging guidance. Patient cooperation is paramount for safe execution of the procedure.\"\n  },\n  {\n    \"question\": \"The most frequently encountered complication following thoracentesis is?\",\n    \"options\": {\n      \"A\": \"Pneumothorax\",\n      \"B\": \"Hemothorax\",\n      \"C\": \"Re-expansion pulmonary edema\",\n      \"D\": \"Infection\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"pleural_procedures\",\n    \"deepDiveExplanation\": \"Pneumothorax is the most common complication of thoracentesis, with rates varying depending on operator experience and use of ultrasound guidance (typically 2-10%). It usually occurs due to lung puncture. Other complications like hemothorax, re-expansion pulmonary edema, and infection are less common.\",\n    \"highYieldPearl\": \"Always consider pneumothorax post-thoracentesis; a chest X-ray is often performed to rule it out, especially if symptoms arise.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options are known complications of thoracentesis, but the question specifically asks for the *most frequently encountered*. Students might be tempted by re-expansion pulmonary edema due to its severity, but it's less common than pneumothorax.\"\n  },\n  {\n    \"question\": \"Optimal chest tube removal criteria for a resolving pneumothorax include air leak cessation and lung re-expansion, confirmed by?\",\n    \"options\": {\n      \"A\": \"Daily Chest X-ray\",\n      \"B\": \"CT Thorax\",\n      \"C\": \"Water seal trial for 24 hours\",\n      \"D\": \"Direct visualization during thoracoscopy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_procedures\",\n    \"deepDiveExplanation\": \"For a pneumothorax, chest tube removal is typically considered when the air leak has ceased (often demonstrated by placing the chest tube to water seal for 12-24 hours without recurrence of bubbling) and the lung is fully re-expanded on chest X-ray. A water seal trial confirms the absence of a persistent air leak under physiological conditions before removal.\",\n    \"highYieldPearl\": \"A successful water seal trial is critical before chest tube removal for pneumothorax, confirming no ongoing air leak and allowing lung expansion.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While daily chest X-rays confirm lung re-expansion, they do not definitively confirm the absence of an air leak under normal physiological conditions. A water seal trial is specifically designed to assess for air leak cessation prior to removal.\"\n  },\n  {\n    \"question\": \"What is the gold standard for immediate confirmation of a correctly placed pleural chest tube?\",\n    \"options\": {\n      \"A\": \"Auscultation of breath sounds\",\n      \"B\": \"Chest X-ray\",\n      \"C\": \"CT Thorax\",\n      \"D\": \"Ultrasound\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pleural_procedures\",\n    \"deepDiveExplanation\": \"Immediately following chest tube insertion, a post-procedure chest X-ray is the standard and most widely accepted method to confirm proper placement within the pleural space, assess lung re-expansion, and rule out complications like pneumothorax or misplacement. While auscultation and ultrasound can provide clues, they are not definitive. CT Thorax offers more detail but is not the immediate, routine confirmation method.\",\n    \"highYieldPearl\": \"Always obtain a post-procedure chest X-ray after chest tube insertion to confirm placement and check for complications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might consider CT Thorax as 'more accurate,' but the question asks for the *immediate* gold standard, which is a readily available and sufficient chest X-ray. Auscultation is unreliable for definitive placement confirmation.\"\n  },\n  {\n    \"question\": \"The initial management strategy for a persistent air leak after chest tube insertion often includes?\",\n    \"options\": {\n      \"A\": \"Immediate surgical consultation for pleurodesis\",\n      \"B\": \"Increasing the level of suction\",\n      \"C\": \"Switching to a Heimlich valve\",\n      \"D\": \"Administering broad-spectrum antibiotics\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pleural_procedures\",\n    \"deepDiveExplanation\": \"A persistent air leak often indicates ongoing communication between the lung and the pleural space. The initial steps typically involve optimizing the chest tube system, which includes ensuring proper tube position, checking for leaks in the tubing system, and often increasing the level of suction (e.g., from -20 cm H2O to -30 cm H2O) to promote lung re-expansion and seal the leak. More invasive options like pleurodesis or surgical intervention are considered if conservative measures fail.\",\n    \"highYieldPearl\": \"Before considering advanced interventions for a persistent air leak, ensure chest tube patency, correct placement, and optimize suction settings.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is to jump to more invasive or definitive treatments (pleurodesis, Heimlich valve) without considering the initial, less invasive optimization steps. Antibiotics are irrelevant unless infection is suspected.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-618.6373291015625}],"createTime":"2025-12-31T07:46:54.620801Z","modelVersion":"gemini-2.5-flash","responseId":"7tRUaYHyJbe0nvgP2IqeqAQ","usageMetadata":{"billablePromptUsage":{"textCount":1051},"candidatesTokenCount":1520,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1520}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":1154,"totalTokenCount":3044,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:49:53.778584+00:00"}
{"metadata":"one-liner|ards_ventilation|ARDS - Lung Protective Ventilation|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"ARDS - Lung Protective Ventilation\".\nSet the \"topic\" field in the JSON to \"ards_ventilation\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.359126213592233,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the recommended tidal volume range for lung-protective ventilation in ARDS?\",\n    \"options\": {\n      \"A\": \"10-12 ml/kg predicted body weight\",\n      \"B\": \"8-10 ml/kg predicted body weight\",\n      \"C\": \"4-8 ml/kg predicted body weight\",\n      \"D\": \"12-15 ml/kg predicted body weight\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"The ARDSNet trial demonstrated a significant mortality benefit with a tidal volume target of 6 ml/kg predicted body weight (PBW), allowing a range of 4-8 ml/kg PBW to maintain plateau pressure below 30 cmH2O. This strategy minimizes volutrauma and barotrauma.\",\n    \"highYieldPearl\": \"Always use Predicted Body Weight (PBW) for tidal volume calculation in ARDS, not actual body weight.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors include historical higher tidal volumes or not specifying 'predicted body weight', which is crucial for correct application.\"\n  },\n  {\n    \"question\": \"The maximum recommended plateau pressure during ARDS lung-protective ventilation is?\",\n    \"options\": {\n      \"A\": \"25 cmH2O\",\n      \"B\": \"30 cmH2O\",\n      \"C\": \"35 cmH2O\",\n      \"D\": \"40 cmH2O\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"A plateau pressure (Pplat) exceeding 30 cmH2O is strongly associated with increased ventilator-induced lung injury (VILI) due to overdistension of aerated lung regions. Pplat reflects the static pressure in the alveoli at the end of inspiration.\",\n    \"highYieldPearl\": \"Plateau pressure is measured during an inspiratory hold and reflects alveolar distending pressure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Candidates might choose a slightly lower value (too conservative) or a higher value, which is dangerous in ARDS.\"\n  },\n  {\n    \"question\": \"Driving pressure in ARDS lung-protective ventilation is calculated as?\",\n    \"options\": {\n      \"A\": \"Peak inspiratory pressure - PEEP\",\n      \"B\": \"Plateau pressure - PEEP\",\n      \"C\": \"Mean airway pressure - PEEP\",\n      \"D\": \"Peak inspiratory pressure - Plateau pressure\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Driving pressure (ΔP) is the difference between plateau pressure and PEEP (Pplat - PEEP). It represents the tidal stretch or distending pressure applied to the functional lung. Studies have shown it to be a strong predictor of mortality, independent of tidal volume and PEEP.\",\n    \"highYieldPearl\": \"Aim to keep driving pressure below 15 cmH2O, ideally less than 13 cmH2O, as it correlates with mortality.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing driving pressure with peak pressure, mean airway pressure, or transpulmonary pressure are common pitfalls. Driving pressure specifically reflects the cyclic change in lung volume.\"\n  },\n  {\n    \"question\": \"Which arterial blood gas finding is often intentionally tolerated during lung-protective ventilation in ARDS?\",\n    \"options\": {\n      \"A\": \"Hypoxemia\",\n      \"B\": \"Respiratory alkalosis\",\n      \"C\": \"Hypercapnia\",\n      \"D\": \"Metabolic acidosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Permissive hypercapnia refers to the strategy of tolerating elevated PaCO2 (leading to respiratory acidosis) as a consequence of using lower tidal volumes to prevent VILI. The pH should generally be maintained above 7.20-7.25 by adjusting bicarbonate if necessary.\",\n    \"highYieldPearl\": \"Lower tidal volumes reduce CO2 clearance, necessitating permissive hypercapnia to protect the lungs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hypoxemia is managed, not intentionally tolerated. Respiratory alkalosis would be the opposite of permissive hypercapnia, and metabolic acidosis is a separate issue.\"\n  },\n  {\n    \"question\": \"The primary goal of applying PEEP in ARDS lung-protective ventilation is to?\",\n    \"options\": {\n      \"A\": \"Reduce airway resistance\",\n      \"B\": \"Prevent end-expiratory alveolar collapse\",\n      \"C\": \"Increase cardiac output\",\n      \"D\": \"Decrease intracranial pressure\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Positive End-Expiratory Pressure (PEEP) in ARDS aims to prevent cyclic opening and closing of collapsed alveoli (atelectrauma), maintain functional residual capacity, improve oxygenation by recruiting collapsed lung units, and reduce intrapulmonary shunting.\",\n    \"highYieldPearl\": \"PEEP helps keep recruited alveoli open, improving V/Q matching and reducing atelectrauma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While PEEP can affect cardiac output or intracranial pressure, these are secondary effects or potential complications, not its primary goal in ARDS ventilation.\"\n  },\n  {\n    \"question\": \"Prone positioning in moderate-to-severe ARDS primarily improves oxygenation by?\",\n    \"options\": {\n      \"A\": \"Increasing cardiac output\",\n      \"B\": \"Redistributing ventilation and perfusion\",\n      \"C\": \"Decreasing pulmonary vascular resistance\",\n      \"D\": \"Reducing metabolic demand\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Prone positioning improves oxygenation by homogenizing the distribution of pleural pressure, which reduces compression atelectasis in dependent lung regions, shifts perfusion to better-ventilated areas, and decreases ventilator-induced lung injury by reducing stress and strain heterogeneity.\",\n    \"highYieldPearl\": \"Prone positioning moves the heart and abdominal contents away from the posterior lung, allowing better ventilation and perfusion in previously compressed areas.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distractors relate to other physiological parameters that are not the primary mechanism of oxygenation improvement in prone positioning.\"\n  },\n  {\n    \"question\": \"Early and continuous neuromuscular blockade is considered in moderate-to-severe ARDS to facilitate?\",\n    \"options\": {\n      \"A\": \"Early patient mobilization\",\n      \"B\": \"Spontaneous breathing efforts\",\n      \"C\": \"Adherence to lung-protective ventilation\",\n      \"D\": \"Enhanced nutritional support\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Neuromuscular blockers (NMBs) are used to eliminate patient-ventilator asynchrony, reduce oxygen consumption, and ensure strict adherence to lung-protective ventilation parameters (e.g., low tidal volume, optimal PEEP) by preventing spontaneous breathing efforts that can worsen VILI. The ACURASYS trial supported its use in severe ARDS.\",\n    \"highYieldPearl\": \"NMBs minimize patient effort and dyssynchrony, which can exacerbate VILI.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"NMBs would prevent spontaneous breathing and early mobilization. Nutritional support is unrelated to NMBs' primary role in ARDS.\"\n  },\n  {\n    \"question\": \"The primary goal of lung-protective ventilation in ARDS is to reduce?\",\n    \"options\": {\n      \"A\": \"Pulmonary hypertension\",\n      \"B\": \"Ventilator-induced lung injury\",\n      \"C\": \"Systemic inflammation\",\n      \"D\": \"Secondary infections\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Lung-protective ventilation strategies are specifically designed to minimize the four components of VILI: barotrauma (excessive pressure), volutrauma (excessive volume), atelectrauma (cyclic opening/closing of alveoli), and biotrauma (release of inflammatory mediators). Reducing VILI leads to improved patient outcomes.\",\n    \"highYieldPearl\": \"VILI is the target of prevention, not a side effect. ARDSNet trial was foundational.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While lung-protective ventilation might indirectly impact systemic inflammation, and pulmonary hypertension can be a complication, the direct and primary goal is reduction of VILI.\"\n  },\n  {\n    \"question\": \"Recruitment maneuvers in ARDS are primarily performed to?\",\n    \"options\": {\n      \"A\": \"Decrease PEEP requirements\",\n      \"B\": \"Open collapsed alveolar units\",\n      \"C\": \"Reduce driving pressure\",\n      \"D\": \"Improve cardiac output\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Recruitment maneuvers involve transiently applying high airway pressures to open collapsed or consolidated lung units, aiming to increase the amount of recruitable lung and improve oxygenation. They are often followed by PEEP titration to maintain recruitment.\",\n    \"highYieldPearl\": \"Recruitment maneuvers are 'openers'; PEEP is a 'keeper' for opened alveoli.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Recruitment maneuvers might transiently increase driving pressure, and their effect on cardiac output is often negative due to increased intrathoracic pressure. They do not directly decrease PEEP requirements.\"\n  },\n  {\n    \"question\": \"Tidal volume calculation for ARDS lung-protective ventilation is based on?\",\n    \"options\": {\n      \"A\": \"Actual body weight\",\n      \"B\": \"Body surface area\",\n      \"C\": \"Predicted body weight\",\n      \"D\": \"End-tidal CO2\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_ventilation\",\n    \"deepDiveExplanation\": \"Lung size is primarily determined by height and sex, not actual body weight. Therefore, predicted body weight (PBW), calculated using height and sex, is used to determine appropriate tidal volumes. This prevents overdistension in obese patients whose actual body weight is disproportionately higher than their lung capacity.\",\n    \"highYieldPearl\": \"PBW formula: 50 + 0.91 (height in cm - 152.4) for males; 45.5 + 0.91 (height in cm - 152.4) for females.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Using actual body weight is a common and dangerous mistake in ARDS ventilation, as it would lead to excessive tidal volumes in overweight or obese patients.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-924.75}],"createTime":"2025-12-31T07:45:28.427978Z","modelVersion":"gemini-2.5-flash","responseId":"mNRUacqPGoHN1AGCsIjgBQ","usageMetadata":{"billablePromptUsage":{"textCount":1038},"candidatesTokenCount":2575,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2575}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2269,"totalTokenCount":5209,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:10.829212+00:00"}
{"metadata":"one-liner|gerd_lung|GERD and Lung Disease|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"GERD and Lung Disease\".\nSet the \"topic\" field in the JSON to \"gerd_lung\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.7243102034168131,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is considered the primary direct mechanism linking GERD to the development of chronic interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Vagal-mediated reflex bronchoconstriction\",\n      \"B\": \"Repeated microaspiration of gastric contents\",\n      \"C\": \"Systemic pro-inflammatory cytokine release\",\n      \"D\": \"Impaired diaphragmatic excursion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"gerd_lung\",\n    \"deepDiveExplanation\": \"Repeated microaspiration of even microscopic amounts of gastric acid and pepsin into the distal airways is a significant pathological mechanism in the development and progression of various chronic lung diseases, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD), by inducing chronic inflammation and fibrotic changes.\",\n    \"highYieldPearl\": \"While vagal reflexes contribute to bronchospasm (e.g., in asthma), microaspiration is the key driver of direct parenchymal damage in GERD-associated chronic lung diseases like IPF.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A (vagal reflex) is a major mechanism for GERD-induced asthma exacerbations and bronchospasm but less directly for parenchymal inflammation and fibrosis. Options C and D are less direct or not primary mechanisms.\"\n  },\n  {\n    \"question\": \"What is the gold standard diagnostic test for pathological gastroesophageal reflux in patients with suspected GERD-related chronic cough?\",\n    \"options\": {\n      \"A\": \"Esophageal manometry\",\n      \"B\": \"Barium esophagogram\",\n      \"C\": \"24-hour esophageal pH monitoring\",\n      \"D\": \"High-resolution impedance-pH monitoring\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"gerd_lung\",\n    \"deepDiveExplanation\": \"While 24-hour esophageal pH monitoring detects acid reflux, high-resolution impedance-pH monitoring is considered the gold standard for evaluating GERD, especially in extra-esophageal manifestations like chronic cough. It can detect both acid and non-acid reflux episodes (liquid and gas), and allows for correlation with symptoms, which is crucial as non-acid reflux can also trigger cough.\",\n    \"highYieldPearl\": \"Non-acid reflux, detectable by impedance monitoring, can be a significant trigger for chronic cough, even when pH monitoring is normal, making impedance-pH monitoring superior for extra-esophageal GERD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Option C (24-hour pH monitoring) is a common answer for general GERD diagnosis, but for extra-esophageal symptoms like chronic cough, where non-acid reflux plays a significant role, impedance-pH monitoring (D) provides more comprehensive data and is thus considered superior/gold standard in these specific contexts. Barium swallow (B) is for anatomical issues, and manometry (A) is for motility, not reflux per se.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-489.6336975097656}],"createTime":"2025-12-31T07:46:28.470364Z","modelVersion":"gemini-2.5-flash","responseId":"1NRUadzaHMiP2_gP0paGOA","usageMetadata":{"billablePromptUsage":{"textCount":1018},"candidatesTokenCount":676,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":676}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1559,"totalTokenCount":2599,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:08.307111+00:00"}
{"metadata":"one-liner|trauma_blast|Trauma and Blast Injuries to Chest|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Trauma and Blast Injuries to Chest\".\nSet the \"topic\" field in the JSON to \"trauma_blast\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4920895467668572,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary mechanism of blast lung injury is due to direct effect of?\",\n    \"options\": {\n      \"A\": \"Projectile fragments\",\n      \"B\": \"Body displacement\",\n      \"C\": \"High-pressure shockwave\",\n      \"D\": \"Thermal burns\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"trauma_blast\",\n    \"deepDiveExplanation\": \"Primary blast injury (PBI) is caused by the direct impact of the blast pressure wave on tissues. Air-filled organs like the lungs (blast lung), ears (tympanic membrane rupture), and gastrointestinal tract are most susceptible due to the impedance mismatch between air and tissue, leading to shear forces and tissue damage. Blast lung is characterized by contusions, hemorrhage, and air emboli.\",\n    \"highYieldPearl\": \"PBI is unique to blast events; secondary, tertiary, and quaternary injuries can occur in other trauma types.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, and D represent secondary, tertiary, and quaternary blast injuries, respectively. Candidates might confuse the primary mechanism with other commonly recognized blast injury types.\"\n  },\n  {\n    \"question\": \"What is the definitive management for a tension pneumothorax?\",\n    \"options\": {\n      \"A\": \"Chest tube thoracostomy\",\n      \"B\": \"Needle decompression\",\n      \"C\": \"Supplemental oxygen\",\n      \"D\": \"Urgent surgical exploration\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"trauma_blast\",\n    \"deepDiveExplanation\": \"Tension pneumothorax is a life-threatening condition requiring immediate intervention. While needle decompression (often via a large-bore cannula in the 2nd intercostal space midclavicular line or 4th/5th intercostal space anterior axillary line) is a life-saving *initial* temporizing measure to relieve pressure, the *definitive* management involves inserting a chest tube (thoracostomy) to continuously drain air and re-expand the lung.\",\n    \"highYieldPearl\": \"Needle decompression converts a tension pneumothorax into a simple pneumothorax, allowing time for definitive chest tube placement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option B (Needle decompression) is a common trap as it is the critical *initial* step. However, the question asks for *definitive* management, which is the chest tube. Surgical exploration (D) is rarely indicated for simple tension pneumothorax unless there's associated massive hemorrhage or complex injury.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-293.2853698730469}],"createTime":"2025-12-31T07:46:11.307935Z","modelVersion":"gemini-2.5-flash","responseId":"w9RUad_lEsOyvPEP9q_RgA0","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":596,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":596}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":1105,"totalTokenCount":2067,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:34.104275+00:00"}
{"metadata":"one-liner|lung_cancer_surgery|Lung Cancer - Surgical Management|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Surgical Management\".\nSet the \"topic\" field in the JSON to \"lung_cancer_surgery\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4166456470438909,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which of the following N-stages is an absolute contraindication for curative surgical resection in NSCLC?\",\n    \"options\": {\n      \"A\": \"N1\",\n      \"B\": \"N2\",\n      \"C\": \"N3\",\n      \"D\": \"N0\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_surgery\",\n    \"deepDiveExplanation\": \"N3 disease, defined as contralateral mediastinal or hilar lymph node involvement, or supraclavicular/scalene lymph node involvement, is generally considered an absolute contraindication to curative surgical resection in NSCLC due to high rates of systemic recurrence and poor survival outcomes. M1 (distant metastasis) is also an absolute contraindication. N2 disease (ipsilateral mediastinal/subcarinal nodes) can be resectable in selected cases, often with neoadjuvant therapy.\",\n    \"highYieldPearl\": \"N3 or M1 disease signifies non-resectable NSCLC for curative intent surgery.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"N2 disease is a common distractor as it represents locally advanced disease, but select N2 cases can be downstaged and resected. N3, however, typically indicates widespread disease beyond the scope of local curative resection.\"\n  },\n  {\n    \"question\": \"The standard anatomical surgical resection for early-stage NSCLC (T1-T2 N0 M0) is which of the following?\",\n    \"options\": {\n      \"A\": \"Wedge resection\",\n      \"B\": \"Segmentectomy\",\n      \"C\": \"Lobectomy\",\n      \"D\": \"Pneumonectomy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_surgery\",\n    \"deepDiveExplanation\": \"Lobectomy with systematic mediastinal lymph node dissection is the standard of care for early-stage NSCLC (T1-T2 N0 M0) as it offers the best balance of local control and survival benefits. Sublobar resections (wedge, segmentectomy) are typically reserved for smaller peripheral tumors (<2 cm) or patients with significant comorbidities precluding lobectomy.\",\n    \"highYieldPearl\": \"Lobectomy with lymphadenectomy is the gold standard for resectable early-stage NSCLC.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Wedge resection and segmentectomy are less extensive resections used in specific scenarios (e.g., very small peripheral tumors, compromised lung function) but are not the 'standard' for all early-stage resectable NSCLC.\"\n  },\n  {\n    \"question\": \"Curative surgical resection of a Pancoast tumor typically involves which approach?\",\n    \"options\": {\n      \"A\": \"Standard lobectomy\",\n      \"B\": \"Bronchial sleeve resection\",\n      \"C\": \"En bloc chest wall resection\",\n      \"D\": \"Bilobectomy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_surgery\",\n    \"deepDiveExplanation\": \"Pancoast tumors (superior sulcus tumors) are NSCLCs located in the apex of the lung, often invading the chest wall, brachial plexus, or subclavian vessels. Curative resection typically requires an en bloc resection of the lung apex, involved chest wall structures (ribs, vertebrae), and sometimes neurovascular structures, often preceded by neoadjuvant chemoradiation to improve resectability and outcomes.\",\n    \"highYieldPearl\": \"Pancoast tumor surgery often requires a multidisciplinary, en bloc chest wall resection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"A standard lobectomy would not adequately address the chest wall invasion characteristic of Pancoast tumors. Bronchial sleeve resection is for central tumors involving the main bronchus, and bilobectomy is for tumors involving two lobes.\"\n  },\n  {\n    \"question\": \"Neoadjuvant chemotherapy or chemoradiation is primarily indicated in NSCLC surgical management for which purpose?\",\n    \"options\": {\n      \"A\": \"To reduce surgical complications\",\n      \"B\": \"To downstage locally advanced disease\",\n      \"C\": \"To prevent distant metastases post-operatively\",\n      \"D\": \"To improve patient nutritional status\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_surgery\",\n    \"deepDiveExplanation\": \"Neoadjuvant therapy (chemotherapy or chemoradiation) is administered before surgery primarily to downstage locally advanced NSCLC (e.g., N2 disease or T3/T4 tumors), making it more amenable to complete surgical resection (R0 resection) and improving overall survival rates. While it may also reduce the risk of local recurrence and potentially distant metastases, its primary role in the surgical context is downstaging and improving resectability.\",\n    \"highYieldPearl\": \"Neoadjuvant therapy downstages locally advanced NSCLC to improve resectability and survival outcomes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While neoadjuvant therapy can reduce the risk of recurrence (C), its direct and primary indication for *surgical management* is to make the tumor surgically resectable or to achieve a more complete resection. It does not directly reduce surgical complications (A) or improve nutritional status (D).\"\n  },\n  {\n    \"question\": \"Compared to open thoracotomy, VATS lobectomy for NSCLC is associated with which of the following?\",\n    \"options\": {\n      \"A\": \"Increased intraoperative blood loss\",\n      \"B\": \"Longer hospital stay\",\n      \"C\": \"Reduced post-operative pain\",\n      \"D\": \"Higher recurrence rates\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_surgery\",\n    \"deepDiveExplanation\": \"Video-assisted thoracic surgery (VATS) lobectomy is a minimally invasive approach that offers several advantages over traditional open thoracotomy for early-stage NSCLC. These benefits include reduced post-operative pain, shorter hospital stay, faster recovery, and comparable oncologic outcomes (e.g., recurrence rates and survival) when performed by experienced surgeons for appropriately selected patients.\",\n    \"highYieldPearl\": \"VATS lobectomy offers reduced morbidity (pain, hospital stay) with equivalent oncologic outcomes for early NSCLC compared to open surgery.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"VATS typically results in *less* blood loss and *shorter* hospital stays. For early-stage NSCLC, recurrence rates are comparable to open surgery, not higher, when appropriate oncologic principles are followed.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-628.3016357421875}],"createTime":"2025-12-31T07:45:37.640858Z","modelVersion":"gemini-2.5-flash","responseId":"odRUadqOJ7jFvPEP5p7G0Ao","usageMetadata":{"billablePromptUsage":{"textCount":1039},"candidatesTokenCount":1508,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1508}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2010,"totalTokenCount":3883,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:56.180325+00:00"}
{"metadata":"one-liner|bronchoscopy_basic|Diagnostic Bronchoscopy Techniques|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Diagnostic Bronchoscopy Techniques\".\nSet the \"topic\" field in the JSON to \"bronchoscopy_basic\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3754751364494419,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which bronchoscopic technique offers the highest diagnostic yield for mediastinal lymph node staging in lung cancer?\",\n    \"options\": {\n      \"A\": \"Conventional Transbronchial Needle Aspiration (TBNA)\",\n      \"B\": \"Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)\",\n      \"C\": \"Bronchoalveolar Lavage (BAL)\",\n      \"D\": \"Transbronchial Lung Biopsy (TBLB)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchoscopy_basic\",\n    \"deepDiveExplanation\": \"EBUS-TBNA allows real-time visualization of mediastinal and hilar lymph nodes, enabling precise needle aspiration under ultrasound guidance. This significantly improves the diagnostic yield and safety compared to conventional TBNA, which relies on anatomical landmarks. It is the gold standard for minimally invasive mediastinal staging in lung cancer.\",\n    \"highYieldPearl\": \"EBUS-TBNA is superior to conventional TBNA for mediastinal lymph node staging due to real-time ultrasound guidance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Conventional TBNA (A) is less accurate due to lack of real-time visualization. BAL (C) and TBLB (D) are not primarily used for lymph node staging.\"\n  },\n  {\n    \"question\": \"A bronchoalveolar lavage fluid demonstrating significant lymphocytosis with a CD4/CD8 ratio > 3:1 is characteristic of which interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Hypersensitivity Pneumonitis\",\n      \"B\": \"Idiopathic Pulmonary Fibrosis\",\n      \"C\": \"Sarcoidosis\",\n      \"D\": \"Cryptogenic Organizing Pneumonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchoscopy_basic\",\n    \"deepDiveExplanation\": \"Sarcoidosis typically presents with a lymphocytic alveolitis, often with a high CD4/CD8 ratio (usually >3.5, but >3:1 is highly suggestive). In contrast, Hypersensitivity Pneumonitis often shows lymphocytosis with a low CD4/CD8 ratio (<1), while IPF typically shows neutrophilia or eosinophilia, and COP often shows mixed cellularity with lymphocytes and neutrophils.\",\n    \"highYieldPearl\": \"High BAL CD4/CD8 ratio (>3:1) is a strong indicator for sarcoidosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Hypersensitivity Pneumonitis (A) also has lymphocytosis but a low CD4/CD8 ratio. IPF (B) and COP (D) do not typically show prominent lymphocytosis with a high CD4/CD8 ratio.\"\n  },\n  {\n    \"question\": \"The most frequent serious complication associated with transbronchial lung biopsy (TBLB) is?\",\n    \"options\": {\n      \"A\": \"Laryngospasm\",\n      \"B\": \"Hypoxemia\",\n      \"C\": \"Pneumothorax\",\n      \"D\": \"Significant Hemorrhage\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchoscopy_basic\",\n    \"deepDiveExplanation\": \"Pneumothorax is the most common serious complication of TBLB, occurring in 1-5% of cases and often requiring chest tube insertion. Significant hemorrhage, while potentially more life-threatening, occurs less frequently (0.5-2%) and is usually self-limiting or manageable with local measures. Laryngospasm and hypoxemia are generally less frequent and more readily managed during the procedure.\",\n    \"highYieldPearl\": \"Pneumothorax is the most common serious complication of TBLB, followed by significant hemorrhage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Significant hemorrhage (D) is also a serious complication but generally less frequent than pneumothorax. Laryngospasm (A) and hypoxemia (B) are often transient and manageable, thus typically not classified as the 'most frequent serious' complications.\"\n  },\n  {\n    \"question\": \"What is a primary advantage of transbronchial lung cryobiopsy over conventional forceps biopsy for interstitial lung disease diagnosis?\",\n    \"options\": {\n      \"A\": \"Reduced risk of pneumothorax\",\n      \"B\": \"Smaller tissue samples\",\n      \"C\": \"Less tissue crush artifact\",\n      \"D\": \"No need for fluoroscopic guidance\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"bronchoscopy_basic\",\n    \"deepDiveExplanation\": \"Transbronchial lung cryobiopsy uses a cryoprobe to freeze and extract tissue, resulting in larger, better-preserved samples with significantly less crush artifact compared to conventional forceps biopsies. This improved tissue quality enhances diagnostic yield for diffuse parenchymal lung diseases. While the risk of pneumothorax is comparable or slightly higher, the diagnostic quality is superior.\",\n    \"highYieldPearl\": \"Cryobiopsy yields larger, less crushed tissue samples, improving diagnostic accuracy for ILD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Cryobiopsy generally has a comparable or even slightly higher risk of pneumothorax (A) than conventional TBLB. It yields larger (B), not smaller, samples. Fluoroscopic guidance (D) is typically still recommended for cryobiopsy to ensure peripheral lesion targeting and reduce complications.\"\n  },\n  {\n    \"question\": \"Bronchial washings and brushings are primarily utilized during bronchoscopy for which diagnostic purpose?\",\n    \"options\": {\n      \"A\": \"Histopathological analysis of tissue architecture\",\n      \"B\": \"Cytological examination for malignancy or infection\",\n      \"C\": \"Assessment of airway hyperresponsiveness\",\n      \"D\": \"Measurement of lung compliance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"bronchoscopy_basic\",\n    \"deepDiveExplanation\": \"Bronchial washings and brushings collect cells from the airway lumen and surface. These samples are then sent for cytological examination to detect malignant cells, identify infectious organisms (bacteria, fungi, viruses), or assess inflammatory changes. Histopathological analysis (A) requires intact tissue architecture, usually obtained via biopsy. Options C and D are not diagnostic uses of washings/brushings.\",\n    \"highYieldPearl\": \"Bronchial washings and brushings are crucial for cytology in malignancy and infection diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Histopathological analysis (A) requires tissue biopsies, not washings/brushings. Options C and D are physiological assessments, not directly related to cellular or microbial analysis from these samples.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-571.8486328125}],"createTime":"2025-12-31T07:46:23.771240Z","modelVersion":"gemini-2.5-flash","responseId":"z9RUaaiJL9-zgLUPj-v-qAI","usageMetadata":{"billablePromptUsage":{"textCount":1041},"candidatesTokenCount":1523,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1523}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":1542,"totalTokenCount":3430,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:39.613222+00:00"}
{"metadata":"one-liner|lam|Lymphangioleiomyomatosis (LAM)|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"Lymphangioleiomyomatosis (LAM)\".\nSet the \"topic\" field in the JSON to \"lam\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.41544768234779095,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The characteristic immunohistochemical marker for lymphangioleiomyomatosis (LAM) cells is?\",\n    \"options\": {\n      \"A\": \"CD68\",\n      \"B\": \"S100\",\n      \"C\": \"HMB-45\",\n      \"D\": \"CK-7\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lam\",\n    \"deepDiveExplanation\": \"Lymphangioleiomyomatosis (LAM) cells are abnormal smooth muscle-like cells that pathognomonically express melanocytic markers, most notably HMB-45 (human melanoma black-45). HMB-45 recognizes the gp100 protein and is crucial for the histological diagnosis of LAM, differentiating it from other cystic lung diseases.\",\n    \"highYieldPearl\": \"HMB-45 positivity is a key diagnostic immunohistochemical feature for LAM cells.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CD68 is a marker for macrophages, S100 for neural crest-derived cells (e.g., melanoma, schwannoma), and CK-7 for epithelial cells. Only HMB-45 is specific for LAM cells in this context.\"\n  },\n  {\n    \"question\": \"The primary therapeutic agent targeting mTOR pathway in Lymphangioleiomyomatosis (LAM) is?\",\n    \"options\": {\n      \"A\": \"Pirfenidone\",\n      \"B\": \"Nintedanib\",\n      \"C\": \"Sirolimus\",\n      \"D\": \"Azithromycin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lam\",\n    \"deepDiveExplanation\": \"Sirolimus (rapamycin) is an mTOR (mammalian target of rapamycin) inhibitor, which has been shown to stabilize lung function, reduce chylous effusions, and improve quality of life in patients with LAM. It targets the dysregulated mTOR pathway, a key driver of LAM cell proliferation and survival. Everolimus is another mTOR inhibitor used for LAM, particularly in the context of Tuberous Sclerosis Complex.\",\n    \"highYieldPearl\": \"mTOR inhibitors (Sirolimus/Everolimus) are the current standard medical treatment for LAM.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Pirfenidone and Nintedanib are antifibrotic drugs used for Idiopathic Pulmonary Fibrosis. Azithromycin has anti-inflammatory properties but is not a primary targeted therapy for LAM.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-240.95965576171875}],"createTime":"2025-12-31T07:45:11.225633Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUaeHiDY3UhMIPlvb66AY","usageMetadata":{"billablePromptUsage":{"textCount":1023},"candidatesTokenCount":580,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":580}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":879,"totalTokenCount":1824,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:03.962405+00:00"}
{"metadata":"one-liner|thoracic_ct|Thoracic CT Interpretation|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Thoracic CT Interpretation\".\nSet the \"topic\" field in the JSON to \"thoracic_ct\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.343519097166805,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which HRCT pattern is considered diagnostic for Usual Interstitial Pneumonia (UIP) in the absence of other causes?\",\n    \"options\": {\n      \"A\": \"Predominant ground-glass opacity\",\n      \"B\": \"Subpleural and basal predominant reticular opacities with honeycombing\",\n      \"C\": \"Upper lobe predominant centrilobular nodules\",\n      \"D\": \"Diffuse crazy-paving pattern\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"The ATS/ERS/JRS/ALAT guidelines define a 'UIP pattern' on HRCT by the presence of honeycombing (often subpleural and basal predominant) with or without peripheral traction bronchiectasis/bronchioloectasis, and reticular abnormality. Ground-glass opacity, if present, should be less extensive than reticular abnormality. Absence of features inconsistent with UIP is also crucial.\",\n    \"highYieldPearl\": \"Honeycombing is the most specific HRCT feature for UIP and is diagnostic in the appropriate clinical context.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A (ground-glass) is non-specific. Option C (centrilobular nodules) suggests hypersensitivity pneumonitis or bronchiolitis. Option D (crazy-paving) is characteristic of pulmonary alveolar proteinosis.\"\n  },\n  {\n    \"question\": \"The 'signet ring sign' on HRCT is characteristic of which pulmonary condition?\",\n    \"options\": {\n      \"A\": \"Pulmonary emphysema\",\n      \"B\": \"Bronchiectasis\",\n      \"C\": \"Sarcoidosis\",\n      \"D\": \"Idiopathic pulmonary fibrosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"The 'signet ring sign' on HRCT refers to a dilated bronchus (the 'ring') adjacent to its accompanying pulmonary artery (the 'gemstone'), where the bronchus lumen is wider than the accompanying artery. This indicates bronchial dilatation, a hallmark of bronchiectasis.\",\n    \"highYieldPearl\": \"A bronchial lumen larger than its accompanying pulmonary artery is the primary CT criterion for bronchiectasis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options are diffuse lung diseases with different characteristic CT features. Emphysema involves parenchymal destruction, sarcoidosis involves perilymphatic nodules, and IPF involves honeycombing.\"\n  },\n  {\n    \"question\": \"On CT, a Hounsfield Unit (HU) value of -800 to -900 is typically indicative of what?\",\n    \"options\": {\n      \"A\": \"Soft tissue mass\",\n      \"B\": \"Active consolidation\",\n      \"C\": \"Emphysematous changes\",\n      \"D\": \"Calcified nodule\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"Hounsfield Units (HU) quantify tissue density on CT. Air is -1000 HU, water is 0 HU, and bone is +1000 HU. Values between -800 and -900 HU represent significantly decreased tissue density, characteristic of air-filled spaces without normal lung parenchyma, such as in emphysema.\",\n    \"highYieldPearl\": \"HU values correlate directly with tissue density: lower (more negative) values indicate less dense tissue (e.g., air), higher (more positive) values indicate denser tissue (e.g., calcification, bone).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Soft tissue masses are typically +20 to +70 HU. Active consolidation is around +30 to +70 HU. Calcified nodules are much higher, typically +100 to +1000 HU.\"\n  },\n  {\n    \"question\": \"Which CT feature is most suggestive of a benign pulmonary nodule?\",\n    \"options\": {\n      \"A\": \"Spiculated margins\",\n      \"B\": \"Doubling time less than 30 days\",\n      \"C\": \"Stable size over two years\",\n      \"D\": \"Solid enhancement exceeding 20 HU\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"A pulmonary nodule stable in size (no change in diameter of 2mm or more) for at least two years is generally considered benign, especially if it's solid. Malignant nodules typically grow, with a doubling time of 20 to 400 days.\",\n    \"highYieldPearl\": \"Stability over 2 years is a strong indicator of benignity for solid pulmonary nodules. This timeframe is extended to 5 years for subsolid nodules.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Spiculated margins, rapid doubling time (less than 30 days is too fast for most primary lung cancers, often suggesting infection or metastasis; however, any growth is suspicious), and significant enhancement are features more commonly associated with malignancy.\"\n  },\n  {\n    \"question\": \"The 'tree-in-bud' pattern on HRCT most commonly indicates which pathological process?\",\n    \"options\": {\n      \"A\": \"Lymphangitic carcinomatosis\",\n      \"B\": \"Bronchiolar inflammation or infection\",\n      \"C\": \"Pulmonary edema\",\n      \"D\": \"Pulmonary alveolar proteinosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"The 'tree-in-bud' pattern represents centrilobular branching linear opacities with associated small nodules, resembling a budding tree branch. It results from impaction of inflamed or infected material within small airways and their distal branches, commonly seen in mycobacterial infections, bacterial bronchiolitis, or aspiration.\",\n    \"highYieldPearl\": \"While infection is the most common cause, 'tree-in-bud' can also be seen in non-infectious conditions like cystic fibrosis, aspiration, or even occasionally in neoplastic conditions like bronchioalveolar carcinoma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Lymphangitic carcinomatosis typically presents with smooth or nodular septal thickening. Pulmonary edema shows diffuse ground-glass or consolidation with septal lines. Alveolar proteinosis classically presents with crazy-paving pattern.\"\n  },\n  {\n    \"question\": \"Which CT sign is most specific for chronic pulmonary embolism?\",\n    \"options\": {\n      \"A\": \"Acute intraluminal filling defect\",\n      \"B\": \"Mosaic attenuation pattern\",\n      \"C\": \"Webs, bands, or intimal irregularities within the pulmonary arterial lumen\",\n      \"D\": \"Right ventricular enlargement\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"Chronic pulmonary embolism (CPE) or chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by organized thrombus that remodels the vessel wall. Webs, bands, intimal irregularities, and recanalized channels are specific signs of chronic thrombus on CT angiography.\",\n    \"highYieldPearl\": \"Acute PE presents as a central, low-attenuation filling defect forming acute angles with the vessel wall, whereas chronic PE shows signs of organization and remodelling.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Acute intraluminal filling defect is characteristic of acute PE. Mosaic attenuation can be seen in various conditions causing air trapping or perfusion abnormalities. Right ventricular enlargement is a sign of pulmonary hypertension, which can be acute or chronic.\"\n  },\n  {\n    \"question\": \"On HRCT, which pattern is highly suggestive of chronic hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"Predominant subpleural honeycombing with basal predominance\",\n      \"B\": \"Upper/mid-lung predominant centrilobular nodules with mosaic attenuation and air trapping\",\n      \"C\": \"Diffuse ground-glass opacities with crazy-paving pattern\",\n      \"D\": \"Lower lobe predominant consolidation with air bronchograms\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"Chronic hypersensitivity pneumonitis classically presents on HRCT with a triad of findings: centrilobular nodules (often ill-defined), mosaic attenuation (due to air trapping and ground-glass), and air trapping (best seen on expiratory scans). These findings often have an upper or mid-lung predominance.\",\n    \"highYieldPearl\": \"The combination of centrilobular nodules, mosaic attenuation, and air trapping should strongly suggest chronic HP, especially with upper/mid-lung involvement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Option A describes UIP. Option C describes pulmonary alveolar proteinosis. Option D suggests organizing pneumonia or bacterial pneumonia.\"\n  },\n  {\n    \"question\": \"What is the primary role of thoracic CT in suspected acute aortic dissection?\",\n    \"options\": {\n      \"A\": \"Assess lung parenchyma for infiltrates\",\n      \"B\": \"Evaluate coronary artery stenosis\",\n      \"C\": \"Identify intimal flap, true and false lumens\",\n      \"D\": \"Quantify myocardial viability\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"CT angiography (CTA) of the chest and abdomen is the gold standard for diagnosing acute aortic dissection. It accurately identifies the intimal flap separating the true and false lumens, characterizes the extent of dissection, and detects complications like branch vessel involvement or rupture.\",\n    \"highYieldPearl\": \"CTA is rapid, widely available, and highly accurate for aortic dissection, making it the preferred imaging modality in acute settings.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Assessing lung parenchyma is a general CT function but not the primary role for suspected dissection. Evaluating coronary stenosis is the role of coronary CTA. Quantifying myocardial viability is typically done with MRI or nuclear medicine scans.\"\n  },\n  {\n    \"question\": \"The 'crazy-paving pattern' on HRCT is most classically associated with which condition?\",\n    \"options\": {\n      \"A\": \"Sarcoidosis\",\n      \"B\": \"Pulmonary alveolar proteinosis\",\n      \"C\": \"Asbestosis\",\n      \"D\": \"Cryptogenic organizing pneumonia\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"The 'crazy-paving pattern' is characterized by diffuse ground-glass opacities superimposed on thickened interlobular and intralobular septa. It is highly characteristic, though not pathognomonic, of pulmonary alveolar proteinosis (PAP) due to alveolar filling with lipoproteinaceous material and associated interstitial thickening.\",\n    \"highYieldPearl\": \"While classic for PAP, crazy-paving can also be seen in acute respiratory distress syndrome (ARDS), pneumonia, pulmonary edema, and even some malignancies.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Sarcoidosis typically shows perilymphatic nodules. Asbestosis causes subpleural fibrosis and pleural plaques. Cryptogenic organizing pneumonia (COP/BOOP) often presents with patchy peripheral consolidation.\"\n  },\n  {\n    \"question\": \"On CT, which type of emphysema predominantly affects the upper lung zones and is strongly associated with smoking?\",\n    \"options\": {\n      \"A\": \"Panlobular emphysema\",\n      \"B\": \"Centrilobular emphysema\",\n      \"C\": \"Paraseptal emphysema\",\n      \"D\": \"Bullous emphysema\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"thoracic_ct\",\n    \"deepDiveExplanation\": \"Centrilobular emphysema (CLE) involves destruction of the central part of the secondary pulmonary lobule, typically sparing the periphery. It is the most common form of emphysema and is strongly linked to smoking, showing a predilection for the upper lung zones.\",\n    \"highYieldPearl\": \"CLE is characterized by multiple small, low-attenuation areas without definable walls in the center of the secondary pulmonary lobule, often with associated bronchiolectasis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Panlobular emphysema (PLE) involves the entire secondary lobule, often with lower lung zone predominance, and is seen in alpha-1 antitrypsin deficiency. Paraseptal emphysema (PSE) primarily affects the periphery of the secondary lobule adjacent to the pleura or septa. Bullous emphysema is a severe form that can be associated with any type, characterized by large air spaces (bullae).\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1008.9155883789063}],"createTime":"2025-12-31T07:46:25.533777Z","modelVersion":"gemini-2.5-flash","responseId":"0dRUaZHKIJ-0gLUP9frpWA","usageMetadata":{"billablePromptUsage":{"textCount":1027},"candidatesTokenCount":2937,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2937}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1711,"totalTokenCount":5012,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:29.046958+00:00"}
{"metadata":"one-liner|lung_volumes|Lung Volumes and Flow-Volume Loops|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Volumes and Flow-Volume Loops\".\nSet the \"topic\" field in the JSON to \"lung_volumes\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.30360146137335214,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which lung volume cannot be directly measured by standard spirometry?\",\n    \"options\": {\n      \"A\": \"Tidal Volume\",\n      \"B\": \"Inspiratory Reserve Volume\",\n      \"C\": \"Expiratory Reserve Volume\",\n      \"D\": \"Residual Volume\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"Residual Volume (RV) is the volume of air remaining in the lungs after a maximal exhalation. Since it cannot be exhaled, it cannot be measured by simple spirometry. Consequently, capacities that include RV (Functional Residual Capacity and Total Lung Capacity) also cannot be directly measured by spirometry.\",\n    \"highYieldPearl\": \"RV, FRC, and TLC require indirect methods such as helium dilution, nitrogen washout, or body plethysmography for measurement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse volumes directly measured with capacities that include RV, like FRC or TLC, which are also not directly measured but are derived from RV.\"\n  },\n  {\n    \"question\": \"The gold standard for measuring Functional Residual Capacity (FRC) in patients with severe airflow obstruction is?\",\n    \"options\": {\n      \"A\": \"Helium dilution\",\n      \"B\": \"Nitrogen washout\",\n      \"C\": \"Body plethysmography\",\n      \"D\": \"Chest X-ray\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"Body plethysmography measures FRC by applying Boyle's law (P1V1=P2V2). It measures all gas in the chest, including trapped air and gas in non-communicating airways, making it more accurate in severe obstruction compared to gas dilution methods which only measure communicating volumes.\",\n    \"highYieldPearl\": \"Gas dilution methods (Helium dilution, Nitrogen washout) underestimate FRC in obstructive diseases due to trapped gas in poorly communicating lung units.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Helium dilution is a common method, but it's not the *gold standard* for patients with severe obstruction because it underestimates FRC in such cases.\"\n  },\n  {\n    \"question\": \"A fixed large airway obstruction typically presents with what characteristic flow-volume loop morphology?\",\n    \"options\": {\n      \"A\": \"Scalloped expiratory limb\",\n      \"B\": \"Flattening of both inspiratory and expiratory limbs\",\n      \"C\": \"Flattening of inspiratory limb only\",\n      \"D\": \"Peak flow shifted left\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"In fixed large airway obstruction, the obstruction is constant regardless of transpulmonary pressure changes during inspiration or expiration. This results in proportional reduction and flattening of both the inspiratory and expiratory limbs of the flow-volume loop.\",\n    \"highYieldPearl\": \"Fixed obstruction examples include tracheal stenosis, goiter, or a foreign body. Variable extrathoracic obstruction causes inspiratory flattening, while variable intrathoracic obstruction causes expiratory flattening.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing fixed from variable obstructions based on which limb is flattened (inspiratory, expiratory, or both) is key for interpreting flow-volume loops.\"\n  },\n  {\n    \"question\": \"Which lung volume is typically increased in obstructive lung diseases like emphysema?\",\n    \"options\": {\n      \"A\": \"Inspiratory Capacity\",\n      \"B\": \"Vital Capacity\",\n      \"C\": \"Residual Volume\",\n      \"D\": \"Expiratory Reserve Volume\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"In obstructive diseases, air trapping occurs due to premature airway closure and loss of elastic recoil. This leads to an increased residual volume (RV), which is the air remaining after maximal exhalation, and often an increased total lung capacity (TLC).\",\n    \"highYieldPearl\": \"Increased RV is a hallmark of air trapping and hyperinflation in obstructive lung diseases, reflecting the inability to fully empty the lungs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While TLC can also be increased, RV is a more direct indicator of air trapping and is always increased in significant obstructive disease. Vital Capacity (VC) is often decreased.\"\n  },\n  {\n    \"question\": \"A restrictive lung disease typically presents with what characteristic flow-volume loop morphology?\",\n    \"options\": {\n      \"A\": \"Reduced peak flow with concave expiratory limb\",\n      \"B\": \"Tall and narrow loop\",\n      \"C\": \"Flattening of inspiratory limb\",\n      \"D\": \"Flattening of expiratory limb\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"In restrictive diseases, lung volumes are reduced proportionally. The flow-volume loop maintains its characteristic shape but is scaled down, appearing 'tall and narrow' due to reduced Total Lung Capacity (TLC) and Vital Capacity (VC), but often with preserved or even increased flow rates relative to lung volume.\",\n    \"highYieldPearl\": \"Reduced TLC is the defining characteristic of restrictive lung disease, leading to a smaller, but often proportionally shaped, flow-volume loop.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The shape itself isn't distorted like in obstructive patterns; it's just smaller overall, indicating reduced lung volumes.\"\n  },\n  {\n    \"question\": \"A FEV1/FVC ratio less than 70% (or below LLN) indicates what physiological abnormality?\",\n    \"options\": {\n      \"A\": \"Restrictive ventilatory defect\",\n      \"B\": \"Obstructive ventilatory defect\",\n      \"C\": \"Reduced lung compliance\",\n      \"D\": \"Increased lung elasticity\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"The FEV1/FVC ratio is the primary spirometric indicator of airflow obstruction. A value below the lower limit of normal (LLN) or a fixed ratio of <0.7 (as per GOLD criteria) is diagnostic of an obstructive ventilatory defect.\",\n    \"highYieldPearl\": \"FEV1/FVC is the most crucial ratio for differentiating obstructive from restrictive patterns in spirometry.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While reduced FVC can occur in both obstructive and restrictive diseases, it's the *ratio* of FEV1 to FVC that specifically points to obstruction.\"\n  },\n  {\n    \"question\": \"Which statement is true regarding the nitrogen washout method for FRC measurement?\",\n    \"options\": {\n      \"A\": \"It measures trapped gas accurately\",\n      \"B\": \"It requires a closed-circuit system\",\n      \"C\": \"It relies on Boyle's Law\",\n      \"D\": \"It underestimates FRC in severe obstruction\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"The nitrogen washout method involves breathing 100% oxygen to wash out nitrogen from the lungs. It measures only the gas in communicating airways. In severe obstruction, trapped gas in non-communicating areas is not measured, leading to an underestimation of FRC.\",\n    \"highYieldPearl\": \"Gas dilution methods (Helium dilution, Nitrogen washout) are less accurate than body plethysmography in severe obstructive lung disease due to the presence of trapped air.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The key is understanding the limitation of gas dilution methods; they only measure communicating lung volumes, missing trapped air.\"\n  },\n  {\n    \"question\": \"The effort-independent portion of the expiratory flow-volume loop is primarily determined by?\",\n    \"options\": {\n      \"A\": \"Muscular effort\",\n      \"B\": \"Airway resistance and elastic recoil\",\n      \"C\": \"Inspiratory muscle strength\",\n      \"D\": \"Upper airway patency\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"During forced expiration, after the initial peak flow, the flow becomes effort-independent. This segment is determined by the dynamic compression of airways (due to intrathoracic pressure) and the elastic recoil of the lung, which drives the airflow against airway resistance.\",\n    \"highYieldPearl\": \"The shape of the effort-independent portion (e.g., FEF25-75%) is crucial for detecting small airway disease, as it reflects the intrinsic properties of the lung and airways.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While initial peak flow is effort-dependent, the later part of expiration is not, due to dynamic airway compression limiting flow even with maximal effort.\"\n  },\n  {\n    \"question\": \"Increased airway resistance primarily manifests on a flow-volume loop as?\",\n    \"options\": {\n      \"A\": \"Decreased inspiratory flow\",\n      \"B\": \"Decreased expiratory flow and a concave pattern\",\n      \"C\": \"Increased lung volumes proportionally\",\n      \"D\": \"Flattening of the inspiratory limb\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"Increased airway resistance, as seen in obstructive diseases, leads to difficulty in exhaling air. This results in reduced expiratory flow rates, a characteristic 'scalloped' or concave appearance of the expiratory limb, and often an increased residual volume/total lung capacity.\",\n    \"highYieldPearl\": \"Concavity of the expiratory limb is a classic spirometric sign of obstructive lung disease, reflecting dynamic airway collapse and increased resistance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While inspiratory flow might be affected in some obstructive conditions, the primary and most pronounced effect of increased airway resistance is on expiration.\"\n  },\n  {\n    \"question\": \"Which spirometric parameter is considered the most sensitive indicator of small airway disease?\",\n    \"options\": {\n      \"A\": \"FEV1\",\n      \"B\": \"FVC\",\n      \"C\": \"PEF\",\n      \"D\": \"FEF25-75%\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_volumes\",\n    \"deepDiveExplanation\": \"FEF25-75% (Forced Expiratory Flow between 25% and 75% of FVC) measures flow rates during the middle portion of forced expiration, which is largely effort-independent and reflects the patency of the small airways. It is often abnormal even when FEV1 is still relatively preserved.\",\n    \"highYieldPearl\": \"FEF25-75% is often the first parameter to show abnormality in early obstructive diseases affecting the small airways, before larger airway involvement significantly reduces FEV1.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"FEV1 and PEF are more reflective of large airway function and overall airflow, though they are also reduced in more advanced small airway disease.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-794.5250244140625}],"createTime":"2025-12-31T07:47:17.220237Z","modelVersion":"gemini-2.5-flash","responseId":"BdVUac24DdiBnvgPh-GVQA","usageMetadata":{"billablePromptUsage":{"textCount":1034},"candidatesTokenCount":2617,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2617}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2613,"totalTokenCount":5596,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:53.589235+00:00"}
{"metadata":"one-liner|cystic_fibrosis|Cystic Fibrosis|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Cystic Fibrosis\".\nSet the \"topic\" field in the JSON to \"cystic_fibrosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2701056667905211,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary genetic defect in Cystic Fibrosis involves which gene?\",\n    \"options\": {\n      \"A\": \"SCN5A\",\n      \"B\": \"CFTR\",\n      \"C\": \"ENaC\",\n      \"D\": \"Alpha-1 antitrypsin\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cystic_fibrosis\",\n    \"deepDiveExplanation\": \"Cystic Fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, located on chromosome 7. This gene encodes a protein that functions as a chloride channel, primarily in epithelial cells, and its dysfunction leads to the characteristic thick, sticky secretions.\",\n    \"highYieldPearl\": \"CFTR gene mutation is the root cause of Cystic Fibrosis, leading to defective chloride transport.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"SCN5A and ENaC are related to ion channels but are not the primary genetic defect in CF. Alpha-1 antitrypsin deficiency causes a distinct lung and liver disease.\"\n  },\n  {\n    \"question\": \"Class II CFTR mutations, like F508del, primarily result in which cellular defect?\",\n    \"options\": {\n      \"A\": \"Reduced protein synthesis\",\n      \"B\": \"Defective processing and trafficking\",\n      \"C\": \"Impaired channel gating\",\n      \"D\": \"Accelerated protein degradation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cystic_fibrosis\",\n    \"deepDiveExplanation\": \"CFTR mutations are classified into six main classes based on their functional consequences. Class II mutations (e.g., F508del, the most common mutation) lead to misfolding of the CFTR protein, causing it to be retained in the endoplasmic reticulum and subsequently degraded. This prevents the protein from reaching the cell surface.\",\n    \"highYieldPearl\": \"F508del (Class II) means the CFTR protein never makes it to the cell membrane due to misfolding and premature degradation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Reduced synthesis (Class I), impaired gating (Class III), and reduced conductance (Class IV) are other classes of CFTR mutations, but Class II specifically relates to processing and trafficking defects.\"\n  },\n  {\n    \"question\": \"Which test is considered the gold standard for diagnosing Cystic Fibrosis?\",\n    \"options\": {\n      \"A\": \"Immunoreactive trypsinogen (IRT) screening\",\n      \"B\": \"Genetic testing for CFTR mutations\",\n      \"C\": \"Quantitative pilocarpine iontophoresis sweat chloride test\",\n      \"D\": \"Nasal potential difference (NPD) measurement\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cystic_fibrosis\",\n    \"deepDiveExplanation\": \"The quantitative pilocarpine iontophoresis sweat chloride test is the gold standard for CF diagnosis. A chloride concentration ≥ 60 mmol/L (in adults and children) is diagnostic of CF, while values between 30-59 mmol/L are intermediate and require further testing. This test directly measures the functional defect in chloride transport.\",\n    \"highYieldPearl\": \"Sweat chloride test is the definitive diagnostic test for CF, reflecting abnormal chloride transport.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"IRT is a newborn screen, not a definitive diagnostic test. Genetic testing confirms the mutation but is not the sole diagnostic gold standard as some mutations have varying clinical significance or are not always detected. NPD is a specialized research or confirmatory test, not typically first-line for diagnosis.\"\n  },\n  {\n    \"question\": \"In adults with Cystic Fibrosis, which pathogen is most commonly associated with chronic lung infection?\",\n    \"options\": {\n      \"A\": \"Staphylococcus aureus\",\n      \"B\": \"Haemophilus influenzae\",\n      \"C\": \"Pseudomonas aeruginosa\",\n      \"D\": \"Aspergillus fumigatus\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"cystic_fibrosis\",\n    \"deepDiveExplanation\": \"While *Staphylococcus aureus* and *Haemophilus influenzae* are common in early childhood CF, *Pseudomonas aeruginosa* becomes the predominant pathogen in older children and adults. It establishes chronic infection, forms biofilms, and contributes significantly to progressive lung damage and decline in lung function.\",\n    \"highYieldPearl\": \"*Pseudomonas aeruginosa* is the leading cause of chronic lung infection and morbidity in adult CF patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"*S. aureus* and *H. influenzae* are common in younger CF patients. *Aspergillus fumigatus* can cause allergic bronchopulmonary aspergillosis (ABPA) in CF, but *Pseudomonas* is the most common chronic bacterial pathogen overall in adults.\"\n  },\n  {\n    \"question\": \"Ivacaftor, a CFTR modulator, primarily functions as which type of agent?\",\n    \"options\": {\n      \"A\": \"Corrector\",\n      \"B\": \"Potentiator\",\n      \"C\": \"Amplifier\",\n      \"D\": \"Stabilizer\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"cystic_fibrosis\",\n    \"deepDiveExplanation\": \"CFTR modulators are drugs that target specific CFTR protein defects. Ivacaftor is a potentiator, meaning it binds to the CFTR protein at the cell surface and increases the opening probability (gating) of the chloride channel, thereby enhancing chloride transport. It is particularly effective for Class III (gating) mutations.\",\n    \"highYieldPearl\": \"Ivacaftor 'potentiates' existing CFTR channels, improving their function, especially in gating mutations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Correctors (e.g., Lumacaftor, Tezacaftor, Elexacaftor) help misfolded Class II CFTR proteins reach the cell surface. Amplifiers and Stabilizers are not standard classifications for CFTR modulators.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-381.9294128417969}],"createTime":"2025-12-31T07:46:18.890931Z","modelVersion":"gemini-2.5-flash","responseId":"ytRUabOwNorfnvgPkraasQ0","usageMetadata":{"billablePromptUsage":{"textCount":1020},"candidatesTokenCount":1414,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1414}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1975,"totalTokenCount":3753,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:49.530169+00:00"}
{"metadata":"one-liner|ards_pathophys|ARDS - Pathophysiology|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"ARDS - Pathophysiology\".\nSet the \"topic\" field in the JSON to \"ards_pathophys\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.26321699712612573,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary pathological event initiating ARDS is direct injury to which structure?\",\n    \"options\": {\n      \"A\": \"Bronchial epithelium\",\n      \"B\": \"Alveolar-capillary membrane\",\n      \"C\": \"Pleural mesothelium\",\n      \"D\": \"Pulmonary artery endothelium\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"ARDS is defined by acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. The initial insult targets the alveolar-capillary membrane, comprising alveolar epithelial cells (Type I and II pneumocytes) and capillary endothelial cells.\",\n    \"highYieldPearl\": \"Direct injury to the alveolar-capillary membrane leads to protein-rich fluid exudation into the alveoli, a hallmark of ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A, C, D represent other lung structures, but the core pathology of ARDS specifically involves the alveolar-capillary unit. Bronchial epithelium damage is more common in conditions like bronchitis or asthma, while pleural or large vessel endothelium damage is not the primary ARDS driver.\"\n  },\n  {\n    \"question\": \"Which components primarily form hyaline membranes in the exudative phase of ARDS?\",\n    \"options\": {\n      \"A\": \"Type II pneumocytes and surfactant\",\n      \"B\": \"Neutrophils and macrophages\",\n      \"C\": \"Fibrin and necrotic Type I pneumocytes\",\n      \"D\": \"Collagen and elastic fibers\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"In the exudative phase, the damaged alveolar-capillary barrier allows protein-rich fluid, including fibrin, to leak into the alveolar space. This combines with cellular debris from necrotic Type I pneumocytes to form the characteristic hyaline membranes, lining the alveolar walls.\",\n    \"highYieldPearl\": \"Hyaline membranes are a histological hallmark of the exudative phase of ARDS, signifying severe alveolar damage and protein leakage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Type II pneumocytes are involved in repair, not hyaline membrane formation (A). Neutrophils and macrophages are inflammatory cells, not the structural components of the membrane (B). Collagen and elastic fibers are components of the extracellular matrix, involved in fibrosis, not acute hyaline membrane formation (D).\"\n  },\n  {\n    \"question\": \"Dysfunction of which alveolar cell type primarily contributes to surfactant deficiency in ARDS?\",\n    \"options\": {\n      \"A\": \"Type I pneumocytes\",\n      \"B\": \"Type II pneumocytes\",\n      \"C\": \"Alveolar macrophages\",\n      \"D\": \"Endothelial cells\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"Type II pneumocytes are cuboidal cells responsible for producing and secreting pulmonary surfactant, which reduces surface tension and prevents alveolar collapse. In ARDS, Type II pneumocytes are often injured, leading to impaired surfactant production and function, contributing to decreased lung compliance and atelectasis.\",\n    \"highYieldPearl\": \"Loss of functional Type II pneumocytes impairs surfactant production, exacerbating alveolar collapse and hypoxemia in ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Type I pneumocytes are primarily involved in gas exchange and are more susceptible to injury, but do not produce surfactant (A). Alveolar macrophages are immune cells (C). Endothelial cells form the capillary lining (D).\"\n  },\n  {\n    \"question\": \"The pulmonary edema in ARDS is characterized primarily by which mechanism?\",\n    \"options\": {\n      \"A\": \"Increased hydrostatic pressure\",\n      \"B\": \"Decreased oncotic pressure\",\n      \"C\": \"Increased microvascular permeability\",\n      \"D\": \"Lymphatic obstruction\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"ARDS is a form of non-cardiogenic pulmonary edema. The defining feature is severe inflammation leading to increased permeability of the alveolar-capillary membrane. This allows protein-rich fluid to leak from the capillaries into the interstitial and alveolar spaces, unlike cardiogenic edema which is due to increased hydrostatic pressure.\",\n    \"highYieldPearl\": \"ARDS edema is 'protein-rich' due to increased permeability, distinguishing it from cardiogenic edema which is 'protein-poor.'\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A and B describe mechanisms of cardiogenic or systemic edema. Lymphatic obstruction (D) is a rare cause of pulmonary edema and not primary to ARDS.\"\n  },\n  {\n    \"question\": \"Refractory hypoxemia in ARDS is predominantly due to which physiological derangement?\",\n    \"options\": {\n      \"A\": \"Increased dead space\",\n      \"B\": \"Diffusion limitation\",\n      \"C\": \"Intrapulmonary shunting\",\n      \"D\": \"Decreased cardiac output\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"In ARDS, damaged alveoli become filled with fluid and collapse (atelectasis), or are perfused but not ventilated. This creates areas of very low ventilation-perfusion (V/Q) ratio, primarily intrapulmonary shunting, where blood flows past non-ventilated alveoli, leading to venous admixture and severe hypoxemia that is often refractory to supplemental oxygen.\",\n    \"highYieldPearl\": \"Intrapulmonary shunting (V/Q = 0) is the main cause of refractory hypoxemia in ARDS, as shunted blood does not participate in gas exchange.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Increased dead space (A) (V/Q = infinity) impairs CO2 elimination more than oxygenation. Diffusion limitation (B) is less significant in ARDS than shunting. Decreased cardiac output (D) can worsen hypoxemia but is not the primary cause of refractory hypoxemia in ARDS itself.\"\n  },\n  {\n    \"question\": \"Which cytokine is considered a key early pro-inflammatory mediator in the ARDS cascade?\",\n    \"options\": {\n      \"A\": \"IL-10\",\n      \"B\": \"TGF-beta\",\n      \"C\": \"TNF-alpha\",\n      \"D\": \"IL-4\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"Tumor Necrosis Factor-alpha (TNF-alpha) along with IL-1 and IL-6 are crucial early pro-inflammatory cytokines released by activated immune cells (e.g., macrophages, neutrophils) in response to the initial lung injury. They amplify the inflammatory response, recruit more immune cells, and contribute to endothelial and epithelial damage.\",\n    \"highYieldPearl\": \"TNF-alpha, IL-1, and IL-6 are central to the early, uncontrolled inflammation in ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"IL-10 and IL-4 are typically anti-inflammatory or involved in allergic responses (A, D). TGF-beta (B) is more associated with fibrosis and the later proliferative/fibrotic phases.\"\n  },\n  {\n    \"question\": \"A characteristic early physiological change in ARDS is a significant decrease in which lung property?\",\n    \"options\": {\n      \"A\": \"Functional residual capacity\",\n      \"B\": \"Lung compliance\",\n      \"C\": \"Airway resistance\",\n      \"D\": \"Diffusing capacity\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"The accumulation of protein-rich fluid, inflammatory cells, and hyaline membranes within the alveoli and interstitium makes the lungs stiff and difficult to inflate. This directly translates to a significant decrease in lung compliance (change in volume for a given change in pressure).\",\n    \"highYieldPearl\": \"Decreased lung compliance is a hallmark of ARDS, necessitating higher ventilatory pressures to achieve adequate tidal volumes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While FRC (A) might decrease due to atelectasis, decreased compliance is a more direct and defining mechanical property change. Airway resistance (C) is not typically increased in ARDS unless there's concomitant bronchospasm. Diffusing capacity (D) will be impaired, but decreased compliance is a more fundamental and early physiological change reflecting the lung mechanics.\"\n  },\n  {\n    \"question\": \"The proliferative phase of ARDS is characterized by which predominant cellular event?\",\n    \"options\": {\n      \"A\": \"Neutrophil extravasation\",\n      \"B\": \"Fibroblast proliferation and collagen deposition\",\n      \"C\": \"Hyaline membrane formation\",\n      \"D\": \"Type I pneumocyte necrosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"Following the initial exudative phase (days 1-7), the proliferative phase (days 7-21) involves attempts at lung repair. This includes proliferation of Type II pneumocytes to repopulate the alveolar epithelium and, importantly, fibroblast proliferation and collagen deposition in the interstitium, laying the groundwork for potential fibrosis.\",\n    \"highYieldPearl\": \"Fibroblast proliferation and collagen deposition define the proliferative phase, which can lead to irreversible lung fibrosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Neutrophil extravasation and Type I pneumocyte necrosis are features of the exudative phase (A, D). Hyaline membrane formation (C) is also a key feature of the exudative phase.\"\n  },\n  {\n    \"question\": \"Neutrophil extravasation into the alveolar space in ARDS is primarily mediated by which class of molecules?\",\n    \"options\": {\n      \"A\": \"Immunoglobulins\",\n      \"B\": \"Chemokine gradients\",\n      \"C\": \"Complement proteins\",\n      \"D\": \"Surfactant proteins\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"Following initial injury and cytokine release, endothelial cells express adhesion molecules (e.g., ICAM-1, VCAM-1). Chemokines (e.g., IL-8, MIP-1alpha) produced by activated alveolar macrophages and epithelial cells create a gradient that attracts and guides neutrophils from the pulmonary capillaries across the endothelium and epithelium into the alveolar space, where they release destructive enzymes and reactive oxygen species.\",\n    \"highYieldPearl\": \"Chemokines are crucial for directed migration (chemotaxis) of neutrophils to the site of inflammation in ARDS.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Immunoglobulins (A) are involved in adaptive immunity. Complement proteins (C) can opsonize pathogens and induce inflammation but are not the primary drivers of directed neutrophil extravasation. Surfactant proteins (D) are involved in innate immunity and surfactant function, not direct neutrophil recruitment.\"\n  },\n  {\n    \"question\": \"Which of the following is a key pathophysiological difference between ARDS and hydrostatic pulmonary edema?\",\n    \"options\": {\n      \"A\": \"Presence of alveolar protein\",\n      \"B\": \"Impaired gas exchange\",\n      \"C\": \"Decreased lung compliance\",\n      \"D\": \"Bilateral infiltrates on CXR\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ards_pathophys\",\n    \"deepDiveExplanation\": \"The fundamental distinction lies in the integrity of the alveolar-capillary barrier. In ARDS, this barrier is compromised, leading to a 'protein-rich' exudate in the alveoli. In hydrostatic (cardiogenic) pulmonary edema, the barrier is largely intact, and fluid extravasation is due to increased hydrostatic pressure, resulting in a 'protein-poor' transudate.\",\n    \"highYieldPearl\": \"Protein content of alveolar fluid is a critical differentiator: high in ARDS, low in cardiogenic edema.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Impaired gas exchange (B), decreased lung compliance (C), and bilateral infiltrates (D) are common features of both ARDS and severe hydrostatic pulmonary edema, making them poor discriminators. The protein content directly reflects the integrity of the alveolar-capillary membrane.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-759.907470703125}],"createTime":"2025-12-31T07:45:12.464598Z","modelVersion":"gemini-2.5-flash","responseId":"iNRUadatHOaEgLUPxb2_UQ","usageMetadata":{"billablePromptUsage":{"textCount":1026},"candidatesTokenCount":2887,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2887}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":3809,"totalTokenCount":7061,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:08.148609+00:00"}
{"metadata":"one-liner|tb_ntm|Nontuberculous Mycobacteria (NTM)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Nontuberculous Mycobacteria (NTM)\".\nSet the \"topic\" field in the JSON to \"tb_ntm\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.36909254067260305,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"A key microbiological criterion for diagnosing NTM lung disease per ATS/IDSA guidelines is?\",\n    \"options\": {\n      \"A\": \"One positive sputum culture\",\n      \"B\": \"Two positive sputum cultures\",\n      \"C\": \"One positive bronchoalveolar lavage culture\",\n      \"D\": \"Biopsy showing granulomas\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_ntm\",\n    \"deepDiveExplanation\": \"The ATS/IDSA diagnostic criteria for NTM lung disease require a combination of clinical, radiographic, and microbiological findings. Microbiologically, it typically necessitates at least two separate expectorated sputum samples positive for NTM, or one positive bronchoalveolar lavage (BAL) culture, or a biopsy positive for NTM with compatible histopathology.\",\n    \"highYieldPearl\": \"Remember the '2 sputum OR 1 BAL OR biopsy' rule for microbiological diagnosis of NTM lung disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A (one positive sputum) is insufficient. Option D (biopsy alone) is incomplete without a positive culture from the biopsy. While one positive BAL (C) is also a criterion, two positive sputa (B) is often the more frequently met initial criterion for non-invasive sampling.\"\n  },\n  {\n    \"question\": \"The most common NTM species causing lung disease globally is?\",\n    \"options\": {\n      \"A\": \"Mycobacterium kansasii\",\n      \"B\": \"Mycobacterium fortuitum\",\n      \"C\": \"Mycobacterium avium complex\",\n      \"D\": \"Mycobacterium abscessus\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_ntm\",\n    \"deepDiveExplanation\": \"Mycobacterium avium complex (MAC), which includes M. avium and M. intracellulare, is the most frequently isolated NTM species from clinical samples and the predominant cause of NTM lung disease worldwide, particularly in immunocompetent individuals.\",\n    \"highYieldPearl\": \"MAC (Mycobacterium avium complex) is the most common cause of NTM lung disease globally.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other NTM species like M. kansasii and M. abscessus are significant causes of lung disease, MAC collectively accounts for the largest proportion of NTM lung infections.\"\n  },\n  {\n    \"question\": \"What is the recommended minimum duration of treatment for MAC lung disease?\",\n    \"options\": {\n      \"A\": \"6 months\",\n      \"B\": \"9 months\",\n      \"C\": \"12 months after culture conversion\",\n      \"D\": \"18 months\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_ntm\",\n    \"deepDiveExplanation\": \"Treatment for Mycobacterium avium complex (MAC) lung disease typically involves a multi-drug regimen (macrolide-based) for a prolonged period. The recommended duration is at least 12 months after the patient achieves culture conversion (i.e., negative sputum cultures).\",\n    \"highYieldPearl\": \"MAC treatment requires a full year of therapy AFTER culture negativity to prevent relapse.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Shorter durations (A, B) are inadequate and associated with higher rates of relapse and drug resistance. Option D (18 months) might be used in more refractory cases, but 12 months post-conversion is the standard minimum.\"\n  },\n  {\n    \"question\": \"Which NTM species is notoriously difficult to treat due to intrinsic macrolide resistance?\",\n    \"options\": {\n      \"A\": \"Mycobacterium kansasii\",\n      \"B\": \"Mycobacterium xenopi\",\n      \"C\": \"Mycobacterium abscessus\",\n      \"D\": \"Mycobacterium gordonae\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_ntm\",\n    \"deepDiveExplanation\": \"Mycobacterium abscessus is well-known for its intrinsic resistance to many antibiotics, including macrolides, particularly due to the inducible erm(41) gene. This resistance makes treatment extremely challenging, often requiring combination therapy with parenteral agents.\",\n    \"highYieldPearl\": \"M. abscessus is the 'problem child' among NTMs due to its inherent drug resistance, especially to macrolides.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other NTMs can develop resistance, M. abscessus has a high degree of intrinsic resistance that complicates therapy from the outset, making it distinct from species like M. kansasii or M. xenopi, which are generally more susceptible to standard regimens.\"\n  },\n  {\n    \"question\": \"Which genetic deficiency is strongly associated with disseminated NTM disease?\",\n    \"options\": {\n      \"A\": \"Alpha-1 antitrypsin deficiency\",\n      \"B\": \"Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation\",\n      \"C\": \"Interferon-gamma (IFN-γ) / Interleukin-12 (IL-12) pathway defects\",\n      \"D\": \"Surfactant Protein B deficiency\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_ntm\",\n    \"deepDiveExplanation\": \"Defects in the interferon-gamma (IFN-γ) and interleukin-12 (IL-12) pathway lead to impaired macrophage activation and are a major genetic predisposition for severe, often disseminated, NTM infections, particularly in pediatric populations.\",\n    \"highYieldPearl\": \"IFN-γ/IL-12 pathway integrity is crucial for immunity against disseminated NTM infections.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While CFTR mutations (B) are a risk factor for NTM lung disease (especially MAC), they are not primarily associated with disseminated NTM disease. Alpha-1 antitrypsin deficiency (A) and Surfactant Protein B deficiency (D) are unrelated to NTM susceptibility in this manner.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-514.8840942382813}],"createTime":"2025-12-31T07:45:37.909117Z","modelVersion":"gemini-2.5-flash","responseId":"odRUab2-N9iBnvgPh-GVQA","usageMetadata":{"billablePromptUsage":{"textCount":1028},"candidatesTokenCount":1395,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1395}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":1405,"totalTokenCount":3168,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:55.674376+00:00"}
{"metadata":"one-liner|lung_cancer_histo|Lung Cancer - Histopathology (NSCLC vs SCLC)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Histopathology (NSCLC vs SCLC)\".\nSet the \"topic\" field in the JSON to \"lung_cancer_histo\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3174295507229695,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which histological feature is most characteristic of Small Cell Lung Carcinoma?\",\n    \"options\": {\n      \"A\": \"Keratin pearls\",\n      \"B\": \"Glandular formation\",\n      \"C\": \"Nuclear molding\",\n      \"D\": \"Prominent nucleoli\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Small Cell Lung Carcinoma (SCLC) is characterized by small cells with scant cytoplasm, finely granular chromatin, absent or inconspicuous nucleoli, and a high mitotic rate. Nuclear molding, where nuclei conform to each other's shapes, is a classic and highly characteristic feature. Crush artifact is also common due to the fragility of the cells.\",\n    \"highYieldPearl\": \"Nuclear molding and crush artifact are key microscopic findings for SCLC. SCLC cells are typically 2-3 times the size of a lymphocyte.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and B describe features of Squamous Cell Carcinoma and Adenocarcinoma, respectively. Prominent nucleoli are usually seen in Large Cell Carcinoma or some adenocarcinomas, not SCLC.\"\n  },\n  {\n    \"question\": \"What is the most common histological subtype of Non-Small Cell Lung Carcinoma?\",\n    \"options\": {\n      \"A\": \"Squamous cell carcinoma\",\n      \"B\": \"Adenocarcinoma\",\n      \"C\": \"Large cell carcinoma\",\n      \"D\": \"Carcinoid tumor\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Adenocarcinoma is the most common subtype of NSCLC, accounting for approximately 40% of all lung cancers. Its incidence has been increasing, particularly in women and non-smokers. It typically arises in the peripheral lung.\",\n    \"highYieldPearl\": \"Adenocarcinoma is the leading cause of lung cancer overall and is more common in non-smokers and women. It often arises peripherally.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Squamous cell carcinoma was historically the most common, but adenocarcinoma has surpassed it. Carcinoid tumor is a distinct neuroendocrine tumor, not a common NSCLC subtype.\"\n  },\n  {\n    \"question\": \"Which immunohistochemical marker is highly specific for pulmonary adenocarcinoma?\",\n    \"options\": {\n      \"A\": \"p40\",\n      \"B\": \"Chromogranin A\",\n      \"C\": \"TTF-1\",\n      \"D\": \"CD56\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Thyroid Transcription Factor-1 (TTF-1) is a nuclear transcription factor expressed in lung and thyroid epithelium. It is a highly sensitive and specific marker for pulmonary adenocarcinoma, along with Napsin A. p40 is a marker for squamous differentiation, while Chromogranin A and CD56 are neuroendocrine markers.\",\n    \"highYieldPearl\": \"TTF-1 and Napsin A are excellent markers for primary lung adenocarcinoma. TTF-1 positivity can also be seen in some SCLCs and thyroid cancers.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"p40 is for squamous cell carcinoma. Chromogranin A and CD56 are for neuroendocrine tumors like SCLC or carcinoids. Confusion often arises with TTF-1's role in both adenocarcinoma and some SCLC, but its specificity for pulmonary adenocarcinoma in the NSCLC context is key.\"\n  },\n  {\n    \"question\": \"Which immunohistochemical marker is most characteristic of squamous cell carcinoma of the lung?\",\n    \"options\": {\n      \"A\": \"TTF-1\",\n      \"B\": \"Napsin A\",\n      \"C\": \"p63\",\n      \"D\": \"Synaptophysin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"p63 and p40 are highly sensitive and specific immunohistochemical markers for squamous cell differentiation. p63 is a nuclear transcription factor, and p40 is an isoform of p63, often preferred due to higher specificity. TTF-1 and Napsin A are for adenocarcinoma, while Synaptophysin is a neuroendocrine marker.\",\n    \"highYieldPearl\": \"p63 and p40 are the go-to markers for squamous cell carcinoma. CK5/6 is another useful marker for squamous differentiation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"TTF-1 and Napsin A are for adenocarcinoma. Synaptophysin is a neuroendocrine marker. Incorrectly associating these can lead to misdiagnosis.\"\n  },\n  {\n    \"question\": \"Which marker is commonly positive in Small Cell Lung Carcinoma due to its neuroendocrine origin?\",\n    \"options\": {\n      \"A\": \"CK7\",\n      \"B\": \"TTF-1\",\n      \"C\": \"Chromogranin A\",\n      \"D\": \"EGFR\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Small Cell Lung Carcinoma (SCLC) is a highly aggressive neuroendocrine tumor. Consequently, it expresses neuroendocrine markers such as Chromogranin A, Synaptophysin, and CD56 (NCAM). TTF-1 can also be positive in SCLC, but Chromogranin A is more specific for its neuroendocrine nature.\",\n    \"highYieldPearl\": \"SCLC consistently expresses neuroendocrine markers like Chromogranin A, Synaptophysin, and CD56, reflecting its origin from neuroendocrine cells.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"TTF-1 is often positive in SCLC but is also a primary marker for adenocarcinoma. EGFR is a molecular target, not a general histopathological marker for SCLC.\"\n  },\n  {\n    \"question\": \"Intercellular bridges and keratinization are hallmark features of which lung cancer type?\",\n    \"options\": {\n      \"A\": \"Adenocarcinoma\",\n      \"B\": \"Small cell carcinoma\",\n      \"C\": \"Squamous cell carcinoma\",\n      \"D\": \"Large cell neuroendocrine carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Squamous cell carcinoma is characterized by evidence of squamous differentiation, which includes the formation of keratin pearls (concentric layers of keratin) and the presence of intercellular bridges (desmosomes visible between cells, giving a 'prickle cell' appearance).\",\n    \"highYieldPearl\": \"Look for keratin pearls and intercellular bridges to identify squamous cell carcinoma. These features represent terminal squamous differentiation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Each lung cancer type has distinct histological features. Confusing these basic characteristics can lead to misidentification.\"\n  },\n  {\n    \"question\": \"Mucin production and glandular differentiation are characteristic of which primary lung malignancy?\",\n    \"options\": {\n      \"A\": \"Squamous cell carcinoma\",\n      \"B\": \"Small cell carcinoma\",\n      \"C\": \"Adenocarcinoma\",\n      \"D\": \"Pleomorphic carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Adenocarcinoma is defined by its glandular differentiation, which can manifest as acinar, papillary, micropapillary, solid, or lepidic growth patterns. Mucin production, either intracellular or extracellular, is a common feature of adenocarcinomas and can be highlighted by special stains like mucicarmine or PAS.\",\n    \"highYieldPearl\": \"Glandular structures and mucin are key histological indicators for adenocarcinoma. Immunohistochemistry with TTF-1 and Napsin A further confirms the diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Squamous cell carcinoma has keratinization, and small cell carcinoma has neuroendocrine features. Pleomorphic carcinoma is a rare variant of NSCLC with mixed histology.\"\n  },\n  {\n    \"question\": \"Scant cytoplasm and ill-defined cell borders are characteristic of which lung cancer histology?\",\n    \"options\": {\n      \"A\": \"Adenocarcinoma\",\n      \"B\": \"Squamous cell carcinoma\",\n      \"C\": \"Small cell carcinoma\",\n      \"D\": \"Large cell neuroendocrine carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Small Cell Lung Carcinoma (SCLC) cells are typically small, with very scant cytoplasm, giving them a 'naked nuclei' appearance. The cell borders are often indistinct, and the nuclei are hyperchromatic with fine, granular chromatin. This contributes to the characteristic nuclear molding and crush artifact.\",\n    \"highYieldPearl\": \"The 'scant cytoplasm' and 'ill-defined cell borders' are crucial for identifying SCLC, along with nuclear molding and finely granular chromatin.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other lung cancer types typically have more abundant or clearly defined cytoplasm. Large cell neuroendocrine carcinoma has more cytoplasm and prominent nucleoli compared to SCLC.\"\n  },\n  {\n    \"question\": \"Which tumor suppressor gene is commonly inactivated in Small Cell Lung Carcinoma?\",\n    \"options\": {\n      \"A\": \"EGFR\",\n      \"B\": \"ALK\",\n      \"C\": \"TP53\",\n      \"D\": \"KRAS\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Small Cell Lung Carcinoma (SCLC) is characterized by a high frequency of inactivation of the tumor suppressor genes TP53 and RB1. These genetic alterations are considered early events in SCLC development. EGFR, ALK, and KRAS are more commonly associated with NSCLC, particularly adenocarcinoma.\",\n    \"highYieldPearl\": \"Co-inactivation of TP53 and RB1 is a defining genetic hallmark of SCLC, distinguishing it from NSCLC which often has oncogene activations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"EGFR, ALK, and KRAS are oncogenes primarily associated with NSCLC, especially adenocarcinoma, and are targets for specific therapies. SCLC is defined by tumor suppressor gene inactivation.\"\n  },\n  {\n    \"question\": \"Which lung cancer subtype is characterized by rapid doubling time and early metastatic spread?\",\n    \"options\": {\n      \"A\": \"Adenocarcinoma\",\n      \"B\": \"Squamous cell carcinoma\",\n      \"C\": \"Small cell carcinoma\",\n      \"D\": \"Large cell carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_histo\",\n    \"deepDiveExplanation\": \"Small Cell Lung Carcinoma (SCLC) is known for its aggressive biological behavior, including rapid cell doubling time, early dissemination, and frequent presentation with metastatic disease (often to brain, liver, bone, and adrenal glands). This contrasts with NSCLC, which generally has slower growth and later metastasis.\",\n    \"highYieldPearl\": \"SCLC is highly aggressive, often presenting with advanced disease due to its rapid growth and early metastasis. This biological characteristic influences its systemic treatment approach.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While all lung cancers can metastasize, SCLC is particularly noted for its aggressive nature and early, widespread metastasis, often limiting surgical options and necessitating systemic therapy from the outset.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-851.0286254882813}],"createTime":"2025-12-31T07:46:22.188180Z","modelVersion":"gemini-2.5-flash","responseId":"ztRUaZS-C86RhMIPz6CV4Q8","usageMetadata":{"billablePromptUsage":{"textCount":1047},"candidatesTokenCount":2681,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2681}],"promptTokenCount":372,"promptTokensDetails":[{"modality":"TEXT","tokenCount":372}],"thoughtsTokenCount":1796,"totalTokenCount":4849,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:57.723145+00:00"}
{"metadata":"one-liner|tb_end_strategy|END TB Strategy and NIKSHAY|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"END TB Strategy and NIKSHAY\".\nSet the \"topic\" field in the JSON to \"tb_end_strategy\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.36077301571096976,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"India's National Strategic Plan aims to eliminate Tuberculosis by which year?\",\n    \"options\": {\n      \"A\": \"2025\",\n      \"B\": \"2030\",\n      \"C\": \"2035\",\n      \"D\": \"2040\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"tb_end_strategy\",\n    \"deepDiveExplanation\": \"The National Strategic Plan for Tuberculosis Elimination (NSP for TB Elimination) 2017-2025 sets an ambitious target for India to eliminate TB by 2025, five years ahead of the global Sustainable Development Goal (SDG) target of 2030. This plan outlines strategies for case finding, treatment, prevention, and building robust systems.\",\n    \"highYieldPearl\": \"India's 2025 target for TB elimination is more ambitious than the global WHO End TB Strategy's 2030 target for reduction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors include the global SDG target (2030) and other arbitrary years. Candidates must differentiate between India's specific national goal and the broader international one.\"\n  },\n  {\n    \"question\": \"Which of the following is NOT a pillar of the WHO End TB Strategy?\",\n    \"options\": {\n      \"A\": \"Integrated patient-centered care and prevention\",\n      \"B\": \"Bold policies and supportive systems\",\n      \"C\": \"Intensified research and innovation\",\n      \"D\": \"Universal health coverage\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_end_strategy\",\n    \"deepDiveExplanation\": \"The WHO End TB Strategy is built on three main pillars: 1. Integrated, patient-centered care and prevention, 2. Bold policies and supportive systems, and 3. Intensified research and innovation. While Universal Health Coverage (UHC) is a crucial enabling factor and a broader health goal, it is not listed as one of the three *explicit* pillars of the End TB Strategy itself.\",\n    \"highYieldPearl\": \"Remember the three explicit pillars: Care/Prevention, Policies/Systems, Research/Innovation. UHC is an enabler, not a pillar.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Universal Health Coverage is a very relevant concept in public health and TB control, making it a plausible but incorrect option. Candidates need to know the specific, formally defined pillars.\"\n  },\n  {\n    \"question\": \"NIKSHAY portal's primary function in the National TB Elimination Program is?\",\n    \"options\": {\n      \"A\": \"Drug logistics and supply chain management\",\n      \"B\": \"Real-time patient notification and monitoring\",\n      \"C\": \"Healthcare worker training modules\",\n      \"D\": \"TB diagnostic kit quality assurance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_end_strategy\",\n    \"deepDiveExplanation\": \"NIKSHAY is the unified ICT-enabled system for notification, patient management, and surveillance for TB in India. It serves as a single window for tracking every TB patient from diagnosis to treatment outcome, facilitating real-time data collection, monitoring, and program management. Notification of TB cases to NIKSHAY is mandatory in India.\",\n    \"highYieldPearl\": \"NIKSHAY is central to TB surveillance, data-driven program management, and mandatory notification in India.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All options relate to aspects of a TB program. The key is to identify the *primary* function of NIKSHAY, which is patient notification, tracking, and monitoring.\"\n  },\n  {\n    \"question\": \"The financial incentive for nutritional support to TB patients, managed through NIKSHAY, is known as?\",\n    \"options\": {\n      \"A\": \"Ayushman Bharat Yojana\",\n      \"B\": \"NIKSHAY Poshan Yojana\",\n      \"C\": \"Pradhan Mantri Jan Arogya Yojana\",\n      \"D\": \"Direct Benefit Transfer for Health\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_end_strategy\",\n    \"deepDiveExplanation\": \"NIKSHAY Poshan Yojana (formerly known as the Direct Benefit Transfer scheme for Nutritional Support to TB Patients) provides Rs. 500 per month to all notified TB patients for the entire duration of their treatment. This is a critical component for improving treatment adherence and outcomes, as malnutrition is a significant risk factor for TB. The payments are processed through the NIKSHAY portal.\",\n    \"highYieldPearl\": \"NIKSHAY Poshan Yojana directly addresses the nutritional needs of TB patients, a key social determinant of health.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other options are related to health schemes in India, but NIKSHAY Poshan Yojana is specific to TB patient nutritional support. Candidates might confuse it with other DBT schemes if they don't know the specific nomenclature.\"\n  },\n  {\n    \"question\": \"The WHO End TB Strategy aims for what reduction in TB deaths by 2030 compared to 2015?\",\n    \"options\": {\n      \"A\": \"50%\",\n      \"B\": \"75%\",\n      \"C\": \"80%\",\n      \"D\": \"95%\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_end_strategy\",\n    \"deepDiveExplanation\": \"The WHO End TB Strategy sets ambitious targets for 2030 relative to the 2015 baseline: 90% reduction in TB incidence rate, 95% reduction in TB deaths, and zero TB-affected families facing catastrophic costs. It's crucial to distinguish between the incidence and mortality targets.\",\n    \"highYieldPearl\": \"The reduction targets for TB incidence (90%) and TB deaths (95%) by 2030 are distinct and often confused. Remember 95% for deaths, 90% for incidence.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"All options are plausible percentage reductions. Candidates must recall the specific, distinct targets for incidence versus mortality. 90% is for incidence, 95% for deaths.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-524.56396484375}],"createTime":"2025-12-31T07:46:20.164286Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUab6DCqHygLUPh5jXkAM","usageMetadata":{"billablePromptUsage":{"textCount":1029},"candidatesTokenCount":1454,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1454}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":2058,"totalTokenCount":3880,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:59.385054+00:00"}
{"metadata":"one-liner|pneumoconioses|Pneumoconioses (Asbestosis, Silicosis)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Pneumoconioses (Asbestosis, Silicosis)\".\nSet the \"topic\" field in the JSON to \"pneumoconioses\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.39662756089823836,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is the most characteristic radiographic finding of asbestos exposure?\",\n    \"options\": {\n      \"A\": \"Honeycombing\",\n      \"B\": \"Pleural plaques\",\n      \"C\": \"Ground glass opacities\",\n      \"D\": \"Eggshell calcifications\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumoconioses\",\n    \"deepDiveExplanation\": \"Pleural plaques are the most common radiographic manifestation of asbestos exposure, often asymptomatic and benign. They are typically bilateral, discrete, and appear on the parietal pleura, diaphragm, and mediastinum. Calcification is common. While asbestosis itself causes interstitial fibrosis (honeycombing), plaques are highly specific to asbestos exposure.\",\n    \"highYieldPearl\": \"Pleural plaques are highly specific for asbestos exposure but do not directly reflect asbestosis severity or predict malignant transformation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Honeycombing is seen in fibrotic asbestosis but is non-specific and also seen in other interstitial lung diseases. Eggshell calcifications are characteristic of silicosis.\"\n  },\n  {\n    \"question\": \"Which cell type primarily initiates the fibrogenic response in silicosis?\",\n    \"options\": {\n      \"A\": \"Type I pneumocyte\",\n      \"B\": \"Alveolar macrophage\",\n      \"C\": \"Fibroblast\",\n      \"D\": \"Neutrophil\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pneumoconioses\",\n    \"deepDiveExplanation\": \"Alveolar macrophages phagocytose inhaled silica particles. Unable to effectively clear them, the macrophages become activated, release reactive oxygen species, and undergo apoptosis or necrosis, which in turn releases pro-inflammatory cytokines, chemokines, and fibrogenic mediators (e.g., TNF-α, IL-1, PDGF, TGF-β). This cascade then activates fibroblasts, leading to collagen deposition and progressive fibrosis.\",\n    \"highYieldPearl\": \"Macrophage activation and subsequent release of fibrogenic mediators are central to silicosis pathogenesis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Fibroblasts are the effector cells responsible for collagen production and fibrosis, but they are activated by signals from the macrophages, which initiate the pathological process.\"\n  },\n  {\n    \"question\": \"Which malignancy has the strongest and most specific association with asbestos exposure?\",\n    \"options\": {\n      \"A\": \"Lung adenocarcinoma\",\n      \"B\": \"Squamous cell carcinoma\",\n      \"C\": \"Malignant mesothelioma\",\n      \"D\": \"Small cell carcinoma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumoconioses\",\n    \"deepDiveExplanation\": \"Malignant mesothelioma is a rare and aggressive cancer of the pleura, peritoneum, or pericardium, almost exclusively linked to asbestos exposure. It has a characteristic long latency period (20-50 years) after initial exposure. While asbestos also increases the risk of lung cancer (all histological types), especially with concomitant smoking, mesothelioma has the strongest and most specific association with asbestos.\",\n    \"highYieldPearl\": \"Malignant mesothelioma is the signature malignancy of asbestos exposure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Lung cancer risk (including adenocarcinoma) is increased by asbestos, but mesothelioma's link is far more specific and dose-dependent, making it the most characteristic asbestos-related malignancy.\"\n  },\n  {\n    \"question\": \"What is the classic radiographic finding of hilar lymph nodes in silicosis?\",\n    \"options\": {\n      \"A\": \"Diffuse enlargement\",\n      \"B\": \"Central necrosis\",\n      \"C\": \"Eggshell calcification\",\n      \"D\": \"Peripheral rim enhancement\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pneumoconioses\",\n    \"deepDiveExplanation\": \"Eggshell calcification refers to calcified lymph nodes with a peripheral rim of calcification and a lucent center. It is highly characteristic, though not pathognomonic, of silicosis, particularly affecting the hilar and mediastinal lymph nodes. It typically indicates chronic and often severe silica exposure.\",\n    \"highYieldPearl\": \"Eggshell calcification of hilar lymph nodes is a hallmark radiographic sign of silicosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Diffuse enlargement is non-specific. Central necrosis can be seen in other granulomatous diseases like tuberculosis. Peripheral rim enhancement is often seen with abscesses or necrotic tumors post-contrast.\"\n  },\n  {\n    \"question\": \"What is the primary therapeutic approach for established pneumoconioses?\",\n    \"options\": {\n      \"A\": \"Immunosuppression\",\n      \"B\": \"Anti-fibrotic drugs\",\n      \"C\": \"Lung transplantation\",\n      \"D\": \"Symptomatic and supportive care\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pneumoconioses\",\n    \"deepDiveExplanation\": \"Currently, there is no specific curative treatment for established pneumoconioses. Management focuses on preventing further exposure, symptomatic relief (e.g., bronchodilators for airflow limitation, oxygen therapy for hypoxemia), managing complications (e.g., recurrent infections, cor pulmonale), and pulmonary rehabilitation. While lung transplantation is an option for severe, end-stage disease, it is not considered the primary or definitive treatment for the disease process itself. Anti-fibrotic drugs are under investigation but not standard definitive therapy.\",\n    \"highYieldPearl\": \"Prevention of exposure is paramount, and treatment for established pneumoconioses is primarily supportive.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Anti-fibrotic drugs (like pirfenidone/nintedanib) are used for Idiopathic Pulmonary Fibrosis (IPF), and their role in pneumoconioses is not yet established as definitive. Lung transplantation is a last-resort for end-stage disease, not a general treatment.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-544.5696411132813}],"createTime":"2025-12-31T07:45:36.340922Z","modelVersion":"gemini-2.5-flash","responseId":"oNRUabrnFJ-0gLUP9frpWA","usageMetadata":{"billablePromptUsage":{"textCount":1041},"candidatesTokenCount":1373,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1373}],"promptTokenCount":372,"promptTokensDetails":[{"modality":"TEXT","tokenCount":372}],"thoughtsTokenCount":1548,"totalTokenCount":3293,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:53.892655+00:00"}
{"metadata":"one-liner|weaning|Weaning from Mechanical Ventilation|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Weaning from Mechanical Ventilation\".\nSet the \"topic\" field in the JSON to \"weaning\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.5713497345918704,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which index is calculated as respiratory frequency divided by tidal volume (f/VT) during a spontaneous breathing trial?\",\n    \"options\": {\n      \"A\": \"CROP index\",\n      \"B\": \"RSBI\",\n      \"C\": \"P0.1\",\n      \"D\": \"NIF\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"weaning\",\n    \"deepDiveExplanation\": \"The Rapid Shallow Breathing Index (RSBI), calculated as respiratory rate (f) divided by tidal volume (VT) in liters, is a widely used predictor of extubation success. A value < 105 breaths/min/L during a spontaneous breathing trial suggests a higher likelihood of successful extubation as it reflects the efficiency of breathing.\",\n    \"highYieldPearl\": \"An RSBI < 105 is one of the strongest predictors for successful extubation in many patient populations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors like CROP index (Compliance, Rate, Oxygenation, Pressure) and NIF (Negative Inspiratory Force) are also weaning predictors but are calculated using different parameters. P0.1 measures respiratory drive, not directly f/VT.\"\n  },\n  {\n    \"question\": \"What is the typical minimum duration for a spontaneous breathing trial (SBT) to assess extubation readiness?\",\n    \"options\": {\n      \"A\": \"15 minutes\",\n      \"B\": \"30 minutes\",\n      \"C\": \"60 minutes\",\n      \"D\": \"120 minutes\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"weaning\",\n    \"deepDiveExplanation\": \"A spontaneous breathing trial (SBT) is the gold standard for assessing readiness for extubation. While protocols vary, a minimum duration of 30 minutes (often up to 120 minutes) is commonly used. Shorter trials may miss patients who fail later due to respiratory muscle fatigue, while excessively long trials may unnecessarily exhaust the patient.\",\n    \"highYieldPearl\": \"The optimal SBT duration balances sensitivity for failure detection with avoiding unnecessary patient distress; 30-120 minutes is the generally accepted range.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Shorter durations (e.g., 15 minutes) are often considered insufficient, while 60 or 120 minutes are also used, but 30 minutes is widely accepted as a minimum for a robust assessment of readiness.\"\n  },\n  {\n    \"question\": \"Weaning failure is defined as reintubation within how many hours of planned extubation?\",\n    \"options\": {\n      \"A\": \"12\",\n      \"B\": \"24\",\n      \"C\": \"48\",\n      \"D\": \"72\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"weaning\",\n    \"deepDiveExplanation\": \"Weaning failure is conventionally defined as the need for reintubation within 48-72 hours of planned extubation. While some studies use 72 hours, 48 hours is a commonly cited and stricter definition that helps standardize research and clinical practice regarding extubation outcomes.\",\n    \"highYieldPearl\": \"Reintubation within 48-72 hours post-extubation is the standard definition of weaning failure.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other timeframes might seem plausible, but 48-72 hours (with 48 hours being a very common benchmark) is the most widely accepted standard in critical care literature for defining weaning failure.\"\n  },\n  {\n    \"question\": \"An elevated P0.1 (airway occlusion pressure at 0.1 seconds) during an SBT indicates which of the following?\",\n    \"options\": {\n      \"A\": \"Increased respiratory drive\",\n      \"B\": \"Reduced respiratory drive\",\n      \"C\": \"Increased respiratory muscle strength\",\n      \"D\": \"Decreased work of breathing\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"weaning\",\n    \"deepDiveExplanation\": \"P0.1, or airway occlusion pressure at 0.1 seconds, is a non-invasive measure of central respiratory drive and inspiratory effort. It is measured by briefly occluding the airway at the beginning of inspiration. An elevated P0.1 (typically >4-6 cmH2O) during an SBT indicates increased respiratory drive, suggesting a high work of breathing or respiratory muscle fatigue, and is a predictor of SBT failure.\",\n    \"highYieldPearl\": \"A high P0.1 indicates increased respiratory drive and inspiratory effort, often predictive of SBT failure due to excessive load or inadequate muscle capacity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Students might confuse P0.1 with measures of muscle strength (e.g., NIF/MIP) or directly with work of breathing. While related to work of breathing, it directly reflects the *drive* to breathe. A low P0.1 suggests insufficient drive, while a high P0.1 suggests an excessive drive for the current load or muscle capacity, predicting failure.\"\n  },\n  {\n    \"question\": \"Prophylactic systemic corticosteroids are generally recommended for which patient group to prevent post-extubation stridor?\",\n    \"options\": {\n      \"A\": \"All patients\",\n      \"B\": \"Patients with COPD\",\n      \"C\": \"Patients with traumatic or prolonged intubation\",\n      \"D\": \"Patients with asthma\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"weaning\",\n    \"deepDiveExplanation\": \"Prophylactic systemic corticosteroids (e.g., methylprednisolone or dexamethasone) are recommended for patients at high risk of post-extubation stridor due to laryngeal edema. High-risk factors include prolonged intubation (>6 days), traumatic intubation, multiple intubation attempts, small ETT size relative to trachea, female gender, and pre-existing airway pathology. They work by reducing airway inflammation and edema.\",\n    \"highYieldPearl\": \"Corticosteroids prevent post-extubation stridor specifically in high-risk patients, mainly those with prolonged or traumatic intubation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While COPD and asthma patients might receive steroids for their underlying conditions, the prophylactic use for *post-extubation stridor* is specifically targeted at those with increased risk of laryngeal edema due to the intubation process itself, not their primary lung disease. It is not a routine recommendation for 'all' patients.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-864.4521484375}],"createTime":"2025-12-31T07:46:21.097874Z","modelVersion":"gemini-2.5-flash","responseId":"zdRUadL8BZ-0gLUP9frpWA","usageMetadata":{"billablePromptUsage":{"textCount":1030},"candidatesTokenCount":1513,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1513}],"promptTokenCount":362,"promptTokensDetails":[{"modality":"TEXT","tokenCount":362}],"thoughtsTokenCount":2654,"totalTokenCount":4529,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:47.71848+00:00"}
{"metadata":"one-liner|asthma_diagnosis|Asthma - Diagnosis and Classification|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Asthma - Diagnosis and Classification\".\nSet the \"topic\" field in the JSON to \"asthma_diagnosis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.35672295959494715,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What percentage increase in FEV1 and absolute change is diagnostic of asthma reversibility?\",\n    \"options\": {\n      \"A\": \"10% and 100mL\",\n      \"B\": \"12% and 200mL\",\n      \"C\": \"15% and 300mL\",\n      \"D\": \"20% and 400mL\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Bronchodilator reversibility is a key diagnostic feature of asthma. A significant response is typically defined as an increase in FEV1 of >12% from baseline AND an absolute increase of >200 mL after administration of a short-acting bronchodilator (e.g., 400 mcg salbutamol). This criterion helps differentiate asthma from other obstructive lung diseases like COPD.\",\n    \"highYieldPearl\": \"Reversibility: >12% and >200mL increase in FEV1 post-bronchodilator.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse the percentage with the absolute value, or recall only one of the two criteria. Both must be met for a positive test.\"\n  },\n  {\n    \"question\": \"What is the PC20 threshold for diagnosing bronchial hyperresponsiveness to methacholine?\",\n    \"options\": {\n      \"A\": \"<1 mg/mL\",\n      \"B\": \"<4 mg/mL\",\n      \"C\": \"<8 mg/mL\",\n      \"D\": \"<16 mg/mL\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"A methacholine challenge test assesses bronchial hyperresponsiveness (BHR), a hallmark of asthma. A positive test is defined as a fall in FEV1 of 20% or more from baseline (PC20) at a methacholine concentration of 8 mg/mL or less. While some guidelines may consider up to 16 mg/mL, <8 mg/mL is a more definitive and commonly accepted threshold for clinical significance.\",\n    \"highYieldPearl\": \"Methacholine PC20 < 8 mg/mL indicates bronchial hyperresponsiveness.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The exact PC20 value can vary slightly between guidelines, but <8 mg/mL is the most common and robust answer. Distracting options might include higher values which indicate less hyperresponsiveness.\"\n  },\n  {\n    \"question\": \"Which FeNO value suggests eosinophilic airway inflammation in adult asthma?\",\n    \"options\": {\n      \"A\": \"<10 ppb\",\n      \"B\": \"10-25 ppb\",\n      \"C\": \">25 ppb\",\n      \"D\": \">50 ppb\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker for type 2 (eosinophilic) airway inflammation. In adults, a FeNO value >50 ppb is strongly suggestive of eosinophilic inflammation and often predicts a good response to inhaled corticosteroids. Values between 25-50 ppb are considered intermediate, while <25 ppb typically indicates low probability of eosinophilic inflammation.\",\n    \"highYieldPearl\": \"FeNO > 50 ppb strongly suggests eosinophilic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"There are different cut-offs for FeNO depending on the context (e.g., ICS responsiveness, severe asthma). A value of >50 ppb is generally accepted as a high indicator of eosinophilic inflammation in adults.\"\n  },\n  {\n    \"question\": \"What FEV1/FVC ratio is suggestive of airflow limitation in adults for asthma diagnosis?\",\n    \"options\": {\n      \"A\": \"<0.70\",\n      \"B\": \"<0.75\",\n      \"C\": \"<0.80\",\n      \"D\": \"<0.85\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Spirometry is essential for asthma diagnosis. A post-bronchodilator FEV1/FVC ratio <0.70 is commonly used to define airflow limitation, particularly in the context of obstructive lung diseases like asthma and COPD. While the lower limit of normal (LLN) is preferred for a more precise diagnosis, the fixed ratio of 0.70 is widely used in clinical practice and for screening.\",\n    \"highYieldPearl\": \"Post-bronchodilator FEV1/FVC < 0.70 indicates airflow limitation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse the FEV1/FVC ratio with other spirometry parameters or recall the pre-bronchodilator ratio instead of the post-bronchodilator one which is crucial for confirmed airflow limitation in asthma.\"\n  },\n  {\n    \"question\": \"Which GINA criterion for asthma control involves daytime symptoms more than twice a week?\",\n    \"options\": {\n      \"A\": \"Well-controlled\",\n      \"B\": \"Partly controlled\",\n      \"C\": \"Uncontrolled\",\n      \"D\": \"Clinically resolved\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"The GINA (Global Initiative for Asthma) guidelines classify asthma control based on a set of criteria over the past 4 weeks. 'Partly controlled' asthma is defined by having one or two of the following: daytime symptoms more than twice a week, any night waking due to asthma, reliever use more than twice a week, or any activity limitation due to asthma.\",\n    \"highYieldPearl\": \"Daytime symptoms >2x/week = Partly controlled asthma (GINA).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Misremembering the frequency cut-offs for each control level is a common trap. Students must differentiate between 'twice a week or less' for well-controlled and 'more than twice a week' for partly controlled.\"\n  },\n  {\n    \"question\": \"Asthma requiring GINA treatment Step 5 or more to remain controlled is classified as?\",\n    \"options\": {\n      \"A\": \"Moderate persistent\",\n      \"B\": \"Uncontrolled\",\n      \"C\": \"Severe\",\n      \"D\": \"Refractory\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"According to GINA guidelines, 'severe asthma' is defined as asthma that requires Step 4 or 5 treatment to remain controlled, or remains 'uncontrolled' despite this treatment. It is a diagnosis of exclusion, requiring confirmation of adherence, correct inhaler technique, and exclusion of comorbidities.\",\n    \"highYieldPearl\": \"GINA Step 5 treatment requirement defines severe asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse 'uncontrolled asthma' (a state of control) with 'severe asthma' (a classification based on treatment intensity or persistence of uncontrolled symptoms despite maximal therapy). Severe asthma requires high-level treatment to achieve control or remains uncontrolled despite it.\"\n  },\n  {\n    \"question\": \"What percentage fall in FEV1 post-exercise confirms exercise-induced bronchoconstriction?\",\n    \"options\": {\n      \"A\": \">5%\",\n      \"B\": \">10%\",\n      \"C\": \">15%\",\n      \"D\": \">20%\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Exercise-induced bronchoconstriction (EIB) is diagnosed by a significant fall in FEV1 after a standardized exercise challenge. A fall of >10% in FEV1 from baseline, or >12% if an absolute fall of >200 mL is also considered, is generally accepted as diagnostic for EIB. Some guidelines may use >15% for a more definitive diagnosis.\",\n    \"highYieldPearl\": \"EIB is confirmed by >10% fall in FEV1 post-exercise.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Similar to bronchodilator reversibility, the exact percentage can vary slightly, but >10% is a widely recognized threshold. Options may include other percentage drops that apply to different diagnostic criteria.\"\n  },\n  {\n    \"question\": \"Which diagnostic test primarily identifies extrinsic triggers in allergic asthma?\",\n    \"options\": {\n      \"A\": \"FeNO\",\n      \"B\": \"Sputum eosinophils\",\n      \"C\": \"Skin prick test\",\n      \"D\": \"Bronchial challenge test\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Allergic asthma is characterized by an immune response to specific environmental allergens. Skin prick tests (SPT) or specific IgE blood tests are the primary methods to identify these extrinsic triggers. SPT involves introducing small amounts of allergens into the skin and observing for a wheal-and-flare reaction, indicating sensitization.\",\n    \"highYieldPearl\": \"Skin prick test identifies extrinsic triggers in allergic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other tests like FeNO and sputum eosinophils indicate inflammation but don't directly identify the specific extrinsic allergen. Bronchial challenge tests confirm hyperresponsiveness, not necessarily the specific trigger.\"\n  },\n  {\n    \"question\": \"What is the gold standard diagnostic test for Aspirin-Exacerbated Respiratory Disease?\",\n    \"options\": {\n      \"A\": \"Serum leukotriene levels\",\n      \"B\": \"Oral aspirin challenge\",\n      \"C\": \"Nasal provocation test\",\n      \"D\": \"Bronchial methacholine challenge\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Aspirin-Exacerbated Respiratory Disease (AERD), also known as Samter's Triad, is diagnosed by a history of reactions to aspirin or NSAIDs. The definitive 'gold standard' for diagnosis, especially in equivocal cases, is a carefully conducted, incremental oral aspirin challenge test under medical supervision, observing for respiratory or other systemic reactions.\",\n    \"highYieldPearl\": \"Oral aspirin challenge is gold standard for AERD diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While nasal provocation tests and elevated leukotriene levels can be suggestive, they are not considered the gold standard. Bronchial methacholine challenge assesses hyperresponsiveness, not aspirin sensitivity.\"\n  },\n  {\n    \"question\": \"What percentage of sputum eosinophils is considered significant for eosinophilic asthma phenotype?\",\n    \"options\": {\n      \"A\": \">1%\",\n      \"B\": \">2%\",\n      \"C\": \">3%\",\n      \"D\": \">4%\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"asthma_diagnosis\",\n    \"deepDiveExplanation\": \"Sputum eosinophilia is a direct measure of eosinophilic airway inflammation and helps phenotype asthma for targeted therapies. A sputum eosinophil count of >3% (or sometimes >2.5%) of total non-squamous cells is generally considered significant for the eosinophilic asthma phenotype.\",\n    \"highYieldPearl\": \"Sputum eosinophils >3% indicates eosinophilic asthma.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The exact percentage can vary slightly in literature (e.g., >2.5% or >3%), but >3% is a widely accepted and high-yield cutoff. Lower percentages might be considered abnormal but not necessarily indicative of significant eosinophilic inflammation.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-987.0524291992188}],"createTime":"2025-12-31T07:46:20.677217Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUaeGqKdW3gLUP6IXQUA","usageMetadata":{"billablePromptUsage":{"textCount":1041},"candidatesTokenCount":2767,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2767}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2248,"totalTokenCount":5381,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:05.548475+00:00"}
{"metadata":"one-liner|dlco|Diffusing Capacity (DLCO)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Diffusing Capacity (DLCO)\".\nSet the \"topic\" field in the JSON to \"dlco\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.37976069778214805,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which gas is typically utilized to measure the diffusing capacity of the lung for carbon monoxide (DLCO)?\",\n    \"options\": {\n      \"A\": \"Oxygen\",\n      \"B\": \"Carbon Dioxide\",\n      \"C\": \"Carbon Monoxide\",\n      \"D\": \"Nitric Oxide\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"The DLCO test measures the transfer of carbon monoxide (CO) from the alveoli to the red blood cells. CO is used because of its high affinity for hemoglobin (approximately 210-250 times that of oxygen), ensuring that its uptake is primarily limited by diffusion across the alveolar-capillary membrane and the amount of hemoglobin available, rather than perfusion.\",\n    \"highYieldPearl\": \"CO's high hemoglobin affinity makes it an ideal tracer gas for assessing the functional integrity of the alveolar-capillary membrane and pulmonary capillary blood volume.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors include other respiratory gases. The core concept is understanding why CO specifically is chosen for this measurement.\"\n  },\n  {\n    \"question\": \"A common physiological factor directly causing a reduced DLCO, even in healthy lungs, is?\",\n    \"options\": {\n      \"A\": \"Polycythemia\",\n      \"B\": \"Pulmonary Hemorrhage\",\n      \"C\": \"Anemia\",\n      \"D\": \"Supine Body Position\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"Anemia reduces the total amount of hemoglobin available in the pulmonary capillaries to bind with carbon monoxide. Since hemoglobin is the primary recipient for CO, a lower hemoglobin concentration directly translates to a reduced measured DLCO. Correction formulas are often applied to adjust DLCO for varying hemoglobin levels.\",\n    \"highYieldPearl\": \"Always consider and correct for anemia when interpreting DLCO results to avoid misdiagnosing lung pathology.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other options like polycythemia and pulmonary hemorrhage increase DLCO. Supine position typically increases DLCO due to better perfusion distribution. The trap is overlooking systemic factors affecting DLCO.\"\n  },\n  {\n    \"question\": \"Which condition typically results in an isolated increase in DLCO?\",\n    \"options\": {\n      \"A\": \"Emphysema\",\n      \"B\": \"Pulmonary Fibrosis\",\n      \"C\": \"Left-to-right cardiac shunt\",\n      \"D\": \"Severe Anemia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"Left-to-right cardiac shunts increase pulmonary blood flow and, consequently, the pulmonary capillary blood volume. An increased capillary blood volume provides more surface area and hemoglobin for CO uptake, leading to an elevated DLCO. Other causes of increased DLCO include pulmonary hemorrhage, polycythemia, and exercise.\",\n    \"highYieldPearl\": \"Increased pulmonary capillary blood volume (e.g., L-R shunt, pulmonary hemorrhage) or increased hemoglobin (polycythemia) can elevate DLCO.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Emphysema and pulmonary fibrosis cause decreased DLCO. Severe anemia reduces DLCO. The trap is confusing conditions that reduce vs. increase DLCO.\"\n  },\n  {\n    \"question\": \"A reduced DLCO with a normal DLCO/VA ratio suggests which type of lung pathology?\",\n    \"options\": {\n      \"A\": \"Interstitial Lung Disease\",\n      \"B\": \"Pulmonary Emphysema\",\n      \"C\": \"Extrapulmonary restriction\",\n      \"D\": \"Pulmonary Hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"The DLCO/VA ratio normalizes the diffusing capacity for alveolar volume (VA). If both DLCO and VA are reduced proportionally, the ratio remains normal. This pattern is characteristic of conditions that reduce overall lung volume without significantly impairing the alveolar-capillary membrane's efficiency, such as chest wall deformities, neuromuscular weakness, or obesity (extrapulmonary restrictive disorders).\",\n    \"highYieldPearl\": \"Normal DLCO/VA ratio with low DLCO suggests a 'small but normal' lung unit, typical of extrapulmonary restriction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Interstitial lung disease and emphysema typically show a reduced DLCO/VA ratio. Pulmonary hypertension often shows an isolated low DLCO with normal lung volumes. The trap is misinterpreting the significance of the ratio.\"\n  },\n  {\n    \"question\": \"DLCO is typically decreased in emphysema but often normal or increased in asthma due to?\",\n    \"options\": {\n      \"A\": \"Airway inflammation\",\n      \"B\": \"Alveolar destruction\",\n      \"C\": \"Bronchial hyperresponsiveness\",\n      \"D\": \"Increased airway resistance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"Emphysema is characterized by the destruction of alveolar walls and associated pulmonary capillaries, leading to a significant reduction in the surface area available for gas exchange and a loss of pulmonary capillary blood volume. Asthma, primarily an airway disease, generally preserves the alveolar-capillary unit and gas exchange surface.\",\n    \"highYieldPearl\": \"DLCO is a key differentiator between emphysema (low DLCO) and other obstructive diseases like asthma or chronic bronchitis (often normal DLCO).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The distractors relate to general features of obstructive lung disease but do not explain the DLCO difference. The core concept is the structural difference at the alveolar level.\"\n  },\n  {\n    \"question\": \"DLCO is inversely proportional to which of the following components according to the Roughton-Forster equation?\",\n    \"options\": {\n      \"A\": \"Alveolar volume\",\n      \"B\": \"Pulmonary capillary blood volume (Vc)\",\n      \"C\": \"Membrane resistance (1/DM)\",\n      \"D\": \"Hemoglobin concentration\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"The Roughton-Forster equation states 1/DL = 1/DM + 1/(θVc), where DL is DLCO, DM is the membrane diffusion component, and θVc represents the pulmonary capillary blood volume component (θ is the rate of CO uptake by RBCs). An increase in membrane resistance (1/DM) directly increases the overall resistance (1/DL), thus decreasing DLCO.\",\n    \"highYieldPearl\": \"DLCO is determined by both the integrity of the alveolar-capillary membrane (DM) and the volume of blood in the pulmonary capillaries (Vc).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Alveolar volume, Vc, and hemoglobin concentration are directly or indirectly proportional to DLCO. The trap lies in understanding the inverse relationship with resistance terms in the equation.\"\n  },\n  {\n    \"question\": \"Elevated carboxyhemoglobin (COHb) levels primarily affect DLCO by?\",\n    \"options\": {\n      \"A\": \"Increasing alveolar volume\",\n      \"B\": \"Reducing available hemoglobin for CO uptake\",\n      \"C\": \"Enhancing CO diffusion across the membrane\",\n      \"D\": \"Decreasing membrane thickness\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"Carboxyhemoglobin (COHb) forms when carbon monoxide binds to hemoglobin. If a patient has elevated COHb levels (e.g., from smoking or environmental exposure), a portion of their hemoglobin is already occupied by CO. During the DLCO test, less hemoglobin is available to bind the inhaled tracer CO, leading to an artificially lower measured DLCO. Correction for COHb is essential.\",\n    \"highYieldPearl\": \"Both anemia and elevated COHb reduce the effective hemoglobin available for the DLCO test, requiring correction for accurate results.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The distractors suggest effects on lung volume or membrane, which are incorrect. The key is understanding COHb's competition for hemoglobin binding sites.\"\n  },\n  {\n    \"question\": \"A shortened breath-hold time during DLCO measurement will primarily lead to which error?\",\n    \"options\": {\n      \"A\": \"Falsely increased DLCO\",\n      \"B\": \"Falsely decreased DLCO\",\n      \"C\": \"No significant change\",\n      \"D\": \"Increased DLCO/VA ratio\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"The DLCO measurement relies on a standardized breath-hold time (typically 8-10 seconds) to allow sufficient time for carbon monoxide to diffuse across the alveolar-capillary membrane and bind to hemoglobin. A shorter breath-hold limits the exposure time and thus the uptake of CO, resulting in an underestimation or falsely decreased DLCO value.\",\n    \"highYieldPearl\": \"Adherence to standardized technique, including breath-hold time, is crucial for reliable and reproducible DLCO results.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is guessing the direction of error or assuming no change. Shorter time means less gas transfer, hence lower DLCO.\"\n  },\n  {\n    \"question\": \"An isolated reduction in DLCO, in the absence of parenchymal lung disease, is a hallmark of?\",\n    \"options\": {\n      \"A\": \"Bronchiectasis\",\n      \"B\": \"Asthma\",\n      \"C\": \"Pulmonary Hypertension\",\n      \"D\": \"Obstructive sleep apnea\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"Pulmonary hypertension (PH) involves remodeling and reduction of the pulmonary vascular bed, which directly decreases the pulmonary capillary blood volume (Vc) component of DLCO. This leads to a significant reduction in DLCO, often with normal lung volumes and spirometry, making it a sensitive indicator for PH.\",\n    \"highYieldPearl\": \"An isolated low DLCO (especially with normal spirometry and lung volumes) should prompt investigation for pulmonary vascular disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Bronchiectasis and asthma primarily affect airways and usually have normal or near-normal DLCO. OSA does not directly cause an isolated low DLCO unless associated with PH.\"\n  },\n  {\n    \"question\": \"In interstitial lung diseases, which PFT parameter best correlates with disease severity and prognosis?\",\n    \"options\": {\n      \"A\": \"Forced Expiratory Volume in 1 second (FEV1)\",\n      \"B\": \"Forced Vital Capacity (FVC)\",\n      \"C\": \"Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)\",\n      \"D\": \"FEV1/FVC ratio\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"dlco\",\n    \"deepDiveExplanation\": \"DLCO directly reflects the functional integrity of the alveolar-capillary membrane and the extent of loss of the pulmonary capillary bed, both of which are severely affected in interstitial lung diseases (ILDs). It often declines earlier and correlates better with the extent of fibrosis, disease progression, and mortality than spirometric values like FVC or FEV1.\",\n    \"highYieldPearl\": \"DLCO is a crucial prognostic marker in ILD, often declining before significant changes in lung volumes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While FVC is also reduced in ILD, DLCO tends to be a more sensitive and specific marker for gas exchange impairment and overall disease burden in ILD. FEV1 and FEV1/FVC are primarily indicators of airflow limitation.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1043.962158203125}],"createTime":"2025-12-31T07:46:39.680645Z","modelVersion":"gemini-2.5-flash","responseId":"39RUacXFKa62vPEPmbPHqAI","usageMetadata":{"billablePromptUsage":{"textCount":1019},"candidatesTokenCount":2749,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2749}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":2249,"totalTokenCount":5362,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:57.382388+00:00"}
{"metadata":"one-liner|tb_drtb|Drug-Resistant TB (MDR/XDR)|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Drug-Resistant TB (MDR/XDR)\".\nSet the \"topic\" field in the JSON to \"tb_drtb\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.24397052527308213,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to which core anti-tubercular drugs?\",\n    \"options\": {\n      \"A\": \"Isoniazid and Ethambutol\",\n      \"B\": \"Isoniazid and Rifampicin\",\n      \"C\": \"Rifampicin and Pyrazinamide\",\n      \"D\": \"Streptomycin and Isoniazid\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"MDR-TB is defined as resistance to at least both Isoniazid (INH) and Rifampicin (RIF), which are the two most potent first-line anti-TB drugs. This definition is crucial for guiding treatment regimens.\",\n    \"highYieldPearl\": \"MDR-TB = INH + RIF resistance. This is the foundational definition for all subsequent DR-TB classifications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options include other first-line drugs, but only INH and RIF together constitute the definition of MDR-TB. Confusing with single drug resistance or other combinations is a common trap.\"\n  },\n  {\n    \"question\": \"Extensively drug-resistant tuberculosis (XDR-TB) is MDR-TB with additional resistance to which drug classes?\",\n    \"options\": {\n      \"A\": \"Fluoroquinolones and any second-line injectable\",\n      \"B\": \"Fluoroquinolones and any Group A drug\",\n      \"C\": \"Bedaquiline and Linezolid\",\n      \"D\": \"Pyrazinamide and Ethambutol\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"The updated WHO definition for XDR-TB is MDR/RR-TB plus resistance to any fluoroquinolone and at least one additional Group A drug (Bedaquiline, Linezolid, Pretomanid). The older definition was MDR-TB plus resistance to any fluoroquinolone and at least one second-line injectable (Amikacin, Kanamycin, Capreomycin). Both are important for exams, but the newer one is more current.\",\n    \"highYieldPearl\": \"XDR-TB = MDR-TB + FQ resistance + at least one Group A drug resistance (Bedaquiline, Linezolid, Pretomanid).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The definition of XDR-TB has evolved. The older definition involving second-line injectables is still frequently tested, but the latest WHO definition includes Group A drugs. Option B reflects the most current WHO definition. Option A is the previous definition, which can be a distractor.\"\n  },\n  {\n    \"question\": \"The most rapid initial diagnostic test for Rifampicin resistance in Mycobacterium tuberculosis is?\",\n    \"options\": {\n      \"A\": \"Phenotypic Drug Susceptibility Testing (DST)\",\n      \"B\": \"Line Probe Assay (LPA)\",\n      \"C\": \"GeneXpert MTB/RIF\",\n      \"D\": \"MGIT culture\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"GeneXpert MTB/RIF is a rapid molecular test that detects M. tuberculosis DNA and mutations associated with Rifampicin resistance directly from sputum samples, providing results within 2 hours. It is endorsed by WHO as the initial diagnostic test for Rifampicin resistance.\",\n    \"highYieldPearl\": \"GeneXpert is the go-to rapid test for RIF resistance, crucial for early DR-TB detection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While LPA also detects RIF resistance rapidly, GeneXpert is considered the most rapid and often the first-line test due to its simplicity and direct use on raw samples. Phenotypic DST and MGIT culture take much longer.\"\n  },\n  {\n    \"question\": \"Rifampicin resistance in Mycobacterium tuberculosis is primarily conferred by mutations in which gene?\",\n    \"options\": {\n      \"A\": \"katG\",\n      \"B\": \"inhA\",\n      \"C\": \"rpoB\",\n      \"D\": \"gyrA\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"Mutations in the rpoB gene, which encodes the beta-subunit of RNA polymerase, are responsible for over 95% of Rifampicin resistance in M. tuberculosis. This is the target for molecular tests like GeneXpert.\",\n    \"highYieldPearl\": \"rpoB gene mutation = Rifampicin resistance. A cornerstone of DR-TB molecular diagnostics.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The other genes listed are associated with resistance to other anti-TB drugs (katG/inhA for INH, gyrA for FQ). Knowing the specific gene-drug association is vital.\"\n  },\n  {\n    \"question\": \"High-level Isoniazid resistance in M. tuberculosis is most commonly associated with mutations in which gene?\",\n    \"options\": {\n      \"A\": \"rpoB\",\n      \"B\": \"katG\",\n      \"C\": \"gyrA\",\n      \"D\": \"embB\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"High-level Isoniazid resistance is predominantly caused by mutations in the katG gene, which encodes catalase-peroxidase. This enzyme activates Isoniazid. Mutations here prevent activation. Low-level resistance is often associated with inhA promoter region mutations.\",\n    \"highYieldPearl\": \"katG mutations confer high-level INH resistance. inhA mutations confer low-level INH resistance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing between katG (high-level) and inhA (low-level) for INH resistance is important. rpoB is for Rifampicin, gyrA for Fluoroquinolones, and embB for Ethambutol.\"\n  },\n  {\n    \"question\": \"Which of the following is classified as a Group A drug in the current WHO regimen for drug-resistant TB?\",\n    \"options\": {\n      \"A\": \"Ethionamide\",\n      \"B\": \"Cycloserine\",\n      \"C\": \"Bedaquiline\",\n      \"D\": \"Para-aminosalicylic acid\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"WHO categorizes DR-TB drugs into Group A (highest priority: Bedaquiline, Linezolid, Moxifloxacin/Levofloxacin, Pretomanid), Group B (next priority: Clofazimine, Cycloserine/Terizidone), and Group C (add-on drugs). Bedaquiline is a cornerstone of current DR-TB regimens.\",\n    \"highYieldPearl\": \"Group A drugs (Bedaquiline, Linezolid, FQs, Pretomanid) are the backbone of modern DR-TB treatment regimens.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Ethionamide, Cycloserine, and PAS are older second-line drugs, now classified as Group B or C, indicating lower priority or specific use cases. Bedaquiline is a newer, highly effective drug in Group A.\"\n  },\n  {\n    \"question\": \"The most common dose-limiting toxicity of Linezolid in drug-resistant TB treatment is?\",\n    \"options\": {\n      \"A\": \"Nephrotoxicity\",\n      \"B\": \"Optic neuropathy\",\n      \"C\": \"Ototoxicity\",\n      \"D\": \"Hepatotoxicity\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"Linezolid, an oxazolidinone, is a crucial drug for DR-TB. Its main dose-limiting toxicities, especially with prolonged use, include myelosuppression (thrombocytopenia, anemia), peripheral neuropathy, and optic neuropathy. Regular monitoring is essential.\",\n    \"highYieldPearl\": \"Linezolid toxicity: Myelosuppression, peripheral neuropathy, optic neuropathy. Monitor blood counts and vision.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While many anti-TB drugs have various toxicities (e.g., aminoglycosides for ototoxicity/nephrotoxicity, INH for hepatotoxicity/neuropathy), optic neuropathy is a classical and significant side effect of Linezolid.\"\n  },\n  {\n    \"question\": \"The duration of the shorter all-oral regimen for MDR-TB without fluoroquinolone resistance is typically?\",\n    \"options\": {\n      \"A\": \"6-9 months\",\n      \"B\": \"9-11 months\",\n      \"C\": \"18-24 months\",\n      \"D\": \"12-15 months\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"The WHO-recommended shorter all-oral regimen for MDR/RR-TB (without FQ resistance) is 9-11 months. This regimen typically includes Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaLM). For patients with FQ resistance, longer individualized regimens are needed.\",\n    \"highYieldPearl\": \"Shorter all-oral MDR-TB regimen (no FQ resistance) = 9-11 months. Significant improvement over longer regimens.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The 18-24 month regimen was the standard for longer MDR-TB treatment. The 6-9 month option might confuse with latent TB treatment or standard DS-TB. Knowing the specific duration for the shorter MDR-TB regimen is key.\"\n  },\n  {\n    \"question\": \"What specific cardiac monitoring is required for patients receiving Bedaquiline for drug-resistant TB?\",\n    \"options\": {\n      \"A\": \"Echocardiogram\",\n      \"B\": \"Holter monitoring\",\n      \"C\": \"Serial ECG for QT interval\",\n      \"D\": \"Cardiac MRI\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"Bedaquiline can prolong the QT interval, increasing the risk of arrhythmias. Therefore, regular ECG monitoring for QT prolongation is mandatory before starting and during Bedaquiline treatment. Concomitant use of other QT-prolonging drugs should be avoided or carefully managed.\",\n    \"highYieldPearl\": \"Bedaquiline = QT prolongation risk. Serial ECG monitoring is crucial for safety.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While all options are cardiac tests, only serial ECG for QT interval is specifically indicated and routinely performed due to Bedaquiline's known side effect. The other tests are not standard for this purpose.\"\n  },\n  {\n    \"question\": \"Resistance to fluoroquinolones in Mycobacterium tuberculosis is most commonly linked to mutations in which genes?\",\n    \"options\": {\n      \"A\": \"rpoB\",\n      \"B\": \"katG\",\n      \"C\": \"gyrA and gyrB\",\n      \"D\": \"embB\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_drtb\",\n    \"deepDiveExplanation\": \"Fluoroquinolones target DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV. Mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene are the most common cause of fluoroquinolone resistance in M. tuberculosis, with gyrB mutations also contributing.\",\n    \"highYieldPearl\": \"Fluoroquinolone resistance = gyrA and gyrB mutations, affecting DNA gyrase.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"This question tests knowledge of specific gene mutations for different drug classes. rpoB (RIF), katG (INH), and embB (Ethambutol) are incorrect for fluoroquinolone resistance.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-697.2677612304688}],"createTime":"2025-12-31T07:46:19.120722Z","modelVersion":"gemini-2.5-flash","responseId":"y9RUaZKvB-aEgLUPxb2_UQ","usageMetadata":{"billablePromptUsage":{"textCount":1024},"candidatesTokenCount":2858,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2858}],"promptTokenCount":372,"promptTokensDetails":[{"modality":"TEXT","tokenCount":372}],"thoughtsTokenCount":1478,"totalTokenCount":4708,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:10.929371+00:00"}
{"metadata":"one-liner|ohs|Obesity Hypoventilation Syndrome|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Obesity Hypoventilation Syndrome\".\nSet the \"topic\" field in the JSON to \"ohs\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.36723241266214623,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which ABG finding in an obese patient (BMI > 30 kg/m²) is essential for Obesity Hypoventilation Syndrome diagnosis, after excluding other causes?\",\n    \"options\": {\n      \"A\": \"Awake PaCO2 > 45 mmHg\",\n      \"B\": \"Asleep PaCO2 > 50 mmHg\",\n      \"C\": \"Awake PaO2 < 60 mmHg\",\n      \"D\": \"Awake pH < 7.35\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ohs\",\n    \"deepDiveExplanation\": \"Obesity Hypoventilation Syndrome (OHS) is defined by the presence of obesity (BMI ≥ 30 kg/m²) and chronic awake alveolar hypoventilation (PaCO2 ≥ 45 mmHg at sea level) that is not explained by other conditions known to cause hypoventilation. The 'awake' component is crucial for diagnosis, distinguishing it from transient hypercapnia during sleep.\",\n    \"highYieldPearl\": \"Awake hypercapnia (PaCO2 ≥ 45 mmHg) in an obese individual (BMI ≥ 30 kg/m²) is the diagnostic hallmark of OHS, after exclusion of other causes of hypoventilation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option B is incorrect as the diagnostic criterion for OHS requires awake hypercapnia. While sleep-disordered breathing is common in OHS, the diagnostic ABG is performed while awake. Options C and D represent consequences or associated findings, not primary diagnostic criteria for OHS itself.\"\n  },\n  {\n    \"question\": \"Impaired central ventilatory drive in Obesity Hypoventilation Syndrome is most strongly associated with dysregulation of which hormone?\",\n    \"options\": {\n      \"A\": \"Ghrelin\",\n      \"B\": \"Adiponectin\",\n      \"C\": \"Leptin\",\n      \"D\": \"Resistin\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ohs\",\n    \"deepDiveExplanation\": \"Leptin, a hormone produced by adipocytes, plays a crucial role in appetite regulation and ventilatory control. In OHS, patients often exhibit leptin resistance, leading to a blunted ventilatory response to hypercapnia and hypoxia. This impaired central chemosensitivity contributes significantly to the chronic alveolar hypoventilation.\",\n    \"highYieldPearl\": \"Leptin resistance is a key pathophysiological mechanism underlying impaired central ventilatory drive in OHS, leading to blunted chemosensitivity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other adipokines (Ghrelin, Adiponectin, Resistin) are involved in metabolic regulation, leptin has the most direct and well-established link to central ventilatory control and its dysregulation in OHS.\"\n  },\n  {\n    \"question\": \"The definitive diagnostic test for chronic hypercapnia in a patient suspected of Obesity Hypoventilation Syndrome is:\",\n    \"options\": {\n      \"A\": \"Nocturnal oximetry\",\n      \"B\": \"Polysomnography\",\n      \"C\": \"Awake arterial blood gas\",\n      \"D\": \"Pulmonary function testing\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ohs\",\n    \"deepDiveExplanation\": \"The diagnosis of OHS requires objective evidence of chronic alveolar hypoventilation, which is best measured by an awake arterial blood gas (ABG) showing a PaCO2 ≥ 45 mmHg. While polysomnography is essential to assess for co-existing sleep apnea, and PFTs help exclude other causes of hypoventilation, the ABG directly confirms the defining hypercapnia.\",\n    \"highYieldPearl\": \"Awake arterial blood gas (ABG) is the gold standard for confirming chronic hypercapnia, a mandatory criterion for OHS diagnosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Polysomnography (B) is crucial to assess for obstructive sleep apnea, which is present in over 90% of OHS patients, but it doesn't directly measure awake hypercapnia. PFTs (D) are important for excluding other causes of hypoventilation but not for diagnosing the hypercapnia itself. Nocturnal oximetry (A) only assesses oxygen saturation, not CO2 retention.\"\n  },\n  {\n    \"question\": \"The cornerstone of initial treatment for Obesity Hypoventilation Syndrome is:\",\n    \"options\": {\n      \"A\": \"Supplemental oxygen therapy\",\n      \"B\": \"Bariatric surgery\",\n      \"C\": \"Non-invasive positive pressure ventilation\",\n      \"D\": \"Diuretics\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ohs\",\n    \"deepDiveExplanation\": \"Non-invasive positive pressure ventilation (NIV), typically CPAP or BiPAP, is the cornerstone of initial treatment for OHS. It improves alveolar ventilation, reduces hypercapnia, and treats co-existing obstructive sleep apnea. While weight loss (often via bariatric surgery) is the definitive long-term solution, NIV provides immediate physiological benefits.\",\n    \"highYieldPearl\": \"NIV (CPAP/BiPAP) is the first-line treatment for OHS, effectively correcting hypoventilation and improving gas exchange.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Supplemental oxygen therapy (A) alone can worsen hypercapnia by blunting hypoxic drive. Bariatric surgery (B) is a long-term solution but not the immediate 'cornerstone' of initial treatment. Diuretics (D) are not a primary treatment for hypoventilation.\"\n  },\n  {\n    \"question\": \"Which cardiovascular complication is frequently associated with Obesity Hypoventilation Syndrome due to chronic hypoxia?\",\n    \"options\": {\n      \"A\": \"Systemic hypertension\",\n      \"B\": \"Left ventricular hypertrophy\",\n      \"C\": \"Pulmonary arterial hypertension\",\n      \"D\": \"Aortic stenosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ohs\",\n    \"deepDiveExplanation\": \"Chronic alveolar hypoventilation and intermittent hypoxia in OHS lead to pulmonary vasoconstriction, which over time can result in pulmonary arterial hypertension (PAH). This increased afterload on the right ventricle can eventually lead to cor pulmonale and right heart failure, making PAH a significant complication of OHS.\",\n    \"highYieldPearl\": \"Chronic hypoxia secondary to OHS frequently causes pulmonary vasoconstriction, leading to pulmonary arterial hypertension and eventually cor pulmonale.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While systemic hypertension (A) and left ventricular hypertrophy (B) can be associated with obesity, pulmonary arterial hypertension (C) is directly linked to the chronic hypoxia and hypercapnia characteristic of OHS due to its impact on the pulmonary vasculature. Aortic stenosis (D) is unrelated.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-583.8995361328125}],"createTime":"2025-12-31T07:45:37.210616Z","modelVersion":"gemini-2.5-flash","responseId":"odRUabjtDIjInvgPnqaBEQ","usageMetadata":{"billablePromptUsage":{"textCount":1024},"candidatesTokenCount":1590,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1590}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1351,"totalTokenCount":3305,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:15.874228+00:00"}
{"metadata":"one-liner|end_of_life|End-of-Life Care in Respiratory Failure|2","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 2 high-yield, unique one-liner conceptual MCQs for the topic: \"End-of-Life Care in Respiratory Failure\".\nSet the \"topic\" field in the JSON to \"end_of_life\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.5416263927112926,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary pharmacological intervention for refractory dyspnea in end-of-life respiratory failure is?\",\n    \"options\": {\n      \"A\": \"Inhaled corticosteroids\",\n      \"B\": \"Systemic opioids\",\n      \"C\": \"Loop diuretics\",\n      \"D\": \"Benzodiazepines\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"end_of_life\",\n    \"deepDiveExplanation\": \"Systemic opioids, particularly morphine, are the first-line treatment for refractory dyspnea in end-of-life care. They reduce the perception of dyspnea by modulating respiratory drive in the brainstem, decreasing ventilatory response to hypercapnia and hypoxia, and reducing anxiety. While other agents like bronchodilators or diuretics might be used if indicated by the underlying cause (e.g., bronchospasm, fluid overload), opioids directly address the sensation of breathlessness.\",\n    \"highYieldPearl\": \"Opioids, when titrated appropriately for dyspnea in end-of-life care, do not hasten death and are crucial for symptom control.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Inhaled corticosteroids are for airway inflammation. Loop diuretics are for fluid overload causing dyspnea. Benzodiazepines reduce anxiety but are not primary for dyspnea itself; they can be adjunctive. The direct pharmacological intervention for the sensation of dyspnea is systemic opioids.\"\n  },\n  {\n    \"question\": \"Which ethical principle primarily guides the use of palliative sedation for intractable suffering in end-of-life respiratory failure?\",\n    \"options\": {\n      \"A\": \"Autonomy\",\n      \"B\": \"Justice\",\n      \"C\": \"Double effect\",\n      \"D\": \"Non-maleficence\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"end_of_life\",\n    \"deepDiveExplanation\": \"The principle of double effect is central to palliative sedation. It states that an action with a good primary intent (alleviating suffering) is ethically permissible, even if it has a foreseeable, but unintended, negative secondary effect (e.g., potential hastening of death due to high doses of sedatives). The intent of palliative sedation is to relieve intractable suffering, not to intentionally end life, distinguishing it from euthanasia.\",\n    \"highYieldPearl\": \"Palliative sedation aims to induce unconsciousness to relieve severe, refractory symptoms, not to intentionally cause death. The 'intent' is key.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While Autonomy (patient's right to choose) and Non-maleficence (do no harm) are fundamental ethical principles in EOL care, the specific justification for using medications that might indirectly shorten life, while primarily intended for symptom relief, falls under the principle of double effect. Justice relates to fair distribution of resources, which is less relevant here.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-357.4734191894531}],"createTime":"2025-12-31T07:45:35.323172Z","modelVersion":"gemini-2.5-flash","responseId":"n9RUaeTcE9-zgLUPj-v-qAI","usageMetadata":{"billablePromptUsage":{"textCount":1037},"candidatesTokenCount":660,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":660}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":1018,"totalTokenCount":2047,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:52.128197+00:00"}
{"metadata":"one-liner|hiv_pulm|HIV and Pulmonary Manifestations|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"HIV and Pulmonary Manifestations\".\nSet the \"topic\" field in the JSON to \"hiv_pulm\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.40994606966270314,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The CD4 count threshold for initiating primary Pneumocystis jirovecii pneumonia prophylaxis in HIV is?\",\n    \"options\": {\n      \"A\": \"CD4 < 100 cells/µL\",\n      \"B\": \"CD4 < 200 cells/µL\",\n      \"C\": \"CD4 < 300 cells/µL\",\n      \"D\": \"CD4 < 400 cells/µL\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hiv_pulm\",\n    \"deepDiveExplanation\": \"Primary prophylaxis for Pneumocystis jirovecii pneumonia (PJP) is recommended for all HIV-infected individuals with a CD4 count less than 200 cells/µL or with a history of oropharyngeal candidiasis, or unexplained fever for more than two weeks, irrespective of CD4 count. It is also indicated if the CD4 percentage is less than 14%. Trimethoprim-sulfamethoxazole (TMP-SMX) is the agent of choice.\",\n    \"highYieldPearl\": \"PJP prophylaxis starts at CD4 < 200 cells/µL, usually with TMP-SMX.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other CD4 thresholds are relevant for different opportunistic infections (e.g., MAC at <50, Toxoplasmosis at <100), but 200 is specific for PJP.\"\n  },\n  {\n    \"question\": \"In advanced HIV, pulmonary tuberculosis often presents with which predominant chest X-ray pattern?\",\n    \"options\": {\n      \"A\": \"Apical cavitations\",\n      \"B\": \"Ghon complex\",\n      \"C\": \"Lower lobe infiltrates\",\n      \"D\": \"Calcified granulomas\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hiv_pulm\",\n    \"deepDiveExplanation\": \"In early HIV infection (CD4 > 350 cells/µL), pulmonary TB often presents similarly to immunocompetent individuals, with upper lobe infiltrates and cavitation. However, in advanced HIV (CD4 < 200 cells/µL), the immune response is severely impaired, leading to atypical presentations. These include lower lobe infiltrates, hilar or mediastinal lymphadenopathy (often without cavitation), diffuse interstitial infiltrates, or even miliary patterns. Lack of cavitation is a key feature in advanced HIV due to reduced granuloma formation.\",\n    \"highYieldPearl\": \"Advanced HIV-TB often shows atypical CXR patterns like lower lobe infiltrates or lymphadenopathy, with less cavitation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Apical cavitations are classic for TB in immunocompetent individuals or early HIV, but less common in advanced HIV, making this a common distractor.\"\n  },\n  {\n    \"question\": \"The definitive diagnostic method for pulmonary Kaposi's Sarcoma in HIV, if lesions are accessible, is?\",\n    \"options\": {\n      \"A\": \"Sputum cytology\",\n      \"B\": \"Bronchial washings\",\n      \"C\": \"Bronchoalveolar lavage\",\n      \"D\": \"Endobronchial biopsy\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"hiv_pulm\",\n    \"deepDiveExplanation\": \"Pulmonary Kaposi's Sarcoma (PKS) is a common manifestation of disseminated Kaposi's Sarcoma in advanced HIV. While imaging (CT scan) can suggest the diagnosis, definitive confirmation requires histopathology. Endobronchial biopsy of visible lesions during bronchoscopy is the most direct and definitive method. However, due to the vascular nature of KS lesions, there is a significant risk of bleeding, and transbronchial biopsy is generally contraindicated. Bronchial washings and BAL may show spindle cells but are not definitive.\",\n    \"highYieldPearl\": \"Endobronchial biopsy confirms pulmonary KS, but caution is needed due to bleeding risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Bronchoalveolar lavage and bronchial washings can provide supportive evidence but are not definitive. Transbronchial biopsy is usually avoided due to bleeding risk, making endobronchial biopsy of visible lesions the preferred definitive method.\"\n  },\n  {\n    \"question\": \"Which non-infectious pulmonary complication is most commonly seen in pediatric HIV patients?\",\n    \"options\": {\n      \"A\": \"Non-specific interstitial pneumonia\",\n      \"B\": \"Cryptogenic organizing pneumonia\",\n      \"C\": \"Lymphoid interstitial pneumonia\",\n      \"D\": \"Pulmonary hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hiv_pulm\",\n    \"deepDiveExplanation\": \"Lymphoid Interstitial Pneumonia (LIP) is a common pulmonary complication in HIV-infected children, often presenting with chronic cough, hypoxemia, and diffuse interstitial infiltrates on CXR. It is characterized by polyclonal lymphocytic infiltration of the alveolar septa and peribronchiolar regions. While other non-infectious complications can occur, LIP is particularly characteristic and more prevalent in pediatric HIV than in adults.\",\n    \"highYieldPearl\": \"LIP is a hallmark non-infectious pulmonary complication in pediatric HIV.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other interstitial pneumonias can occur in HIV, but LIP has a strong association with pediatric HIV, making it the most distinctive choice.\"\n  },\n  {\n    \"question\": \"The recommended first-line treatment for Pneumocystis jirovecii pneumonia in HIV patients is?\",\n    \"options\": {\n      \"A\": \"Azithromycin\",\n      \"B\": \"Dapsone\",\n      \"C\": \"Trimethoprim-sulfamethoxazole\",\n      \"D\": \"Pentamidine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hiv_pulm\",\n    \"deepDiveExplanation\": \"Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for treating Pneumocystis jirovecii pneumonia (PJP) due to its high efficacy and relatively low cost. The typical regimen involves high-dose oral or intravenous TMP-SMX for 21 days. For patients intolerant to TMP-SMX, alternative regimens include clindamycin plus primaquine, or intravenous pentamidine, or atovaquone. Dapsone is primarily used for prophylaxis or as an alternative for mild PJP.\",\n    \"highYieldPearl\": \"TMP-SMX is the undisputed first-line treatment for PJP in HIV.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Dapsone and Pentamidine are alternative agents or used for prophylaxis, but TMP-SMX remains the first-line treatment, making them plausible distractors.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-643.2053833007813}],"createTime":"2025-12-31T07:45:52.041655Z","modelVersion":"gemini-2.5-flash","responseId":"sNRUabfFAs6RhMIPz6CV4Q8","usageMetadata":{"billablePromptUsage":{"textCount":1028},"candidatesTokenCount":1569,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1569}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":3000,"totalTokenCount":4933,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:06.405278+00:00"}
{"metadata":"one-liner|mv_modes|Mechanical Ventilation - Modes and Settings|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Mechanical Ventilation - Modes and Settings\".\nSet the \"topic\" field in the JSON to \"mv_modes\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3825080329603185,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which ventilatory mode guarantees a set tidal volume but allows patient-triggered, pressure-limited spontaneous breaths?\",\n    \"options\": {\n      \"A\": \"Assist Control Volume (ACV)\",\n      \"B\": \"Pressure Control Ventilation (PCV)\",\n      \"C\": \"Pressure Regulated Volume Control (PRVC)\",\n      \"D\": \"Synchronized Intermittent Mandatory Ventilation (SIMV)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Pressure Regulated Volume Control (PRVC) is a dual-mode that delivers volume-targeted, pressure-controlled breaths. It guarantees a set tidal volume by automatically adjusting the inspiratory pressure, while also allowing patient-triggered breaths and spontaneous breathing during the cycle, which are pressure-limited.\",\n    \"highYieldPearl\": \"PRVC combines the advantages of volume control (guaranteed volume) and pressure control (variable flow, pressure limitation, patient comfort).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"ACV in volume mode guarantees volume but doesn't inherently pressure-limit spontaneous breaths. PCV doesn't guarantee volume. SIMV can be volume-controlled, but PRVC specifically targets volume with pressure control and allows pressure-limited spontaneous breaths.\"\n  },\n  {\n    \"question\": \"In which ventilatory mode is every delivered breath pressure-limited and time-cycled?\",\n    \"options\": {\n      \"A\": \"Volume Control (VC)\",\n      \"B\": \"Pressure Control Ventilation (PCV)\",\n      \"C\": \"Pressure Support Ventilation (PSV)\",\n      \"D\": \"Synchronized Intermittent Mandatory Ventilation (SIMV)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"In Pressure Control Ventilation (PCV), the ventilator delivers breaths at a pre-set inspiratory pressure for a pre-set inspiratory time. The tidal volume delivered is variable and depends on lung compliance, resistance, and patient effort. Every breath, whether mandatory or patient-triggered, is pressure-limited and time-cycled.\",\n    \"highYieldPearl\": \"PCV prioritizes controlling airway pressure, making it lung-protective, but tidal volume is variable.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"VC is volume-cycled. PSV is flow-cycled. SIMV can incorporate PCV, but PCV itself defines breaths that are pressure-limited and time-cycled.\"\n  },\n  {\n    \"question\": \"The primary physiological goal of Inverse Ratio Ventilation (IRV) is to improve which gas exchange parameter?\",\n    \"options\": {\n      \"A\": \"Carbon dioxide elimination\",\n      \"B\": \"Inspiratory flow rate\",\n      \"C\": \"Oxygenation\",\n      \"D\": \"Airway resistance\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Inverse Ratio Ventilation (IRV) prolongs the inspiratory time (Ti) relative to the expiratory time (Te), creating an I:E ratio greater than 1:1. This increases the mean airway pressure, which in turn helps recruit collapsed alveoli, improves oxygen diffusion across the alveolar-capillary membrane, and reduces intrapulmonary shunting, thus enhancing oxygenation.\",\n    \"highYieldPearl\": \"IRV increases mean airway pressure to improve oxygenation, often at the cost of increased intrinsic PEEP and potential hemodynamic compromise.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While IRV can affect CO2 elimination and airway resistance, its primary therapeutic target is to improve oxygenation in refractory hypoxemia, especially in ARDS.\"\n  },\n  {\n    \"question\": \"In Pressure Support Ventilation (PSV), what is the primary cycling criterion for inspiration termination?\",\n    \"options\": {\n      \"A\": \"Set inspiratory time\",\n      \"B\": \"Set tidal volume\",\n      \"C\": \"Inspiratory flow drops to a percentage of peak\",\n      \"D\": \"Patient effort ceases\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Pressure Support Ventilation (PSV) is a spontaneous mode where the ventilator provides a set positive pressure assist during inspiration. The breath is typically patient-triggered and flow-cycled, meaning inspiration ends when the inspiratory flow rate decreases to a pre-set percentage (e.g., 25%) of the peak inspiratory flow.\",\n    \"highYieldPearl\": \"PSV is a flow-cycled, pressure-limited, patient-triggered mode, commonly used for weaning.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"A and B are characteristics of time-cycled (PCV) and volume-cycled (VCV) modes, respectively. D is too vague; the ventilator uses a specific flow criterion to detect the end of patient effort and cycle off.\"\n  },\n  {\n    \"question\": \"Airway Pressure Release Ventilation (APRV) primarily functions to optimize which aspect of lung mechanics?\",\n    \"options\": {\n      \"A\": \"Peak inspiratory pressure\",\n      \"B\": \"Alveolar recruitment and oxygenation\",\n      \"C\": \"Carbon dioxide removal efficiency\",\n      \"D\": \"Inspiratory flow rate\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Airway Pressure Release Ventilation (APRV) is a mode of ventilation that maintains a high continuous positive airway pressure (P-high) for a prolonged period, periodically releasing it to a lower pressure (P-low) for a very short duration. This strategy promotes alveolar recruitment, prevents de-recruitment, and improves oxygenation by maintaining a high mean airway pressure and allowing spontaneous breathing at both pressure levels.\",\n    \"highYieldPearl\": \"APRV is an 'open lung' strategy often used in ARDS, emphasizing sustained recruitment and spontaneous breathing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"While APRV can affect CO2 removal (via spontaneous breaths and release phase) and indirectly peak pressure, its core design is to optimize oxygenation through sustained alveolar recruitment, similar to an inverse ratio ventilation with spontaneous breathing.\"\n  },\n  {\n    \"question\": \"What is the primary determinant of delivered tidal volume in Pressure Control (PC) mode?\",\n    \"options\": {\n      \"A\": \"Set inspiratory pressure\",\n      \"B\": \"Inspiratory time\",\n      \"C\": \"Lung compliance and resistance\",\n      \"D\": \"All of the above\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"In Pressure Control (PC) mode, the delivered tidal volume is a dependent variable. It is determined by the set inspiratory pressure, the duration of the inspiratory time, and the patient's respiratory mechanics, specifically lung compliance (how easily the lung expands) and airway resistance (opposition to airflow). A change in any of these factors will alter the tidal volume.\",\n    \"highYieldPearl\": \"Tidal volume in PCV is a 'result,' not a 'setting.'\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While the set inspiratory pressure is a direct control, neglecting inspiratory time or patient's lung mechanics would be an incomplete understanding of tidal volume generation in PCV. This is a common conceptual trap.\"\n  },\n  {\n    \"question\": \"Which ventilatory mode allows spontaneous breathing at two distinct, pre-set positive pressure levels?\",\n    \"options\": {\n      \"A\": \"Continuous Positive Airway Pressure (CPAP)\",\n      \"B\": \"Bilevel Positive Airway Pressure (BiPAP)\",\n      \"C\": \"Adaptive Support Ventilation (ASV)\",\n      \"D\": \"Airway Pressure Release Ventilation (APRV)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Bilevel Positive Airway Pressure (BiPAP) provides two distinct levels of positive pressure: inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The patient can breathe spontaneously at both these levels, with IPAP assisting inspiration and EPAP maintaining airway patency during expiration.\",\n    \"highYieldPearl\": \"BiPAP is essentially non-invasive pressure support with PEEP, allowing spontaneous breaths at two pressure levels.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CPAP provides a single pressure level. While APRV involves two pressure levels (P-high and P-low) and allows spontaneous breathing, BiPAP is the classic mode defined by distinct IPAP and EPAP for spontaneous breaths. ASV is a closed-loop adaptive mode.\"\n  },\n  {\n    \"question\": \"For patients with severe ARDS, the initial mechanical ventilation strategy typically emphasizes which setting?\",\n    \"options\": {\n      \"A\": \"High tidal volumes\",\n      \"B\": \"Low PEEP\",\n      \"C\": \"Permissive hypercapnia\",\n      \"D\": \"High inspiratory pressure\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"The ARDSNet protocol revolutionized ARDS management by demonstrating improved survival with a lung-protective ventilation strategy. This involves using low tidal volumes (e.g., 6 mL/kg predicted body weight), which often leads to inadequate CO2 elimination and a rise in PaCO2 (hypercapnia). This 'permissive hypercapnia' is accepted to avoid ventilator-induced lung injury (VILI) from high tidal volumes and pressures.\",\n    \"highYieldPearl\": \"Low tidal volume (6ml/kg PBW) is key in ARDS, leading to permissive hypercapnia, not high tidal volumes or pressures.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"A, B, and D represent strategies that are either contraindicated or not the primary emphasis in severe ARDS. High tidal volumes and high inspiratory pressures increase VILI risk. Low PEEP would worsen oxygenation and de-recruit alveoli. Permissive hypercapnia is a *consequence* of the lung-protective strategy, but it is a tolerated and often necessary aspect of the initial settings.\"\n  },\n  {\n    \"question\": \"In Volume Control (VC) mode, increasing the inspiratory flow rate primarily leads to a decrease in which parameter?\",\n    \"options\": {\n      \"A\": \"Peak inspiratory pressure\",\n      \"B\": \"Inspiratory time\",\n      \"C\": \"Expiratory time\",\n      \"D\": \"Mean airway pressure\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"In Volume Control (VC) mode, a set tidal volume is delivered. If the inspiratory flow rate is increased, the ventilator delivers that volume more quickly. Since Volume = Flow x Time, an increased flow rate for a fixed volume necessarily leads to a shorter inspiratory time. This can decrease mean airway pressure and may increase peak inspiratory pressure due to higher resistance.\",\n    \"highYieldPearl\": \"Higher flow in VCV means faster delivery of TV, thus shorter Ti.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Increasing flow rate in VCV generally *increases* peak inspiratory pressure due to higher resistance, so A is incorrect. It shortens inspiratory time, which might slightly increase expiratory time if respiratory rate is constant, but the direct effect is on inspiratory time. Mean airway pressure generally decreases with shorter Ti.\"\n  },\n  {\n    \"question\": \"Which mechanical ventilation setting is primarily responsible for preventing alveolar collapse at end-expiration?\",\n    \"options\": {\n      \"A\": \"Tidal volume\",\n      \"B\": \"Respiratory rate\",\n      \"C\": \"Positive End-Expiratory Pressure (PEEP)\",\n      \"D\": \"Inspiratory pressure\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"mv_modes\",\n    \"deepDiveExplanation\": \"Positive End-Expiratory Pressure (PEEP) is the pressure maintained in the lungs at the end of expiration. Its primary function is to prevent alveolar collapse (atelectasis), improve functional residual capacity (FRC), and enhance oxygenation by keeping alveoli open. It achieves this by counteracting the natural tendency of the lungs to deflate completely.\",\n    \"highYieldPearl\": \"PEEP prevents alveolar collapse and improves oxygenation by increasing FRC.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Tidal volume and inspiratory pressure relate to inspiration and gas delivery, not specifically preventing end-expiratory collapse. Respiratory rate affects minute ventilation but not directly alveolar patency at end-expiration.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1119.9835205078125}],"createTime":"2025-12-31T07:47:23.937168Z","modelVersion":"gemini-2.5-flash","responseId":"C9VUadCZOcO1ld8PjZuwwAU","usageMetadata":{"billablePromptUsage":{"textCount":1038},"candidatesTokenCount":2928,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2928}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2478,"totalTokenCount":5771,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:56.015334+00:00"}
{"metadata":"one-liner|tb_pathogenesis|TB Pathogenesis and Immunity|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"TB Pathogenesis and Immunity\".\nSet the \"topic\" field in the JSON to \"tb_pathogenesis\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.34976824151655106,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary cell infected by *Mycobacterium tuberculosis* upon alveolar deposition is the:\",\n    \"options\": {\n      \"A\": \"Type II pneumocyte\",\n      \"B\": \"Alveolar macrophage\",\n      \"C\": \"Neutrophil\",\n      \"D\": \"Dendritic cell\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Upon inhalation, *M. tuberculosis* bacilli reach the alveoli and are primarily phagocytosed by alveolar macrophages. These macrophages are the initial host cells where the bacteria attempt to replicate, often evading destruction.\",\n    \"highYieldPearl\": \"Alveolar macrophages are the first line of cellular defense and the initial site of *M. tuberculosis* replication in the lung.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While neutrophils are early responders and dendritic cells present antigen, the alveolar macrophage is the primary cell where *M. tuberculosis* establishes initial infection and attempts intracellular replication.\"\n  },\n  {\n    \"question\": \"What is the primary function of granuloma formation in tuberculosis?\",\n    \"options\": {\n      \"A\": \"Facilitate bacterial dissemination\",\n      \"B\": \"Induce host immunosuppression\",\n      \"C\": \"Contain mycobacterial replication\",\n      \"D\": \"Enhance tissue destruction\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Granulomas are organized aggregates of immune cells, primarily macrophages (epithelioid cells, giant cells) and lymphocytes, formed to wall off and contain *M. tuberculosis* infection, limiting its spread and replication.\",\n    \"highYieldPearl\": \"The granuloma is the hallmark lesion of tuberculosis, acting as a dynamic structure for host control.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While granulomas can eventually undergo caseous necrosis leading to tissue destruction, their initial and primary immune purpose is to contain the infection and prevent dissemination, not to facilitate it or induce immunosuppression.\"\n  },\n  {\n    \"question\": \"The most crucial cytokine for activating macrophages to kill intracellular *Mycobacterium tuberculosis* is:\",\n    \"options\": {\n      \"A\": \"IL-4\",\n      \"B\": \"IL-10\",\n      \"C\": \"IFN-gamma\",\n      \"D\": \"TGF-beta\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Interferon-gamma (IFN-gamma) is a critical Th1 cytokine produced predominantly by CD4+ T cells and NK cells. It activates macrophages, enhancing their ability to phagocytose, fuse phagosomes with lysosomes, and kill intracellular *M. tuberculosis*.\",\n    \"highYieldPearl\": \"IFN-gamma is central to protective immunity against TB, driving macrophage activation and granuloma maintenance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"IL-4 is a Th2 cytokine, IL-10 is an immunosuppressive cytokine, and TGF-beta is involved in fibrosis and immune regulation, none of which directly activate macrophages for mycobacterial killing like IFN-gamma.\"\n  },\n  {\n    \"question\": \"Which T-cell subset is predominantly responsible for protective immunity against *Mycobacterium tuberculosis*?\",\n    \"options\": {\n      \"A\": \"CD8+ cytotoxic T cells\",\n      \"B\": \"CD4+ Th2 cells\",\n      \"C\": \"CD4+ Th1 cells\",\n      \"D\": \"Regulatory T cells\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"CD4+ Th1 cells are paramount in anti-TB immunity. They produce IFN-gamma, which activates macrophages, and IL-2, which promotes T cell proliferation. While CD8+ T cells play a role in lysing infected cells, the Th1 CD4+ response is considered central for containing the infection.\",\n    \"highYieldPearl\": \"A robust Th1 (CD4+) response, characterized by IFN-gamma production, is essential for controlling *M. tuberculosis* infection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CD8+ T cells contribute, but CD4+ Th1 cells are the primary drivers of macrophage activation. Th2 cells are generally not protective, and regulatory T cells dampen the immune response.\"\n  },\n  {\n    \"question\": \"A key mechanism *Mycobacterium tuberculosis* uses to survive within macrophages is by inhibiting:\",\n    \"options\": {\n      \"A\": \"Apoptosis\",\n      \"B\": \"Phagolysosome fusion\",\n      \"C\": \"Antigen presentation\",\n      \"D\": \"NADPH oxidase activity\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"*M. tuberculosis* actively prevents the fusion of its phagosome with the macrophage lysosome, thereby avoiding exposure to the lysosomal acidic environment and degradative enzymes. This allows the bacteria to replicate within a 'safe' compartment.\",\n    \"highYieldPearl\": \"Inhibition of phagolysosome fusion is a classic and critical virulence strategy of *M. tuberculosis* for intracellular survival.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While *M. tuberculosis* can influence other host processes like apoptosis and antigen presentation, and can resist reactive oxygen species, the most well-established and primary mechanism for intracellular survival is blocking phagolysosome maturation.\"\n  },\n  {\n    \"question\": \"Latent tuberculosis infection is best characterized by the presence of *M. tuberculosis* without:\",\n    \"options\": {\n      \"A\": \"Host immune response\",\n      \"B\": \"Granuloma formation\",\n      \"C\": \"Clinical symptoms of active disease\",\n      \"D\": \"Positive tuberculin skin test\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Latent TB infection (LTBI) is a state of persistent immune response to *M. tuberculosis* antigens without evidence of clinically active TB disease. Individuals with LTBI usually have a positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA) and typically have contained granulomas.\",\n    \"highYieldPearl\": \"LTBI is an asymptomatic state where the host immune system has contained the infection, preventing active disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"LTBI *does* involve a host immune response and granuloma formation, and typically results in a positive TST/IGRA. The defining feature is the absence of active disease symptoms.\"\n  },\n  {\n    \"question\": \"Which *Mycobacterium tuberculosis* virulence factor is primarily associated with cord formation and macrophage toxicity?\",\n    \"options\": {\n      \"A\": \"Lipoarabinomannan (LAM)\",\n      \"B\": \"Trehalose dimycolate (Cord factor)\",\n      \"C\": \"ESAT-6\",\n      \"D\": \"Mycolic acid\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Trehalose dimycolate (TDM), also known as Cord factor, is a glycolipid found on the cell wall of *M. tuberculosis*. It is responsible for the 'cording' morphology seen in virulent strains and contributes significantly to macrophage toxicity and granuloma formation.\",\n    \"highYieldPearl\": \"Cord factor (TDM) is a major virulence factor contributing to the characteristic serpentine growth pattern and host cell damage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"LAM is involved in phagolysosome arrest and cytokine modulation. ESAT-6 is a secreted protein involved in phagosomal rupture and antigenicity. Mycolic acid is a general component of the mycobacterial cell wall, but 'Cord factor' specifically refers to TDM and its associated virulence properties.\"\n  },\n  {\n    \"question\": \"The tuberculin skin test (Mantoux) is an example of which type of hypersensitivity reaction?\",\n    \"options\": {\n      \"A\": \"Type I\",\n      \"B\": \"Type II\",\n      \"C\": \"Type III\",\n      \"D\": \"Type IV\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"The tuberculin skin test (TST) is a classic example of a Type IV, or delayed-type hypersensitivity (DTH) reaction. It involves T-cell mediated immunity, where sensitized T cells (primarily Th1 CD4+) react to mycobacterial antigens injected intradermally, leading to an inflammatory response 48-72 hours later.\",\n    \"highYieldPearl\": \"The Mantoux test is a cell-mediated (Type IV) immune response, not antibody-mediated.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Type I is immediate IgE-mediated (allergies). Type II is antibody-dependent cytotoxicity. Type III is immune complex-mediated. Type IV is cell-mediated, specifically delayed-type hypersensitivity.\"\n  },\n  {\n    \"question\": \"Reactivation tuberculosis commonly occurs due to a decline in the host's cellular immunity, particularly affecting:\",\n    \"options\": {\n      \"A\": \"B lymphocyte function\",\n      \"B\": \"Natural killer cell activity\",\n      \"C\": \"CD4+ T cell numbers/function\",\n      \"D\": \"Neutrophil chemotaxis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"Reactivation of latent TB, where contained bacteria begin to multiply and cause active disease, is most strongly associated with impaired CD4+ T cell immunity. This is prominently seen in HIV infection, immunosuppressive therapy, or other states of T-cell compromise.\",\n    \"highYieldPearl\": \"CD4+ T cell integrity is paramount for maintaining latency and preventing TB reactivation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While other immune components contribute, the decline in CD4+ T cell numbers or function is the most critical factor leading to the loss of control over latent *M. tuberculosis*.\"\n  },\n  {\n    \"question\": \"The BCG vaccine primarily aims to stimulate which type of immune response against *Mycobacterium tuberculosis*?\",\n    \"options\": {\n      \"A\": \"Humoral immunity\",\n      \"B\": \"Mucosal immunity\",\n      \"C\": \"Cell-mediated immunity\",\n      \"D\": \"Innate immunity\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_pathogenesis\",\n    \"deepDiveExplanation\": \"BCG (Bacille Calmette–Guérin) is a live attenuated vaccine designed to induce a robust cell-mediated immune response, specifically a Th1 response. This involves the activation of T lymphocytes and macrophages, which are crucial for controlling intracellular *M. tuberculosis*.\",\n    \"highYieldPearl\": \"BCG's protective effect is mediated by the induction of a strong Th1 cell-mediated immune response.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"BCG primarily stimulates adaptive cell-mediated immunity. While it might have some effects on innate immunity, and indirectly on mucosal immunity, its main goal is to prime the T-cell response, not humoral immunity.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-926.5360717773438}],"createTime":"2025-12-31T07:46:46.466087Z","modelVersion":"gemini-2.5-flash","responseId":"5tRUaae5HLjFvPEP5p7G0Ao","usageMetadata":{"billablePromptUsage":{"textCount":1032},"candidatesTokenCount":2649,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2649}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2127,"totalTokenCount":5141,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:50:03.010249+00:00"}
{"metadata":"one-liner|lung_cancer_staging|Lung Cancer - Diagnosis and Staging|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Diagnosis and Staging\".\nSet the \"topic\" field in the JSON to \"lung_cancer_staging\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4653195310545572,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which non-invasive imaging modality is most sensitive for detecting mediastinal lymph node metastasis in NSCLC prior to biopsy?\",\n    \"options\": {\n      \"A\": \"CT Thorax with contrast\",\n      \"B\": \"PET-CT\",\n      \"C\": \"MRI Chest\",\n      \"D\": \"Ultrasound Thorax\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"PET-CT (Positron Emission Tomography-Computed Tomography) utilizes 18F-FDG uptake to identify metabolically active tumor tissue, including lymph nodes. It has a higher sensitivity and negative predictive value for detecting mediastinal lymph node metastasis compared to conventional CT alone, making it a crucial tool for initial non-invasive N-staging in non-small cell lung cancer (NSCLC) and guiding subsequent invasive procedures.\",\n    \"highYieldPearl\": \"PET-CT is superior to CT for non-invasive mediastinal nodal staging and detection of occult distant metastases in NSCLC.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While CT can show enlarged lymph nodes, it is less specific than PET-CT. MRI is generally not the primary modality for mediastinal nodal staging. Ultrasound is used for peripheral or pleural lesions, not deep mediastinal nodes.\"\n  },\n  {\n    \"question\": \"What is the primary staging system traditionally used for Small Cell Lung Cancer (SCLC)?\",\n    \"options\": {\n      \"A\": \"TNM staging\",\n      \"B\": \"Limited vs. Extensive Disease\",\n      \"C\": \"Masaoka staging\",\n      \"D\": \"Ann Arbor staging\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"Small Cell Lung Cancer (SCLC) is characterized by rapid growth and early metastatic spread. For treatment stratification, it is traditionally staged into two categories: 'Limited Disease' (confined to one hemithorax, mediastinum, and regional lymph nodes that can be encompassed in a single radiation field) and 'Extensive Disease' (beyond these limits, including distant metastases). This simplified system guides chemotherapy and radiation decisions.\",\n    \"highYieldPearl\": \"SCLC's rapid dissemination makes the two-stage (Limited/Extensive) system more practical for initial treatment decisions than detailed TNM.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While TNM staging can be applied to SCLC, the Limited vs. Extensive Disease system remains the most widely used clinical staging method for guiding treatment. Masaoka is for thymoma, and Ann Arbor is for lymphoma.\"\n  },\n  {\n    \"question\": \"Which imaging study is mandatory for all patients diagnosed with Small Cell Lung Cancer (SCLC) for comprehensive staging?\",\n    \"options\": {\n      \"A\": \"Brain MRI with contrast\",\n      \"B\": \"Bone scan\",\n      \"C\": \"Adrenal CT\",\n      \"D\": \"Liver ultrasound\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"SCLC has a high propensity for early brain metastasis, with up to 10-15% of patients presenting with brain involvement. Therefore, mandatory brain imaging, preferably MRI with contrast due to its higher sensitivity, is a critical component of initial staging to detect occult metastases and guide management, including prophylactic cranial irradiation.\",\n    \"highYieldPearl\": \"Brain MRI is crucial for SCLC staging due to the high risk of occult brain metastases at presentation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While SCLC can metastasize to bone, adrenals, and liver, brain metastasis is particularly common and often asymptomatic at presentation, requiring specific dedicated imaging beyond routine body scans.\"\n  },\n  {\n    \"question\": \"A malignant pleural effusion in non-small cell lung cancer (NSCLC) automatically confers what TNM stage designation?\",\n    \"options\": {\n      \"A\": \"T2\",\n      \"B\": \"T3\",\n      \"C\": \"T4\",\n      \"D\": \"M1a\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"According to the 8th edition of the TNM staging system for lung cancer, a malignant pleural or pericardial effusion, or pleural nodules, are classified as M1a. This indicates distant metastasis, signifying advanced, unresectable disease, regardless of the primary tumor (T) or nodal (N) status.\",\n    \"highYieldPearl\": \"Malignant pleural effusion in NSCLC always signifies metastatic disease (M1a), indicating unresectable stage IV disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse this with T-stages related to local invasion. However, any malignant effusion indicates dissemination beyond local/regional disease, hence M1a, which is a metastatic stage.\"\n  },\n  {\n    \"question\": \"Which lymph node station is most consistently accessible for sampling via Endobronchial Ultrasound (EBUS) in lung cancer staging?\",\n    \"options\": {\n      \"A\": \"Supraclavicular (1)\",\n      \"B\": \"Hilar (10)\",\n      \"C\": \"Subcarinal (7)\",\n      \"D\": \"Internal mammary (6)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) is highly effective for sampling mediastinal and hilar lymph nodes. The subcarinal lymph node station (station 7) is typically located posterior to the carina and is consistently well-visualized and accessible for aspiration via EBUS, making it a common target for N-staging.\",\n    \"highYieldPearl\": \"EBUS is excellent for sampling paratracheal (2, 4) and subcarinal (7) lymph nodes, crucial for N-staging.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While hilar nodes (10) are also accessible, station 7 is often considered the most consistently targetable central mediastinal station. Supraclavicular nodes are usually accessed externally. Internal mammary nodes are not typically accessible by EBUS.\"\n  },\n  {\n    \"question\": \"What is the preferred diagnostic modality for biopsy of a peripheral lung lesion suspicious for cancer?\",\n    \"options\": {\n      \"A\": \"Bronchoscopy with transbronchial biopsy\",\n      \"B\": \"CT-guided percutaneous needle aspiration\",\n      \"C\": \"Endobronchial ultrasound\",\n      \"D\": \"Mediastinoscopy\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"For peripheral lung lesions (typically in the outer one-third of the lung), CT-guided percutaneous needle aspiration (PCNA) offers the highest diagnostic yield (often >90%). It allows direct targeting of the lesion under real-time imaging guidance, which is superior to bronchoscopy for lesions not accessible via the airways.\",\n    \"highYieldPearl\": \"CT-guided biopsy is the go-to for peripheral lung masses, offering high diagnostic yield.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Bronchoscopy yield for peripheral lesions is lower, especially for smaller or more peripherally located ones. EBUS is for mediastinal/hilar nodes. Mediastinoscopy is for mediastinal node staging.\"\n  },\n  {\n    \"question\": \"What is considered the definitive 'gold standard' for pathological N-staging in Non-Small Cell Lung Cancer (NSCLC)?\",\n    \"options\": {\n      \"A\": \"PET-CT\",\n      \"B\": \"EBUS-TBNA\",\n      \"C\": \"Mediastinoscopy\",\n      \"D\": \"Thoracoscopy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"While EBUS-TBNA provides excellent diagnostic yield for mediastinal lymph nodes, mediastinoscopy remains the gold standard for definitive pathological confirmation of mediastinal lymph node involvement (N2/N3 disease). It allows direct visualization and excision of larger tissue samples from multiple critical lymph node stations (e.g., 2R, 4R, 7), providing the most accurate and comprehensive pathological N-stage.\",\n    \"highYieldPearl\": \"Mediastinoscopy provides the most accurate pathological N-stage for NSCLC, crucial for surgical eligibility.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"PET-CT is functional imaging, not pathological. EBUS-TBNA is highly effective for sampling but mediastinoscopy provides a more definitive and often larger tissue sample for comprehensive pathological assessment. Thoracoscopy is primarily for pleural disease or peripheral lesions.\"\n  },\n  {\n    \"question\": \"In SCLC, 'Limited Disease' implies disease confined to one hemithorax and what other characteristic?\",\n    \"options\": {\n      \"A\": \"Ipsilateral supraclavicular nodes only\",\n      \"B\": \"Contralateral hilar nodes\",\n      \"C\": \"Regional lymph nodes encompassed in a single radiation field\",\n      \"D\": \"Malignant pleural effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"The traditional definition of Limited Disease SCLC includes disease confined to one hemithorax, the mediastinum, and regional lymph nodes (ipsilateral hilar, mediastinal, and ipsilateral supraclavicular nodes) that can be encompassed within a single, tolerable radiation port. Contralateral hilar nodes or a malignant pleural effusion would classify the disease as 'Extensive'.\",\n    \"highYieldPearl\": \"Limited SCLC is defined by disease within a single, tolerable radiation field, encompassing ipsilateral regional nodes.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and B represent specific nodal involvements. The key distinguishing factor for 'Limited Disease' is the ability to encompass all disease within a single radiation field. A malignant pleural effusion (D) always indicates extensive disease.\"\n  },\n  {\n    \"question\": \"A tumor in the main bronchus, 1.5 cm distal to the carina, without carinal involvement, is classified as which T-stage?\",\n    \"options\": {\n      \"A\": \"T1\",\n      \"B\": \"T2\",\n      \"C\": \"T3\",\n      \"D\": \"T4\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"According to the 8th edition TNM staging for NSCLC, a tumor in the main bronchus, regardless of its distance from the carina, but without actual involvement of the carina, is classified as T2. T1 tumors do not involve the main bronchus. Carinal involvement would upgrade the tumor to T4.\",\n    \"highYieldPearl\": \"Main bronchus involvement (without carinal involvement) automatically designates a tumor as at least T2, irrespective of size.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This question tests precise knowledge of TNM criteria. T1 is for peripheral tumors not involving the main bronchus. T4 is for carinal involvement. The distance from the carina is relevant for T2 vs T3 only if it's less than 2 cm from the carina AND involving the carina, which is not the case here.\"\n  },\n  {\n    \"question\": \"What finding in NSCLC staging would classify the patient as M1b?\",\n    \"options\": {\n      \"A\": \"Malignant pleural effusion\",\n      \"B\": \"Contralateral lung nodule\",\n      \"C\": \"Single adrenal metastasis\",\n      \"D\": \"Separate tumor nodule in a different ipsilateral lobe\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_staging\",\n    \"deepDiveExplanation\": \"According to the 8th edition TNM staging system, M1b refers to a single extrathoracic metastasis (e.g., in the brain, bone, liver, or adrenal gland). M1a includes intrathoracic metastatic disease such as malignant pleural/pericardial effusion, pleural nodules, or a contralateral lung nodule. Separate tumor nodule in a different ipsilateral lobe is T4.\",\n    \"highYieldPearl\": \"M1b denotes a single extrathoracic metastatic site, distinguishing it from M1a (intrathoracic metastases) or multiple extrathoracic metastases (M1c).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Malignant pleural effusion (A) and contralateral lung nodule (B) are M1a. A separate tumor nodule in a different ipsilateral lobe (D) is T4. The key is 'single extrathoracic metastasis' for M1b.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1395.0279541015625}],"createTime":"2025-12-31T07:46:20.645058Z","modelVersion":"gemini-2.5-flash","responseId":"zNRUacKvJ7KJ1dkP1aL2qAk","usageMetadata":{"billablePromptUsage":{"textCount":1041},"candidatesTokenCount":2998,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2998}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":3274,"totalTokenCount":6640,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:23.604528+00:00"}
{"metadata":"one-liner|hap_vap|Hospital-Acquired and Ventilator-Associated Pneumonia|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Hospital-Acquired and Ventilator-Associated Pneumonia\".\nSet the \"topic\" field in the JSON to \"hap_vap\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.2600140561735441,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Hospital-acquired pneumonia typically develops after how many hours of hospital admission?\",\n    \"options\": {\n      \"A\": \"12\",\n      \"B\": \"24\",\n      \"C\": \"36\",\n      \"D\": \"48\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Hospital-acquired pneumonia (HAP) is defined as pneumonia that was not incubating at the time of hospital admission and develops 48 hours or more after admission. If it develops within 48 hours, it is considered community-acquired pneumonia (CAP), unless specific risk factors for HAP are present.\",\n    \"highYieldPearl\": \"HAP = pneumonia developing ≥48 hours after hospital admission.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The 24-hour mark is often associated with surgical site infections or other acute post-op complications, but for pneumonia, the 48-hour threshold is standard.\"\n  },\n  {\n    \"question\": \"Which risk factor is most strongly associated with multidrug-resistant (MDR) pathogens in HAP?\",\n    \"options\": {\n      \"A\": \"Age > 60 years\",\n      \"B\": \"Diabetes mellitus\",\n      \"C\": \"Prior intravenous antibiotic use within 90 days\",\n      \"D\": \"Chronic obstructive pulmonary disease\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Prior intravenous antibiotic use within 90 days is a major risk factor for MDR pathogens in both HAP and VAP, significantly increasing the likelihood of organisms like MRSA, Pseudomonas aeruginosa, and extended-spectrum beta-lactamase (ESBL) producers. While other options are general risk factors for HAP, they do not specifically indicate MDR pathogens as strongly.\",\n    \"highYieldPearl\": \"Recent IV antibiotic use (within 90 days) is a critical indicator for MDR pathogen coverage in HAP/VAP empiric therapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Age and comorbidities like diabetes or COPD increase the risk of HAP generally, but prior antibiotic use directly drives antibiotic resistance selection pressure, making it the strongest predictor for MDR pathogens.\"\n  },\n  {\n    \"question\": \"The most definitive diagnostic method for VAP, though often impractical, is?\",\n    \"options\": {\n      \"A\": \"Endotracheal aspirate culture\",\n      \"B\": \"Protected specimen brush (PSB) culture\",\n      \"C\": \"Blood culture\",\n      \"D\": \"Sputum Gram stain\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Protected specimen brush (PSB) culture or quantitative bronchoalveolar lavage (BAL) culture are considered the most definitive methods for VAP diagnosis due to their ability to obtain samples with minimal contamination from the upper airway, and the use of quantitative thresholds to distinguish infection from colonization. Endotracheal aspirates are easily contaminated and less specific. Blood cultures are positive in only a minority of VAP cases.\",\n    \"highYieldPearl\": \"Quantitative cultures from PSB or BAL offer the highest diagnostic accuracy for VAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Endotracheal aspirates are common but have high false-positive rates due to colonization. Blood cultures are specific but insensitive. Sputum Gram stain is useful for initial guidance but not definitive diagnosis.\"\n  },\n  {\n    \"question\": \"Which antibiotic class is typically *not* part of initial empiric therapy for suspected VAP with risk factors for Pseudomonas?\",\n    \"options\": {\n      \"A\": \"Carbapenems\",\n      \"B\": \"Anti-pseudomonal cephalosporins\",\n      \"C\": \"Fluoroquinolones\",\n      \"D\": \"Macrolides\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Macrolides (e.g., azithromycin, clarithromycin) are generally not active against Pseudomonas aeruginosa and are thus not used for empiric coverage of this pathogen in VAP. Carbapenems (e.g., meropenem, imipenem), anti-pseudomonal cephalosporins (e.g., ceftazidime, cefepime), and anti-pseudomonal fluoroquinolones (e.g., ciprofloxacin, levofloxacin) are all options for Pseudomonas coverage.\",\n    \"highYieldPearl\": \"Macrolides lack anti-pseudomonal activity; never use them for empiric Pseudomonas coverage in VAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All other options include antibiotics with anti-pseudomonal activity. Macrolides are often used in CAP, which might lead to confusion, but they are inappropriate for HAP/VAP with Pseudomonas risk.\"\n  },\n  {\n    \"question\": \"Elevating the head of the bed to 30-45 degrees is a critical component of the VAP prevention strategy known as the?\",\n    \"options\": {\n      \"A\": \"Ventilator Weaning Protocol\",\n      \"B\": \"VAP Bundle\",\n      \"C\": \"Sepsis Protocol\",\n      \"D\": \"ICU Mobility Protocol\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Elevating the head of the bed to 30-45 degrees is a key component of the 'VAP Bundle,' a set of evidence-based interventions designed to prevent ventilator-associated pneumonia. Other components typically include daily sedation interruption, daily assessment of readiness for extubation, peptic ulcer disease prophylaxis, and deep venous thrombosis prophylaxis, along with oral care with chlorhexidine.\",\n    \"highYieldPearl\": \"Head of bed elevation is a fundamental part of the VAP Bundle to prevent aspiration.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While daily sedation interruption and early mobilization are also VAP prevention strategies, they are distinct components. The question asks about the *strategy* that includes head elevation, which is the overarching VAP Bundle.\"\n  },\n  {\n    \"question\": \"Which biomarker is most useful for guiding antibiotic de-escalation or discontinuation in VAP?\",\n    \"options\": {\n      \"A\": \"C-reactive protein\",\n      \"B\": \"Erythrocyte sedimentation rate\",\n      \"C\": \"Procalcitonin\",\n      \"D\": \"White blood cell count\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Procalcitonin (PCT) levels are more specific for bacterial infections than other inflammatory markers like CRP or WBC count. Serial measurements of PCT can help guide the decision to de-escalate or discontinue antibiotics in VAP, as declining levels indicate resolving bacterial infection, thereby reducing antibiotic exposure and resistance.\",\n    \"highYieldPearl\": \"Procalcitonin aids in antibiotic stewardship by guiding de-escalation in VAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CRP, ESR, and WBC count are general inflammatory markers and are less specific for bacterial infection resolution compared to procalcitonin, which has been shown in studies to safely reduce antibiotic duration.\"\n  },\n  {\n    \"question\": \"Empiric coverage for MRSA in VAP typically involves which antibiotic class?\",\n    \"options\": {\n      \"A\": \"Beta-lactams\",\n      \"B\": \"Aminoglycosides\",\n      \"C\": \"Glycopeptides\",\n      \"D\": \"Tetracyclines\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Glycopeptide antibiotics, primarily vancomycin, are the cornerstone of empiric therapy for suspected MRSA in VAP. Linezolid (an oxazolidinone) is another alternative. Beta-lactams are generally ineffective against MRSA due to altered penicillin-binding proteins. Aminoglycosides lack significant activity against MRSA. While some tetracyclines (e.g., doxycycline, tigecycline) have activity, they are not first-line empiric agents for severe VAP due to resistance patterns or side effects.\",\n    \"highYieldPearl\": \"Vancomycin (a glycopeptide) is the primary choice for empiric MRSA coverage in VAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Many beta-lactams are used for Gram-positive coverage, but MRSA is specifically resistant to them. Aminoglycosides are typically for Gram-negative coverage.\"\n  },\n  {\n    \"question\": \"Ventilator-associated pneumonia is defined as pneumonia developing more than how many hours after endotracheal intubation?\",\n    \"options\": {\n      \"A\": \"12\",\n      \"B\": \"24\",\n      \"C\": \"36\",\n      \"D\": \"48\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Ventilator-associated pneumonia (VAP) is a type of HAP that specifically refers to pneumonia developing more than 48 hours after endotracheal intubation and initiation of mechanical ventilation. This timeline helps differentiate it from pneumonia present at the time of intubation or early-onset pneumonia.\",\n    \"highYieldPearl\": \"VAP = pneumonia developing ≥48 hours after intubation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Similar to HAP, the 48-hour mark is the crucial distinction for VAP. Knowing both HAP and VAP definitions' timelines is essential.\"\n  },\n  {\n    \"question\": \"Previous broad-spectrum antibiotic use is a significant risk factor for VAP caused by which pathogen?\",\n    \"options\": {\n      \"A\": \"Streptococcus pneumoniae\",\n      \"B\": \"Haemophilus influenzae\",\n      \"C\": \"Acinetobacter baumannii\",\n      \"D\": \"Mycoplasma pneumoniae\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Previous broad-spectrum antibiotic use (especially within the last 90 days) is a strong risk factor for colonization and subsequent infection with highly resistant Gram-negative bacteria, such as Acinetobacter baumannii and Pseudomonas aeruginosa, as well as MRSA and ESBL-producing Enterobacteriaceae. The other pathogens listed are more typically associated with community-acquired infections or are less strongly linked to prior broad-spectrum antibiotic use in the context of HAP/VAP MDR risk.\",\n    \"highYieldPearl\": \"Prior broad-spectrum antibiotics increase the risk of MDR Gram-negatives like Acinetobacter in VAP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"S. pneumoniae and H. influenzae are common CAP pathogens. M. pneumoniae is an atypical pathogen. Acinetobacter is a classic MDR HAP/VAP pathogen highly associated with prior antibiotic exposure.\"\n  },\n  {\n    \"question\": \"The recommended duration of antibiotic therapy for most cases of VAP without specific complications is usually?\",\n    \"options\": {\n      \"A\": \"3-5 days\",\n      \"B\": \"7 days\",\n      \"C\": \"10-14 days\",\n      \"D\": \"21 days\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hap_vap\",\n    \"deepDiveExplanation\": \"Current guidelines (e.g., IDSA/ATS 2016) recommend a shorter course of antibiotic therapy, typically 7 days, for most cases of VAP, provided the patient has demonstrated clinical improvement. Longer courses (10-14 days) were previously standard but are now reserved for specific situations like necrotizing pneumonia, severe immunosuppression, or infection with certain non-fermenting Gram-negative bacilli (e.g., P. aeruginosa, Acinetobacter) that may require prolonged treatment.\",\n    \"highYieldPearl\": \"For uncomplicated VAP, 7 days of antibiotics is often sufficient.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The historical recommendation was 10-14 days, which might still be chosen by some. However, evidence supports shorter durations for most cases to reduce antibiotic resistance and side effects. 3-5 days is generally too short for VAP, and 21 days is reserved for highly complicated or specific fungal/mycobacterial infections.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-754.560791015625}],"createTime":"2025-12-31T07:45:56.232962Z","modelVersion":"gemini-2.5-flash","responseId":"tNRUaYKcDorfnvgPkraasQ0","usageMetadata":{"billablePromptUsage":{"textCount":1049},"candidatesTokenCount":2902,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2902}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":1370,"totalTokenCount":4642,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:50.901433+00:00"}
{"metadata":"one-liner|pulm_rehab|Pulmonary Rehabilitation|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Rehabilitation\".\nSet the \"topic\" field in the JSON to \"pulm_rehab\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3543687864135832,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"What is considered a core component of pulmonary rehabilitation programs?\",\n    \"options\": {\n      \"A\": \"Bronchodilator therapy optimization\",\n      \"B\": \"Oxygen supplementation\",\n      \"C\": \"Exercise training\",\n      \"D\": \"Antibiotic prophylaxis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pulm_rehab\",\n    \"deepDiveExplanation\": \"Pulmonary rehabilitation is a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies, including, but not limited to, exercise training, education, and psychosocial support, aimed at improving the physical and psychological condition of people with chronic respiratory disease and promoting the long-term adherence of health-enhancing behaviors. Exercise training is universally considered the cornerstone of pulmonary rehabilitation.\",\n    \"highYieldPearl\": \"Exercise training is the most fundamental and indispensable component of pulmonary rehabilitation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other options like bronchodilator therapy and oxygen may be part of overall management, they are not core *components* of the rehabilitation program itself, which focuses on behavioral and physical interventions.\"\n  },\n  {\n    \"question\": \"Which patient population primarily benefits from pulmonary rehabilitation according to current guidelines?\",\n    \"options\": {\n      \"A\": \"Patients with mild asthma\",\n      \"B\": \"Patients with acute pneumonia\",\n      \"C\": \"Patients with stable symptomatic COPD\",\n      \"D\": \"Patients with latent tuberculosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pulm_rehab\",\n    \"deepDiveExplanation\": \"Pulmonary rehabilitation is strongly recommended for patients with stable symptomatic COPD across all GOLD stages who experience dyspnea, reduced exercise tolerance, and impaired quality of life. Evidence also supports its use in other chronic respiratory conditions like interstitial lung disease, bronchiectasis, and pre/post-lung transplant.\",\n    \"highYieldPearl\": \"COPD patients with persistent symptoms and exercise limitation are the primary target for pulmonary rehabilitation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Mild asthma usually doesn't warrant PR; acute conditions like pneumonia are not suitable. Latent TB is asymptomatic and not a target for PR.\"\n  },\n  {\n    \"question\": \"A key objective measure used to assess functional capacity improvement post-pulmonary rehabilitation is the:\",\n    \"options\": {\n      \"A\": \"Forced Expiratory Volume in 1 second (FEV1)\",\n      \"B\": \"Diffusing capacity of the lungs for carbon monoxide (DLCO)\",\n      \"C\": \"Six-minute walk test (6MWT)\",\n      \"D\": \"Arterial blood gas (ABG) analysis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pulm_rehab\",\n    \"deepDiveExplanation\": \"The Six-minute walk test (6MWT) is a widely used, objective, and reproducible measure to assess functional exercise capacity and response to interventions like pulmonary rehabilitation. It reflects daily activity tolerance. While FEV1 and DLCO assess lung function, and ABG assesses gas exchange, they are not direct measures of functional exercise capacity improvement due to rehabilitation.\",\n    \"highYieldPearl\": \"6MWT distance is a primary outcome measure for functional improvement in pulmonary rehabilitation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"FEV1, DLCO, and ABG measure physiological parameters but don't directly quantify functional capacity or endurance, which is what PR primarily aims to improve.\"\n  },\n  {\n    \"question\": \"What is the generally recommended minimum duration for an effective outpatient pulmonary rehabilitation program?\",\n    \"options\": {\n      \"A\": \"2-4 weeks\",\n      \"B\": \"4-6 weeks\",\n      \"C\": \"8-12 weeks\",\n      \"D\": \"16-20 weeks\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pulm_rehab\",\n    \"deepDiveExplanation\": \"Current guidelines from ATS/ERS recommend a minimum duration of 6-8 weeks for pulmonary rehabilitation, with most benefits seen and sustained with programs lasting 8-12 weeks or longer. Shorter programs may not provide sufficient time for physiological adaptations and behavior change.\",\n    \"highYieldPearl\": \"Aim for at least 8-12 weeks of pulmonary rehabilitation for optimal and sustained benefits.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Shorter durations (A, B) are generally insufficient to achieve significant and lasting improvements. While longer programs (D) might be beneficial, 8-12 weeks is the established minimum for effectiveness.\"\n  },\n  {\n    \"question\": \"Pulmonary rehabilitation primarily improves exercise tolerance in COPD patients by reducing:\",\n    \"options\": {\n      \"A\": \"Airway inflammation\",\n      \"B\": \"Dynamic hyperinflation\",\n      \"C\": \"Systemic hypoxia\",\n      \"D\": \"Mucus production\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pulm_rehab\",\n    \"deepDiveExplanation\": \"While PR does not significantly alter lung function (like FEV1), it improves exercise tolerance primarily by reducing dynamic hyperinflation, which is the progressive increase in end-expiratory lung volume during exercise due to expiratory flow limitation. This reduction allows for increased inspiratory capacity, delaying the onset of dyspnea and fatigue. It also improves muscle strength and efficiency, reducing lactic acid accumulation.\",\n    \"highYieldPearl\": \"PR's impact on dynamic hyperinflation is a key mechanism for improving exercise tolerance in COPD.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"PR does not directly target airway inflammation or mucus production (these are managed by pharmacotherapy). While it can indirectly improve oxygen utilization, it does not primarily reduce systemic hypoxia at rest, but rather improves the ventilatory response to exercise.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-479.4609680175781}],"createTime":"2025-12-31T07:45:20.263323Z","modelVersion":"gemini-2.5-flash","responseId":"kNRUaZuJENbTnvgP-NrG0A4","usageMetadata":{"billablePromptUsage":{"textCount":1024},"candidatesTokenCount":1353,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1353}],"promptTokenCount":363,"promptTokensDetails":[{"modality":"TEXT","tokenCount":363}],"thoughtsTokenCount":1117,"totalTokenCount":2833,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:01.289012+00:00"}
{"metadata":"one-liner|abg|Arterial Blood Gas Interpretation|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Arterial Blood Gas Interpretation\".\nSet the \"topic\" field in the JSON to \"abg\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.312414155360175,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which formula estimates the expected respiratory compensation for metabolic acidosis?\",\n    \"options\": {\n      \"A\": \"Kassirer-Bleich\",\n      \"B\": \"Henderson-Hasselbalch\",\n      \"C\": \"Winter's\",\n      \"D\": \"Stewart's\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"Winter's formula (Expected PaCO2 = 1.5 * HCO3 + 8 +/- 2) is specifically used to calculate the expected compensatory PaCO2 in a patient with metabolic acidosis. This helps determine if there is an appropriate respiratory compensation or a co-existing respiratory disorder.\",\n    \"highYieldPearl\": \"Winter's formula is crucial for identifying mixed acid-base disorders when metabolic acidosis is present.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse Winter's formula with other acid-base equations. Knowing the specific application of each formula is key.\"\n  },\n  {\n    \"question\": \"The anion gap is calculated using which primary serum electrolyte concentrations?\",\n    \"options\": {\n      \"A\": \"Na, K, Cl\",\n      \"B\": \"Na, Cl, HCO3\",\n      \"C\": \"Na, K, HCO3\",\n      \"D\": \"K, Cl, HCO3\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"The anion gap (AG) is calculated as [Na+] - ([Cl-] + [HCO3-]). It represents the concentration of unmeasured anions (e.g., albumin, phosphate, sulfate, organic acids) minus unmeasured cations. Potassium is typically excluded due to its relatively low concentration and minimal impact on the gap.\",\n    \"highYieldPearl\": \"Anion Gap = Na+ - (Cl- + HCO3-). Remember to exclude potassium from the calculation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"A common mistake is to include potassium (K+) in the anion gap calculation. While technically a cation, its concentration is usually too small to significantly impact the clinical utility of the calculation.\"\n  },\n  {\n    \"question\": \"The delta-delta ratio (or delta gap) is primarily used to assess for which acid-base condition?\",\n    \"options\": {\n      \"A\": \"Acute respiratory acidosis\",\n      \"B\": \"Compensated metabolic alkalosis\",\n      \"C\": \"Mixed metabolic acidosis\",\n      \"D\": \"Simple respiratory alkalosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"The delta-delta ratio (or delta gap) helps differentiate between a pure high anion gap metabolic acidosis (HAGMA) and a mixed disorder involving HAGMA and a normal anion gap metabolic acidosis (NAGMA) or metabolic alkalosis. It compares the change in anion gap to the change in bicarbonate. A ratio significantly different from 1-2 suggests a mixed metabolic disorder.\",\n    \"highYieldPearl\": \"A delta-delta ratio outside the 1-2 range indicates a mixed metabolic acidosis (HAGMA + NAGMA or HAGMA + Metabolic Alkalosis).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might not understand the specific utility of the delta-delta ratio, which is to uncover hidden metabolic disorders co-existing with a primary HAGMA. It's not for simple, compensated, or primary respiratory disorders.\"\n  },\n  {\n    \"question\": \"In chronic respiratory acidosis, renal compensation primarily involves an increase in which parameter?\",\n    \"options\": {\n      \"A\": \"Urinary ammonia excretion\",\n      \"B\": \"Serum bicarbonate\",\n      \"C\": \"Serum chloride\",\n      \"D\": \"Plasma lactate\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"In chronic respiratory acidosis, the kidneys compensate by increasing bicarbonate reabsorption and hydrogen ion excretion. This leads to an increase in serum bicarbonate levels, which helps buffer the excess CO2 and normalize the pH. Urinary ammonia excretion is part of the H+ excretion but the direct measurable systemic effect is increased serum HCO3.\",\n    \"highYieldPearl\": \"Chronic respiratory acidosis leads to compensatory renal bicarbonate retention, aiming to normalize pH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While increased urinary ammonia excretion is part of the renal compensatory mechanism, the most direct and measurable systemic parameter reflecting this compensation on ABG/serum electrolytes is the rise in serum bicarbonate.\"\n  },\n  {\n    \"question\": \"Which condition is a classic cause of normal anion gap metabolic acidosis?\",\n    \"options\": {\n      \"A\": \"Lactic acidosis\",\n      \"B\": \"Diabetic ketoacidosis\",\n      \"C\": \"Renal tubular acidosis\",\n      \"D\": \"Methanol poisoning\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"Normal anion gap metabolic acidosis (NAGMA), also known as hyperchloremic metabolic acidosis, occurs when bicarbonate loss is compensated by an increase in chloride. Renal tubular acidosis (RTA), diarrhea, and administration of large volumes of normal saline are classic causes. Lactic acidosis, diabetic ketoacidosis, and methanol poisoning are all causes of high anion gap metabolic acidosis (HAGMA).\",\n    \"highYieldPearl\": \"NAGMA is often caused by GI bicarbonate loss (diarrhea) or renal bicarbonate wasting (RTA).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options are causes of metabolic acidosis, but only Renal Tubular Acidosis (and diarrhea) typically presents with a normal anion gap. The other options are classic causes of high anion gap metabolic acidosis.\"\n  },\n  {\n    \"question\": \"Base Excess (BE) quantifies the non-respiratory component of acid-base disorders relative to what?\",\n    \"options\": {\n      \"A\": \"Standard pH\",\n      \"B\": \"Normal bicarbonate level\",\n      \"C\": \"A titratable acid or base\",\n      \"D\": \"Normal buffer base\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"Base Excess (or Deficit) is a measure of the non-respiratory (metabolic) component of an acid-base disorder. It represents the amount of strong acid or base required to titrate 1 liter of blood to a pH of 7.4 at a PaCO2 of 40 mmHg and a temperature of 37°C. It essentially quantifies the deviation of the total buffer base from its normal value.\",\n    \"highYieldPearl\": \"Base Excess directly reflects the metabolic component and overall body buffer status, independent of respiratory influence.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Students might incorrectly associate Base Excess solely with bicarbonate levels. While related, BE accounts for all blood buffers (hemoglobin, plasma proteins, phosphate) and provides a more comprehensive picture of the metabolic component than just HCO3-.\"\n  },\n  {\n    \"question\": \"Which ABG parameter directly measures the partial pressure of oxygen dissolved in arterial plasma?\",\n    \"options\": {\n      \"A\": \"SaO2\",\n      \"B\": \"PaO2\",\n      \"C\": \"SpO2\",\n      \"D\": \"DO2\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"PaO2 (partial pressure of arterial oxygen) directly measures the amount of oxygen physically dissolved in the arterial plasma. SaO2 (arterial oxygen saturation) and SpO2 (pulse oximetry saturation) measure the percentage of hemoglobin saturated with oxygen. DO2 (oxygen delivery) is a calculated value representing the total amount of oxygen delivered to the tissues.\",\n    \"highYieldPearl\": \"PaO2 reflects dissolved oxygen, while SaO2/SpO2 reflect oxygen bound to hemoglobin.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing PaO2 with SaO2 or SpO2 is common. PaO2 is a pressure, representing dissolved oxygen, while SaO2/SpO2 represent the percentage saturation of hemoglobin.\"\n  },\n  {\n    \"question\": \"A near-normal pH with significant abnormalities in both PaCO2 and HCO3 suggests which type of acid-base disturbance?\",\n    \"options\": {\n      \"A\": \"Simple compensated disorder\",\n      \"B\": \"Simple uncompensated disorder\",\n      \"C\": \"Mixed acid-base disorder\",\n      \"D\": \"Primary respiratory alkalosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"If the pH is near normal, but both the primary respiratory (PaCO2) and metabolic (HCO3) components are significantly abnormal in opposite directions (e.g., high PaCO2 and high HCO3; or low PaCO2 and low HCO3), it strongly suggests a mixed acid-base disorder. In a simple compensated disorder, one primary abnormality drives the pH change, and the other component shifts to compensate, usually not resulting in 'significant abnormalities' in both that balance each other out to a near-normal pH.\",\n    \"highYieldPearl\": \"Near-normal pH with both PaCO2 and HCO3 significantly abnormal points to a mixed disorder, where two primary disturbances are cancelling each other's pH effects.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is to mistake this for a 'fully compensated' simple disorder. While compensation aims to normalize pH, 'significant abnormalities' in both components beyond expected compensation ranges usually indicates two concurrent primary disorders.\"\n  },\n  {\n    \"question\": \"Acute hyperventilation primarily leads to a decrease in which arterial blood gas parameter?\",\n    \"options\": {\n      \"A\": \"PaO2\",\n      \"B\": \"HCO3\",\n      \"C\": \"PaCO2\",\n      \"D\": \"Base Excess\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"Hyperventilation is the process of breathing faster and/or deeper than metabolically necessary, leading to increased excretion of carbon dioxide (CO2). This reduces the partial pressure of CO2 in arterial blood (PaCO2), causing respiratory alkalosis (increased pH). The bicarbonate (HCO3) would decrease later as a compensatory mechanism (renal excretion) if hyperventilation persists (chronic).\",\n    \"highYieldPearl\": \"Acute hyperventilation directly 'blows off' CO2, decreasing PaCO2 and causing respiratory alkalosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse the primary effect (PaCO2 decrease) with the subsequent compensatory metabolic changes (HCO3 decrease). The question specifies 'primarily leads to,' referring to the initial direct effect.\"\n  },\n  {\n    \"question\": \"For every 10 mmHg increase in PaCO2 in acute respiratory acidosis, serum bicarbonate typically increases by how much?\",\n    \"options\": {\n      \"A\": \"0.1-0.2 mEq/L\",\n      \"B\": \"1-2 mEq/L\",\n      \"C\": \"3-4 mEq/L\",\n      \"D\": \"5-6 mEq/L\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"abg\",\n    \"deepDiveExplanation\": \"In acute respiratory acidosis, for every 10 mmHg increase in PaCO2 above 40 mmHg, the serum bicarbonate (HCO3-) concentration typically increases by 1-2 mEq/L due to immediate buffering by non-bicarbonate buffers (e.g., hemoglobin). This is a relatively small change compared to chronic compensation. In chronic respiratory acidosis, the increase is 3-4 mEq/L per 10 mmHg rise in PaCO2 due to renal compensation.\",\n    \"highYieldPearl\": \"Acute respiratory acidosis: HCO3 increases by 1-2 mEq/L for every 10 mmHg PaCO2 rise. Chronic: 3-4 mEq/L.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The main trap is confusing the compensatory response in acute vs. chronic respiratory acidosis. The magnitude of bicarbonate change is different due to the involvement of renal compensation in chronic states.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-896.9410400390625}],"createTime":"2025-12-31T07:46:24.095897Z","modelVersion":"gemini-2.5-flash","responseId":"0NRUaZntBZ2klu8P06qV2Q4","usageMetadata":{"billablePromptUsage":{"textCount":1025},"candidatesTokenCount":2871,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2871}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1957,"totalTokenCount":5192,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:48.642116+00:00"}
{"metadata":"one-liner|pleural_effusion|Pleural Effusion - Approach and Diagnosis|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pleural Effusion - Approach and Diagnosis\".\nSet the \"topic\" field in the JSON to \"pleural_effusion\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.4500171151761106,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which of the following is NOT a primary criterion for exudative pleural effusion by Light's criteria?\",\n    \"options\": {\n      \"A\": \"Pleural fluid protein/serum protein ratio >0.5\",\n      \"B\": \"Pleural fluid LDH/serum LDH ratio >0.6\",\n      \"C\": \"Pleural fluid LDH >2/3 upper limit of normal serum LDH\",\n      \"D\": \"Pleural fluid glucose <60 mg/dL\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Light's criteria are used to differentiate transudates from exudates. They include a pleural fluid protein/serum protein ratio >0.5, a pleural fluid LDH/serum LDH ratio >0.6, and pleural fluid LDH >2/3 upper limit of normal serum LDH. Pleural fluid glucose levels, while important for characterizing certain exudates, are not part of Light's original diagnostic criteria.\",\n    \"highYieldPearl\": \"Light's criteria are highly sensitive (95%) for exudates but can misclassify up to 25% of transudates (especially in patients on diuretics) as exudates.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Option D is a characteristic of specific exudates (e.g., empyema, rheumatoid effusion) and is often tested alongside Light's criteria, making it a common distractor for those who don't recall the exact three criteria.\"\n  },\n  {\n    \"question\": \"The gold standard for diagnosing tuberculous pleural effusion is?\",\n    \"options\": {\n      \"A\": \"Pleural fluid adenosine deaminase (ADA) level\",\n      \"B\": \"Pleural fluid interferon-gamma (IFN-γ) level\",\n      \"C\": \"Pleural biopsy with histology and mycobacterial culture\",\n      \"D\": \"Pleural fluid GeneXpert MTB/RIF\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"While pleural fluid ADA, IFN-γ, and GeneXpert are highly useful diagnostic tools for tuberculous pleurisy, the definitive 'gold standard' involves obtaining pleural tissue (via medical thoracoscopy or VATS) for histological examination (looking for granulomas) and mycobacterial culture. Pleural fluid cultures alone are often negative (25-50% sensitivity).\",\n    \"highYieldPearl\": \"Pleural fluid culture for Mycobacterium tuberculosis is positive in less than 25% of cases; tissue biopsy significantly improves diagnostic yield.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A, B, and D are all strong indicators for TB but are not the 'gold standard' which typically implies definitive tissue diagnosis or culture from the affected site.\"\n  },\n  {\n    \"question\": \"A pleural fluid pH less than 7.20 in an exudate is most characteristic of?\",\n    \"options\": {\n      \"A\": \"Malignant effusion\",\n      \"B\": \"Complicated parapneumonic effusion/empyema\",\n      \"C\": \"Tuberculous pleural effusion\",\n      \"D\": \"Rheumatoid pleural effusion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"A pleural fluid pH below 7.20 indicates significant acid production due to glucose metabolism by bacteria and inflammatory cells, or impaired hydrogen ion efflux. This finding is a critical indicator for complicated parapneumonic effusions or empyema, often mandating chest tube drainage.\",\n    \"highYieldPearl\": \"Pleural fluid pH <7.20 (or pH <7.00 in some guidelines) is a key criterion for chest tube drainage in parapneumonic effusions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Malignant and rheumatoid effusions can also cause low pleural fluid pH, but pH <7.20 is most classically and critically associated with complicated parapneumonic effusions and empyema due to its implications for management.\"\n  },\n  {\n    \"question\": \"A pleural fluid triglyceride level greater than 110 mg/dL is diagnostic of?\",\n    \"options\": {\n      \"A\": \"Pseudochylothorax\",\n      \"B\": \"Chylothorax\",\n      \"C\": \"Cholesterol effusion\",\n      \"D\": \"Pancreatic effusion\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Chylothorax results from the leakage of chyle (lymph rich in triglycerides) from the thoracic duct into the pleural space. A pleural fluid triglyceride level >110 mg/dL is the primary diagnostic criterion. If values are equivocal (e.g., 50-110 mg/dL), lipoprotein electrophoresis to detect chylomicrons can confirm the diagnosis.\",\n    \"highYieldPearl\": \"Chylothorax fluid is typically milky in appearance. If triglycerides are <50 mg/dL, chylothorax is excluded. If between 50-110 mg/dL, look for chylomicrons.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Pseudochylothorax also appears milky but is characterized by high cholesterol, not triglycerides. Cholesterol effusion is a less specific term often referring to pseudochylothorax.\"\n  },\n  {\n    \"question\": \"Which pleural fluid parameter best differentiates pseudochylothorax from chylothorax?\",\n    \"options\": {\n      \"A\": \"Pleural fluid protein\",\n      \"B\": \"Pleural fluid LDH\",\n      \"C\": \"Pleural fluid cholesterol\",\n      \"D\": \"Pleural fluid cell count\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Both chylothorax and pseudochylothorax (also known as cholesterol effusion) can have a milky appearance. The key differentiator is their lipid content: chylothorax has high triglycerides (>110 mg/dL), while pseudochylothorax has very high cholesterol (>200 mg/dL, often >500 mg/dL) and cholesterol crystals. Pseudochylothorax typically occurs in chronic effusions.\",\n    \"highYieldPearl\": \"Pseudochylothorax is a 'cholesterol effusion' often associated with chronic conditions like tuberculosis, rheumatoid pleurisy, or trapped lung.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While triglycerides are diagnostic for chylothorax, the question asks for the best differentiator *between* the two, making cholesterol the specific marker for pseudochylothorax.\"\n  },\n  {\n    \"question\": \"For a persistent, undiagnosed exudative pleural effusion after initial thoracentesis, the next diagnostic step is often?\",\n    \"options\": {\n      \"A\": \"Repeat thoracentesis with expanded tests\",\n      \"B\": \"Medical thoracoscopy with pleural biopsy\",\n      \"C\": \"Positron emission tomography (PET) scan\",\n      \"D\": \"Bronchoscopy with bronchoalveolar lavage\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"If initial pleural fluid analysis (including cytology, microbiology, biochemicals) from thoracentesis is non-diagnostic for a persistent exudative effusion, medical thoracoscopy (or video-assisted thoracoscopic surgery - VATS) with direct visualization and targeted pleural biopsies offers the highest diagnostic yield for conditions like malignancy or tuberculosis, often exceeding 90%.\",\n    \"highYieldPearl\": \"When a pleural effusion remains undiagnosed after thorough fluid analysis, direct pleural visualization and biopsy (thoracoscopy/VATS) is the most effective next step.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Repeat thoracentesis might be done if initial samples were insufficient, but for truly 'undiagnosed,' a more invasive, higher-yield procedure is indicated. PET scans are useful for malignancy staging but less for primary diagnosis of the effusion's cause. Bronchoscopy is generally less helpful unless there's a suspicion of endobronchial lesion or pneumonia with secondary effusion.\"\n  },\n  {\n    \"question\": \"Markedly low pleural fluid glucose (<30 mg/dL) is a hallmark feature of which exudative effusion?\",\n    \"options\": {\n      \"A\": \"Malignant effusion\",\n      \"B\": \"Tuberculous effusion\",\n      \"C\": \"Rheumatoid pleural effusion\",\n      \"D\": \"Parapneumonic effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Extremely low pleural fluid glucose (<30 mg/dL) is a characteristic finding in rheumatoid pleural effusions, caused by impaired glucose transport and high consumption by inflammatory cells in the pleural space. Other conditions like empyema and esophageal rupture can also cause very low glucose, but rheumatoid pleurisy is a classic association.\",\n    \"highYieldPearl\": \"Rheumatoid effusions often present with very low glucose, very low pH, and high LDH, mimicking an empyema biochemically.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While empyema also causes low glucose, the 'markedly low' (<30 mg/dL) distinction is particularly associated with rheumatoid effusions. Malignant effusions can cause low glucose but typically not to this extreme level.\"\n  },\n  {\n    \"question\": \"A pleural fluid hematocrit greater than 50% of the peripheral blood hematocrit defines?\",\n    \"options\": {\n      \"A\": \"Bloody effusion\",\n      \"B\": \"Hemorrhagic effusion\",\n      \"C\": \"Hemothorax\",\n      \"D\": \"Traumatic effusion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Any effusion with red blood cells is 'bloody,' but a true hemothorax, indicating significant bleeding into the pleural space (often requiring urgent drainage), is specifically defined by a pleural fluid hematocrit that is greater than 50% of the patient's peripheral blood hematocrit. This differentiates it from a traumatic tap or minor hemorrhage.\",\n    \"highYieldPearl\": \"A 'bloody tap' typically has a pleural fluid hematocrit less than 1% of peripheral hematocrit, while a 'hemorrhagic effusion' has 1-50%.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"'Bloody effusion' and 'hemorrhagic effusion' are general descriptive terms. 'Hemothorax' is a specific diagnostic entity with clinical and management implications, defined by the hematocrit ratio.\"\n  },\n  {\n    \"question\": \"Which imaging modality is considered superior for detecting and characterizing pleural fluid loculations?\",\n    \"options\": {\n      \"A\": \"Chest X-ray (PA and lateral)\",\n      \"B\": \"Lateral decubitus chest X-ray\",\n      \"C\": \"Thoracic ultrasound\",\n      \"D\": \"Computed Tomography (CT) scan\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Thoracic ultrasound is superior for detecting and characterizing pleural fluid loculations due to its real-time, dynamic nature. It can visualize septations, differentiate fluid from pleural thickening, and accurately guide thoracentesis. While CT can also show loculations, ultrasound is often preferred for its accessibility, lack of radiation, and dynamic assessment for intervention.\",\n    \"highYieldPearl\": \"Thoracic ultrasound is invaluable for guiding thoracentesis, identifying the safest and most productive site, and assessing fluid complexity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CT scan is excellent for overall thoracic anatomy and pathology, but for specifically characterizing fluid loculations and guiding procedures, ultrasound often provides more dynamic and real-time information. Chest X-rays are poor for detecting loculations.\"\n  },\n  {\n    \"question\": \"A very high pleural fluid ADA level (>70 U/L) is most indicative of?\",\n    \"options\": {\n      \"A\": \"Tuberculous pleurisy\",\n      \"B\": \"Malignant pleural effusion\",\n      \"C\": \"Rheumatoid pleural effusion\",\n      \"D\": \"Empyema\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"pleural_effusion\",\n    \"deepDiveExplanation\": \"Adenosine deaminase (ADA) is an enzyme primarily found in lymphocytes. Elevated pleural fluid ADA levels are highly suggestive of tuberculous pleurisy, especially in regions with high TB prevalence. Levels above 70 U/L have high sensitivity and specificity for TB, though other conditions like lymphoma or empyema can also cause elevated ADA.\",\n    \"highYieldPearl\": \"A low ADA (<30 U/L) virtually rules out TB pleurisy, especially in high prevalence areas. A high ADA is suggestive but requires clinical correlation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While malignant effusions and empyema can sometimes have moderately elevated ADA, 'very high' levels (>70 U/L) are most strongly associated with tuberculous pleurisy, particularly in endemic areas. Lymphoma can also cause very high ADA.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1387.852783203125}],"createTime":"2025-12-31T07:46:18.690859Z","modelVersion":"gemini-2.5-flash","responseId":"ytRUaauVKsOyvPEP9q_RgA0","usageMetadata":{"billablePromptUsage":{"textCount":1044},"candidatesTokenCount":3084,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3084}],"promptTokenCount":369,"promptTokensDetails":[{"modality":"TEXT","tokenCount":369}],"thoughtsTokenCount":3680,"totalTokenCount":7133,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:53:28.559554+00:00"}
{"metadata":"one-liner|ph_classification|Pulmonary Hypertension - Classification|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Hypertension - Classification\".\nSet the \"topic\" field in the JSON to \"ph_classification\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3117771959032677,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"According to the 6th World Symposium on PH (2018), pulmonary hypertension is defined by a mean pulmonary arterial pressure (mPAP) greater than what value at rest?\",\n    \"options\": {\n      \"A\": \"20 mmHg\",\n      \"B\": \"25 mmHg\",\n      \"C\": \"15 mmHg\",\n      \"D\": \"30 mmHg\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"The definition of pulmonary hypertension was revised at the 6th World Symposium on Pulmonary Hypertension (Nice, 2018) from a mean pulmonary arterial pressure (mPAP) > 25 mmHg to mPAP > 20 mmHg at rest, measured by right heart catheterization. This change reflects evidence that outcomes begin to worsen at lower pressure thresholds.\",\n    \"highYieldPearl\": \"The 2018 Nice definition of PH (mPAP > 20 mmHg) is crucial. For Pulmonary Arterial Hypertension (Group 1), additional criteria are PCWP ≤ 15 mmHg and PVR > 2 Wood units.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The most common trap is selecting the older definition of 25 mmHg. Candidates must be updated with the latest classification guidelines.\"\n  },\n  {\n    \"question\": \"Which condition is classified under Group 1 Pulmonary Arterial Hypertension (PAH)?\",\n    \"options\": {\n      \"A\": \"Left Ventricular Systolic Dysfunction\",\n      \"B\": \"Chronic Obstructive Pulmonary Disease\",\n      \"C\": \"Portal Hypertension\",\n      \"D\": \"Chronic Thromboembolic Pulmonary Hypertension\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Group 1 Pulmonary Arterial Hypertension (PAH) includes conditions where PH arises from intrinsic pathology of the pulmonary arterioles. Portal hypertension-associated PAH is a specific subtype within Group 1, alongside idiopathic, heritable, drug/toxin-induced, connective tissue diseases, HIV, and congenital heart disease.\",\n    \"highYieldPearl\": \"Remember the specific etiologies listed under Group 1 PAH. Portal hypertension, HIV infection, and systemic sclerosis are common examples in exams.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Each incorrect option represents another major WHO PH group (Group 2, 3, and 4 respectively), making them plausible distractors if the specific classifications are not clear.\"\n  },\n  {\n    \"question\": \"Pulmonary hypertension due to left heart disease is categorized under which WHO group?\",\n    \"options\": {\n      \"A\": \"Group 1\",\n      \"B\": \"Group 2\",\n      \"C\": \"Group 3\",\n      \"D\": \"Group 4\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Group 2 Pulmonary Hypertension is the most common form of PH and encompasses all conditions where PH is secondary to left heart disease, including left ventricular systolic or diastolic dysfunction and valvular heart disease (e.g., mitral stenosis, aortic stenosis/regurgitation).\",\n    \"highYieldPearl\": \"Group 2 PH is characterized by elevated left-sided filling pressures (PCWP > 15 mmHg). It can be isolated post-capillary (PVR ≤ 2 Wood units) or combined pre- and post-capillary (PVR > 2 Wood units).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"This is a foundational question. The trap would be confusing the primary causes of PH with other categories. Group 2 is distinctly 'left heart disease'.\"\n  },\n  {\n    \"question\": \"Which of the following conditions is a primary cause of Group 3 Pulmonary Hypertension?\",\n    \"options\": {\n      \"A\": \"HIV infection\",\n      \"B\": \"Interstitial Lung Disease\",\n      \"C\": \"Chronic Hemolytic Anemia\",\n      \"D\": \"Congenital Heart Disease\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Group 3 Pulmonary Hypertension is associated with lung diseases and/or hypoxia. This group includes conditions like COPD, interstitial lung disease (ILD), sleep-disordered breathing, alveolar hypoventilation disorders, and chronic exposure to high altitude. ILD is a significant cause within this group.\",\n    \"highYieldPearl\": \"Think 'lung disease and hypoxia' for Group 3. The pulmonary vasoconstriction and remodeling are primarily driven by alveolar hypoxia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"HIV infection, chronic hemolytic anemia, and congenital heart disease are all causes of Group 1 PAH, making them strong distractors. Correct classification of these specific conditions is key.\"\n  },\n  {\n    \"question\": \"Chronic Thromboembolic Pulmonary Hypertension (CTEPH) falls under which WHO classification group?\",\n    \"options\": {\n      \"A\": \"Group 1\",\n      \"B\": \"Group 2\",\n      \"C\": \"Group 3\",\n      \"D\": \"Group 4\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a distinct entity classified as Group 4 PH. It results from incomplete resolution of pulmonary emboli, leading to chronic obstruction and remodeling of the pulmonary arteries.\",\n    \"highYieldPearl\": \"CTEPH is unique as it is potentially curable with Pulmonary Endarterectomy (PEA) surgery. Distinguishing it from other forms of PH is critical for management.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing CTEPH with other forms of PH, especially Group 1 PAH, is a common error. While both are pre-capillary, their etiologies and treatments differ vastly.\"\n  },\n  {\n    \"question\": \"Pulmonary hypertension due to multifactorial or unclear mechanisms, such as sarcoidosis or chronic renal failure, belongs to which WHO group?\",\n    \"options\": {\n      \"A\": \"Group 1\",\n      \"B\": \"Group 3\",\n      \"C\": \"Group 4\",\n      \"D\": \"Group 5\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Group 5 Pulmonary Hypertension is a heterogeneous category for PH with unclear and/or multifactorial mechanisms. It includes various conditions like hematologic disorders (e.g., chronic hemolytic anemia, myeloproliferative disorders), systemic inflammatory diseases (e.g., sarcoidosis, histiocytosis X), metabolic disorders, and chronic renal failure on dialysis.\",\n    \"highYieldPearl\": \"Group 5 is the 'miscellaneous' group. If a condition doesn't fit neatly into Groups 1-4, it often belongs here. Recognize common examples like sarcoidosis, chronic renal failure, and thyroid disorders.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The diffuse nature of Group 5 makes it a potential trap. Candidates might try to force these conditions into other groups (e.g., sarcoidosis into Group 3 due to lung involvement, but its PH mechanism is often multifactorial beyond hypoxia).\"\n  },\n  {\n    \"question\": \"Pre-capillary pulmonary hypertension is hemodynamically defined by what combination of parameters?\",\n    \"options\": {\n      \"A\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR > 2 Wood units\",\n      \"B\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR > 2 Wood units\",\n      \"C\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR ≤ 2 Wood units\",\n      \"D\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR ≤ 2 Wood units\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Pre-capillary PH (Groups 1, 3, 4, and some Group 5) is characterized by an elevated mean pulmonary arterial pressure (mPAP > 20 mmHg), a normal or low pulmonary capillary wedge pressure (PCWP ≤ 15 mmHg), indicating the primary pathology is in the pulmonary arterioles, and an elevated pulmonary vascular resistance (PVR > 2 Wood units).\",\n    \"highYieldPearl\": \"The PCWP is the key differentiator: normal (≤15 mmHg) for pre-capillary, elevated (>15 mmHg) for post-capillary. PVR indicates the 'resistance' component.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This question tests the precise hemodynamic definitions, which are critical for diagnosis and classification. Mixing up the PCWP and PVR thresholds, or their normal/abnormal values, is the main trap.\"\n  },\n  {\n    \"question\": \"What hemodynamic profile defines isolated post-capillary pulmonary hypertension?\",\n    \"options\": {\n      \"A\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR > 2 Wood units\",\n      \"B\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR ≤ 2 Wood units\",\n      \"C\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR > 2 Wood units\",\n      \"D\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR ≤ 2 Wood units\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Isolated post-capillary PH (IPH), typically seen in Group 2 PH (left heart disease), is defined by an elevated mPAP (> 20 mmHg), an elevated PCWP (> 15 mmHg) reflecting increased left atrial pressure, and a normal pulmonary vascular resistance (PVR ≤ 2 Wood units). This indicates passive back-pressure from the left heart without significant intrinsic pulmonary vascular remodeling.\",\n    \"highYieldPearl\": \"In IPH, the PVR is normal, implying that the pulmonary vasculature is passively responding to increased left heart pressures. If PVR is also high, it becomes combined pre- and post-capillary PH (CPH).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Differentiating IPH from combined pre- and post-capillary PH (CPH) is crucial. The PVR value is the distinguishing factor when PCWP is elevated. Option A describes CPH.\"\n  },\n  {\n    \"question\": \"Combined pre- and post-capillary pulmonary hypertension (CPH) is characterized by which hemodynamic parameters?\",\n    \"options\": {\n      \"A\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR > 2 Wood units\",\n      \"B\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR ≤ 2 Wood units\",\n      \"C\": \"mPAP > 20 mmHg, PCWP > 15 mmHg, PVR > 2 Wood units\",\n      \"D\": \"mPAP > 20 mmHg, PCWP ≤ 15 mmHg, PVR ≤ 2 Wood units\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Combined pre- and post-capillary pulmonary hypertension (CPH) occurs when there is significant left heart disease (leading to elevated PCWP > 15 mmHg) AND concurrent intrinsic pulmonary vascular remodeling (leading to elevated PVR > 2 Wood units). The mPAP is, of course, also elevated (> 20 mmHg). This reflects a more severe form of Group 2 PH.\",\n    \"highYieldPearl\": \"CPH indicates both a 'back-pressure' problem from the left heart and a 'resistance' problem within the pulmonary arteries. Management often involves addressing both aspects.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This question directly contrasts with isolated post-capillary PH. The key differentiator is the elevated PVR in CPH, which is normal in IPH. Options A, B, and D represent other PH hemodynamic profiles.\"\n  },\n  {\n    \"question\": \"Vasoreactivity testing is primarily relevant for classifying and guiding treatment in which WHO PH group?\",\n    \"options\": {\n      \"A\": \"Group 2\",\n      \"B\": \"Group 3\",\n      \"C\": \"Group 4\",\n      \"D\": \"Group 1\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_classification\",\n    \"deepDiveExplanation\": \"Acute vasoreactivity testing, typically performed during right heart catheterization, is primarily indicated for patients with Group 1 Pulmonary Arterial Hypertension (PAH), specifically idiopathic, heritable, and drug/toxin-induced PAH. A positive response identifies a small subset of patients who may benefit from high-dose calcium channel blockers.\",\n    \"highYieldPearl\": \"A positive vasoreactivity test is defined by a fall in mPAP by ≥ 10 mmHg to achieve an mPAP ≤ 40 mmHg, with an increased or unchanged cardiac output. It is NOT recommended for routine use in other PH groups.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in assuming vasoreactivity testing is broadly applicable across all PH groups. Its utility is highly specific to a subset of Group 1 PAH, which is a critical point for PG-level understanding.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-983.3452758789063}],"createTime":"2025-12-31T07:46:17.087438Z","modelVersion":"gemini-2.5-flash","responseId":"ydRUaY6rBbKJ1dkP1aL2qAk","usageMetadata":{"billablePromptUsage":{"textCount":1045},"candidatesTokenCount":3154,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3154}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":2503,"totalTokenCount":6021,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:56.897017+00:00"}
{"metadata":"one-liner|occupational_lung|Occupational Lung Diseases Overview|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Occupational Lung Diseases Overview\".\nSet the \"topic\" field in the JSON to \"occupational_lung\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3813237874859179,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The pathological hallmark of silicosis is the presence of lung nodules composed primarily of?\",\n    \"options\": {\n      \"A\": \"Concentric layers of collagen\",\n      \"B\": \"Aggregates of alveolar macrophages\",\n      \"C\": \"Collections of multinucleated giant cells\",\n      \"D\": \"Necrotizing granulomas\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"occupational_lung\",\n    \"deepDiveExplanation\": \"Silicosis is characterized by the formation of silicotic nodules, which pathologically consist of concentric layers of hyalinized collagen, often with birefringent silica particles visible under polarized light. While macrophages ingest silica, the characteristic lesion is the fibrotic nodule.\",\n    \"highYieldPearl\": \"Concentric collagenous nodules with birefringent particles are pathognomonic for silicosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option B describes initial macrophage response but not the definitive fibrotic nodule. Options C and D relate to other granulomatous diseases or reactions.\"\n  },\n  {\n    \"question\": \"Which diagnostic procedure is considered the gold standard for confirming chronic hypersensitivity pneumonitis?\",\n    \"options\": {\n      \"A\": \"High-resolution computed tomography (HRCT) thorax\",\n      \"B\": \"Bronchoalveolar lavage (BAL) with lymphocytosis\",\n      \"C\": \"Surgical lung biopsy\",\n      \"D\": \"Serum precipitins to suspected antigens\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"occupational_lung\",\n    \"deepDiveExplanation\": \"While HRCT, BAL, and serum precipitins provide strong supportive evidence, a surgical lung biopsy remains the gold standard for definitively diagnosing chronic hypersensitivity pneumonitis, especially when other features are equivocal. It allows for the identification of characteristic histological patterns like poorly formed granulomas, bronchiolocentric inflammation, and interstitial fibrosis.\",\n    \"highYieldPearl\": \"For chronic HP, surgical lung biopsy provides definitive histological confirmation, especially when clinical and radiological findings are not conclusive.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"BAL lymphocytosis is highly suggestive but not definitive. HRCT shows characteristic patterns but can overlap with other ILDs. Serum precipitins indicate exposure, not necessarily disease.\"\n  },\n  {\n    \"question\": \"The most common malignancy associated with asbestos exposure is?\",\n    \"options\": {\n      \"A\": \"Pleural mesothelioma\",\n      \"B\": \"Lung adenocarcinoma\",\n      \"C\": \"Laryngeal carcinoma\",\n      \"D\": \"Peritoneal mesothelioma\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"occupational_lung\",\n    \"deepDiveExplanation\": \"While mesothelioma is highly specific to asbestos exposure, lung cancer (predominantly adenocarcinoma) is numerically the most common malignancy associated with asbestos, especially in smokers. The risk is synergistic with smoking.\",\n    \"highYieldPearl\": \"Asbestos exposure significantly increases the risk of lung cancer, even more so in smokers. Mesothelioma is highly specific but less common overall.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Many candidates incorrectly choose mesothelioma due to its strong and specific association with asbestos. However, statistically, lung cancer is more prevalent.\"\n  },\n  {\n    \"question\": \"Recurrent 'Monday chest tightness' is characteristic of which occupational lung disease?\",\n    \"options\": {\n      \"A\": \"Silicosis\",\n      \"B\": \"Byssinosis\",\n      \"C\": \"Farmer's lung\",\n      \"D\": \"Coal worker's pneumoconiosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"occupational_lung\",\n    \"deepDiveExplanation\": \"Byssinosis, caused by exposure to cotton, flax, or hemp dust, classically presents with chest tightness and dyspnea that is worse on the first day of the work week ('Monday chest tightness') and improves later in the week, recurring with re-exposure.\",\n    \"highYieldPearl\": \"'Monday chest tightness' is pathognomonic for byssinosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The other options do not typically present with this specific Monday-recurrent symptom pattern, making byssinosis a distinct entity.\"\n  },\n  {\n    \"question\": \"Regular screening for Coal Worker's Pneumoconiosis (CWP) primarily involves which imaging modality?\",\n    \"options\": {\n      \"A\": \"Chest X-ray with ILO classification\",\n      \"B\": \"High-resolution computed tomography (HRCT) thorax\",\n      \"C\": \"Spirometry\",\n      \"D\": \"Pulmonary function tests including DLCO\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"occupational_lung\",\n    \"deepDiveExplanation\": \"For routine surveillance and screening of CWP, chest X-rays interpreted using the International Labour Organization (ILO) classification system for pneumoconioses are the primary and most cost-effective method. HRCT is used for further evaluation of complicated CWP or when findings are equivocal on CXR, but not for initial mass screening.\",\n    \"highYieldPearl\": \"ILO classification of chest X-rays is the standard for screening and epidemiological studies of pneumoconioses.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"HRCT is more sensitive but not the primary screening tool. Spirometry and PFTs assess lung function but do not directly detect the presence of pneumoconiosis.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-486.56915283203125}],"createTime":"2025-12-31T07:45:55.882938Z","modelVersion":"gemini-2.5-flash","responseId":"s9RUafrxNcj9ld8P_9fN0Q0","usageMetadata":{"billablePromptUsage":{"textCount":1040},"candidatesTokenCount":1276,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1276}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":871,"totalTokenCount":2511,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:41.678592+00:00"}
{"metadata":"one-liner|nsip_iip|NSIP and Other IIPs|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"NSIP and Other IIPs\".\nSet the \"topic\" field in the JSON to \"nsip_iip\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.38366800437914594,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Among idiopathic interstitial pneumonias, which typically has the best prognosis?\",\n    \"options\": {\n      \"A\": \"Usual Interstitial Pneumonia (UIP)\",\n      \"B\": \"Nonspecific Interstitial Pneumonia (NSIP)\",\n      \"C\": \"Acute Interstitial Pneumonia (AIP)\",\n      \"D\": \"Desquamative Interstitial Pneumonia (DIP)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Nonspecific Interstitial Pneumonia (NSIP) generally has a better prognosis compared to other major idiopathic interstitial pneumonias like UIP (Idiopathic Pulmonary Fibrosis) and AIP. While DIP also has a good prognosis, NSIP is often cited as having one of the best prognoses among the more common IIPs, particularly the cellular pattern. 5-year survival rates for NSIP are significantly higher than for UIP.\",\n    \"highYieldPearl\": \"Prognosis hierarchy (best to worst): DIP/RB-ILD > NSIP > UIP > AIP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse DIP/RB-ILD with NSIP for 'best prognosis'. While DIP/RB-ILD have excellent prognoses, NSIP is frequently highlighted in comparisons with UIP, and its overall prognosis is generally favorable, especially the cellular subtype.\"\n  },\n  {\n    \"question\": \"Histopathologically, NSIP is characterized by which of the following patterns?\",\n    \"options\": {\n      \"A\": \"Temporal heterogeneity with fibroblastic foci\",\n      \"B\": \"Spatial heterogeneity with honeycombing\",\n      \"C\": \"Temporal and spatial homogeneity of inflammation and/or fibrosis\",\n      \"D\": \"Predominant diffuse alveolar damage\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Nonspecific Interstitial Pneumonia (NSIP) is characterized by a uniform (homogeneous) inflammation and/or fibrosis across the lung parenchyma, both in terms of its distribution (spatial homogeneity) and the stage of injury (temporal homogeneity). This contrasts sharply with UIP, which exhibits distinct temporal and spatial heterogeneity.\",\n    \"highYieldPearl\": \"NSIP = Homogeneous; UIP = Heterogeneous (patchy, different ages of lesions).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Options A and B describe features of Usual Interstitial Pneumonia (UIP). Option D describes Acute Interstitial Pneumonia (AIP). Understanding the key histological distinctions between IIPs is crucial.\"\n  },\n  {\n    \"question\": \"The hallmark histological feature of usual interstitial pneumonia (UIP) is?\",\n    \"options\": {\n      \"A\": \"Lymphocytic infiltration with germinal centers\",\n      \"B\": \"Organizing pneumonia pattern\",\n      \"C\": \"Fibroblastic foci with temporal and spatial heterogeneity\",\n      \"D\": \"Diffuse alveolar damage with hyaline membranes\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"The histological diagnosis of Usual Interstitial Pneumonia (UIP) relies on the presence of four key features: temporal and spatial heterogeneity, fibroblastic foci, honeycombing, and absence of features suggesting an alternative diagnosis. Fibroblastic foci are areas of active fibroblast and myofibroblast proliferation, representing ongoing injury and repair, and are considered a defining characteristic.\",\n    \"highYieldPearl\": \"UIP = Fibroblastic foci + Honeycombing + Temporal/Spatial Heterogeneity.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A refers to Lymphocytic Interstitial Pneumonia (LIP). Option B refers to Cryptogenic Organizing Pneumonia (COP). Option D refers to Acute Interstitial Pneumonia (AIP) or ARDS. Distinguishing these specific histological patterns is vital.\"\n  },\n  {\n    \"question\": \"Acute exacerbation of IPF is best defined by which of the following?\",\n    \"options\": {\n      \"A\": \"New onset bacterial pneumonia in an IPF patient\",\n      \"B\": \"Unexplained acute respiratory worsening with new bilateral ground-glass opacity/consolidation\",\n      \"C\": \"Acute decompensated heart failure in an IPF patient\",\n      \"D\": \"Pulmonary embolism causing acute dyspnea in an IPF patient\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"An acute exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) is an acute, clinically significant respiratory worsening due to an unidentified cause (i.e., not infection, heart failure, pulmonary embolism, etc.) in a patient with underlying IPF. It is typically characterized by new bilateral ground-glass opacity and/or consolidation on HRCT, superimposed on the UIP pattern.\",\n    \"highYieldPearl\": \"AE-IPF = Acute worsening + no identifiable cause + new GGO/consolidation on HRCT.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The key to AE-IPF is that other identifiable causes of acute worsening must be ruled out. Options A, C, and D describe common conditions that can acutely worsen respiratory status but are not considered idiopathic acute exacerbations of IPF.\"\n  },\n  {\n    \"question\": \"Desquamative interstitial pneumonia (DIP) and Respiratory Bronchiolitis-ILD (RB-ILD) are strongly associated with which factor?\",\n    \"options\": {\n      \"A\": \"Systemic autoimmune diseases\",\n      \"B\": \"Specific drug toxicities\",\n      \"C\": \"Cigarette smoking\",\n      \"D\": \"Environmental dust exposures\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Desquamative interstitial pneumonia (DIP) and Respiratory Bronchiolitis-Interstitial Lung Disease (RB-ILD) are both considered smoking-related interstitial lung diseases. They are almost exclusively seen in current or former heavy cigarette smokers. Cessation of smoking is a crucial part of their management.\",\n    \"highYieldPearl\": \"DIP and RB-ILD are classic 'Smoker's ILDs'.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other factors can cause ILD, for DIP and RB-ILD, smoking is the overwhelming and defining association. Misattributing these to other causes is a common error.\"\n  },\n  {\n    \"question\": \"The first-line treatment for cryptogenic organizing pneumonia (COP) is typically?\",\n    \"options\": {\n      \"A\": \"Nintedanib\",\n      \"B\": \"Cyclophosphamide\",\n      \"C\": \"High-dose systemic corticosteroids\",\n      \"D\": \"Azathioprine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Cryptogenic Organizing Pneumonia (COP), also known as Bronchiolitis Obliterans Organizing Pneumonia (BOOP), is one of the most steroid-responsive interstitial lung diseases. High-dose systemic corticosteroids are the mainstay of treatment, often leading to complete clinical and radiological resolution.\",\n    \"highYieldPearl\": \"COP = Highly steroid-responsive IIP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Nintedanib is an anti-fibrotic used in IPF. Cyclophosphamide and Azathioprine are immunosuppressants used in some connective tissue disease-associated ILDs or severe, refractory IIPs, but not typically first-line for COP. Recognizing COP's unique steroid responsiveness is key.\"\n  },\n  {\n    \"question\": \"Which genetic mutation is most strongly associated with familial idiopathic pulmonary fibrosis?\",\n    \"options\": {\n      \"A\": \"CFTR gene mutations\",\n      \"B\": \"Alpha-1 antitrypsin deficiency\",\n      \"C\": \"TERT and SFTPC mutations\",\n      \"D\": \"MTHFR gene polymorphism\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Familial idiopathic pulmonary fibrosis (familial IPF) is associated with several genetic mutations, most notably in genes encoding components of the telomerase complex (TERT and TERC) and surfactant proteins (SFTPC, SFTPA2). These mutations lead to telomere shortening and surfactant dysfunction, respectively, contributing to the fibrotic process. The MUC5B promoter variant is also a strong risk factor for both familial and sporadic IPF.\",\n    \"highYieldPearl\": \"Familial IPF genes: TERT, TERC (telomerase), SFTPC, SFTPA2 (surfactant), MUC5B promoter.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"CFTR mutations are associated with cystic fibrosis. Alpha-1 antitrypsin deficiency is linked to emphysema and liver disease. MTHFR polymorphism is related to homocysteine metabolism and cardiovascular risk, not directly IPF.\"\n  },\n  {\n    \"question\": \"The presence of fibroblastic foci on lung biopsy is most characteristic of which interstitial pneumonia?\",\n    \"options\": {\n      \"A\": \"Nonspecific Interstitial Pneumonia (NSIP)\",\n      \"B\": \"Cryptogenic Organizing Pneumonia (COP)\",\n      \"C\": \"Usual Interstitial Pneumonia (UIP)\",\n      \"D\": \"Lymphocytic Interstitial Pneumonia (LIP)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"Fibroblastic foci are aggregates of fibroblasts and myofibroblasts embedded in a myxoid stroma, representing areas of active collagen deposition and remodeling. Their presence is a defining and pathognomonic histological feature of Usual Interstitial Pneumonia (UIP), distinguishing it from other interstitial lung diseases.\",\n    \"highYieldPearl\": \"Fibroblastic foci are essentially diagnostic of UIP in the appropriate clinical context.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While other ILDs can have fibrosis, the specific morphology and distribution of fibroblastic foci are unique to UIP. NSIP has more uniform fibrosis, COP has intraluminal polyps of granulation tissue, and LIP is characterized by lymphoid aggregates.\"\n  },\n  {\n    \"question\": \"The characteristic HRCT pattern for NSIP (Nonspecific Interstitial Pneumonia) often includes which finding?\",\n    \"options\": {\n      \"A\": \"Peripheral, subpleural honeycombing with basal predominance\",\n      \"B\": \"Predominant ground-glass opacities with relative subpleural sparing\",\n      \"C\": \"Randomly distributed micronodules with perilymphatic distribution\",\n      \"D\": \"Upper lobe predominant centrilobular emphysema\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"NSIP on HRCT typically presents with predominant ground-glass opacity, often with associated reticulation and traction bronchiectasis. A key distinguishing feature from UIP is the relative subpleural sparing and the absence or less extensive honeycombing compared to UIP. The distribution is often basal and peripheral but can be more diffuse and less 'patchy' than UIP.\",\n    \"highYieldPearl\": \"NSIP HRCT = GGO + Reticulation + Traction Bronchiectasis + Relative Subpleural Sparing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Option A describes the typical HRCT pattern of UIP/IPF. Option C suggests sarcoidosis or hypersensitivity pneumonitis. Option D describes emphysema, not an IIP. Recognizing the subtle HRCT differences between IIPs is crucial for diagnosis.\"\n  },\n  {\n    \"question\": \"Lymphocytic Interstitial Pneumonia (LIP) is histologically characterized by prominent infiltration of the lung parenchyma by which cell type?\",\n    \"options\": {\n      \"A\": \"Neutrophils\",\n      \"B\": \"Eosinophils\",\n      \"C\": \"Mature lymphocytes and plasma cells\",\n      \"D\": \"Type II pneumocytes\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"nsip_iip\",\n    \"deepDiveExplanation\": \"As its name suggests, Lymphocytic Interstitial Pneumonia (LIP) is characterized by a diffuse interstitial infiltration of mature lymphocytes, plasma cells, and histiocytes, often with prominent lymphoid hyperplasia and germinal centers. This pattern distinguishes it from other IIPs and is frequently associated with autoimmune diseases (e.g., Sjögren's syndrome) or immunodeficiency (e.g., HIV).\",\n    \"highYieldPearl\": \"LIP = Lymphocytic infiltration + lymphoid hyperplasia; often linked to Sjögren's/HIV.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The name 'Lymphocytic' itself is a strong clue. Neutrophilic infiltrates are seen in acute infections or ARDS. Eosinophilic infiltrates characterize eosinophilic pneumonias. Type II pneumocyte hyperplasia can be seen in various lung injuries but is not the primary defining feature of LIP.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1156.759033203125}],"createTime":"2025-12-31T07:45:31.723417Z","modelVersion":"gemini-2.5-flash","responseId":"m9RUadmTLJyvgLUP3OuiyAM","usageMetadata":{"billablePromptUsage":{"textCount":1016},"candidatesTokenCount":3015,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":3015}],"promptTokenCount":367,"promptTokensDetails":[{"modality":"TEXT","tokenCount":367}],"thoughtsTokenCount":2735,"totalTokenCount":6117,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:13.696205+00:00"}
{"metadata":"one-liner|ph_treatment|Pulmonary Hypertension - Treatment|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Pulmonary Hypertension - Treatment\".\nSet the \"topic\" field in the JSON to \"ph_treatment\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.25222111512341816,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"First-line therapy for Group 1 Pulmonary Arterial Hypertension (PAH) with low-risk features often involves which drug class?\",\n    \"options\": {\n      \"A\": \"Prostacyclin Analogs\",\n      \"B\": \"Endothelin Receptor Antagonists\",\n      \"C\": \"Phosphodiesterase-5 Inhibitors\",\n      \"D\": \"Calcium Channel Blockers\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"For low-risk Group 1 PAH patients, oral monotherapy with a Phosphodiesterase-5 Inhibitor (e.g., sildenafil, tadalafil) or an Endothelin Receptor Antagonist (e.g., ambrisentan, macitentan) is typically recommended. Current guidelines often favor initial combination therapy for intermediate or high-risk patients. PDE5i work by inhibiting the degradation of cGMP, leading to vasodilation.\",\n    \"highYieldPearl\": \"Initial monotherapy for low-risk PAH often starts with PDE5i or ERA; initial combination therapy is increasingly preferred for intermediate/high risk.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Students might confuse initial monotherapy options or jump to more aggressive treatments without considering risk stratification. Calcium channel blockers are only for vasoreactive responders.\"\n  },\n  {\n    \"question\": \"Which drug class used in pulmonary hypertension treatment primarily inhibits the degradation of cyclic guanosine monophosphate (cGMP)?\",\n    \"options\": {\n      \"A\": \"Endothelin Receptor Antagonists\",\n      \"B\": \"Prostacyclin Analogs\",\n      \"C\": \"Soluble Guanylate Cyclase Stimulators\",\n      \"D\": \"Phosphodiesterase-5 Inhibitors\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil and tadalafil, block the enzyme PDE5, which is responsible for breaking down cGMP. Increased cGMP levels lead to smooth muscle relaxation and vasodilation in the pulmonary vasculature.\",\n    \"highYieldPearl\": \"PDE5i (e.g., sildenafil, tadalafil) enhance the effects of nitric oxide by preventing cGMP degradation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing PDE5i with sGC stimulators (like riociguat) is a common trap, as both affect the NO-cGMP pathway but at different points.\"\n  },\n  {\n    \"question\": \"Severe hepatic impairment is a contraindication for which of the following pulmonary hypertension medications?\",\n    \"options\": {\n      \"A\": \"Sildenafil\",\n      \"B\": \"Bosentan\",\n      \"C\": \"Treprostinil\",\n      \"D\": \"Riociguat\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Bosentan, an Endothelin Receptor Antagonist (ERA), is known for its potential hepatotoxicity and requires monthly monitoring of liver function tests. Severe hepatic impairment is a contraindication due to the risk of drug-induced liver injury. Other ERAs like ambrisentan and macitentan also carry this risk but to a lesser degree than bosentan.\",\n    \"highYieldPearl\": \"Bosentan carries a black box warning for hepatotoxicity and requires strict LFT monitoring.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might not recall specific drug contraindications or side effects, especially for older, high-risk drugs like bosentan. Other PH drugs might have hepatic metabolism but not severe hepatic impairment as a contraindication.\"\n  },\n  {\n    \"question\": \"Which medication is specifically approved for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH)?\",\n    \"options\": {\n      \"A\": \"Ambrisentan\",\n      \"B\": \"Selexipag\",\n      \"C\": \"Riociguat\",\n      \"D\": \"Iloprost\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Riociguat, a soluble guanylate cyclase (sGC) stimulator, is the only medication specifically approved for the treatment of inoperable CTEPH or persistent/recurrent CTEPH after surgical pulmonary endarterectomy. It works by directly stimulating sGC and also sensitizing sGC to endogenous nitric oxide, increasing cGMP production.\",\n    \"highYieldPearl\": \"Riociguat is the only approved drug for inoperable/persistent CTEPH.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might incorrectly choose other PAH-specific drugs, not realizing Riociguat's unique indication for CTEPH.\"\n  },\n  {\n    \"question\": \"Which pulmonary hypertension drug directly stimulates soluble guanylate cyclase to increase cGMP production?\",\n    \"options\": {\n      \"A\": \"Macitentan\",\n      \"B\": \"Epoprostenol\",\n      \"C\": \"Riociguat\",\n      \"D\": \"Tadalafil\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Riociguat is a soluble guanylate cyclase (sGC) stimulator. It directly stimulates sGC, which is an enzyme in the nitric oxide (NO) signaling pathway, leading to increased production of cGMP and subsequent vasodilation. It also sensitizes sGC to endogenous NO.\",\n    \"highYieldPearl\": \"Riociguat's dual action: direct sGC stimulation and sensitization to NO.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing the mechanism of sGC stimulators (Riociguat) from PDE5 inhibitors (Tadalafil) is key. Both affect cGMP but at different points in the pathway.\"\n  },\n  {\n    \"question\": \"When is lung transplantation considered a definitive treatment option for pulmonary arterial hypertension?\",\n    \"options\": {\n      \"A\": \"Early-stage disease\",\n      \"B\": \"Mild symptoms with oral therapy\",\n      \"C\": \"Progressive disease despite maximal medical therapy\",\n      \"D\": \"PH secondary to left heart disease\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Lung transplantation is reserved for patients with severe, progressive pulmonary arterial hypertension who have failed to respond adequately to maximal medical therapy and continue to have a poor prognosis. It is a last-resort definitive treatment for selected patients.\",\n    \"highYieldPearl\": \"Lung transplant is a 'rescue' therapy for refractory PAH, not a primary option.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy-Medium\",\n    \"trapAnalysis\": \"Students might consider it for earlier stages, but it's a high-risk procedure reserved for end-stage disease.\"\n  },\n  {\n    \"question\": \"Which prostacyclin analog requires continuous intravenous infusion due to its very short half-life?\",\n    \"options\": {\n      \"A\": \"Treprostinil\",\n      \"B\": \"Selexipag\",\n      \"C\": \"Epoprostenol\",\n      \"D\": \"Iloprost\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Epoprostenol has an extremely short half-life (approximately 3-5 minutes), necessitating continuous intravenous infusion via a central venous catheter and a portable pump. Any interruption can lead to rapid clinical deterioration and death. Treprostinil has a longer half-life and can be given subcutaneously, intravenously, orally, or inhaled. Iloprost is inhaled. Selexipag is an oral IP receptor agonist.\",\n    \"highYieldPearl\": \"Epoprostenol's short half-life mandates continuous IV infusion, making it logistically challenging but highly effective.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Confusing the different prostacyclin analogs and their routes of administration/half-lives. Treprostinil has more flexible delivery options.\"\n  },\n  {\n    \"question\": \"Combining an Endothelin Receptor Antagonist with a Phosphodiesterase-5 Inhibitor in PAH aims to target which primary pathways?\",\n    \"options\": {\n      \"A\": \"Endothelin and nitric oxide pathways\",\n      \"B\": \"Prostacyclin and endothelin pathways\",\n      \"C\": \"Nitric oxide and calcium pathways\",\n      \"D\": \"Serotonin and prostacyclin pathways\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Combination therapy in PAH often targets different pathophysiological pathways to achieve synergistic effects. ERAs block the endothelin pathway (a potent vasoconstrictor and proliferator), while PDE5i enhance the nitric oxide (NO) pathway (a potent vasodilator). This dual targeting leads to improved outcomes.\",\n    \"highYieldPearl\": \"PAH combination therapy typically targets distinct pathways: NO, endothelin, and prostacyclin.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might mix up the pathways targeted by different drug classes. Knowing the three main pathways (NO, endothelin, prostacyclin) is crucial.\"\n  },\n  {\n    \"question\": \"Calcium channel blockers are considered for which specific group of pulmonary arterial hypertension patients?\",\n    \"options\": {\n      \"A\": \"All patients with Group 1 PAH\",\n      \"B\": \"Patients demonstrating a positive acute vasoreactivity test\",\n      \"C\": \"Those with underlying connective tissue disease-associated PAH\",\n      \"D\": \"Patients with severe right heart failure at diagnosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"Calcium channel blockers (e.g., nifedipine, diltiazem, amlodipine) are only effective and recommended for a small subset (approximately 5-10%) of Group 1 PAH patients who show a positive response to an acute vasoreactivity test during right heart catheterization. These patients typically have a better prognosis and respond well to CCBs.\",\n    \"highYieldPearl\": \"CCBs are only for 'vasoreactive responders' in PAH, a small but prognostically distinct group.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Misapplication of CCBs to all PAH patients or those with severe disease, rather than the specific vasoreactive subset, is a common error.\"\n  },\n  {\n    \"question\": \"Which drug class acts as a selective prostacyclin IP receptor agonist, bypassing the need for exogenous prostacyclin?\",\n    \"options\": {\n      \"A\": \"Endothelin Receptor Antagonists\",\n      \"B\": \"Phosphodiesterase-5 Inhibitors\",\n      \"C\": \"Soluble Guanylate Cyclase Stimulators\",\n      \"D\": \"IP Receptor Agonists\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"ph_treatment\",\n    \"deepDiveExplanation\": \"IP receptor agonists, such as selexipag, are oral medications that selectively stimulate the prostacyclin (IP) receptor. This mimics the effects of prostacyclin, leading to vasodilation and anti-proliferative effects, without directly administering prostacyclin analogs.\",\n    \"highYieldPearl\": \"Selexipag is an oral IP receptor agonist, a distinct class from prostacyclin analogs but targeting the same pathway.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Students might confuse IP receptor agonists with prostacyclin analogs. While both target the prostacyclin pathway, IP receptor agonists are synthetic, orally active drugs that directly stimulate the receptor.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-692.5991821289063}],"createTime":"2025-12-31T07:45:59.253823Z","modelVersion":"gemini-2.5-flash","responseId":"t9RUaf--D5yvgLUP3OuiyAM","usageMetadata":{"billablePromptUsage":{"textCount":1035},"candidatesTokenCount":2746,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2746}],"promptTokenCount":364,"promptTokensDetails":[{"modality":"TEXT","tokenCount":364}],"thoughtsTokenCount":1250,"totalTokenCount":4360,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:18.473249+00:00"}
{"metadata":"one-liner|spirometry|Spirometry - Technique and Interpretation|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Spirometry - Technique and Interpretation\".\nSet the \"topic\" field in the JSON to \"spirometry\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.33646955223649316,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which spirometric parameter is most sensitive for early small airway disease?\",\n    \"options\": {\n      \"A\": \"FEV1\",\n      \"B\": \"FVC\",\n      \"C\": \"FEV1/FVC ratio\",\n      \"D\": \"FEF25-75%\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"FEF25-75% (Forced Expiratory Flow between 25% and 75% of the FVC) reflects flow rates from the small to medium-sized airways. It is often considered a more sensitive indicator of early or mild small airway obstruction than FEV1 or FEV1/FVC, as these larger airway parameters may remain normal until the disease is more advanced.\",\n    \"highYieldPearl\": \"FEF25-75% is the most sensitive spirometric indicator of small airway dysfunction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might choose FEV1/FVC if they think of obstruction generally, but the question specifies 'early small airway disease' which points to FEF25-75% as a more specific and sensitive marker.\"\n  },\n  {\n    \"question\": \"What percentage change in FEV1 and volume defines significant bronchodilator reversibility?\",\n    \"options\": {\n      \"A\": \"Increase of ≥10% and ≥100mL\",\n      \"B\": \"Increase of ≥12% and ≥200mL\",\n      \"C\": \"Increase of ≥15% and ≥200mL\",\n      \"D\": \"Increase of ≥20% and ≥100mL\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"According to ATS/ERS guidelines, significant bronchodilator reversibility in adults is defined as an increase of ≥12% from baseline AND an absolute increase of ≥200 mL in either FEV1 or FVC following bronchodilator administration. This criterion helps distinguish reversible airway obstruction (e.g., asthma) from largely irreversible obstruction (e.g., COPD).\",\n    \"highYieldPearl\": \"Bronchodilator reversibility: ≥12% AND ≥200mL increase in FEV1 or FVC.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other percentage or volume combinations might be close, but the specific '12% and 200mL' rule is a standard, frequently tested fact.\"\n  },\n  {\n    \"question\": \"A fixed large airway obstruction typically manifests as which flow-volume loop pattern?\",\n    \"options\": {\n      \"A\": \"Scooped expiratory limb\",\n      \"B\": \"Reduced inspiratory limb with normal expiratory\",\n      \"C\": \"Flattening of both inspiratory and expiratory limbs\",\n      \"D\": \"Reduced expiratory limb with normal inspiratory\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"Fixed large airway obstruction (e.g., tracheal stenosis, goiter, tumor) causes a limitation to airflow during both inspiration and expiration. This results in a plateau or flattening of both the inspiratory and expiratory limbs of the flow-volume loop, giving it a 'box-like' or 'truncated' appearance. This contrasts with variable obstructions, where the effect is more pronounced on one limb depending on intra- or extrathoracic location.\",\n    \"highYieldPearl\": \"Fixed large airway obstruction = flattened inspiratory and expiratory limbs.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Distinguishing between fixed, variable intrathoracic, and variable extrathoracic obstructions based on flow-volume loop patterns is crucial. The 'flattening of both limbs' is specific to fixed obstructions.\"\n  },\n  {\n    \"question\": \"What is the minimum acceptable exhalation time for adult spirometry?\",\n    \"options\": {\n      \"A\": \"3 seconds\",\n      \"B\": \"4 seconds\",\n      \"C\": \"6 seconds\",\n      \"D\": \"10 seconds\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"According to ATS/ERS guidelines, an acceptable forced exhalation in adults must last for a minimum of 6 seconds, or until a plateau (no volume change for at least 1 second) is achieved, or until the patient cannot exhale further. For children, the minimum is 3 seconds. Ensuring adequate exhalation time is critical for accurate FVC and FEV1 measurements.\",\n    \"highYieldPearl\": \"Minimum exhalation time for adult spirometry is 6 seconds.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"The 3-second rule applies to children, which might be a distractor. For adults, 6 seconds is the standard.\"\n  },\n  {\n    \"question\": \"The primary spirometric differentiator between obstructive and restrictive patterns is?\",\n    \"options\": {\n      \"A\": \"FEV1\",\n      \"B\": \"FVC\",\n      \"C\": \"FEV1/FVC ratio\",\n      \"D\": \"TLC\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"The FEV1/FVC ratio is the hallmark spirometric parameter for distinguishing between obstructive and restrictive ventilatory patterns. A reduced FEV1/FVC ratio (below the 5th percentile or <0.70 fixed ratio) indicates obstruction. While FVC can be reduced in both patterns, and FEV1 is reduced in obstruction (and often restriction), the ratio is key. TLC (Total Lung Capacity) is measured by plethysmography or gas dilution, not spirometry, and is definitively used to confirm restriction.\",\n    \"highYieldPearl\": \"FEV1/FVC ratio is the primary spirometric differentiator for ventilatory patterns.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"TLC is the gold standard for confirming restriction, but it's not a spirometric measurement. The question asks for a spirometric differentiator.\"\n  },\n  {\n    \"question\": \"Which spirometric maneuver directly assesses dynamic lung volumes and flows?\",\n    \"options\": {\n      \"A\": \"Slow Vital Capacity (SVC)\",\n      \"B\": \"Forced Vital Capacity (FVC)\",\n      \"C\": \"Inspiratory Capacity (IC)\",\n      \"D\": \"Tidal Volume (VT)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"The Forced Vital Capacity (FVC) maneuver involves a maximal forced exhalation after a maximal inspiration. This maneuver generates flow-volume and volume-time curves, from which dynamic lung volumes (like FEV1, FVC) and flow rates (like PEF, FEF25-75%) are derived. SVC, IC, and VT are measures of static or resting lung volumes/capacities, though SVC is a maximal exhalation, it's performed slowly, not forcibly, thus not assessing dynamic flows.\",\n    \"highYieldPearl\": \"FVC maneuver directly measures dynamic lung volumes and flows.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"SVC is a vital capacity measurement, but the 'forced' aspect of FVC is what makes it dynamic, involving time-dependent flows, unlike the slow maneuver.\"\n  },\n  {\n    \"question\": \"What is the primary criterion for an acceptable start of forced exhalation?\",\n    \"options\": {\n      \"A\": \"Peak flow achieved within 1 second\",\n      \"B\": \"No hesitation or false starts\",\n      \"C\": \"Exhalation ≥ 6 seconds\",\n      \"D\": \"Smooth, continuous flow\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"An acceptable start to a forced expiratory maneuver requires a 'good blast' – a rapid, forceful exhalation with no hesitation, coughing, or false starts before the peak flow is achieved. This ensures that the FEV1 (Forced Expiratory Volume in 1 second) accurately reflects the maximal initial airflow. Other options are criteria for the end of the test or overall maneuver quality, not specifically the start.\",\n    \"highYieldPearl\": \"Acceptable spirometry starts with a 'good blast' - no hesitation, rapid peak flow.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While achieving peak flow quickly is important, the 'no hesitation' aspect is the fundamental criterion for the *start* of the maneuver. A cough or hesitation at the beginning can significantly invalidate the FEV1.\"\n  },\n  {\n    \"question\": \"For spirometry, what is the minimum number of acceptable maneuvers required?\",\n    \"options\": {\n      \"A\": \"One\",\n      \"B\": \"Two\",\n      \"C\": \"Three\",\n      \"D\": \"Four\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"According to ATS/ERS standards, a spirometry test is considered valid if at least three acceptable maneuvers are performed. From these, the two best maneuvers (with the highest sum of FEV1 and FVC) must meet repeatability criteria (FEV1 and FVC within 150 mL of each other). While up to eight maneuvers may be performed, three acceptable ones are the minimum to ensure reproducibility and reliability.\",\n    \"highYieldPearl\": \"Minimum of three acceptable spirometry maneuvers for a valid test.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Students might confuse the 'two repeatable' with the 'minimum acceptable' total. You need at least three acceptable maneuvers to ensure you can select two that meet repeatability criteria.\"\n  },\n  {\n    \"question\": \"Flow-volume loop showing flattened inspiratory, but normal expiratory limb indicates?\",\n    \"options\": {\n      \"A\": \"Fixed large airway obstruction\",\n      \"B\": \"Variable intrathoracic obstruction\",\n      \"C\": \"Variable extrathoracic obstruction\",\n      \"D\": \"Small airway obstruction\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"A variable extrathoracic obstruction (e.g., vocal cord dysfunction, goiter compressing trachea) is worse during inspiration when negative intrathoracic pressure collapses the airway, leading to a flattened inspiratory limb. During expiration, positive intrathoracic pressure tends to hold the airway open, so the expiratory limb remains relatively normal. Fixed obstructions flatten both limbs, and variable intrathoracic obstructions affect the expiratory limb more.\",\n    \"highYieldPearl\": \"Flattened inspiratory, normal expiratory limb = variable extrathoracic obstruction.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"This question requires precise knowledge of how different types of airway obstructions affect the flow-volume loop, specifically distinguishing between fixed, variable intrathoracic, and variable extrathoracic patterns.\"\n  },\n  {\n    \"question\": \"Which spirometric finding suggests air trapping when compared to FVC?\",\n    \"options\": {\n      \"A\": \"Increased FEV1/FVC ratio\",\n      \"B\": \"Decreased FVC\",\n      \"C\": \"Increased RV/TLC\",\n      \"D\": \"Slow Vital Capacity (SVC) significantly greater than FVC\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"spirometry\",\n    \"deepDiveExplanation\": \"Air trapping occurs when air is retained in the lungs due to airway collapse during forced exhalation, often seen in obstructive diseases. When a patient exhales slowly (SVC), airways are less likely to collapse, allowing more complete emptying of the lungs. Thus, if SVC is significantly greater than FVC (usually >200mL or >10%), it suggests air trapping. Increased RV/TLC is a definite sign of air trapping/hyperinflation but is measured by plethysmography, not spirometry.\",\n    \"highYieldPearl\": \"SVC > FVC suggests air trapping, indicating dynamic airway collapse.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While increased RV/TLC definitively indicates air trapping/hyperinflation, it is not a spirometric parameter. The question asks for a 'spirometric finding'. The difference between SVC and FVC is a key spirometric indicator of air trapping.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-975.4252319335938}],"createTime":"2025-12-31T07:46:17.652935Z","modelVersion":"gemini-2.5-flash","responseId":"ydRUaYftJ_rDvPEPlfOwQQ","usageMetadata":{"billablePromptUsage":{"textCount":1039},"candidatesTokenCount":2899,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2899}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":1959,"totalTokenCount":5223,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:46:53.182373+00:00"}
{"metadata":"one-liner|tb_eptb_cns_skeletal|CNS and Skeletal TB|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"CNS and Skeletal TB\".\nSet the \"topic\" field in the JSON to \"tb_eptb_cns_skeletal\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3569281430050414,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The gold standard for confirming Tuberculous Meningitis diagnosis is?\",\n    \"options\": {\n      \"A\": \"CSF ADA\",\n      \"B\": \"CSF GeneXpert MTB/RIF\",\n      \"C\": \"CSF culture for M. tuberculosis\",\n      \"D\": \"CSF protein and glucose analysis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"While rapid molecular tests like GeneXpert MTB/RIF offer high sensitivity and specificity for Tuberculous Meningitis (TBM), CSF culture on solid (e.g., Löwenstein-Jensen) or liquid media remains the gold standard for definitive diagnosis, confirmation of viability, and drug susceptibility testing, despite its longer turnaround time (weeks).\",\n    \"highYieldPearl\": \"Culture provides definitive proof and drug susceptibility, making it the gold standard, even if slower than molecular tests.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"GeneXpert is an excellent rapid diagnostic tool, but 'gold standard' typically implies definitive isolation and characterization, which only culture provides. CSF ADA and biochemical analysis are supportive but not definitive.\"\n  },\n  {\n    \"question\": \"Which CSF parameter is typically lowest in Tuberculous Meningitis?\",\n    \"options\": {\n      \"A\": \"Protein concentration\",\n      \"B\": \"Glucose concentration\",\n      \"C\": \"Cell count\",\n      \"D\": \"Chloride concentration\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"In Tuberculous Meningitis, the CSF glucose concentration is typically significantly reduced (<40 mg/dL or <40% of blood glucose) due to increased utilization by mycobacteria and inflammatory cells, and impaired glucose transport across inflamed meninges. Protein is usually elevated, and a lymphocytic pleocytosis (elevated cell count) is common. Chloride levels are not a primary diagnostic marker.\",\n    \"highYieldPearl\": \"Low CSF glucose, high protein, and lymphocytic pleocytosis are classic CSF findings in TBM.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Elevated protein and cell count are also characteristic but are 'high' parameters. The question specifically asks for the 'lowest' parameter, which is glucose.\"\n  },\n  {\n    \"question\": \"Adjuvant corticosteroids are recommended in Tuberculous Meningitis for which clinical stage?\",\n    \"options\": {\n      \"A\": \"Stage I only\",\n      \"B\": \"Stage II and III only\",\n      \"C\": \"Stage I, II, and III\",\n      \"D\": \"Stage III only\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"Randomized controlled trials, particularly the landmark study by Thwaites et al., have shown a significant mortality benefit of adjuvant corticosteroids (e.g., dexamethasone) in Tuberculous Meningitis across all clinical stages (I, II, and III), although the benefit is most pronounced in Stage II and III. Current WHO guidelines recommend their use in all stages.\",\n    \"highYieldPearl\": \"Steroids are crucial adjuncts in TBM, reducing inflammation and improving outcomes across the disease spectrum.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While the benefit is more dramatic in severe stages (II and III), evidence supports their use in Stage I as well, making 'all stages' the correct and most up-to-date answer.\"\n  },\n  {\n    \"question\": \"The most common site for skeletal tuberculosis is the?\",\n    \"options\": {\n      \"A\": \"Knee joint\",\n      \"B\": \"Hip joint\",\n      \"C\": \"Vertebral column\",\n      \"D\": \"Small bones of hands and feet\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"The vertebral column, leading to Pott's disease (tuberculous spondylitis), is by far the most common site for skeletal tuberculosis, accounting for approximately 50-60% of all osteoarticular TB cases. Other common sites include the hip and knee joints, but they are less frequent than spinal involvement.\",\n    \"highYieldPearl\": \"Pott's disease = vertebral TB = most common skeletal TB manifestation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"All listed options can be affected by skeletal TB, but the vertebral column holds the highest prevalence, making it the most common site.\"\n  },\n  {\n    \"question\": \"What is the most sensitive imaging modality for early detection of Pott's spine?\",\n    \"options\": {\n      \"A\": \"Plain X-ray\",\n      \"B\": \"Computed Tomography (CT) scan\",\n      \"C\": \"Magnetic Resonance Imaging (MRI)\",\n      \"D\": \"Bone scintigraphy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"MRI offers superior soft tissue contrast and is the most sensitive imaging modality for detecting early changes in Pott's spine, including bone marrow edema, discitis, paraspinal abscesses, epidural collections, and spinal cord compression, often before changes are visible on plain X-rays or CT scans.\",\n    \"highYieldPearl\": \"MRI excels in early detection and assessing soft tissue and neural involvement in spinal TB.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Plain X-rays have poor sensitivity for early lesions. CT is excellent for bone destruction but less sensitive than MRI for soft tissue and early marrow changes. Bone scintigraphy is sensitive for metabolic activity but lacks anatomical detail.\"\n  },\n  {\n    \"question\": \"A definitive indication for surgical intervention in Pott's spine is?\",\n    \"options\": {\n      \"A\": \"Mild back pain unresponsive to analgesics\",\n      \"B\": \"Stable kyphotic deformity\",\n      \"C\": \"Progressive neurological deficit\",\n      \"D\": \"Small paravertebral abscess without compression\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"Progressive neurological deficit (e.g., paraplegia, paresis) due to spinal cord compression is a strong and definitive indication for surgical decompression in Pott's spine. Other indications include severe kyphosis (>60 degrees in children, >90 degrees in adults), intractable pain, and large abscesses unresponsive to antitubercular therapy (ATT) or threatening vital structures.\",\n    \"highYieldPearl\": \"Neurological compromise is the most critical surgical indication in Pott's disease.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Mild pain and stable kyphosis are usually managed conservatively. A small abscess without compression might also be managed medically. The key is 'progressive neurological deficit,' indicating urgent need for intervention.\"\n  },\n  {\n    \"question\": \"The most common neurological complication of Tuberculous Meningitis in children is?\",\n    \"options\": {\n      \"A\": \"Seizures\",\n      \"B\": \"Hydrocephalus\",\n      \"C\": \"Cranial nerve palsies\",\n      \"D\": \"Tuberculoma formation\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"Hydrocephalus, particularly communicating hydrocephalus, is the most frequent and often severe neurological complication of Tuberculous Meningitis in children. It results from inflammatory exudates obstructing CSF flow at the basal cisterns or impairing absorption by arachnoid granulations, often necessitating shunt placement.\",\n    \"highYieldPearl\": \"Hydrocephalus is a major cause of morbidity and mortality in pediatric TBM, often requiring neurosurgical intervention.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Seizures, cranial nerve palsies, and tuberculomas are also common complications of TBM, but hydrocephalus typically has the highest incidence and significant impact on outcome in children.\"\n  },\n  {\n    \"question\": \"Tuberculous dactylitis primarily results from which type of spread?\",\n    \"options\": {\n      \"A\": \"Direct inoculation\",\n      \"B\": \"Lymphatic dissemination\",\n      \"C\": \"Hematogenous dissemination\",\n      \"D\": \"Contiguous spread from adjacent soft tissue\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"Tuberculous dactylitis, also known as 'spina ventosa' when affecting short tubular bones, is typically a manifestation of hematogenous dissemination of Mycobacterium tuberculosis from a primary focus, usually in the lungs. The bacilli reach the bone marrow via the bloodstream.\",\n    \"highYieldPearl\": \"Most extrapulmonary TB, including bony lesions like dactylitis, results from hematogenous spread.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While lymphatic spread is crucial for initial infection, and contiguous spread can occur with advanced lesions, the primary mechanism for establishing dactylitis in the small bones is hematogenous seeding.\"\n  },\n  {\n    \"question\": \"The recommended minimum duration of antitubercular treatment for Tuberculous Meningitis is?\",\n    \"options\": {\n      \"A\": \"6 months\",\n      \"B\": \"9 months\",\n      \"C\": \"12 months\",\n      \"D\": \"18 months\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"The recommended duration for antitubercular treatment in Tuberculous Meningitis is generally longer than for pulmonary TB due to the severity of the disease and challenges in drug penetration into the central nervous system. WHO and many national guidelines recommend a minimum of 9-12 months of treatment. In India, the NTEP guidelines often specify 9 months.\",\n    \"highYieldPearl\": \"TBM requires longer treatment (9-12 months) compared to pulmonary TB (6 months) due to CNS involvement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"6 months is the standard for drug-sensitive pulmonary TB. 12-18 months might be considered in severe or complicated cases, but 9 months is the established minimum for drug-sensitive TBM.\"\n  },\n  {\n    \"question\": \"What is the most rapid and sensitive molecular test for Tuberculous Meningitis diagnosis?\",\n    \"options\": {\n      \"A\": \"CSF conventional PCR for MTB\",\n      \"B\": \"CSF GeneXpert MTB/RIF\",\n      \"C\": \"CSF Line Probe Assay (LPA)\",\n      \"D\": \"CSF Loop-mediated Isothermal Amplification (TB-LAMP)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"tb_eptb_cns_skeletal\",\n    \"deepDiveExplanation\": \"GeneXpert MTB/RIF is a fully automated, cartridge-based nucleic acid amplification test (NAAT) endorsed by WHO as the most rapid, sensitive, and specific molecular test for diagnosing TBM from CSF samples. It simultaneously detects M. tuberculosis DNA and rifampicin resistance mutations, providing results within 2 hours. Its sensitivity for TBM is superior to conventional PCR.\",\n    \"highYieldPearl\": \"GeneXpert is the preferred rapid molecular test for TBM due to its high sensitivity, speed, and simultaneous RIF resistance detection.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Conventional PCR for MTB is sensitive but may be less so than GeneXpert for TBM, and doesn't detect RIF resistance. LPA requires culture or concentrated samples and focuses on resistance. TB-LAMP is also rapid but GeneXpert is more widely adopted and validated for TBM diagnosis.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-991.189453125}],"createTime":"2025-12-31T07:46:29.816712Z","modelVersion":"gemini-2.5-flash","responseId":"1dRUacjsMaWRhMIPn9HYmQ8","usageMetadata":{"billablePromptUsage":{"textCount":1028},"candidatesTokenCount":2777,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2777}],"promptTokenCount":371,"promptTokensDetails":[{"modality":"TEXT","tokenCount":371}],"thoughtsTokenCount":2360,"totalTokenCount":5508,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:58.406665+00:00"}
{"metadata":"one-liner|lung_cancer_chemo|Lung Cancer - Chemotherapy and Targeted Therapy|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"Lung Cancer - Chemotherapy and Targeted Therapy\".\nSet the \"topic\" field in the JSON to \"lung_cancer_chemo\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.23672807965959822,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which specific EGFR mutation is associated with primary resistance to first-generation EGFR TKIs?\",\n    \"options\": {\n      \"A\": \"Exon 19 deletion\",\n      \"B\": \"L858R\",\n      \"C\": \"T790M\",\n      \"D\": \"Exon 20 insertion\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"EGFR Exon 20 insertions constitute 4-12% of all EGFR mutations in NSCLC and are inherently resistant to first and second-generation EGFR TKIs. Amivantamab and Mobocertinib are approved for this subtype.\",\n    \"highYieldPearl\": \"EGFR Exon 20 insertions are distinct from common activating mutations (Exon 19 del, L858R) and require specific targeted therapies due to primary TKI resistance.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Candidates might confuse primary resistance (Exon 20 insertion) with acquired resistance (T790M). Exon 19 deletion and L858R are common activating mutations sensitive to first-gen TKIs.\"\n  },\n  {\n    \"question\": \"What is the most common acquired on-target resistance mechanism to Osimertinib in EGFR-mutated NSCLC?\",\n    \"options\": {\n      \"A\": \"MET amplification\",\n      \"B\": \"HER2 amplification\",\n      \"C\": \"EGFR C797S mutation\",\n      \"D\": \"Small cell transformation\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"The EGFR C797S mutation is the most common on-target resistance mechanism to Osimertinib, particularly when Osimertinib is used after prior first/second-generation TKI therapy. It prevents Osimertinib from binding irreversibly to the EGFR kinase domain.\",\n    \"highYieldPearl\": \"C797S is a 'gatekeeper' mutation for Osimertinib, analogous to T790M for earlier TKIs. Off-target resistance mechanisms like MET amplification are also common.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"MET amplification is a common acquired resistance mechanism to Osimertinib but is 'off-target'. The question specifically asks for 'on-target' resistance, which refers to changes in the EGFR gene itself.\"\n  },\n  {\n    \"question\": \"Which ALK inhibitor is recommended as first-line treatment for ALK-positive advanced NSCLC?\",\n    \"options\": {\n      \"A\": \"Crizotinib\",\n      \"B\": \"Alectinib\",\n      \"C\": \"Ceritinib\",\n      \"D\": \"Brigatinib\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Alectinib has demonstrated superior efficacy and central nervous system (CNS) penetration compared to Crizotinib, making it the preferred first-line ALK inhibitor for ALK-positive advanced NSCLC. Brigatinib and Lorlatinib are also strong first-line options.\",\n    \"highYieldPearl\": \"Alectinib, Brigatinib, and Lorlatinib are all considered superior to Crizotinib in the first-line setting for ALK+ NSCLC due to better efficacy, especially in the brain.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Crizotinib was the first ALK inhibitor but has been largely superseded by newer, more potent agents with better CNS activity. All options are ALK inhibitors, but the question asks for the 'recommended first-line'.\"\n  },\n  {\n    \"question\": \"Which chemotherapy agent is contraindicated in NSCLC patients with pre-existing clinically significant hemoptysis?\",\n    \"options\": {\n      \"A\": \"Pemetrexed\",\n      \"B\": \"Carboplatin\",\n      \"C\": \"Bevacizumab\",\n      \"D\": \"Docetaxel\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Bevacizumab, a VEGF inhibitor, is associated with an increased risk of hemorrhage, including pulmonary hemorrhage. Therefore, it is contraindicated in NSCLC patients with recent hemoptysis or squamous cell histology due to higher risk of bleeding.\",\n    \"highYieldPearl\": \"Bevacizumab should be avoided in NSCLC patients with squamous histology or recent hemoptysis due to increased risk of fatal pulmonary hemorrhage.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The other agents are standard chemotherapeutic drugs and do not carry a specific contraindication for hemoptysis to the same extent as Bevacizumab. This is a critical safety consideration for VEGF inhibitors.\"\n  },\n  {\n    \"question\": \"Which targeted agent is indicated for MET exon 14 skipping mutations in advanced NSCLC?\",\n    \"options\": {\n      \"A\": \"Crizotinib\",\n      \"B\": \"Capmatinib\",\n      \"C\": \"Osimertinib\",\n      \"D\": \"Dabrafenib\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Capmatinib and Tepotinib are specific MET inhibitors approved for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Crizotinib has some activity but is not specifically approved for this indication.\",\n    \"highYieldPearl\": \"MET exon 14 skipping mutations define a distinct molecular subtype of NSCLC, treatable with specific MET inhibitors like Capmatinib or Tepotinib.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Crizotinib is an ALK/ROS1/MET inhibitor, but Capmatinib is a more potent and specific MET inhibitor approved for exon 14 skipping. Osimertinib is for EGFR, Dabrafenib for BRAF.\"\n  },\n  {\n    \"question\": \"What is the standard first-line chemotherapy backbone for extensive stage Small Cell Lung Cancer (SCLC)?\",\n    \"options\": {\n      \"A\": \"Cisplatin + Pemetrexed\",\n      \"B\": \"Carboplatin + Paclitaxel\",\n      \"C\": \"Cisplatin/Carboplatin + Etoposide\",\n      \"D\": \"Gemcitabine + Vinorelbine\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"The combination of a platinum agent (Cisplatin or Carboplatin) with Etoposide remains the cornerstone of first-line chemotherapy for extensive stage SCLC. Immunotherapy (e.g., Atezolizumab or Durvalumab) is often added to this backbone.\",\n    \"highYieldPearl\": \"Platinum-etoposide is the classic and still standard chemotherapy for SCLC, now often combined with immunotherapy for improved survival.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Other regimens are used in NSCLC (e.g., Pemetrexed, Paclitaxel) but are not standard for SCLC. The question specifically asks for SCLC.\"\n  },\n  {\n    \"question\": \"Which of the following is a common immune-related adverse event (irAE) affecting the endocrine system with PD-1 inhibitors?\",\n    \"options\": {\n      \"A\": \"Colitis\",\n      \"B\": \"Pneumonitis\",\n      \"C\": \"Hypothyroidism\",\n      \"D\": \"Dermatitis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Immune checkpoint inhibitors can cause inflammation in various organs. Hypothyroidism (thyroiditis) is a common endocrine irAE, often requiring thyroid hormone replacement. Other endocrine irAEs include hypophysitis and adrenal insufficiency.\",\n    \"highYieldPearl\": \"Endocrine irAEs, especially thyroid dysfunction, are common and often permanent, requiring lifelong hormone replacement.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Colitis, pneumonitis, and dermatitis are also common irAEs but affect the gastrointestinal, respiratory, and integumentary systems, respectively. The question specifies 'endocrine system'.\"\n  },\n  {\n    \"question\": \"What is the recommended targeted therapy combination for BRAF V600E mutated advanced NSCLC?\",\n    \"options\": {\n      \"A\": \"Erlotinib + Bevacizumab\",\n      \"B\": \"Dabrafenib + Trametinib\",\n      \"C\": \"Alectinib + Ceritinib\",\n      \"D\": \"Osimertinib + Ramucirumab\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Dabrafenib (a BRAF inhibitor) combined with Trametinib (a MEK inhibitor) is the approved and recommended targeted therapy for NSCLC patients with a BRAF V600E mutation. This combination improves efficacy and reduces resistance.\",\n    \"highYieldPearl\": \"BRAF V600E mutation in NSCLC is treated similarly to melanoma, with combined BRAF and MEK inhibition for synergistic effect.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Each option represents a combination of targeted agents, but only Dabrafenib + Trametinib specifically targets the BRAF pathway. The other combinations are for different molecular targets or are not standard.\"\n  },\n  {\n    \"question\": \"Which gene fusion is a target for Crizotinib in advanced NSCLC?\",\n    \"options\": {\n      \"A\": \"EGFR exon 19 deletion\",\n      \"B\": \"KRAS G12C\",\n      \"C\": \"ROS1 rearrangement\",\n      \"D\": \"BRAF V600E\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"Crizotinib is a multi-targeted tyrosine kinase inhibitor active against ALK, ROS1, and MET. It was the first approved targeted agent for ALK-positive NSCLC and is also effective in ROS1-rearranged NSCLC.\",\n    \"highYieldPearl\": \"Crizotinib's activity extends beyond ALK to include ROS1 rearrangements, making it a crucial agent for both these less common but targetable fusions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"EGFR, KRAS, and BRAF are common mutations but are not targeted by Crizotinib. Crizotinib primarily targets fusions (ALK, ROS1) and to some extent MET amplification.\"\n  },\n  {\n    \"question\": \"Which biomarker is typically required before initiating Nivolumab or Pembrolizumab in NSCLC without targetable mutations?\",\n    \"options\": {\n      \"A\": \"EGFR mutation status\",\n      \"B\": \"ALK rearrangement\",\n      \"C\": \"PD-L1 expression\",\n      \"D\": \"KRAS mutation status\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"lung_cancer_chemo\",\n    \"deepDiveExplanation\": \"For most indications in NSCLC (especially as monotherapy in the first-line), PD-L1 expression (measured by TPS or CPS) is a crucial biomarker to predict response to PD-1/PD-L1 inhibitors like Nivolumab and Pembrolizumab. Higher PD-L1 expression generally correlates with better response.\",\n    \"highYieldPearl\": \"PD-L1 expression is a key predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC, especially in the first-line setting for monotherapy.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"EGFR, ALK, and KRAS are driver mutations that dictate the use of targeted therapies, not immune checkpoint inhibitors. The question specifies 'without targetable mutations', directing towards immunotherapy biomarkers.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-662.838623046875}],"createTime":"2025-12-31T07:46:43.572289Z","modelVersion":"gemini-2.5-flash","responseId":"49RUaYH3IpyvgLUP3OuiyAM","usageMetadata":{"billablePromptUsage":{"textCount":1050},"candidatesTokenCount":2800,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2800}],"promptTokenCount":370,"promptTokensDetails":[{"modality":"TEXT","tokenCount":370}],"thoughtsTokenCount":1036,"totalTokenCount":4206,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:32.318251+00:00"}
{"metadata":"one-liner|copd_management|COPD - Management and Exacerbations|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"COPD - Management and Exacerbations\".\nSet the \"topic\" field in the JSON to \"copd_management\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.24969461058502143,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The recommended initial bronchodilator therapy for a newly diagnosed COPD Group A patient is?\",\n    \"options\": {\n      \"A\": \"Short-acting beta-agonist (SABA) or short-acting muscarinic antagonist (SAMA) prn\",\n      \"B\": \"Long-acting beta-agonist (LABA)\",\n      \"C\": \"Long-acting muscarinic antagonist (LAMA)\",\n      \"D\": \"LABA + LAMA combination\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"According to GOLD guidelines, Group A COPD patients (low symptoms, low exacerbation risk) should be managed with a short-acting bronchodilator (SABA or SAMA) on an as-needed basis to relieve symptoms. If symptoms persist, a long-acting bronchodilator can be considered.\",\n    \"highYieldPearl\": \"GOLD Group A: SABA/SAMA prn for symptom relief.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Distractors include long-acting bronchodilators, which are for higher symptom/risk groups (B, C, D) or if Group A patients remain symptomatic after initial SABA/SAMA trial. The key is 'initial' and 'Group A'.\"\n  },\n  {\n    \"question\": \"In COPD, inhaled corticosteroids (ICS) are primarily indicated as part of maintenance therapy for patients with a history of?\",\n    \"options\": {\n      \"A\": \"Frequent exacerbations\",\n      \"B\": \"Significant emphysema\",\n      \"C\": \"Persistent chronic cough\",\n      \"D\": \"Alpha-1 antitrypsin deficiency\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"ICS are not recommended as monotherapy in COPD. They are primarily indicated as part of combination therapy (ICS/LABA or ICS/LABA/LAMA) for patients with a history of frequent (≥2 moderate or ≥1 severe) exacerbations despite appropriate bronchodilator therapy, or in those with elevated blood eosinophil counts (e.g., ≥300 cells/μL) who are prone to exacerbations.\",\n    \"highYieldPearl\": \"ICS in COPD: exacerbations or high eosinophils, always with LABA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Many students associate ICS with asthma, and while there's an overlap, its role in COPD is specific to exacerbation risk and eosinophil count, not just any symptom like chronic cough or structural changes like emphysema.\"\n  },\n  {\n    \"question\": \"Roflumilast is indicated in severe COPD with chronic bronchitis and a history of?\",\n    \"options\": {\n      \"A\": \"Frequent exacerbations\",\n      \"B\": \"Significant pulmonary hypertension\",\n      \"C\": \"Early-onset emphysema\",\n      \"D\": \"Refractory hypoxemia\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"Roflumilast, a phosphodiesterase-4 inhibitor, is an add-on therapy indicated for severe and very severe COPD patients (FEV1 < 50% predicted) who have a chronic bronchitis phenotype and a history of frequent exacerbations, despite optimal bronchodilator therapy, to reduce exacerbation rates.\",\n    \"highYieldPearl\": \"Roflumilast: Severe COPD, chronic bronchitis, frequent exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The key here is the specific phenotype (chronic bronchitis) and the history of frequent exacerbations, not just general severe COPD or other complications like pulmonary hypertension.\"\n  },\n  {\n    \"question\": \"Non-invasive positive pressure ventilation (NIPPV) is indicated in acute COPD exacerbation with respiratory acidosis and?\",\n    \"options\": {\n      \"A\": \"Hypercapnia\",\n      \"B\": \"Isolated hypoxemia\",\n      \"C\": \"Normal or elevated pH\",\n      \"D\": \"Metabolic alkalosis\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"NIPPV is a cornerstone in the management of acute COPD exacerbations complicated by acute respiratory failure, specifically when there is respiratory acidosis (pH < 7.35) and hypercapnia (PaCO2 > 45 mmHg). It improves gas exchange, reduces work of breathing, and decreases the need for invasive mechanical ventilation.\",\n    \"highYieldPearl\": \"NIPPV for AECOPD: respiratory acidosis + hypercapnia.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Isolated hypoxemia without hypercapnia or acidosis is usually managed with oxygen therapy. NIPPV's primary benefit in AECOPD is to offload respiratory muscles and improve CO2 clearance.\"\n  },\n  {\n    \"question\": \"Long-term oxygen therapy (LTOT) in stable COPD is indicated for patients with a PaO2 consistently below?\",\n    \"options\": {\n      \"A\": \"60 mmHg\",\n      \"B\": \"70 mmHg\",\n      \"C\": \"80 mmHg\",\n      \"D\": \"90 mmHg\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"LTOT is indicated for stable COPD patients with severe resting hypoxemia, defined as a PaO2 ≤ 55 mmHg or SaO2 ≤ 88% while breathing room air. It is also indicated if PaO2 is between 56-59 mmHg or SaO2 is 89% in the presence of evidence of pulmonary hypertension, peripheral edema suggesting congestive heart failure, or polycythemia (hematocrit > 55%). The threshold of 60 mmHg is often used as a general cutoff.\",\n    \"highYieldPearl\": \"LTOT: PaO2 ≤ 55 mmHg or ≤ 59 mmHg with complications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Other oxygen saturation values are distractors. The specific threshold of 55 mmHg (or 60 mmHg as a common clinical rounding) is critical for this indication.\"\n  },\n  {\n    \"question\": \"Antibiotics are indicated in an acute COPD exacerbation characterized by increased dyspnea, sputum volume, and?\",\n    \"options\": {\n      \"A\": \"Sputum purulence\",\n      \"B\": \"Fever\",\n      \"C\": \"Wheezing\",\n      \"D\": \"Chest pain\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"According to modified Anthonisen criteria, antibiotics are indicated for an acute COPD exacerbation if a patient presents with all three cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence. They are also indicated if two of these cardinal symptoms are present, one of which is increased sputum purulence, or if severe exacerbation requires mechanical ventilation.\",\n    \"highYieldPearl\": \"Antibiotics in AECOPD: Anthonisen's triad (dyspnea, sputum volume, sputum purulence) or two with purulence.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Fever, wheezing, and chest pain are general symptoms that can occur but are not specific indicators for antibiotic use in AECOPD as per guidelines. Sputum purulence is the key bacterial indicator.\"\n  },\n  {\n    \"question\": \"Which vaccination is strongly recommended annually for all COPD patients?\",\n    \"options\": {\n      \"A\": \"Influenza\",\n      \"B\": \"Pneumococcal polysaccharide vaccine (PPSV23)\",\n      \"C\": \"Tetanus, diphtheria, and acellular pertussis (Tdap)\",\n      \"D\": \"Human papillomavirus (HPV)\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"Annual influenza vaccination is strongly recommended for all COPD patients to reduce the risk of lower respiratory tract infections and exacerbations. Pneumococcal vaccination (PCV13 and PPSV23) is also recommended but not annually for all. Tdap is a one-time recommendation, and HPV is not relevant for COPD management.\",\n    \"highYieldPearl\": \"Annual influenza vaccine is critical for all COPD patients.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Pneumococcal vaccine is a common distractor as it's also important for COPD patients, but it's not given annually to all.\"\n  },\n  {\n    \"question\": \"The recommended initial bronchodilator strategy for a newly diagnosed COPD Group D patient is?\",\n    \"options\": {\n      \"A\": \"LAMA monotherapy\",\n      \"B\": \"LABA monotherapy\",\n      \"C\": \"LABA + LAMA combination\",\n      \"D\": \"ICS + LABA combination\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"For GOLD Group D patients (high symptoms, high exacerbation risk), the initial recommended bronchodilator therapy is a combination of a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). ICS/LABA is an alternative if blood eosinophils are high, or if the patient has a history of asthma/asthma-COPD overlap syndrome, or if LABA/LAMA fails to control exacerbations and eosinophils are high.\",\n    \"highYieldPearl\": \"GOLD Group D: Start with LABA+LAMA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Monotherapy with LABA or LAMA is for less severe groups (B or C). ICS+LABA is an option for Group D but often considered after LABA+LAMA, especially if eosinophils are low, or as a step-up for frequent exacerbations.\"\n  },\n  {\n    \"question\": \"Low-dose, long-term azithromycin in COPD is considered for patients with a history of?\",\n    \"options\": {\n      \"A\": \"Frequent exacerbations\",\n      \"B\": \"Chronic productive cough only\",\n      \"C\": \"Alpha-1 antitrypsin deficiency\",\n      \"D\": \"Significant pulmonary fibrosis\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"Low-dose, long-term (e.g., three times weekly) azithromycin can be considered in former or current smokers with COPD, especially those with a history of frequent exacerbations (despite optimal inhaled therapy), to reduce the risk of future exacerbations. Its mechanism is thought to be primarily anti-inflammatory and immunomodulatory, rather than purely antimicrobial.\",\n    \"highYieldPearl\": \"Long-term azithromycin for COPD: frequent exacerbations.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium-Hard\",\n    \"trapAnalysis\": \"Chronic productive cough is a symptom of COPD but not the primary indication for long-term azithromycin. Alpha-1 antitrypsin deficiency has its own specific augmentation therapy. Pulmonary fibrosis is a different disease process.\"\n  },\n  {\n    \"question\": \"The recommended duration of systemic corticosteroids for an acute COPD exacerbation is typically?\",\n    \"options\": {\n      \"A\": \"5 days\",\n      \"B\": \"10 days\",\n      \"C\": \"14 days\",\n      \"D\": \"21 days\"\n    },\n    \"correctAnswer\": \"A\",\n    \"topic\": \"copd_management\",\n    \"deepDiveExplanation\": \"Current guidelines recommend a short course of systemic corticosteroids for acute COPD exacerbations, typically 5 days. Studies have shown that a 5-day course is as effective as longer courses (e.g., 10-14 days) in improving FEV1 and reducing treatment failure, while minimizing side effects.\",\n    \"highYieldPearl\": \"AECOPD systemic steroids: 5-day course is sufficient.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Older protocols often used longer durations (10-14 days), making these common distractors. The shift to shorter courses is an important update.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-713.3775024414063}],"createTime":"2025-12-31T07:46:31.098304Z","modelVersion":"gemini-2.5-flash","responseId":"19RUaYCABpHplu8P_-zfqQw","usageMetadata":{"billablePromptUsage":{"textCount":1038},"candidatesTokenCount":2857,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2857}],"promptTokenCount":368,"promptTokensDetails":[{"modality":"TEXT","tokenCount":368}],"thoughtsTokenCount":1373,"totalTokenCount":4598,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:28.929974+00:00"}
{"metadata":"one-liner|ebus|Endobronchial Ultrasound (EBUS)|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Endobronchial Ultrasound (EBUS)\".\nSet the \"topic\" field in the JSON to \"ebus\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.41097219366776316,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"The primary role of EBUS-TBNA in lung cancer is for which of the following?\",\n    \"options\": {\n      \"A\": \"Diagnosis of peripheral lung nodules\",\n      \"B\": \"N-staging of mediastinal and hilar lymph nodes\",\n      \"C\": \"Tumor debulking\",\n      \"D\": \"Assessment of pleural effusion etiology\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ebus\",\n    \"deepDiveExplanation\": \"Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) is the gold standard for sampling mediastinal and hilar lymph nodes (N1, N2, N3 stations) in lung cancer staging. It provides real-time ultrasound guidance for needle aspiration, significantly improving the diagnostic yield for malignancy, sarcoidosis, and other mediastinal pathologies. This minimally invasive procedure has largely replaced surgical mediastinoscopy for N-staging in many centers.\",\n    \"highYieldPearl\": \"EBUS-TBNA is crucial for accurate N-staging in lung cancer, guiding therapeutic decisions (e.g., neoadjuvant therapy vs. surgery).\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Options A, C, and D represent other aspects of lung disease management or different bronchoscope-based procedures. While EBUS can assist in peripheral nodule diagnosis (via radial EBUS), its primary role in lung cancer is unequivocally N-staging with convex probe EBUS-TBNA. Misinterpreting the 'primary role' can lead to selecting a less impactful application.\"\n  },\n  {\n    \"question\": \"Which mediastinal lymph node station is preferentially sampled by EBUS-TBNA over mediastinoscopy?\",\n    \"options\": {\n      \"A\": \"Station 2R (Right upper paratracheal)\",\n      \"B\": \"Station 4L (Left lower paratracheal)\",\n      \"C\": \"Station 7 (Subcarinal)\",\n      \"D\": \"Station 10R (Right hilar)\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ebus\",\n    \"deepDiveExplanation\": \"EBUS-TBNA offers superior access to several mediastinal lymph node stations compared to surgical mediastinoscopy. Specifically, station 7 (subcarinal) and station 4L (left lower paratracheal) are more easily and safely accessed by EBUS-TBNA. While mediastinoscopy can access stations 2R, 4R, and 7, EBUS provides a less invasive approach with real-time guidance, making it the preferred initial diagnostic modality for these stations, especially station 7.\",\n    \"highYieldPearl\": \"Subcarinal (station 7) and left lower paratracheal (station 4L) lymph nodes are particularly well-accessed by EBUS-TBNA.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"All options represent mediastinal lymph node stations relevant to lung cancer. The trap lies in knowing the comparative anatomical access of EBUS-TBNA versus mediastinoscopy. While EBUS can sample all listed stations, station 7 and 4L are often highlighted as areas where EBUS has a distinct advantage over mediastinoscopy in terms of safety and ease of access.\"\n  },\n  {\n    \"question\": \"Which EBUS technique is primarily indicated for guiding biopsy of peripheral lung lesions?\",\n    \"options\": {\n      \"A\": \"Convex probe EBUS-TBNA\",\n      \"B\": \"Radial EBUS\",\n      \"C\": \"Linear EBUS\",\n      \"D\": \"Endoscopic ultrasound (EUS)\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"ebus\",\n    \"deepDiveExplanation\": \"Radial EBUS utilizes a mini-probe that can be passed through the working channel of a bronchoscope. This probe generates 360-degree images, allowing for localization of peripheral lung lesions and guiding biopsy tools (e.g., forceps, cryoprobes, brushes) to the target. In contrast, convex probe EBUS (also known as linear EBUS) is designed for visualizing and sampling mediastinal and hilar lymph nodes and peribronchial lesions. EUS (Endoscopic Ultrasound) is primarily for gastrointestinal applications, though EUS-B-FNA (EUS-Bronchial-FNA) can access posterior mediastinal nodes.\",\n    \"highYieldPearl\": \"Radial EBUS is for peripheral lesions, while convex/linear EBUS is for mediastinal/hilar nodes and central peribronchial lesions.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"Confusing the applications of different EBUS types is a common trap. Convex/Linear EBUS is for central structures and lymph nodes, whereas Radial EBUS is specifically designed for navigating to and localizing peripheral lung lesions. Option D (EUS) is incorrect as it's a different modality, though EUS-B-FNA does exist for specific mediastinal nodes.\"\n  },\n  {\n    \"question\": \"EBUS differentiates lymph nodes from vascular structures primarily by detecting what?\",\n    \"options\": {\n      \"A\": \"Size and shape\",\n      \"B\": \"Echogenicity patterns\",\n      \"C\": \"Doppler flow\",\n      \"D\": \"Presence of calcification\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ebus\",\n    \"deepDiveExplanation\": \"EBUS machines are equipped with Doppler capabilities, which allow for the detection of blood flow within structures. Lymph nodes are typically avascular or have minimal flow, whereas vascular structures (arteries, veins) will exhibit significant Doppler signals. This real-time differentiation is crucial to avoid puncturing vessels during EBUS-TBNA, preventing complications like hemorrhage. While size, shape, and echogenicity can provide clues, Doppler flow is the definitive real-time method for distinguishing vascular from non-vascular structures.\",\n    \"highYieldPearl\": \"Always use Doppler to confirm a non-vascular target before EBUS-TBNA to prevent bleeding complications.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While size, shape, and echogenicity can offer hints, they are not definitive. A large, hypoechoic structure could be a lymph node or an aneurysm. Doppler flow provides direct evidence of vascularity, making it the most critical differentiating factor in real-time EBUS. Over-reliance on morphological features alone is the trap.\"\n  },\n  {\n    \"question\": \"The diagnostic yield of EBUS-TBNA for mediastinal lymphadenopathy in sarcoidosis typically exceeds what percentage?\",\n    \"options\": {\n      \"A\": \"60%\",\n      \"B\": \"75%\",\n      \"C\": \"85%\",\n      \"D\": \"95%\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"ebus\",\n    \"deepDiveExplanation\": \"EBUS-TBNA has a high diagnostic yield for sarcoidosis, often reported in the range of 85-95%. This makes it a highly effective and minimally invasive method for confirming the diagnosis of sarcoidosis by identifying non-caseating granulomas in mediastinal lymph nodes. Its high success rate has significantly reduced the need for more invasive surgical biopsies like mediastinoscopy for sarcoidosis diagnosis.\",\n    \"highYieldPearl\": \"EBUS-TBNA is the preferred initial diagnostic test for sarcoidosis with mediastinal lymphadenopathy due to its high yield and minimal invasiveness.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap is underestimating the high diagnostic yield of EBUS-TBNA in sarcoidosis. While options A and B might be plausible for other conditions or older techniques, EBUS-TBNA's efficacy in sarcoidosis is well-established at a very high percentage. Option D, while sometimes achievable, is at the very top end of reported ranges, so 'exceeds 85%' is the most appropriate and commonly cited general threshold.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-741.8048095703125}],"createTime":"2025-12-31T07:45:27.987559Z","modelVersion":"gemini-2.5-flash","responseId":"l9RUaaejPLKJ1dkP1aL2qAk","usageMetadata":{"billablePromptUsage":{"textCount":1024},"candidatesTokenCount":1805,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1805}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":1597,"totalTokenCount":3768,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:52.725835+00:00"}
{"metadata":"one-liner|long_covid|Long COVID / Post-COVID Syndrome|5","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 5 high-yield, unique one-liner conceptual MCQs for the topic: \"Long COVID / Post-COVID Syndrome\".\nSet the \"topic\" field in the JSON to \"long_covid\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.709791493041353,"citationMetadata":{"citations":[{"endIndex":6592,"startIndex":6360,"uri":"https://post.parliament.uk/long-covid-the-long-term-health-effects-of-covid-19/"},{"endIndex":6766,"startIndex":6505,"uri":"https://www.health.tas.gov.au/health-topics/coronavirus-covid-19/what-do-if-you-test-positive/post-covid-19-condition-long-covid"}]},"content":{"parts":[{"text":"[\n  {\n    \"question\": \"According to WHO, Post-COVID-19 condition is characterized by symptoms persisting for at least how long from illness onset?\",\n    \"options\": {\n      \"A\": \"2 weeks\",\n      \"B\": \"4 weeks\",\n      \"C\": \"8 weeks\",\n      \"D\": \"12 weeks\"\n    },\n    \"correctAnswer\": \"D\",\n    \"topic\": \"long_covid\",\n    \"deepDiveExplanation\": \"The World Health Organization (WHO) defines Post COVID-19 condition (Long COVID) as symptoms that persist for at least 3 months (12 weeks) from the onset of acute COVID-19, with symptoms lasting for at least 2 months and not explained by an alternative diagnosis. This formal definition distinguishes it from the post-acute phase (4-12 weeks).\",\n    \"highYieldPearl\": \"Remember the 12-week (3-month) threshold for the formal WHO definition of Post-COVID-19 condition.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"The trap lies in the common misconception that 'Long COVID' begins after 4 weeks. While symptoms beyond 4 weeks are considered 'post-acute COVID-19,' the formal WHO definition for 'Post-COVID-19 condition' specifies a minimum of 3 months (12 weeks) from onset.\"\n  },\n  {\n    \"question\": \"What is the most common persistent pulmonary function test abnormality observed in Long COVID patients?\",\n    \"options\": {\n      \"A\": \"Obstructive pattern\",\n      \"B\": \"Restrictive pattern\",\n      \"C\": \"Impaired diffusion capacity (DLCO)\",\n      \"D\": \"Increased total lung capacity\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"long_covid\",\n    \"deepDiveExplanation\": \"Impaired diffusion capacity for carbon monoxide (DLCO) is a frequently reported and often persistent abnormality in patients recovering from COVID-19, particularly those with severe disease and ongoing respiratory symptoms in Long COVID. It reflects microvascular damage, gas exchange impairment, and sometimes residual interstitial changes, even in the absence of overt fibrotic changes on imaging.\",\n    \"highYieldPearl\": \"DLCO impairment is a hallmark PFT finding in Long COVID, indicating persistent gas exchange abnormalities.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While some patients might have mild restrictive patterns, DLCO impairment is more consistently and specifically associated with the persistent dyspnea and exercise intolerance characteristic of Long COVID pulmonary sequelae. Obstructive patterns are less common unless pre-existing conditions are present.\"\n  },\n  {\n    \"question\": \"Which immunological phenomenon is increasingly recognized as a key contributor to Long COVID pathophysiology?\",\n    \"options\": {\n      \"A\": \"Type IV hypersensitivity\",\n      \"B\": \"Persistent viral reservoir\",\n      \"C\": \"Autoimmunity\",\n      \"D\": \"T-cell exhaustion\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"long_covid\",\n    \"deepDiveExplanation\": \"Autoimmunity, characterized by the presence of autoantibodies (e.g., against G-protein coupled receptors, interferons) and dysregulated immune responses, is a leading hypothesis for the diverse and persistent symptoms of Long COVID. Other mechanisms include persistent viral reservoirs, chronic inflammation, endothelial dysfunction, and gut dysbiosis, all of which can interact with or trigger autoimmune processes.\",\n    \"highYieldPearl\": \"Autoimmunity is a major immunological mechanism proposed for Long COVID, alongside persistent viral reservoirs and chronic inflammation.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Persistent viral reservoir is a strong hypothesis for the *cause* or *trigger* of some Long COVID symptoms, but autoimmunity describes the *immunological mechanism* by which the body's immune system mistakenly attacks its own tissues, often stimulated by the initial infection or lingering viral components. T-cell exhaustion might occur but isn't the primary 'key contributor' recognized for the broad symptom complex.\"\n  },\n  {\n    \"question\": \"Which symptom complex is considered a cardinal feature of Post-COVID Syndrome, often leading to significant disability?\",\n    \"options\": {\n      \"A\": \"Persistent anosmia and ageusia\",\n      \"B\": \"Chronic fatigue and post-exertional malaise\",\n      \"C\": \"New-onset hypertension and diabetes\",\n      \"D\": \"Recurrent deep vein thrombosis\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"long_covid\",\n    \"deepDiveExplanation\": \"Chronic fatigue, often accompanied by post-exertional malaise (PEM), is one of the most debilitating and universally reported symptoms in Long COVID. PEM, a worsening of symptoms after even minor physical or mental exertion, is highly characteristic and significantly impacts quality of life and functional capacity, often resembling Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).\",\n    \"highYieldPearl\": \"Chronic fatigue and post-exertional malaise (PEM) are defining and often most disabling symptoms of Long COVID.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While anosmia/ageusia can persist, and hypertension/diabetes can be consequences or comorbidities, and DVT can occur, chronic fatigue and PEM are the most defining and disabling features of the syndrome's impact on daily life and are central to its diagnostic criteria in many frameworks.\"\n  },\n  {\n    \"question\": \"What is the primary focus of current therapeutic strategies for Long COVID?\",\n    \"options\": {\n      \"A\": \"Antiviral eradication\",\n      \"B\": \"Immunomodulation\",\n      \"C\": \"Symptomatic and multidisciplinary support\",\n      \"D\": \"High-dose steroid therapy\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"long_covid\",\n    \"deepDiveExplanation\": \"Given the complex, heterogeneous nature of Long COVID and the lack of specific, approved treatments, current management primarily focuses on symptomatic relief, rehabilitation (e.g., pulmonary rehabilitation, cognitive therapy), and a multidisciplinary approach tailored to the individual's specific constellation of symptoms. This involves managing pain, dyspnea, fatigue, cognitive dysfunction, and mental health issues.\",\n    \"highYieldPearl\": \"Current Long COVID management is primarily symptomatic and supportive, utilizing a multidisciplinary approach.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Easy\",\n    \"trapAnalysis\": \"While antiviral eradication and immunomodulation are areas of active research and potential future therapies, they are not currently the *primary focus* of established therapeutic strategies for the broad spectrum of Long COVID symptoms due to lack of definitive evidence for widespread application. Steroids are used in acute severe COVID but not as a primary long-term therapy for Long COVID symptoms generally.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-1084.5614013671875}],"createTime":"2025-12-31T07:45:11.698565Z","modelVersion":"gemini-2.5-flash","responseId":"h9RUacXRKvK53NoPy4ivuQM","usageMetadata":{"billablePromptUsage":{"textCount":1029},"candidatesTokenCount":1528,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":1528}],"promptTokenCount":365,"promptTokensDetails":[{"modality":"TEXT","tokenCount":365}],"thoughtsTokenCount":2841,"totalTokenCount":4734,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:45:48.276265+00:00"}
{"metadata":"one-liner|hrct_ild|HRCT Patterns in ILD|10","request":{"contents":[{"parts":[{"text":"You are an expert Pulmonology Professor designing questions for the NEET-SS and INI-SS exams.\nYour task is to generate high-yield, \"One-Liner\" conceptual MCQs.\n\nCRITICAL RULES:\n1. NO clinical vignettes. NO \"A 45-year-old male presents with...\".\n2. Focus on: Direct facts, Mechanisms of action, Diagnostic \"Gold Standards\", Drug of Choice, Specific Criteria (e.g., Light's, GOLD stages), and High-Yield Timelines.\n3. Length: The question itself must be under 30 words.\n4. Difficulty: Must be \"Post-Graduate Level\" (NEET-SS/INI-SS).\n5. Format: Standard JSON array of objects.\n\nJSON Structure:\n{\n  \"question\": \"The most sensitive test for detecting early bronchiectasis is?\",\n  \"options\": {\n    \"A\": \"Chest X-Ray\",\n    \"B\": \"HRCT Thorax\",\n    \"C\": \"MRI Chest\",\n    \"D\": \"Spirometry\"\n  },\n  \"correctAnswer\": \"B\",\n  \"topic\": \"topic_id\",\n  \"deepDiveExplanation\": \"...\",\n  \"highYieldPearl\": \"...\",\n  \"examStyle\": \"NEET-SS\",\n  \"difficulty\": \"Easy\",\n  \"trapAnalysis\": \"...\"\n}\n\nGenerate exactly 10 high-yield, unique one-liner conceptual MCQs for the topic: \"HRCT Patterns in ILD\".\nSet the \"topic\" field in the JSON to \"hrct_ild\".\nEnsure the questions are distinct and cover essential pg-level concepts for this specific topic."}],"role":"user"}],"generationConfig":{"responseMimeType":"application/json","temperature":0.7}},"status":"","response":{"candidates":[{"avgLogprobs":-0.3217787328554469,"content":{"parts":[{"text":"[\n  {\n    \"question\": \"Which HRCT finding is essential for a 'definite UIP' pattern diagnosis?\",\n    \"options\": {\n      \"A\": \"Ground glass opacity\",\n      \"B\": \"Honeycombing\",\n      \"C\": \"Centrilobular nodules\",\n      \"D\": \"Pleural plaques\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Honeycombing, defined as clustered cystic airspaces (typically 3-10 mm, but up to 2.5 cm) with thick, well-defined walls, is the hallmark of a definite Usual Interstitial Pneumonia (UIP) pattern on HRCT. It indicates advanced fibrosis and, along with traction bronchiectasis/bronchiolectasis and a peripheral, basal predominance, forms the diagnostic criteria for definite UIP according to ATS/ERS guidelines.\",\n    \"highYieldPearl\": \"Honeycombing is pathognomonic for advanced fibrosis in UIP and is a mandatory criterion for a 'definite UIP' HRCT pattern.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Ground glass opacity can be present in UIP but is not *essential* for a 'definite' pattern; it is more prominent in NSIP or active inflammation. Centrilobular nodules are typical for HP, and pleural plaques for asbestosis.\"\n  },\n  {\n    \"question\": \"Subpleural sparing is a characteristic HRCT feature of which interstitial lung disease pattern?\",\n    \"options\": {\n      \"A\": \"UIP\",\n      \"B\": \"NSIP\",\n      \"C\": \"HP\",\n      \"D\": \"LCH\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Non-Specific Interstitial Pneumonia (NSIP) often presents with subpleural sparing on HRCT, meaning the most peripheral lung tissue adjacent to the pleura is relatively spared compared to the deeper lung parenchyma. This feature helps differentiate NSIP from UIP, which typically shows peripheral predominance without sparing.\",\n    \"highYieldPearl\": \"Subpleural sparing is a key distinguishing feature of NSIP from UIP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"UIP shows peripheral predominance *without* sparing, making 'A' an incorrect choice. HP is characterized by mosaic attenuation and centrilobular nodules, while LCH features bizarre cysts and stellate nodules.\"\n  },\n  {\n    \"question\": \"The 'head cheese sign' on HRCT is highly suggestive of which interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Sarcoidosis\",\n      \"B\": \"Hypersensitivity Pneumonitis\",\n      \"C\": \"LAM\",\n      \"D\": \"UIP\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"The 'head cheese sign' refers to a mosaic pattern of attenuation with three distinct densities: normal lung, ground glass opacity, and air trapping (low attenuation). This pattern is highly suggestive of chronic Hypersensitivity Pneumonitis (HP), reflecting a combination of inflammatory changes and small airway obstruction.\",\n    \"highYieldPearl\": \"The 'head cheese sign' is a characteristic HRCT finding in chronic Hypersensitivity Pneumonitis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While mosaic attenuation can occur in other conditions (e.g., small airway disease), the specific 'head cheese' combination of three densities strongly points towards HP. Sarcoidosis has perilymphatic nodules, LAM has diffuse thin-walled cysts, and UIP has honeycombing.\"\n  },\n  {\n    \"question\": \"Perilymphatic nodular distribution on HRCT is characteristic of which interstitial lung disease?\",\n    \"options\": {\n      \"A\": \"Asbestosis\",\n      \"B\": \"Silicosis\",\n      \"C\": \"Sarcoidosis\",\n      \"D\": \"LAM\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Sarcoidosis typically demonstrates a perilymphatic distribution of nodules on HRCT. This means the nodules are clustered along bronchovascular bundles, subpleural regions, and interlobular septa, often with an upper and mid-zone predominance. These nodules may coalesce to form larger masses or conglomerate fibrosis.\",\n    \"highYieldPearl\": \"Perilymphatic nodules with upper/mid-zone predominance are a hallmark of Sarcoidosis on HRCT.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Silicosis also has nodules but often more diffuse or centrilobular with an upper lobe predominance, and can feature eggshell calcification. Asbestosis is characterized by pleural plaques and lower lobe fibrosis. LAM presents with diffuse cysts.\"\n  },\n  {\n    \"question\": \"Bizarrely shaped cysts with associated stellate nodules, sparing costophrenic angles, suggests which ILD?\",\n    \"options\": {\n      \"A\": \"LAM\",\n      \"B\": \"LCH\",\n      \"C\": \"UIP\",\n      \"D\": \"COP\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Pulmonary Langerhans Cell Histiocytosis (LCH) typically presents on HRCT with a combination of cysts and nodules. The cysts are often bizarrely shaped (not uniformly round like in LAM) and variable in size, frequently associated with stellate nodules. A key differentiating feature is the characteristic sparing of the costophrenic angles and lung bases.\",\n    \"highYieldPearl\": \"LCH: Bizarre cysts + stellate nodules + upper/mid-zone predominance + costophrenic sparing.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"LAM also has cysts, but they are typically thin-walled, round, and diffuse without associated nodules. Emphysema shows areas of low attenuation but usually not well-defined cysts. UIP is fibrotic, and COP shows consolidation.\"\n  },\n  {\n    \"question\": \"Diffuse, thin-walled, round cysts with normal lung volumes are characteristic of which ILD?\",\n    \"options\": {\n      \"A\": \"Emphysema\",\n      \"B\": \"LCH\",\n      \"C\": \"LAM\",\n      \"D\": \"Pneumocystis pneumonia\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Lymphangioleiomyomatosis (LAM) is characterized by numerous diffuse, thin-walled, round, well-circumscribed cysts of varying sizes on HRCT. These cysts are typically distributed throughout the lung parenchyma, and lung volumes are usually normal or increased. There are typically no associated nodules or ground glass opacities.\",\n    \"highYieldPearl\": \"Diffuse, thin-walled, round cysts with normal lung volumes are pathognomonic for LAM.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"LCH has cysts but they are often irregular and associated with stellate nodules. Emphysema shows areas of low attenuation but typically not well-defined, uniform cysts. Pneumocystis pneumonia presents with ground glass opacities, not cysts.\"\n  },\n  {\n    \"question\": \"Peripheral and peribronchial consolidation with ground glass opacities, sometimes migratory, is typical for which ILD?\",\n    \"options\": {\n      \"A\": \"UIP\",\n      \"B\": \"NSIP\",\n      \"C\": \"COP\",\n      \"D\": \"DIP\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Cryptogenic Organizing Pneumonia (COP), also known as Bronchiolitis Obliterans Organizing Pneumonia (BOOP), characteristically presents with patchy, often peripheral or peribronchial, consolidation on HRCT. Ground glass opacities can also be seen, and the consolidations may be migratory. The 'reverse halo sign' (atoll sign) is also highly suggestive of COP.\",\n    \"highYieldPearl\": \"Peripheral consolidation and ground glass opacities, especially if migratory, suggest COP.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"UIP and NSIP are primarily reticular/fibrotic patterns. DIP is characterized mainly by ground glass opacity, predominantly in the lower lobes, but typically without consolidations.\"\n  },\n  {\n    \"question\": \"Pleural plaques and lower lobe predominant subpleural reticular opacities define which pneumoconiosis on HRCT?\",\n    \"options\": {\n      \"A\": \"Silicosis\",\n      \"B\": \"Coal Worker's Pneumoconiosis\",\n      \"C\": \"Asbestosis\",\n      \"D\": \"Berylliosis\"\n    },\n    \"correctAnswer\": \"C\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Asbestosis is an interstitial lung disease caused by asbestos exposure. On HRCT, it is characterized by the presence of pleural plaques (often calcified, diaphragmatic, or parietal) and subpleural reticular opacities with architectural distortion, typically involving the lower lobes. Honeycombing may be present in advanced stages.\",\n    \"highYieldPearl\": \"Asbestosis = Pleural plaques + lower lobe predominant subpleural fibrosis.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"Silicosis typically presents with upper lobe predominant nodules and 'eggshell' calcification of hilar lymph nodes. Coal Worker's Pneumoconiosis shows small, rounded opacities, often in the upper lobes. Berylliosis can mimic sarcoidosis.\"\n  },\n  {\n    \"question\": \"Which HRCT feature *excludes* a 'definite UIP' pattern according to ATS/ERS guidelines?\",\n    \"options\": {\n      \"A\": \"Honeycombing\",\n      \"B\": \"Subpleural sparing\",\n      \"C\": \"Traction bronchiectasis\",\n      \"D\": \"Peripheral predominance\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"The ATS/ERS guidelines for the diagnosis of Idiopathic Pulmonary Fibrosis (IPF) specify HRCT patterns. A 'definite UIP' pattern requires honeycombing, traction bronchiectasis, and peripheral/basal predominance. Conversely, features such as 'subpleural sparing', extensive ground glass opacity, or predominant consolidation are considered features that *exclude* a definite UIP pattern and suggest an alternative diagnosis (e.g., NSIP for subpleural sparing).\",\n    \"highYieldPearl\": \"Subpleural sparing is an exclusion criterion for a 'definite UIP' HRCT pattern.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Hard\",\n    \"trapAnalysis\": \"Options A, C, and D are all *features* of a definite UIP pattern. The question specifically asks for an *exclusion* criterion, which tests a deeper understanding of the diagnostic guidelines.\"\n  },\n  {\n    \"question\": \"Widespread ground glass opacity on HRCT without significant reticulation primarily suggests which pathological process?\",\n    \"options\": {\n      \"A\": \"Irreversible fibrosis\",\n      \"B\": \"Active inflammation\",\n      \"C\": \"Cystic degeneration\",\n      \"D\": \"Air trapping\"\n    },\n    \"correctAnswer\": \"B\",\n    \"topic\": \"hrct_ild\",\n    \"deepDiveExplanation\": \"Ground glass opacity (GGO) on HRCT represents partial filling of airspaces, interstitial thickening, or partial collapse of alveoli. While GGO can be seen with early fibrosis, widespread GGO without significant reticulation or honeycombing is generally considered a potentially reversible sign of active inflammation (e.g., in NSIP, HP, COP, or acute exacerbation) or alveolar filling. Extensive fibrosis typically presents with reticulation and honeycombing.\",\n    \"highYieldPearl\": \"Widespread GGO (without significant fibrosis) indicates potentially reversible active inflammation or alveolar filling.\",\n    \"examStyle\": \"NEET-SS\",\n    \"difficulty\": \"Medium\",\n    \"trapAnalysis\": \"While GGO can precede fibrosis, its widespread presence *without* significant reticulation or honeycombing points more towards an inflammatory process that may be reversible. Irreversible fibrosis is characterized by architectural distortion, reticulation, and honeycombing. Cystic degeneration is seen in LAM/LCH, and air trapping is a sign of small airway disease.\"\n  }\n]"}],"role":"model"},"finishReason":"STOP","score":-919.0000610351563}],"createTime":"2025-12-31T07:46:19.270915Z","modelVersion":"gemini-2.5-flash","responseId":"y9RUacPEEIHzgLUP9pvcyAs","usageMetadata":{"billablePromptUsage":{"textCount":1017},"candidatesTokenCount":2856,"candidatesTokensDetails":[{"modality":"TEXT","tokenCount":2856}],"promptTokenCount":366,"promptTokensDetails":[{"modality":"TEXT","tokenCount":366}],"thoughtsTokenCount":2765,"totalTokenCount":5987,"trafficType":"ON_DEMAND"}},"processed_time":"2025-12-31T07:47:20.08587+00:00"}
